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Abstract 
Substantial progress has been made in the last few decades in the therapeutic and surgical 
treatment of CRC designed to improve survival. However, treatments tailored to the individual 
patient based on the mutation and gene expression profiles of CRC remain elusive. Rectal 
cancer, in particular, has come under scrutiny because of the wide variation in response rates to 
neoadjuvant radiotherapy, which may be linked to the high degree of hypoxia observed in this 
cancer. The cell killing potential of radiation is determined by the presence of oxygen and 
reactive oxygen species (ROS). ROS can be induced during inflammation and may cause genetic 
damage and cellular transformation, aiding radiation-induced DNA damage. Dual oxidase 2 
(DUOX2) is a major source of ROS in the intestine and this study aims to evaluate the 
expression of DUOX2 and its maturation factor (DUOXA2) in both normal and neoplastic 
tissue, including rectal cancer, to determine whether oxygen tension can influence gene 
expression and to measure the outcome of exposure to irradiation (IR) in rectal cancer cell lines 
expressing different levels of DUOX2/DUOXA2. MicroRNAs (miRNAs) were also investigated 
as potential markers of hypoxia in rectal cancer cell lines and tissue. 
DUOX2 and DUOXA2 expression was found to be low in normal mucosal tissue, highly 
expressed in adenomas and moderately expressed in cancers, indicating a potential link between 
elevated ROS levels and tumour progression. Rectal cancer cell lines were used to show in vitro 
that DUOX2 expression was upregulated in response to a reduction in oxygen tension (2 % O2) 
and that the alteration in DUOX2 expression was independent of COX2 and HIF-1α expression. 
With the addition of IR, cells with high DUOX2 expression showed high levels of DNA damage 
and low numbers of stem-like cells (CD24) indicating susceptibility to IR. Cells with low 
DUOX2 expression showed low levels of DNA damage, high survival rate and a high quantity of 
CD24+ cells indicating resistance to IR. A number of consistently upregulated miRNAs were 
also identified in cells lines maintained in hypoxia. Follow-up investigations showed miR-210 to 
be consistently upregulated in hypoxic regions of rectal cancer and to target the iron sulphur 
cluster homolog (ISCU) gene both in vitro and in vivo. ISCU is an essential part of the 
mitochondrial electron transport chain and can control ROS production. Both DUOX2 and 
miR-210 have significant promise as markers of hypoxia in rectal cancers and warrant further 
investigation as markers of response to neoadjuvant radiotherapy. 
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HSP60 Heat shock protein 60 
IFNγ Interferon gamma 
IGF2 Insulin-like growth factor 2 
IGF2R Insulin-like growth factor 2 receptor 
IGFBP3 Insulin-like growth factor binding protein 3 
ISCU Iron sulfur cluster homolog 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LGR5 Leucine-rich repeat containing G protein-coupled receptor 5 
MAPK Mitogen-activated protein kinase 
MCM2 Minichromosome maintenance 2 
Mertk C-mer proto-oncogene tyrosine kinase (mouse) 
MGMT O-6-methylguanine-DNA methyltransferase 
MINT1 Methylated in tumour 1 
MINT2 Methylated in tumour 2 
MINT31 Methylated in tumour 31 
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 
MSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 
MSH3 MutS homolog 3 
MSH6 MutS homolog 6 
MYH MutY homolog 
NEUROG1 Neurogenin 1 
NOX1-5 NADPH oxidase 1 to 5 
NPTX1 Neuronal pentraxin 1 
p14ARF Alternate reading frame product of Cyclin-dependent kinase inhibitor 2A (CDKN2A) 
p16INK4α Cyclin-dependent kinase inhibitor 2A (CDKN2A) 
PGE2 Prostaglandin E2 
PMS2 Post meiotic segregation increased 2 
POLDIP2 Polymerase delta interacting protein 2 
PR1 Protected region 1 
PRKDC Protein kinase, DNA-activated, catalytic polypeptide 
RAD52 RAD52 homolog 
Recc1 Replication factor C (activator 1) 1 (mouse) 
RPLPO Human large ribosomal protein 
RUNX3 Runt-related transcription factor 3 
SMAD2 SMAD family member 2 
SMAD4 SMAD family member 4 
SMAD7 SMAD family member 7 
SOCS1 Suppressor of cytokine signalling 1 
STK11 Serine/threonine kinase 11 
TGFB1 Transforming growth factor, beta 1 
TGFBR2 Transforming growth factor, beta receptor II 
TLR-5 Toll-like receptor 5 
TP53 Tumour protein 53 
UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 
VEGF Vascular endothelial growth factor 
VHL von Hippel-Lindau 
WNT Wingless-type MMTV integration site family 
WRN Merner syndrome, RecQ helicase-like 
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Chapter 1 Introduction 
The following chapter provides an introduction to colorectal cancer epidemiology, genetics and the influences behind 
this PhD thesis. It will cover CRC as combined colon and rectal cancers unless otherwise stated. In particular the 
focus is on rectal cancer, its response to preoperative therapy and possible predictive biomarkers. 
Colorectal cancer (CRC) in Europe was the most common form of cancer (13.6 %) and the 
second most common form of cancer-related death (12.3 %) in 20081. CRC consists of colon 
and rectal cancer, of which rectal cancer incidence is just over a third (36 %)2. Rectal cancers, 
once diagnosed, most often follow a course of preoperative therapy with subsequent surgical 
excision of the tumour. Preoperative therapy is used as a local control strategy, to reduce the risk 
of tumour cells remaining after surgery and to lower the risk of local recurrence.  Currently about 
half of rectal cancer patients who receive preoperative therapy show downsizing of the tumour, 
but the rest have an absence of response3. Despite the wealth of information about colorectal 
cancer, little is known about the reasons behind these differing response rates to preoperative 
therapy. A biomarker that could predict whether a rectal tumour would respond to therapy 
would be a significant step forward in improving patient care. This thesis focuses on rectal 
cancer and its response to preoperative radiotherapy in order to find a valuable biomarker of 
therapy response. 
1.1 Colorectal cancer summary 
Worldwide in 2008, CRC was the third most commonly diagnosed cancer (9.7 %) after lung and 
breast cancer, and the fourth most common form of cancer-related mortality (8 %) after lung, 
stomach and liver cancers4. The incidence was estimated to be 1233 per 100,000 worldwide in 
2008 with the estimated number of deaths at 608 per 100,000. The epidemiology of CRC varies 
greatly between the sexes; incidence is higher in men than in women with 662,000 new cases in 
men compared to 569,000 new cases in women worldwide, and mortality rates are also higher in 
men than women. Global regions also have differing epidemiology; developed regions have 60 % 
of the total number of cases and the highest mortality rate in both sexes is in Central and Eastern 
Europe and the lowest mortality rates in Middle Africa4. Despite increasing incidence, CRC-
related mortality rates in the UK have been falling for the last 30 years and survival rates have 
almost doubled5 due to advances in diagnostics, therapies and surgical techniques. Early 
detection is a huge factor in decreasing mortality, with 90 % five-year survival rates for stage 1 
disease falling rapidly to 6 % with the presence of metastases6.  
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CRC cancers can be separated into familial and sporadic cases. Familial cases account for about 6 
% of all CRC7 and arise from an inherited genetic tendency towards cancer. Familial cancers 
were not studied in this project because they already had a genetic predisposition to cancer and 
their outcomes relatively well documented. Sporadic cancers are those without obvious inherited 
predispositions that develop as a result of an accumulation of genetic alterations which leads to 
altered cell function. CRC tumours progress in a step-wise process: the adenoma-carcinoma 
sequence (chapter 1.2), where the malignant transformation of early adenomas into a cancer 
typically occurs in a well-established sequence or cascade, commonly called a Vogelgram (figure 
3). Most tumours tend to develop from a normal cell that has acquired an initiating mutation, 
which provides a selective advantage to the cell8.  
Current opinions regarding the molecular pathways that lead to CRC suggest that there are three 
main pathways for progression from polyp to cancer; two of these are chromosomal instability 
(CIN, chapter 1.2.2) and microsatellite instability (MSI, chapter 1.2.3). The third group is the 
CpG island methylator phenotype (CIMP, chapter 1.2.4), an epigenetic event characterising up to 
20 % of CRCs9. CRCs can be divided into these subtypes so treatment can be tailored and 
outcomes can be predicted. Recently a fourth group of CRCs has been identified that does not 
show the characteristics of CIN, MSI or CIMP10. These tumours are referred to as microsatellite 
and chromosome stable (MACS, chapter 1.2.5)11 or MSI-CIN- near-diploid12 cancers.  
1.1.1 Rectal cancer 
CRC consists of colon and rectal cancers with a ratio of 2:1 respectively6. The rectum is the 
terminal 12-15 cm section of the intestine, extending from the sigmoid flexure to the anus. It is 
covered by the peritoneum (lining of the abdominal cavity) in front and on both sides in the 
upper third, and only covered on the front in its middle third. There is no peritoneal covering in 
the lower third, the rectal ampulla. Rectal cancer occurs below the recto-sigmoid junction, in the 
canal that leads to and terminates in the anus. The cells in the wall of the colon are similar to 
those of the rectum, both being columnar, non-ciliated epithelial cells, but both differ from those 
of the anus (stratified squamous epithelial cells). Most (>95 %) tumours that arise in the colon 
and rectum are adenocarcinomas13, tumours that originate from glands in the intestinal mucosa, 
whereas tumours initiating in the anal canal are typically squamous cell carcinomas. Tumours 
most often begin in the lining of the bowel with a group of cells that grow to form early 
adenomas, which acquire further mutations that transform into an invasive cancer. Tumours 
progress from early adenomas to invading the muscle layer of the intestine, spread to the 
lymphatic vessels and eventually metastasise to other distant organs.  
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Despite the walls of the colon and rectum being similar on a cellular level, the anatomy of the 
rectum is different to that of the colon (figure 1) and this influences the growth and invasion of 
rectal cancers. The lymphatic drainage of the rectum and the proximity of the pelvic bones and 
muscular floor of the pelvis to the rectum mean that the cancer can invade the bone and muscle 
layer more easily. Invasion of a cancer into bone and muscle means that it is more difficult to 
remove the entire cancer at surgery without leaving any residue. Residual cancer cells left in the 
pelvic cavity mean that rectal cancers have a tendency to recur locally. A figure of the 
distribution of cases within the large intestine is given below (figure 1). 
 
1. Figure 1. Percentage distribution of bowel cancer cases in the UK 2006-2008. Image from 
cancerresearch.org.uk6. 
The diagram shows the anatomy and location of CRC cases for two years in the UK. The 
number of rectal cancer cases made up 27 %, under one third of the number of CRC cases 
between 2006 and 2008. 
1.1.2 Risk factors 
There are modifiable lifestyle factors that can affect the risk of CRC in addition to the inherited 
predispositions. It is known that CRC incidence is strongly associated with a Western lifestyle 
including diet, obesity, physical exercise, alcohol and tobacco use, use of non-steroidal anti-
inflammatory drugs (NSAIDS), statins, hormone replacement therapy, family history of the 
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disease and having a genetic predisposition14 15. Family history of the disease is collated by 
interviewing blood relatives of a patient who has presented with a particular disease and such 
knowledge can identify predisposition to cancer, particularly where a number of family members 
from two or more generations are affected. Genetic predisposition is a genetic alteration carried 
by an individual, which influences their phenotype or leads to a disease, e.g. APC germline 
mutations in FAP. Genetic testing can be used to identify those individuals at risk who are 
genetically predisposed. The phenotypes can be modified by the environmental conditions. 
1.1.2.1 Environmental risks 
Risk factors for rectal cancer are often not the same as those for colon cancer, possibly due to 
their size, location and the differing substances that pass through. However, it has been shown 
that diet significantly affects the risk of CRC as a whole. In one study16, high intake of red and 
processed meats increased the relative risk over ten years of developing CRC in a person aged 50 
from 1.21 % to 1.71 % (p=0.001). The authors postulated that this could be due to the greater 
amounts of heme in red meats compared with poultry (no affect on CRC risk), which “stimulates 
the production of endogenous N-nitroso compounds”16 that are linked to CRC risk17. The same 
study also looked at the effect of dietary fish and found that increased fish intake was 
significantly associated with reduced risk of developing CRC (p<0.001) showing a risk reduction 
from 1.86 % to 1.28 %16. This reduction was linked to the left side of the colon and the rectum 
only, not the right side of the colon, and there was no interaction between fish and red meat 
intake meaning that loss of one dietary component did not explain the significant risk of the 
other. Fish contains n-3 fatty acids which are known to inhibit carcinogenesis18 and this may help 
to explain the risk reduction.  
Dietary fibre has been researched extensively and has been shown by many to be associated with 
decreased risk of colon cancer19-21 but few have found any associated with rectal cancer. One 
study, using a large cohort of rectal cancer patients and conducting patient interviews to 
determine the dietary information, found that high vegetable intake produced a 28 % reduction 
in rectal cancer risk and that fibre intake was inversely associated with rectal cancer22. The 
opposite effect was seen with high intake of refined-grain products, causing an increase risk of 
rectal cancer. 
Obesity in men and alcohol consumption has a direct relationship with rectal cancer, which is 
not seen in women23 24. Body mass index (BMI), as an indicator of obesity, showed a significantly 
positive relationship with risk of rectal cancer in men but not in women, with a 12 % increase 
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per 5-unit higher BMI25. Although the risk of cancer is greater, there does not seem to be an 
increase in poor long term outcomes in obese patients compared with non-obese patients; the 
only differences have been shown to be a longer operative time and length of hospital stay in 
obese patients26. Alcohol consumption has been shown to increase the risk of rectal cancer in 
men and a review of 12 studies24 detailed that three found a significant association and the 
remaining found a positive but non-significant correlation. The reason for this association in 
men could be due to the increased consumption of alcohol by men in these studies compared to 
women. Other alcohol-related studies have been published detailing in more depth the changes, 
both genetic and epigenetic, that specific types of alcohol can contribute to rectal cancer. One 
study27 found that beer significantly increased the risk of having a TP53 mutation (although no 
association with rectal tumours overall), whilst red wine reversed that trend, but it was not 
significant. The study also showed a significant association between alcohol consumption and 
CIMP positive rectal tumours, whereas CIMP positive colon tumours were not associated with 
alcohol27. A possible reason for the reduced risk of rectal cancer with red wine intake could be 
due to the polyphenols in the wine, which have antioxidant properties; this effect is limited to 
red wine only. In a summary paper on rectal cancer risk in Canada28 physical inactivity, energy 
intake and obesity were all shown to contribute to increased cancer risk and all had an additive 
effect.  
1.1.2.2 Genetic risks 
Although most people who are diagnosed with CRC do not have an inherited risk ~30 % have 
an inherited risk of CRC29. There are two clusters of hereditary CRC risk; well characterised 
familial syndromes (summarised in table 1), where the patient has inherited genetic mutations 
that lead to high risk of CRC (approximately 5 %30), and the remaining 20 - 25 % is caused by 
less penetrant (recessive) but more commonly inherited polymorphisms.  
The majority of the syndromic cases are HNPCC (hereditary nonpolyposis colorectal cancer, 
also known as Lynch syndrome, 2-4 % of all CRCs30) which is marked by a reduced number of 
polyps compared to other syndromes, mutations in mismatch repair genes and therefore a high 
level of MSI30. Familial adenomatous polyposis (FAP) and MYH-associated polyposis (MAP) 
also produce adenomatous polyps and have mutations in APC and MYH respectively31. 
Adenomatous polyps are epithelial polyps that arise from glands in the mucosa of the intestine 
and are the precursors to malignant adenocarcinoma. Hamartomatous (benign, tumour-like) 
polyps are present in other inherited syndromes such as Peutz-Jeghers Syndrome (PJS) and 
Juvenile Polyposis Syndrome (JPS) which consist of a disorganised mass of cells. These cells 
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grow at the same rate as the normal cells and so are usually benign with a low potential for 
malignancy. Autosomal dominant syndromes include FAP, HNPCC, PJS and JPS. MAP is the 
only recessive inherited disorder30.  
1. Table 1. Features of inherited CRC syndromes. Adapted from Migliore et al, Jasperson et al 
and Fearon29-31. 
Syndrome Genes involved 
Lifetime 
cancer risk 
Features 
HNPCC 
(Lynch 
Syndrome) 
hMLH1, hMSH2, 
hMSH6, hPMS2, 
EpCAM 
50-80 % 
Reduced polyposis. Right-sided cancers with 
prevalence of MSI. Other cancers include 
endometrial, stomach and ovarian. 
FAP APC 100 % 
Multiple polyps (>100) and adenomas. Average age 
of CRC diagnosis is 39 if untreated. Gastric polyps 
in 50 % and some stomach adenomas. 
MAP MYH 80 % 
Phenotype similar to but less severe than FAP and 
with hyperplastic polyps. Predisposition to duodenal 
adenomas. Autosomal recessive. 
PJS STK11 39 % 
Small bowel hamartomatous polyps, (>90 % lifetime 
risk). Mucocutaneous pigmentation (e.g. lips, buccal 
mucosa and periorbital area). 
JPS 
SMAD4, 
BMPR1A, 
39% 
Rare, early-onset. Multiple hamartomatous and 
juvenile polyps in colon and stomach. Congenital 
defects in 15 % of cases.  
 
Other than the inherited syndromes, people who have a first-degree relative with rectal cancer 
have approximately twice the average risk30. This risk is associated with common inherited 
alterations called single nucleotide polymorphisms (SNPs) that have been identified either 
through focussing on candidate genes linked to CRC development (e.g. APC and VEGF) or 
through genome-wide association studies (GWAS) to identify susceptibility genes. The GWAS 
have identified susceptibility loci mapping to at least fourteen different locations32 of which six 
are close to three members of the bone morphogenetic protein (BMP) pathway, a signal 
transduction pathway that acts to prevent CRC initiation33. These SNPs independently 
predispose people to CRC and as they are common in the population, but have low penetrance, 
they explain the remaining ~20-25 % inherited risk of CRC.  
1.1.2.3 Bowel disease risks 
Patients with chronic inflammatory conditions, such as long-standing inflammation of the bowel 
(IBD), ulcerative colitis (UC) or Crohn’s disease, are at an increased risk of developing CRC over 
their lifetimes34. Persistent inflammation of the bowel lining can cause dysplasia which leads to 
cancer. During this chronic inflammation, cell proliferation is enhanced to promote healing. 
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However, the inflammatory cells present release reactive oxygen species (ROS) to target the 
proliferating cells (normally to fight infections) leading to oxidative stress which induces DNA 
damage35. Prolonged inflammation and stress can result in permanent DNA damage, often 
consisting of mutations in TP53, and selection of cells that have a survival or growth advantage. 
Once TP53 mutation has occurred, the cell cycle becomes dysregulated and proliferation 
enhanced leading to an accumulation of other genetic defects and progression to cancer36. 
Tumours arising in patients with IBD are similar to sporadic cancers but they deviate in the 
order of acquired mutations that lead to CRC36. Sporadic tumours start with mutation of APC, 
followed by mutations in either KRAS or BRAF, and eventually TP53 (discussed in chapter 1.2). 
However, in cancers resulting from inflamed regions, TP53 gene mutations occur as an initial 
event; in biopsy samples LOH was detected in 6 % of samples without dysplasia, 9 % with 
indefinite dysplasia, 33 % with low-grade dysplasia, 63 % with high-grade dysplasia and 85 % 
with cancer36. APC mutation is known to be a late event because changes in this gene are rarely 
detected in colitic mucosa as mutations or loss of APC occurs in less than 6 % of tumours37 38. 
Genetic testing is used for high-risk groups that are recommended for increased surveillance and 
these include patients with a family history of adenomas or CRC, with any form of long-lasting 
IBD and patients with a known inherited syndrome. The screening for genetic abnormalities 
includes testing for CIN, MSI and CIMP and other underlying germline mutations. This is 
practical for the high-risk patients but there is little use for this type of screen on a population 
basis; it is time-consuming, expensive and unreliable if samples are sent by post.  
1.1.3 Screening 
In the UK there is a national bowel cancer screening programme in place through the NHS that 
offers screening every two years for people between 60 and 69. The programme aims to check 
for cancer, polyps and nonpolyploid lesions that could develop into cancer. Screening for CRC 
achieves early diagnosis which greatly enhances survival rates; early stage cancers have 90 % 5-
year survival rate compared to late-stage cancers (6.6 % 5 year survival)5.  
Several types of test are used to screen for CRC and are split into two categories; non-invasive 
test and invasive tests. Non-invasive tests include faecal occult blood testing (FOBT) and faecal 
DNA testing. The second category uses more invasive methods to detect cancer and advanced 
lesions; proctosigmoidoscopy, colonoscopy, double-contrast Barium enema with X-ray, 
computed tomography colonography (CTC) and genetic testing. 
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1.1.3.1 Non-invasive screening 
gFOBT (guaiac-based FOBT) is an ‘oxidative conversion of a colourless compound into a 
coloured one in the presence of pseudoperoxidase activity of haemoglobin’39. It tests multiple 
samples of faeces for the presence of blood that should indicate the presence of a tumour. A 
Cochrane review of 4 randomised controlled trials showed that the benefit of gFOBT screening 
is that it can reduce the relative risk of CRC mortality by 16 %; however, it also suggests that 
over 80 % of positive tests were false40. False-positives can result from dietary components (e.g. 
red meat, radishes) or from other medical conditions such as stomach ulcers or haemorrhoids. 
The psychological consequences of a false-positive result on the patient and the possible negative 
effects of further investigations are obviously undesirable. gFOBT has a very low sensitivity for 
advanced adenomas and it has been shown to have low uptake with patients who are offered 
screening by this method40. Currently new methods are being developed to address these issues. 
However, the major advantages of this test include safety, low costs and easily accessible stool 
samples so it can be used in countries without sufficient funds for a more sensitive or invasive 
test.  
A more recent development of the gFOBT test is the faecal immunochemical test (FIT or 
iFOBT) that detects the presence of haemoglobin in faeces using antibodies.  This method is less 
affected by dietary or other components in the stool due to the specificity of the antibodies to 
human haemoglobin41. From the results, an estimate can be made of the concentration of 
haemoglobin in the sample to give a quantitative outcome, which cannot be determined from 
gFOBT. Furthermore, analysis of multiple iFOBT results can determine a cut-off concentration; 
decreasing the cut-off increases sensitivity and increasing the cut-off increases specificity42. This 
test only requires two stool samples and so results in an increased sensitivity compared to 
gFOBT but the disadvantages are that the samples are unstable at ambient temperature so can 
deteriorate and iFOBT is more expensive42. As it is a relatively recent test, there is no data as yet 
on the effect on mortality or on the advised frequency of testing and all positive results are 
recommended for further investigation with colonoscopy.  
Faecal DNA testing examines the stool for genetic abnormalities in sloughed off cells that could 
have come from a colorectal cancer or adenoma. This is an emerging tool as more genetic 
markers are constantly being discovered and developed. The technique detects mutations in the 
cells of an adenoma that are mixed with stool as it passes and these cells can be isolated and 
analysed for mutations that could indicate the presence of a cancer or pre-cancerous lesion42. 
The sensitivity of faecal DNA testing depends on the number and type of DNA markers used 
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and on the method of extraction of DNA. A recent review suggests that detection sensitivity can 
range from 46 to 94 % using a single marker and from 71 to 91 % using a combination of 
markers43. The same review found that detection rates increase with adenoma size; 63 % detected 
tumours less than 1 cm, 78 % of tumours 2 cm or more and 90 % of tumours detected of 3 cm 
or more. This is important because of the relationship between increasing adenoma size and 
progression to cancer. Faecal DNA testing is thought to be more sensitive for precursor lesions 
and early adenomas than FOBT44, but as there are many possible genetic markers of cancer and 
adenomas, it is difficult to select an absolute panel of markers that would detect every lesion in 
every patient. Faecal DNA tests are much more expensive to carry out than FOBTs and there is 
a need to have standardised markers in order for their efficacy to be comprehensively studied. 
1.1.3.2 Invasive screening 
Of the more invasive methods of screening patients for CRC and adenomas, 
proctosigmoidoscopy and colonoscopy is the next step in diagnosis if the patient has had a 
positive FOBT or DNA test. Both of these procedures involve inspection of the intestine for 
abnormalities or signs of cancer and are used because ~75 % of CRCs are seen in the lower 
portion of the intestine; the rectum or the sigmoid colon45. Proctosigmoidoscopy is a procedure 
where a short sigmoidoscope (60 cm) is inserted into the rectum to view any rectal abnormalities 
and take biopsies for pathologic diagnosis. Proctosigmoidoscopy screening has been shown to 
result in a 70-80 % reduction in mortality from CRC39. One study46 showed that in addition to a 
reduction in mortality, this screen reduced the incidence of CRC by 33 %. They also found that 
to prevent one death from CRC only 489 people needed to be screened46. A colonoscopy uses an 
endoscope to view the whole of the inside of the large bowel, but in addition to detecting lesions 
and cancers in the rectum and sigmoid colon, it also detects abnormalities in the ascending and 
transverse colon. The current screening system in the UK consists of a FOBT with follow up 
investigation of colonoscopy if the FOBT is positive. Currently, a screening programme using 
flexible sigmoidoscopy is being discussed and will be introduced on a national scale in the future. 
Colonoscopy is more sensitive than proctosigmoidoscopy in detecting both adenomas and 
carcinomas and an American study found that the mortality rate decreased 3 % for every 1 % 
increase in colonoscopy use47. A trial in the UK found adenomas in 12 % of patients and cancer 
in 0.3 %; however, there was no evidence to suggest that there was a concurrent reduction in 
mortality using a sigmoidoscope for CRC screening45. However, the disadvantages of 
colonoscopy are that it is expensive, invasive and there are small risks associated with the 
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procedure, such as bleeding and bowel perforation, which although low reduce the appeal of this 
screening method on a population-wide basis. 
1.1.3.3 Imaging procedures 
A double-contrast barium enema is used to visualise the inside of the bowel without using a 
sigmoidoscope or colonoscope. It used a liquid, flushed into the bowel to coat the mucosal 
surface with barium that can be seen using an x-ray. Multiple images are made whilst changing 
the patient’s position in order to reveal the whole bowel. The x-ray shows any swellings, polyps 
or cancerous protrusions that may be malignant or pre-malignant tumours. This technique is 
used because it is relatively inexpensive and safer than more invasive techniques, however, the 
effectiveness is not well documented other than a study showing that there is a one in five 
chance that a tumour will be missed48. Barium enemas are no longer as popular as they once 
were but are useful in countries where widespread colonoscopy or CT scans are impractical or 
too expensive.  
Computed tomographic colonoscopy (CTC) is a minimally invasive test that permits structural 
evaluation of the colorectum. CTC shows lesions in the colon and rectum by reconstructing a 
two- or three-dimensional image from two or more scans. Its sensitivity is comparable to a 
colonoscopy for large lesions (>10 mm) but reduced for detecting small or flat adenomas. In a 
meta-analysis for the detection of large polyps only, sensitivity was 93 % and specificity 97 %, 
but this decreased when medium and small polyps were included to 45-97 % sensitivity and 26-
97 % specificity49. This range indicates that CTC is a viable tool to detect large and medium 
polyps but too variable to accurately detect small polyps. The advantages of this technique 
include its safety; there is a low risk of complications because the procedure is minimally 
invasive. With advances in technology, reduction in cost and computerised cancer detection 
software, this technique may ultimately become more generally accepted as the primary screening 
model. However, this procedure requires adequate preparation of the bowel in advance and the 
radiation exposures from repeated screening and re-screening are not yet quantified49. 
Of these screening methods, FOBT has been shown to significantly reduce CRC mortality and 
morbidity rates and is very cost-effective; however, there are unwanted side-effects that 
colonoscopy and other imaging tests have attempted to overcome with little success. DNA 
testing and non-invasive imaging is still a new technique and with better technology, better 
results will surely emerge.  
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1.1.4 Staging 
Once cancer or a pre-cancerous lesion has been identified, a patient’s lesion is investigated 
further to determine the stage of the tumour. The Tumour, Node and Metastasis (TNM) staging 
system for CRC denotes depth and extent of tumour invasion through the wall of the intestine 
(T), involvement of regional and distal lymph nodes (N) and presence or absence of local or 
distant metastasis (M). The staging of CRC is an estimate of the amount of invasion and spread 
of the cancer as determined by histopathological examination of the resected tumour or biopsy 
and by clinical examination of the patient. Accurate staging is necessary for patient diagnosis and 
aids appropriate choice of therapy and timing of surgery.  
There are three staging systems for colon and rectal cancer; TNM staging for solid tumours, 
overall stage grouping (Stage I to IV) and Dukes’ stage (originally devised for rectal cancers but 
now used for all colonic and rectal tumours).  
TNM staging is used as the standard staging system for a number of different tumour types as it 
gives greater precision for identification of type of tumour. The American Joint Committee on 
Cancer (2006)50 gives TNM definitions as the following: T0-4 as T0: no evidence of primary 
tumour, T1: the tumour invades the submucosa, T2: invasion into the muscularis propria, T3: 
further invasion of the tumour through the muscularis propria into the subserosa or into 
nonperitonealised pericolic or perirectal tissue, and T4: the most invasive tumour stage, is the 
stage at which the tumour “directly invades other organs or structures and/or perforates visceral 
peritoneum”. N0-2 corresponds to the amount of nodal involvement with N0 having no 
involvement, N1 involving of one to three local lymph nodes and N2 where the tumour spreads 
to distant or multiple local lymph nodes. M0 or 1 dictates the presence and degree of metastasis, 
with M0 indicating no metastasis and M1 showing distant metastasis. This system ensures that 
staging is a reliable and constant marker of disease progression and prognosis across multiple 
types of cancer. 
Clinical staging occurs after physical or radiologic examination, but before surgery. This stage is 
denoted with a lower case ‘c’ before the tumour stage (i.e. cT2N0). After surgery, a pathological 
examination of the resected specimen occurs and additional information about the stage of the 
cancer is recorded. Pathological examination reveals more information about the amount of 
invasion and involvement of lymph nodes than clinical examination and is denoted with a lower 
case ‘p’ before the stage (i.e. pT2N1M0). Clinical stage determines the most appropriate type of 
treatment for the stage of tumour but the stage may be altered post-therapy due to tumour 
regression. 
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Overall staging describes the progression of a cancer as one of four stages. This is given after the 
TNM stage is assigned and determines the appropriate type of treatment and follow up for the 
patient (table 2). Stages I, II and III indicate more extensive disease with progressively worse 
prognosis (increasing tumour size, nodal involvement and tumour invasion of local organs) and 
Stage IV indicates that the cancer has metastasised51. 
2. Table 2. Description of overall staging system of colorectal cancer in relation to TNM 
staging6 
Stage Description TNM status 
I Caner in inner lining of bowel T1-2, N0, M0 
II Cancer invasion of local organs, no lymph node involvement T3-4, N0, M0 
III Cancer spread to Lymph nodes T1-4, N1-2, M0 
IV Cancer metastasised to distant organs T1-4, N1-2, M1 
 
The TNM staging system is a uniform tumour classification for multiple types of cancer but 
initially the system devised for CRC, and more generally used, was Dukes’ stage52. This method 
was devised by CE Dukes, published in 1932, and consists of four stages relating to the extent 
and progression to the colorectal tumour; Dukes’ A, B and C. A further Dukes’ stage, Dukes’ D, 
was added at a later date but it is not widely used and is more commonly known instead as Stage 
IV or advanced disease. Dukes’ A corresponds to penetration of the tumour into the submucosa; 
Dukes’ B, tumour penetrates through muscularis propria; Dukes’ C1, tumour penetrates 
muscularis propria and has lymph node involvement; Dukes’ C2, penetration into and through 
muscularis propria and has lymph node involvement; Dukes’ D, tumour spread distally, past 
lymph nodes. Dukes’ stages A-D closely relates to overall Stage I-IV and both relate to survival 
data (table 3).  
3. Table 3. The survival and incidence of CRC in relation to Stage5 
Overall Stage Dukes’ Stage 
Survival post surgery 
(5 years) 
Number diagnosed 
(% of total diagnosed) 
Stage I Dukes’ A 90 % 10 % 
Stage II Dukes’ B 77 % 24 % 
Stage III Dukes’ C 48 % 24 % 
Stage IV Dukes’ D 6 % 9 % (33 % unknown) 
 
There have been many reviews on the best model to stratify carcinomas but the most widely 
used and most comprehensive is the TNM staging system. The stage determines the patient 
outcome, survival, treatment regimes and time of surgery and is therefore an important factor to 
ascertain correctly. 
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1.1.5 Therapy 
Standard therapy for CRC is dependent upon stage. At Stage I, the cancer has not spread 
through the wall of the bowel so is easy to remove with immediate surgery and there is a low 
possibility that any cancerous cells will be left behind. Stage II and Stage III, however, are 
sometimes treated with some form of therapy prior to (preoperative) or after surgery 
(postoperative). Therapy has the aim of either shrinking the tumour rendering it more easily 
removable by surgery and/or reducing the possibility of post-surgery local recurrence. Cancer 
defined as Stage IV has spread to distant organs so treatment for this stage has more palliative 
than curative intent. Palliative treatment can include chemoradiotherapy (CRT) and surgery with 
the aim of improving quality of life by relieving pain, aiding normal function of the bowel and 
avoiding long-term complications.  
There are currently two different types of treatment therapy: chemotherapy and radiotherapy, 
however, radiotherapy is not used on colon cancer.. For rectal cancer therapy is provided 
depending upon tumour stage, according to NICE guidance in the UK53. Radiotherapy is used to 
shrink the tumour to make it easier to operate on, to allow clear resection margins and to reduce 
the risk of recurrence. Clear resection margins may be difficult to achieve without radiotherapy 
for locally advanced rectal cancer because of the low location of the rectum in the pelvis. 
Chemotherapy for rectal cancer is used either concurrently to radiotherapy to sensitise the cells 
depending upon stage of cancer, or post-surgery to reduce the risk of cancer recurrence.  
1.1.5.1 Chemotherapy 
Chemotherapy is the administration (orally or intravenously) of a drug that inhibits growth of a 
tumour by affecting the rapidly dividing cancer cells. The drugs can kill the cells by causing them 
to apoptose (programmed cell death). There are eight agents licensed in the US and Europe for 
use in the treatment of CRC: 5-Fluorouracil, Floxuridine, Capecitabine, Irinotecan, Oxaliplatin, 
Cetuximab, Panitumumab, and Bevacizumab54. The outcome results of trials that test these drugs 
include overall survival (OS), disease-free survival (DFS), rate of recurrence, toxicity and curative 
resection status, all post-operatively. 
Fluoropyrimidines 
5-FU has been the mainstay of treatment for CRC chemotherapy since its introduction in 195755. 
It is a fluorinated pyrimidine administered intravenously which acts by inhibiting thymidylate 
synthase and in turn prevents pyrimidine nucleotide synthesis. This reaction is an important step 
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in DNA replication and if inhibited leads to disturbances in the cell’s ability to synthesis DNA 
which causes cell cycle arrest and apoptosis. 5-FU is most often administered alongside 
Leucovorin (LV), also known as Folinic acid, because it stabilises 5-FU’s interaction with 
thymidylate synthase. Other variants of 5-FU are available, e.g. FUDR and Capecitabine. FUDR, 
also known as floxuridine, is an intravenously administered analogue of 5-FU that is broken 
down in the liver into its active form and has primarily been used in the treatment and palliative 
care of liver metastases from CRC. Capecitabine is an orally administered alternative and is 
converted into 5-FU where the concentration of thymidine phosphorylase is high. This 
phosphorylase is upregulated in tumours after irradiation giving Capecitabine selective 
conversion to 5-FU in tumours. 
LV with 5-FU has been shown to improve OS and tumour response rate when compared to 5-
FU alone in the treatment of advanced CRC56. FUDR has been shown to reduce occurrences of 
liver metastases and increase DFS in stage III CRC when delivered preoperatively in 
combination with another drug, Oxaliplatin57, however, randomised studies comparing hepatic 
infusion of FUDR to surgery alone do not report significant survival differences58. Capecitabine 
has been shown to have increased activity and efficacy in tumours following irradiation with 
subsequent tumour regression59. 5-FU agents including Capecitabine are regularly used due to 
their low toxicity, safety, patient tolerance and ability to downstage tumours and lymph nodes 
prior to surgery, therefore enabling more curative resections60.  
Recently there has been some debate as to the significance of MSI CRC and the effect of 5-FU-
based therapy. Initially a report found that stage III MSI CRCs had a better prognosis with 5-FU 
chemotherapy. However, although more studies have since been published, the survival benefit 
of 5-FU-based therapy in MSI CRCs has yet to reach significance and some evidence is 
contradictory; one study has found a worse survival in MSI CRC patients61. 
Oxaliplatin 
Oxaliplatin is a platinum agent that leads to impaired DNA replication and apoptosis of cancer 
cells. It has been shown to increase DFS and improve OS when added to 5-FU and LV and is 
used as a radiosensitising agent62. Oxaliplatin is known to have a synergistic effect when added to 
pyrimidines (e.g. 5-FU). This drug increases the rate of complete pathological response and is a 
well-tolerated drug with low toxicity63. Oxaliplatin, infusional 5-FU and LV is known as 
FOLFOX and, when given to colon cancer patients in an adjuvant setting, resulted in a 
significant (23 %) improvement of DFS compared to 5-FU and LV alone64. The Roche 
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NO16968 trial compared treatment groups who received Capecitabine plus Oxaliplatin (together 
known as XELOX) with groups who received 5-FU and LV. They reported a significant 
improvement in 3-year DFS with XELOX which corresponded to a 20% relative risk 
reduction65. 
Irinotecan 
As an inhibitor of topoisomerase I, Irinotecan is a drug that disrupts DNA replication and has 
been used in addition to 5-FU since its introduction in the 1990s. Topoisomerase I is an enzyme 
that catalyses breakage and reattachment of DNA strands during DNA replication and by 
inhibiting this enzyme breaks in DNA result which leads to cell death. Randomised trials on 
Irinotecan and 5-FU with LV in colon cancer have returned disappointing results; of three 
studies, one reported it did not improve DFS or OS, another reported no significant three-year 
difference in survival and the last study reported poorer three-year DFS in patients who received 
Irinotecan62. Irinotecan also has variable toxicity with patients who have a UGT1A1 genotype. 
These patients have lower than normal capacity to clear Irinotecan from their system and so this 
results in significantly higher toxicity66.  
Targeted therapies 
Monoclonal antibodies are targeted therapies used as anti-cancer drugs to target directly the 
cancer cells and either stimulate the body’s immune system to destroy the cancer cells or prevent 
tumour growth by blocking specific cell receptors. Cetuximab, Panitumumab and Bevacizumab 
are all monoclonal antibodies and are usually given in combination with other chemotherapy 
drugs. Cetuximab and Panitumumab are inhibitors of epidermal growth factor receptor (EGFR), 
which is a receptor involved in signalling pathways for cell proliferation, growth and cell death. 
EGFR is overexpressed in CRC (up to 80 % of tumours) and is associated with poorer 
prognosis62. For cetuximab to be effective the tumour cells need to express wild-type KRAS and 
genetic testing is now a routine procedure before the administration of Cetuximab. Cetuximab 
has been shown to improve the activity of other chemotherapeutic agents, but tumours with 
mutated KRAS are resistant to its effects67. Cetuximab, when used in combination with 
Irinotecan, results in a synergistic effect; patients treated with both had a 22.9 % response rate 
compared to 10.8 % with Cetuximab alone and survival time was marginally increased with the 
combination therapy68. Panitumumab is a fully human antibody and so is generally associated 
with fewer immune complications than Cetuximab (approximately one-third murine)69. 
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Panitumumab has activity against EGFR and the response rate of 9 % is similar to that of 
Cetuximab70.  
Bevacizumab is an antibody that is inhibitory for vascular endothelial growth factor (VEGF). 
VEGF is a protein that stimulates new blood vessel formation; angiogenesis. In tumours 
angiogenesis is important for the cells as it provides new vessels to deliver oxygen and nutrient 
supplies needed for growth and angiogenesis enables tumour cells to move to other parts of the 
body (metastasis). Inhibition of VEGF serves to prevent proliferation of the tumour and to 
control its spread. Restoring the tumour vasculature to normal can also improve delivery of 
drugs to the tumour. The addition of Bevacizumab to a combination of Oxaliplatin, 5-FU and 
Leucovorin (FOLFOX4) has been shown to significantly increase overall response rates and 
increase progression-free survival when compared to FOLFOX4 or Bevacizumab alone71.  
Combined therapy 
Combination therapies have been extensively reviewed with significant advantages for most 
different combinations, but it is unclear as to which combination is the most effective. The 
optimal mixture and timing of chemotherapeutic drugs may depend upon the stage of the 
disease, molecular profile of the tumour (CIN/MSI/CIMP) and any other underlying conditions 
such as IBD. The combination regimes approved by the Food and Drug Administration include 
IFL (Irinotecan, oral 5-FU and Leucovorin), FOLFIRI (Irinotecan, infused 5-FU and 
Leucovorin), FOLFOX (Oxaliplatin, infused 5-FU and Leucovorin), 5-FU and Bevacizumab, 
and Cetuximab and Irinotecan (for Irinotecan-refractory disease)58. FOLFOX is one of the most 
promising combinations with significant results for rate of response, time to progression and OS 
when compared to IFL and IROX (Irinotecan and Oxaliplatin)72.  
1.1.5.2 Timing of chemotherapy 
Whether preoperative or postoperative, the timing of chemotherapy is an essential management 
strategy. Due to the location of rectal cancers, chemotherapy is used, most often in combination 
with radiotherapy, to reduce the risk of recurrence and to sensitise the tumour to radiation. 
There are a few considerations that are specific for rectal cancer and all are dependent upon the 
Stage; what type of radiation should be used, whether postoperative chemotherapy is necessary 
for all patients and if surgery should be altered depending on the response of the tumour to 
therapy. 
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Preoperative 
The benefits of giving patients chemotherapy preoperatively are that it can downstage the 
tumour rendering it more easily resectable, it is less toxic than postoperative therapy and the 
patient is more likely to complete the course73. The disadvantages are that the type of 
chemotherapy given is entirely dependent on the Stage of the tumour and this can lead to over-
treatment of early Stage tumours and undesirable side-effects that could have been avoided if the 
tumour had been accurately staged. There are some patients, those with Stage I disease, who do 
not need preoperative therapy and can have surgery straight away. Stage IV disease requires 
preoperative therapy in order to render the tumour resectable at surgery. However, there is a 
debate about the best preoperative treatment for Stage II and III because tumours are not all 
node positive, have very different predicted CRM status and may not all need chemotherapy. A 
recent review advises on chemotherapy regimens for Stage II and III; preoperative 
chemotherapy should be offered to Stage II patients with a close CRM, and in Stage III patients 
‘should be offered CRT because chemotherapy reduces the risk of local recurrence in 
conjunction with the administration of radiotherapy’73. 
Postoperative 
Postoperative chemotherapy showed no difference in DFS or OS when compared to 
preoperative treatment but preoperative therapy was shown to be less toxic and improved local 
control74. However, colon cancer patients often receive postoperative treatment and this may be 
an incentive to add postoperative therapy to rectal cancer treatment with late Stage disease. 
Many questions still remain about the timing of different types of therapy in rectal cancers, but 
the overall consensus is that preoperative therapy is much less harmful and can reduce the risk of 
local recurrence. 
1.1.5.3 Chemo-resistance 
Tumour resistance to chemotherapy is a serious limitation when using chemotherapeutic agents. 
Investigations are underway to research the mechanisms of resistance to 5-FU and to find 
biomarkers to predict tumour response. One study showed that APRIL mRNA, a cell survival 
and proliferation mRNA, was a putative predictive biomarker in CRC chemo-resistance54. 
APRIL was upregulated in tumours that had received chemoradiotherapy and in a 5-FU-resistant 
cell line, but not in tumours that received radiotherapy alone. Drugs are often used in 
combination to increase sensitivity of a tumour that is partially resistant to certain treatments, or 
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to reverse resistance; Cetuximab-based therapy demonstrated a response in patients who had 
previously had irinotecan-resistant disease75.  
1.1.5.4 Radiotherapy 
In rectal cancer, as stated before, radiotherapy is used in conjunction with chemotherapy to 
produce lower incidences of cancer recurrence and to downstage tumours76. Rectal cancer is 
lower in the pelvis and more difficult to remove by surgery so the addition of radiotherapy 
before surgery allows more curative resections. Radiotherapy is the administration of ionising 
radiation delivered specifically to a tumour, avoiding the surrounding healthy tissue in order to 
disrupt the cell’s DNA and cause apoptosis. Recent advances include more targeted beams of 
radiation and a reduction in the amount of adjacent tissue included. There are two methods of 
administration of radiotherapy; short-course and long-course regimes. Short-course radiation 
therapy (SCRT) consists of five doses of 5 Gy in one week (Gy is the unit of absorbed radiation) 
with surgery the following week. Long-course radiation therapy (LCRT) consists of 45-50 Gy in 
total, split into 25-33 doses of 1.8 or 2 Gy spread over one month with surgery scheduled 4-8 
weeks post-therapy. SCRT is the method most commonly used and therefore the most 
extensively studied77-80. 
SCRT, when prescribed to rectal cancer patients prior to surgery in the Swedish Rectal Cancer 
Trial, resulted in a local recurrence rate of 11 %, lower than the group who had surgery alone (27 
%), and improved OS77. Another trial, the Dutch Colorectal Cancer Group, reported similar 
observations in CRC patients with local recurrence rates of 2.4 % in patients who received 
radiotherapy plus surgery compared to 8.2 % in the surgery-only group, but they did not show 
any significant difference in OS of the two groups78. Despite non-significant reported OS, the 
evidence is clear that there is a significant improvement in local recurrence rates with the 
addition of radiotherapy for Stage II and III CRC. 
There are currently no randomised clinical trials that have published long-term data comparing 
SCRT to LCRT in rectal cancer, but a systematic review of the literature showed that both 
methods of administering radiation for lower rectal cancer are as effective as each other in terms 
of OS, recurrence and toxicity79. One randomised trial currently in progress, the Stockholm III 
trial, allocated patients with rectal cancer to either SCRT plus surgery within one week, SCRT 
plus surgery after 4-8 weeks or LCRT plus surgery after 4-8 weeks81. This study has shown, so 
far, that there are no significant differences in postoperative complications or toxicity between 
groups, but SCRT plus immediate surgery had the highest complication rate.  
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1.1.5.5 Timing of radiotherapy 
A report on the timing of administration of radiotherapy in CRC has shown that preoperative 
radiotherapy can reduce local recurrence compared to postoperative radiotherapy, with a longer 
time to surgery and concurrent chemotherapy resulting in greater downstaging. However, the 
difference in survival between the two groups is minimal82. The same effect has been seen when 
comparing preoperative CRT to either preoperative radiotherapy or chemotherapy alone where 
there is no difference in OS74 83.  
Meta-analyses have been conducted on the available published literature on radiation for CRC 
and most conclude that there are lower recurrence rates with preoperative radiation. The 
Colorectal Cancer Collaborative Group compared data of 8507 CRC patients from 22 
randomised trials allocated to preoperative radiotherapy, postoperative radiotherapy or no 
radiotherapy and found a marginal difference in OS but reduced risk of local recurrence in the 
radiotherapy group compared to surgery alone. The authors found that postoperative 
radiotherapy reduces recurrence but not as effectively as preoperative radiotherapy84.  
In comparing the timing of surgery, it has been suggested that due to the reasonable  percentage 
(15-30 %85) of patients with pCR (pathological complete response) after therapy (mostly with 
early stage tumours), a non-surgical treatment may be all that is needed; a “wait and see” 
approach86. The advantages of this are the avoidance of surgery and associated morbidity and 
mortality. This method was feasible, with strict selection criteria and advanced imaging, for 20 
patients in a study in the Netherlands who all showed cCR after CRT and stayed disease-free 
after a mean follow-up time of 25 months87. The same was true for a larger study of 71 patients 
with stage II rectal cancers who were closely followed up after CRT, instead of surgery88. The 
results showed that only 5 % of patients had local recurrence, but these were all recoverable by 
surgery88. However, 23 patients who experienced local recurrence were excluded from this study, 
which would have altered the data. Despite these successes, this approach is difficult to apply 
generally because of the different stages of cancer, the difference in radiation techniques and the 
challenge in identifying those patients who would be suitable for this approach89. The “wait and 
see” policy may become more widespread with advances in chemotherapeutic agents and 
radiotherapy in the future.  
1.1.5.6 Radio-resistance 
The mechanisms of resistance to radiotherapy are multiple; the tumour is too hypoxic, has 
inherent cell resistance (potentially a high proportion of more resistant cancer stem cells) or has 
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repopulation after therapy. The amount of oxygen present in the tumour is directly correlated 
with radiotherapy response and currently anti-angiogenic drugs are used to normalise the 
vasculature to increase oxygen delivery and the ability of chemotherapy to reach the tumour 
cells, thus increasing radiation sensitivity90. If the tumour has a population of cells that still have 
intact DNA repair pathways and an increased level of ROS scavengers, they may be able to 
survive the radiation in a similar way to normal cells. Cancer stem cells can repopulate the 
tumour between therapy and surgery, and can recover quickly between radiation treatments 
therefore reducing the sensitivity to radiation91. Repopulation of the tumour after therapy may be 
due to a combination of the previous mechanisms and will contribute to overall resistance of the 
tumour. 
1.1.5.7 Chemoradiotherapy 
A combination of chemotherapy and radiotherapy (CRT) has become more popular in the last 
ten years. In CRC, CRT has been shown to increase pathological complete response (pCR) and 
decrease rates of local recurrence when compared to each therapy alone. However, radiotherapy 
is not generally used in colon cancers and therefore the following information regards patients 
with rectal cancer receiving CRT.  
A recent clinical trial has compared different regimes of CRT before and after surgery for rectal 
cancer with the groups as follows; preoperative radiotherapy, preoperative CRT, preoperative 
radiotherapy plus postoperative chemotherapy, and finally, preoperative CRT plus postoperative 
chemotherapy. The authors reported no difference in OS of DFS over a period of 5 years but a 
significantly higher incidence of local recurrence in the group receiving preoperative radiotherapy 
alone (17.1 %) compared to all three other groups (8.7 %, 9.6 % and 7.6 % respectively)92.  
For locally advanced rectal cancer (Stage II and III) it has been reported that preoperative CRT 
compared much more favourably to postoperative CRT with reduced toxicity and greatly 
reduced incidence of local recurrence74. Preoperative versus postoperative CRT has been 
investigated by another group who found that patients had reduced residual disease in 
preoperative CRT, but no difference in OS, DFS or numbers of complete curative resections 
between the groups93. 
In summary, preoperative CRT is the best available treatment for patients with rectal cancer. 
Preoperative CRT results in reduced recurrence rates, lower toxicity and has greater adherence to 
the regime. 
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1.1.6 Rectal cancer surgery 
Surgery for rectal cancer is conducted in nearly all cases of local disease. Resection has to be 
completed leaving clear (free of tumour) resection margins, removing local vasculature and 
performing a lymphadenectomy (removal of lymph nodes to pathologically diagnose stage of 
cancer). Resection margins are significantly associated with local recurrence; R0 resections 
(complete resection; no evidence of residual microscopic cancer) have low recurrence rates and 
R1-2 (incomplete resection; microscopic or macroscopic cancer remaining) produce high rates of 
local and distal recurrence94. In the past, resection margins have been recommended to be more 
than 5 cm at the distal margin, but subsequent research has shown that reducing this to a margin 
of 2 cm does not compromise incidence of local recurrence or survival95. A positive CRM occurs 
when tumour tissue has infiltrated through the walls of the bowel and tumour cells or a positive 
lymph node are found more than 1 mm from the non-peritonealised (not within the abdominal 
cavity) soft tissue edge95. With the addition of CRT, resection margins are reduced with 
concurrent down-staging of tumours from preoperative therapy. A positive CRM is an important 
predictive marker for recurrence in patients with rectal cancer and is most often found in 
patients with a higher stage disease.  
Curative resection (R0) for rectal cancer surgery began with Miles’ description of abdomino-
perineal excision (APE) in 190896, whereby the mass of the rectum is removed en bloc, including 
the lymphatic vessels and mesorectum, by a joint abdominal and perineal approach. This 
approach reduced the recurrence rate from 95 % to 29.5 % in patients in the study who received 
this operation97. The main disadvantage of this procedure was that it invariably included a 
permanent colostomy (a surgically constructed connection between the colon and the external 
abdominal wall to allow the removal of faecal waste). Balfour described one of the first 
sphincter-preserving surgical techniques for mid to high rectal cancers: a ‘pull-through’ 
technique where the distal colon was sutured to the inner anal canal98. This initially resulted in 
high mortality rates due to leakage at the suture site, but improvements were made and the safety 
of the procedure established by Dixon in 1948, reporting a mortality of 2.6 %97. 
In patients with low rectal cancers, sphincter-preserving resection is much more challenging than 
for high or mid rectal cancers but it is attempted to improve the patients’ postoperative quality of 
life. Sphincter preservation was made possible with the introduction of a technique that connects 
the two parts of the bowel together: anastomosis. The instruments used to perform this 
operation have become advanced in recent decades with the invention of mechanical circular 
stapling devices that restore the continuity of the bowel and lead to better functional outcomes 
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and quality of life99. These devices have increased the possibilities of sphincter preserving surgery 
even for cancers in the distal rectum and anal canal and have reduced the risk of anastomotic 
leakage100. 
Total mesorectal excision (TME) is currently the treatment of choice as it removes the part of 
the rectum containing the cancer along with the mesorectal tissue (a fold of the peritoneum that 
supports the rectum). TME is associated with a significantly reduced risk of local recurrence 
(from 12-20 % before TME to 4 % after its invention)97 and the degree of postoperative 
function is associated with the site of anastomosis; faecal incontinence is higher in patients with a 
low anastomosis7. In recent years, laparoscopic TME (also known as keyhole surgery) has 
become more common due to its minimally invasive technique providing the potential to 
minimise postoperative mortality, reduce hospital stays, give a faster return to functionality, and 
decrease analgesic requirements. Its feasibility for the upper third of the rectum is high but the 
lower two thirds of the rectum need adequate resection margins to reduce local recurrence and 
improve survival, which is difficult without open surgery. The anatomical location of the rectum 
means that there are major challenges when using laparoscopic surgery to remove a rectal cancer: 
the rectum is confined in a small space within the pelvis and there have been concerns regarding 
the ability of surgeons to achieve satisfactory TME and to determine clear resection margins. To 
date, OS and recurrence data show that laparoscopic surgery is comparable to open resection but 
that the laparoscopic procedure results in better short term patient care and recovery101 102. 
In patients with early stage rectal cancer or with large or sessile lesions, transanal endoscopic 
micro-surgery (TEMS) is performed. TEMS is a minimally invasive technique that involves 
removal of polyps or lesions transanally. Although it has not often been used in the past due to 
the high cost of equipment, it is being promoted as a valuable therapeutic option with reports of 
low to zero mortality and low recurrence rates. Patients have very fast recovery times and 
discharge can be within 24 hours. The incidence of postoperative complications is lower than in 
patients who receive radical rectal cancer surgery and in cases that have recurrence; the TEMS 
can be repeated on the patients103. 
In the last few years, the debate has changed direction towards whether radical surgery is 
necessary after CRT. If a patient responds to CRT with clinical downstaging of the tumour or 
complete response, is it necessary to have full surgery to diagnose the extent of downstaging? 
Unfortunately the techniques used to determine the stage of the tumour are not sufficient to 
accurately predict downstaging or response so most often, surgery is still performed.  Although 
there is also a proposal for the “wait and see” approach, as discussed earlier.   
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1.1.7 Recurrence, metastasis and response to therapy 
Whilst colon cancer tends to recur at distant sites, local recurrence of rectal cancer is a major 
problem. Prevention of recurrence is one of the main issues in CRC, especially in the treatment 
of rectal cancer. Currently the most predictive markers of local control (eradication of cancer 
from the specific area to prevent recurrence) following radiotherapy are CRM involvement, 
nodal involvement and vascular invasion. If a cancer possesses all three of these predictive 
markers, it is unlikely that it has been eradicated completely with either radiation or surgery. An 
incomplete surgical resection (R1-2) leaves microscopic or macroscopic tumour tissue behind 
resulting in a much higher risk of postoperative recurrence. Other than incomplete resection, 
nodal involvement is also a predictor of local recurrence; in one study, patients with node-
positive disease had a local recurrence rate of 21 %7 so postoperative therapy is recommended 
for these patients to prevent recurrence. The main reduction in recent years of local recurrence 
rates for rectal cancer has come from the advent of TME, application of combined therapy and 
better diagnosis of stage and recurrence prediction. 
Metastatic disease occurs when the cancer has spread to distal organs via the lymph nodes and 
cancer begins to accumulate in other areas of the body. Treatment of metastatic disease is mostly 
palliative but can improve survival, temporarily improve quality of life and reduce pain. The sites 
where rectal tumours most often metastasise to are the liver, lungs and local lymph nodes, but 
occasionally metastases are found in the pancreas. Recently, with new chemotherapy drugs 
becoming available, treatment for metastatic rectal cancer has improved. Survival after treatment 
with only 5-FU was one year which improved to around 2 years average survival with the 
addition of targeted therapies and other drugs7. The 5 year survival rate for patients with initially 
unresectable colorectal liver metastases has been reported to be in the range of 30-40% when 
given preoperative chemotherapy to enable resection104. Targeted drugs have been the main 
advance in the treatment of metastatic CRC: Cetuximab, Bevacizumab and Panitumumab; 
however, although they have shown efficacy in increasing the rates of resection of metastases, 
these drugs have had hugely varied effect on survival and progression of the tumour7. 
Response to therapy is varied among rectal cancer patients and is an unknown factor when 
administering CRT. In one study of 30 patients with locally advanced rectal cancer, CRT was 
given and MRI results showed that 63 % had tumour shrinkage and 17 % had a change in T 
stage105.  Some patients in this study also had nodal downstaging, which would have reduced the 
risk of metastasis and recurrence. Another group106 found that pCR in patients who initially had 
locally advanced rectal cancer indicated a favourable outcome; these patients (who had pCR after 
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therapy) had recurrence in only 1.6 %, metastases in 8.9 % and 5-year OS was 90 %. These 
results clearly show that patients who have pCR have a better prognosis. A recent trial has found 
that there is also a difference in response rates between patients undergoing short-course CRT or 
long-course CRT. Long-course CRT had the effect of greater pCR (13.1 %) compared to short-
course CRT (2.7 %) and greater downstaging (39.1 %) compared to short-course CRT (21.6 %, 
p=0.07)107. Currently there is a call for introduction of local excision strategies for patients with 
pCR, for example increasing the use of TEMS would be less risky and could increase the quality 
of life compared to TME. Long-term outcome has suggested that this strategy would have an 
advantage for these patients showing that there was no significant difference between patients 
with pCR who received TME or local excision108.  
1.1.8 Risk stratification and predictors of response to radiotherapy 
In patients with rectal cancer there are different rates of response to radiotherapy. A subset of 
patients have tumours that do not respond to treatment whereas others have tumours that 
respond significantly; the tumour has down-staged or has pCR, clinical measures of response to 
therapy. Some studies have reported the use of molecular markers in an attempt to predict 
response rates of a tumour to therapy109-111. Prediction of response using molecular biomarkers 
would allow identification of patients who have a high potential for complete response after 
therapy and this would allow treatment to be tailored specifically. Tailored treatment plans will 
become more common as biomarkers become available that classify patients into appropriate 
treatment groups according to their risk (risk stratification) of response to a given therapy.   
A French study of 417 patients showed that 44 % did not respond to radiotherapy3, whereas the 
remainder showed either partial or complete response assessed by a lowering of T stage between 
pre- and post-therapy. An option available for locally advanced rectal cancer patients who 
respond to treatment is the ‘wait and see’ approach where patients do not receive surgery, but 
instead are observed and monitored for recurrence and metastasis85. However, the ‘wait and see’ 
approach has so far relied upon retrospective examinations, but more long term prospective 
studies are warranted. Despite the varying degrees of response, there are no reliable genetic 
predictors to enable stratification of patients. Relatively few studies have used gene expression 
analysis for discriminating patients. One of these is a study where the difference in expression 
profiles between responders and non-responders provided a panel of 33 genes that predicted 
response with an accuracy of 82.4 %112. However, patient numbers were low (n=52) and larger 
studies are needed to provide a smaller, more accurate list of genes to discriminate between the 
responder and non-responder sample groups. A smaller list of genes might be easier to use in a 
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clinical diagnostic setting, rather than 33 genes providing a potentially uncertain result. A gene 
proposed as a predictor of response in rectal cancer is hPEB4 (human 
phosphatidylethanolamine-binding protein 4), over expression of which reduces apoptosis by 
inhibiting MAPK and the Bcl/Caspase apoptotic molecules111.  In the cohort of 86 patients 
investigated in this study, high hPEB4 expression was associated with poor response to 
radiotherapy leading to radio-resistance. A further study in 69 patients found that high GHRH-R 
(growth hormone-releasing hormone receptor) and Hsp90 (Heat shock protein 90) were 
independent predictors of poor response and currently drug inhibitors of these proteins are 
being tested as an alternative treatment for non-responders113. Although these studies are useful, 
they are underpowered in terms of sample numbers and need repeating in a large panel of rectal 
cancers. Further validation in large independent sets would then be needed prior to use in the 
clinic. 
Single nucleotide polymorphisms (SNPs) carried in the germline may also confer advantages or 
disadvantages in the response to radiotherapy. One study into SNPs investigated the predictive 
use of polymorphisms in three genes; thymidylate synthase, epidermal growth factor receptor 
(EGFR) and epidermal growth factor (EGF), and found that the combination of thymidylate 
synthase and EGF analysis identified a small group of patients with complete response, however, 
these markers did not identify all responders and no combination could predict more than 87 % 
risk of being a non-complete responder114.  
A study into a panel of eight CRC cell lines found that regenerating islet-derived protein 4 
(REG4) was linked to response to radiation with cells with high REG4 showing higher survival 
rates and reduced DNA damage109. This gene was linked to significantly different expression 
levels in non-responders than responders109. In addition, the transcription factor TCF4 has been 
linked to sensitivity of CRC cells to radiation; expression of TCF4 in CRC cells was positively 
correlated to resistance to chemoradiation and an absence of TCF4 in these cell lines caused a 
significant increase in sensitivity measured by colony formation, DNA damage and cell cycle 
analysis110. A handful of other cell line analyses have been tested or validated in a clinical setting. 
They remain only predicted markers of response in cellular models, which may provide 
interesting information on mechanisms of response.  
Despite the wealth of information about the different response of rectal cancer to preoperative 
radiotherapy115, there is no successful research that has lead to fully validated genetic predictors 
of response. Alternatively, multiple clinicopathological factors have been linked to tumour 
response, including carcinoembryonic antigen level <3.0 ng/ml, non-fixed tumour (tumour 
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mobility), and circumferential extent <50 %116. These were significantly linked to good tumour 
response to therapy and were able to independently predict good response116. Other prognostic 
markers (markers that are associated with survival) include microsatellite instability (MSI) is the 
insertion or deletion of short repetitive DNA sequences that are the result of mutations in DNA 
mismatch repair genes. This is a prognostic marker because cancers with high frequency MSI 
have been shown to have significantly improved prognosis compared to microsatellite stable 
tumours117 (further discussed in chapter 1.2.3 and 1.2.5). This may be due to the fact that the 
DNA is disrupted due to the mutated mismatch repair genes. If the DNA is not normal, there 
are systems within the cell that recognise the abnormality and initiate cell death. MSI is also a 
possible prognostic marker of response to therapy, as discussed previously. 
Other prognostic markers of CRC are mutations in APC, KRAS and TP53 (figure 3). According 
to one study, more than 90 % of patients have alterations in TP53 and APC (and other genes 
involved in the WNT signalling pathway (Wingless-type MMTV integration site family of 
proteins, a network of proteins involved in embryogenesis, cancer and normal adult cell 
processes))118. Mutations in APC, a tumour suppressor gene (TSG), often lead to a truncated 
protein causing prevention of beta-catenin binding and therefore inhibition of beta-catenin 
degradation119. When APC is mutated, beta-catenin builds up and is translocated to the nucleus 
where it can act to transcribe target genes involved in carcinogenesis.  
Molecular markers can also be used to predict the response to chemotherapy. The most 
significant of these markers is KRAS status with regard to monoclonal antibody therapies 
(Cetuximab and Panitumumab)120. Cetuximab and Panitumumab are inhibitors of EGFR but 
patients that have KRAS mutations do not respond to the antibody therapy. This is due to the 
KRAS mutation causing signalling of the EGF pathway whether EGFR is inhibited or not. 
Therefore, the efficacy of EGFR-targeted therapy is limited to patients with wild type KRAS. 
Patients are often pre-screened in the clinic to determine their KRAS status as it has a significant 
bearing on the patient’s response to therapy. This pre-screening can therefore be used to predict 
the outcome of therapy.  
In recent years, the increase in genetic information about CRC and its molecular and metabolic 
pathways has lead to an increase in therapies that target specific pathways or molecules. The 
identification of new molecular biomarkers can aid in the discovery of new therapeutic 
approaches, new drugs and possibly preventative medicine. Biomarkers can also be used to 
stratify risk. A successful biomarker would allow stratification of people at high risk of getting 
cancer and people at low risk, as well as response or non-response to therapy. Biomarkers of 
46 
 
response to CRT are needed so that they can be incorporated into clinical tests to predict this 
effect so that there is an increase in pCR and a reduction in recurrence. 
1.2 Genetics of CRC   
Colon and rectal cancers have similar tumourigenesis pathways. In CRC, there are genetic and 
epigenetic (events that occur outside the DNA, for example, methylation) events that lead to 
cancer. The processes that drive carcinogenesis are currently disputed with two viewpoints. The 
first is the genetic instability pathway defined by Fearon and Vogelstein8 (discussed in section 
1.2.2) where an increased mutation rate during the initial stages of cancer formation drives the 
acquisition of more mutations, leading to cancer8. The second process is the clonal evolution 
model121 where the normal mutation rate leads to the creation of a cancer stem cell or progenitor 
that acquires a selective advantage over normal cells leading to clonal expansion sufficient to 
cause cancer. This clonal evolution model imitates Darwinian evolution in that there are selective 
restraints and local competition for space and resources that the cells must overcome and adapt 
in order to survive. 
1.2.1 Clonal evolution and cancer stem cells 
The clonal evolution model121 is proposed to start with a carcinogen-induced change in a normal 
cell to produce a diploid tumour cell, followed by clonal expansion, genetic instability and 
selection of progeny, eventually creating a tumour formed of subpopulations of different tumour 
cells with advantages over normal and other tumour cells (figure 2).  
Stem cells are self-renewing cells with a high proliferative capacity that produce cells that develop 
into all the differentiated cells of the tissue. There are many proposed markers for stem cells, 
most notable in the intestine is LGR5, a marker discovered from studying the mouse small 
intestine122, as well as CD133123 and Bmi1124. Other marker proteins including CD24, CD44, 
CD29, CD166 and ALDH1 have also been used to describe intestinal stem cells125 126.  
Cancer stem cells (CSCs) are a proposed subset of tumour cells that can self-renew and are 
thought by some to have either initiated the tumour or have the ability to sustain tumourigenesis 
or repopulate the tumour after therapy. Within a tumour, cells often exhibit different properties 
and proliferative capacities as part of tumour heterogeneity. The mechanisms underlying this 
heterogeneity are of particular research interest because studying these CSCs could reveal the 
extent of therapy resistant and sensitive cells, and those that could have initiated the tumour 
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originally. The cancer stem cell model occurs whereby a subset of cells (CSCs) generates clusters 
of tumour cells based on its self-renewal and tumourigenic capacity.  
 
2. Figure 2. Two models explaining tumour evolution from Polyak 2007127. A, CSC hypothesis 
where progeny of the CSC are differentiated and cannot self-renew. Only the CSC can accumulate the 
genetic changes to progress the tumour. B, clonal evolution where tumour cells are determined by their 
cell of origin, the acquired genetic and epigenetic alterations and the surrounding cells. All tumour cells 
can undergo self-renewal and so all can contribute to tumour progression127. 
CSCs have been linked to a number of pathological features of tumours, namely metastases and 
resistance to therapy128. Not all cells in the tumour have the potential to metastasise but CSCs 
have been put forward as one mechanism in pancreatic cancers metastasising to the liver where 
only CD133+CXCR4+ cells metastasised129. The therapeutic implications of CSCs are numerous; 
because these cells have the ability to repopulate the tumour after removal if any cells remain; all 
CSCs need to be eradicated permanently. Some studies have sought to solve this problem by 
differentiating CSCs through administering BMP causing a reduction in tumour-forming 
ability125. Due to the resistance of CSCs, either through their enhanced repair mechanisms, 
hypoxic environment, slow-cycling nature or production of anti-apoptotic proteins, these cells 
are the ones that need to be specifically targeted in order to remove the tumour and prevent 
recurrence. New drugs to target CSCs have been partially successful but more research is needed 
to further understand this emerging subject. 
A recent study130 into colon cancer lineages sought to determine which model best described the 
colon cancer growth and found that metastatic colon cancer contained stem-like cells that had 
the capacity to produce a tumour in vivo (in mice). However, they also found CIN within the 
CSCs130 suggesting that both models can occur in the same tumour. 
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There are well-defined genetic pathways that can lead to cancer and when a CRC is diagnosed, 
tests are performed to determine to which category the tumour is assigned. Pathways include 
chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator 
phenotype (CIMP). A further category, microsatellite and chromosome stable (MACS) cancers is 
emerging from the cancers that are not defined as CIN or MSI.  Determining the genetic 
pathway can aid therapy selection as response to therapy can be different, as described in section 
1.1.7.  
 
3. Figure 3: A Vogelgram depicting two of the major pathways from adenoma to carcinoma 
in CRC: CIN and MSI8 131 
1.2.2 Chromosomal instability 
CIN is the model of genomic instability that displays linear progression from polyp to adenoma 
to cancer with well-known alterations in the genome at each stage with the final stage of the 
cancer developing metastatic potential. In this way, tumours develop mutations of CIN genes 
that allow an increased rate of mutation in oncogenes and tumour suppressor genes leading to 
progression of a cancer. This is a widely accepted model of tumour development and in CRC it 
is one of the best systems to explain cancer growth132. 
The CIN pathway is the main way in which CRC arises and is characterised by an imbalance in 
the number of chromosomes per cell (aneuploidy). Whole or parts of chromosomes can be lost 
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(loss of heterozygosity, LOH) or replicated (amplified) during cell division and this type of 
genetic change is present in up to 70% of CRCs131. It is not clear whether CIN is the initiating 
factor providing the cells with mutagenic capacity or if the initiating event is the first mutation in 
APC that causes chromosomal instability, however, it is unlikely that APC mutation alone causes 
CIN in CRC132. Recent studies propose that this type of cancer development is due to clonal 
expansion by progression through selection of a series of mutations without acquiring a mutator 
phenotype133. Regardless of the initiating mutation, the sequence of events of the CIN pathway 
in causing cancer is fairly well documented, with one of the first events being activation of Wnt 
signalling (figure 4) by the loss of APC function. In the intestine, differentiation of cells as they 
move up the crypt is under the control of Wnt and bone morphogenic protein (BMP) signalling: 
as Wnt decreases and BMP increases, cells differentiate and move towards the apex of the villi. 
When Wnt is high in the bottom and middle of the crypt, cells tend towards proliferation, but 
when Wnt is low and BMP is high, cells tend to differentiate and eventually slough off from the 
top of the villus134. In a normal cell when Wnt (the initiating signal ligand) is not present, it leads 
to downstream binding of APC to β-catenin, GSK3β (glycogen synthase kinase-3β) and axin 
(figure 4). This complex phosphorylates β-catenin and leads to its degradation causing 
suppression of the Wnt signal and prevention of transcription of target genes. In the presence of 
the Wnt ligand, or with dysfunctional APC, the APC-β-catenin-GSK3β-axin complex does not 
form and therefore β-catenin is not degraded. There is an accumulation of β-catenin that 
translocates to the nucleus, binding to Lef/Tcf (figure 4) where it transcribes multiple target 
genes involved in tumour growth and invasion. 
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4. Figure 4. The Wnt pathway: off (left) and on (right). In the absence of Wnt, β-catenin 
complexes to APC, axin and GSK3-β and is then phosphorylated in order to be targeted for degradation. 
No Wnt target genes are transcribed when Wnt is off. In the presence of Wnt, β-catenin is uncoupled 
from the APC degradation complex, accumulates in the cytoplasm and is translocated to the nucleus. 
Once inside the nucleus, β-catenin forms a transcriptionally active complex with Lef/Tcf transcription 
factors and these activate target oncogenes. The target genes include genes involved in proliferation, 
signalling, differentiation and components of the Wnt pathway itself suggesting that when Wnt signalling 
is active, it is an auto-regulating pathway135 136. 
The KRAS mutation is considered to be the next event after APC mutation that occurs in the 
CIN pathway leading to carcinoma. The KRAS gene is located on chromosome 12p (the small 
arm of chromosome 12) and when mutated it becomes an oncogene (a gene that helps the 
malignant transformation of a cell into cancer). Mutations occur in exon 2 (codon 12 and 13), 
exon 4 (codon 146) and occasionally exon 3 (codon 61) which lead to activated signalling of the 
RAS pathway in 30% to 50% of CRCs137. The RAS signalling pathway regulates multiple cellular 
processes including control of cell cycle progression, regulation of cellular growth, proliferation 
and survival. EGFR is a target gene for monoclonal antibody therapy as discussed earlier 
(chapter 1.1.5.1). 
TP53 is a TSG that responds to oxidative stress and DNA damage. It has been called the 
‘guardian of the genome’ due to the high numbers of pathways that it regulates137. Mutation of 
TP53 has been proposed as a late event in the adenoma-carcinoma sequence of CIN and is 
thought to be associated with prognosis; those patients with mutated TP53 have been shown to 
have worse survival when treated with chemotherapy than those with wild type TP53 treated 
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with chemotherapy138. There does not seem to be a difference in survival in patients treated with 
surgery alone despite different TP53 status138. 
Other events in the adenoma-carcinoma sequence for chromosomal instability are loss of 18q 
and SMAD4, along with over expression of COX2 (cyclooxygenase-2 is a gene involved in 
angiogenesis, which along with prostaglandin E2 regulates proliferation and survival). Loss of 
18q, the long arm of chromosome 18, contains several important TSGs; SMAD7, SMAD4, 
SMAD2 and DCC, and loss of these are associated with poor prognosis in CRC7.  
CIN has been shown to be associated with a poorer prognostic outcome compared to those 
patients that have MSI tumours, including lower rates of OS and lower DFS131. 
1.2.3 Microsatellite Instability 
MSI is characterised by a defective mismatch repair (MMR) system that causes accumulation of 
errors in the DNA sequence. Microsatellites are repetitive DNA sequences that are common in 
the human genome and are highly variable between individuals. MMR is a mechanism for fixing 
errors in the DNA sequence that arise during DNA replication and for repairing DNA damage. 
If the mismatch repair genes are mutated or the proteins are not fully functional, this can lead to 
errors by slippage in microsatellites resulting in microsatellite instability (MSI). This frameshift 
mutation phenotype known as MSI is present in up to 15% of CRCs and is associated with a 
better prognosis compared to patients with CIN or MSI negative tumours131. 
The genetic pathway of MSI that leads to cancer is not the same as that of CIN tumours. The 
initial step is still thought to be altered Wnt signalling and the majority of MSI tumours have lost 
MLH1 and MSH2117 which allows the higher rate of mutations that causes the subsequent cancer 
development. Following altered Wnt signalling, mutations occur in BRAF (the BRAF protein 
acts down-stream of KRAS and is involved in cell division and differentiation; when mutated it 
becomes an oncogene) and KRAS117. These events are thought to initiate from the altered 
mismatch repair genes, including MLH1 downregulation by promoter methylation (the 
conversion of a cytosine to 5-methylcytosine in a specific region of the promoter most often 
causing repression of the gene). This switching off of an essential mismatch repair gene may lead 
to more frequent disruption of DNA containing microsatellite repeated sequences, contributing 
further to the instability of the genome. The enhanced genomic instability can then cause even 
more accelerated accumulation of mutations leading to tumour progression. The next step in 
MSI+ tumours is mutation of microsatellites in MSH3 and MSH6, also involved in mismatch 
repair and mutated microsatellites in TGFβ receptor 2 (TGFBR2), IGF2R (insulin-like growth 
52 
 
factor 2 receptor) and BAX (BCL-2-associated X protein)131. These all contribute to the 
progression of the malignant transformation from polyp to carcinoma. 
CRC showing CIN and MSI have different prognoses and can be used, therefore, as a 
stratification factor, but there are invariably other factors that need to be taken into account 
when deciding what type of treatment to administer. 
1.2.4 CIMP and DNA methylation 
A subgroup of CRCs can be classified by epigenetic changes to the DNA called the CpG island 
methylator phenotype (CIMP). This is characterised by methylation at three or more of a panel 
of specific loci and is associated with MSI in patients without germline mutations in MMR genes 
and with frequent BRAF V600E mutation131. CIMP positive (CIMP+) tumours have a well-
defined clinical and pathological profile of association with female sex, poor differentiation of 
tumours and a proximal tumour location (ascending and transverse colon) and can be split into 
CIMP high and CIMP low tumours139. The CIMP+ tumours do not usually follow the classic 
adenoma-carcinoma pathway alterations in APC, TP53 or 18q; instead they develop tumours by 
promoter hyper-methylation, are associated with MSI causing inactivation of tumour suppressor 
genes, have more frequent BRAF mutations and less frequent LOH140. Methylation of the 
promoter region of a gene causes transcriptional repression and therefore silencing of the gene. 
Methylation of CIMP-related markers originally included MINT1, MINT2, MINT31, p16INK4α, 
and MLH1, which are frequently used to identify tumours with this phenotype139. Other markers 
have since been added and the best choice of markers that relate to a choice of outcomes is in 
dispute (some panels of markers can associate with survival and others with recurrence). These 
include CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CRABP1, HIC1, IGFBP3, MGMT 
and WRN139 141. Since CIMP+ tumours rarely occur in the rectum, there is little evidence for the 
effect on prognosis of MSI and CIMP for rectal tumours. There is one study that evaluates the 
effect of epigenetic and genetic changes on survival in rectal adenocarcinomas142; it shows that 
there is a difference in frequency of genetic changes between colon and rectal tumours. For 
example, when comparing MSI-high rectal tumours with the same colon tumours, rectal tumours 
have fewer BRAF mutations, less MLH1 methylation, and less CIMP compared to colon 
tumours142. The CIMP status supports the predicted differences between colon and rectal 
cancers because CIMP is associated with proximal colonic tumours. 
A study that investigated the effects of CIMP in rectal cancers receiving therapy showed that 
CIMP was a marker of high-risk patients as it increased the likelihood of metastases and had a 
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much poorer DFS143. Although CIMP+ is a small subset of rectal cancers, it could be used as a 
marker to identify patients that might need alternative treatment or closer follow-up to diagnose 
metastases quickly. The survival outcome of CIMP+ and hypomethylated rectal tumours is still 
debated and needs to be further investigated to understand fully the effects of this phenotype 
and its interactions with other genetics changes. 
Epigenetic modifications through DNA methylation are inherited changes in gene expression 
and most CpG sites are methylated in the human genome with small area where there is a much 
reduced level of DNA methylation, called CpG islands. DNA methylation is the addition of a 
methyl group to cytosine, producing 5-methylcytosine, which occurs on the dinucleotide group 
CG. Within the DNA sequence, most often in the promoter regions of genes, there are groups 
of these CG dinucleotides called CpG sites (cytosine-phosphate-guanine), forming CpG islands. 
CpG islands are very densely packed with CG dinucleotides (more than 60%) compared to the 
rest of the genome. In normal cells, the regions that are most frequently methylated are CpG 
poor regions and CpG islands tend to stay unmethylated. This unmethylated state is most likely 
to be a requirement for transcription and when the CpG sites within promoter regions are 
methylated, it often results in silencing of the gene (figure 5). This silencing occurs by 
transcriptional repression, whereby the transcription factors cannot bind to the DNA due to the 
methylated CpG sites and so cannot transcribe the gene.  
 
5. Figure 5. Methylated and unmethylated DNA. Methylated regions in red and unmethylated 
regions in green. Methylation causes suppression of gene expression. 
Epigenetic modifications can affect the progression of a cancer by altering expression of genes. 
This epigenetic transcriptional silencing in the genome is thought to exacerbate tumourigenesis 
by silencing TSGs and the reduced ROS levels may prevent cellular senescence144 leading to 
aberrant cell growth. Other types of epigenetic modifications include histone acetylation, 
whereby chromatin is structurally remodelled causing gene inactivation, and miRNA binding to 
mRNA causing down regulation of expression29. Recently, different areas of DNA methylation 
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have been identified, including CpG island shores. CpG island shores are located more than 2 kb 
upstream of the CpG island and methylation of these areas is also associated with transcriptional 
silencing and they are differentially methylated between specific tissues145. Similar to CpG islands, 
CpG island shores are also thought to have aberrant DNA methylation in cancers leading to 
aberrant gene expression. 
1.2.5 MACS 
As well as CIMP+ tumours, there are tumours that have hypomethylation and are inversely 
associated with CIMP and MSI, therefore representing a different pathway to colorectal 
tumourigenesis146. This hypomethylation can lead to the activation of oncogenes such as c-MYC 
leading to neoplasia (abnormal proliferation of cells) but is not associated with the clinical or 
pathological features of CIMP+ tumours (site, differentiation, stage)147. These cancers have been 
described by some as microsatellite and chromosome stable (MACS) cancers that make up the 
remaining 30-40 % of sporadic CRCs11. MACS have been shown to have low CIMP, better 
prognosis than CIN, are more common in the left colon and are associated with specific loci that 
could be used as a marker of this genotype11. 
1.3 Mouse model of radiation-induced susceptibility to polyposis 
Radiation forms a key part of the therapy regime of patients with rectal cancer. To create a 
mouse model of CRC that is sensitive to ionising radiation, a backcross of [ApcMin/+] x 
[BALB/c] was produced148. The BALB/c mouse is a model of sensitivity to radiation-induced 
damage and is more susceptible to tumour development148. The ApcMin/+ mouse is a model of 
human familial adenomatous polyposis that has a mutated Apc gene (conversion T/A to A/T at 
nucleotide 2549, codon 850). The germline Apc mutation leads to multiple intestinal neoplasia 
(Min), a condition that exhibits numerous adenomas throughout the intestinal tract, but mostly 
in the small bowel, and rarely allows the mice to survive beyond 120 days149 . ApcMin/+ mice 
mimic the human condition of FAP; both have multiple colon adenomas but in the mouse, most 
polyps occur in the small intestine, whereas in the human condition polyps predominantly occur 
in the colon and rectum. Another difference to human cancer is that the mouse model rarely 
develops carcinomas; the polyps do not progress further along the adenoma-carcinoma 
sequence, probably due to the relatively short life span of these animals. 
The BALB/c mouse model has polymorphisms (natural variations in the gene sequence between 
individuals) in the DNA repair gene, Prkdc, which is associated with a reduction in protein kinase 
activity, defective DNA double strand break repair and sensitivity to radiation-induced 
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tumours148. This gene produces a protein involved in cellular response to damage by radiation148. 
Irradiation was shown to increase adenoma incidence in N2 backcrossed Min mice
148. With 
interval mapping and permutation testing (looking in the genome for loci that affect a 
quantitative trait (quantitative trait loci, QTL), in this case radiation sensitivity causing intestinal 
neoplasia), it was revealed that there is an association between part of chromosome 16 and 
increased susceptibility to adenoma induction by irradiation148. In further analysis of this 
backcross, more regions were found to be significantly linked to radiation induced tumour 
multiplicity: a region on chromosome 2, two regions on chromosome 5 and two regions on 
chromosome 16. These regions include genes such as: Duox2, Bubr1, Mertk, Dll4, Casc5 and Bub1 
on chromosome 2; Centd1, Recc1 and Cxcl5 on chromosome 5, and Prkdc on chromosome 16, 
among others150.  
In summary, the identified QTL regions are highly likely to contain the controlling genes of 
susceptibility to radiation-induced tumourigenesis in the ApcMin/+ mouse. Within these regions, 
candidate genes that may be the reason for the loci have been identified. One of these candidate 
genes is Duox2, which is differentially expressed between the BALB/c and C57BL/6151. We have 
investigated this gene further in human CRCs and found the gene promoter to be methylated in 
a significant number of cases152. 
1.4 DUOX2 
Dual oxidase 2 (DUOX2) is a member of the NADPH oxidase (Nicotinamide adenine 
dinucleotide phosphate oxidase, NOX) family of proteins. The NOX family are membrane 
bound proteins that generate reactive oxygen species (ROS) (see section 1.4.2) and consist of 
NOX1, 2, 3, 4 and NOX5, along with a second group of two DUOX enzymes, DUOX1 and 
DUOX2. The NOX1-4 and NOX5 (short) enzymes are transmembrane proteins that have six 
transmembrane α-helices and an extracellular flavoprotein domain. NOX5 (long) and both 
DUOX proteins also contain two extracellular calcium-binding sites, meaning that calcium 
regulates the action of DUOX. In addition, DUOX1 and DUOX2 contain a peroxidase domain 
that protrudes inside the cell (figure 6). The NOX family generate superoxide by the transfer of 
electrons across the cell membrane and binding them to extracellular oxygen (figure 6). DUOX 
proteins do not produce superoxide; instead they generate hydrogen peroxide as a result of the 
electron transfer across the membrane.  
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6. Figure 6. NOX family of proteins taken from Drummond et al 2011153. The catalytic 
transmembrane core domains shown in green, cytostolic organisers and activators in orange and dark 
green and small GTPases in light blue. POLDIP2 in pink is a regulator of NOX4 activity. Maturation and 
stabilisation factors are separate proteins shown in red. EF hand motifs are in yellow, which bind to Ca+ 
and the extracellular peroxidase-like domain of DUOX proteins is shown in purple153. 
The human DUOX genes are located in chromosome 15q15.3 and are 16 kb apart with opposite 
transcriptional orientations (figure 7). DUOX2 is 1548 nucleotides long and is regulated by a 
maturation factor, DUOXA2. The combination of the DUOX2 protein with DUOXA2 permits 
exit of the protein from the endoplasmic reticulum, proper translocation to the membrane and 
full activity once in place154. As DUOX2 and DUOXA2 are located next to each other (figure 7), 
but on opposite strands of the DNA, it has been suggested that there is a common bidirectional 
promoter that controls expression of both genes155.  
 
7. Figure 7. Location of DUOX2 and DUOXA2 on chromosome 15. Black arrows indicate 
orientation of the gene. 
DUOX proteins are expressed in the thyroid gland, salivary gland and digestive tract156 157. The 
function of DUOX2 is to produce H2O2 (and NADP
+) from NADPH and oxygen. In the 
thyroid gland, where DUOX2 is highly expressed, the production of H2O2 is needed for 
hormone biosynthesis. This link was discovered by the identification of patients suffering from 
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hypothyroidism because of mutations in DUOX2. In addition to its expression in the thyroid, 
DUOX2 is also expressed along the respiratory and digestive tract. In the respiratory tract, it has 
been demonstrated that DUOX2-generated H2O2 kills bacteria in conjunction with 
lactoperoxidase and thiocyanate (synthesised to hypothiocyanite, a bactericide). In this process, 
DUOX2 is induced by interferon gamma (IFNγ) and the killing effect is important for host 
defence158. The hydrogen peroxide produced by DUOX1 and 2 in the intestine has been shown 
to play a role in gut immunity; in Drosophila, duox2 has been shown to be up and down 
regulated depending on microbial status. The gene produces ROS to cause oxidative damage in 
infectious microbes but allows commensal microbes to survive (“gut microbe homeostasis”)159. 
Downstream targets of DUOX2 are those proteins that are stimulated by ROS production and 
oxidative stress including pathways of apoptosis, inflammation and damage to DNA. Specifically, 
DUOX2 has been found to target TP53 by a DUOX2 and NOX4 knockdown causing a 
compensating increase in TP53. This shows that ROS production by DUOX2 targets and 
inhibits TP53 and this could play a role in cell cycle regulation160. It has recently been shown that 
ROS production by DUOX2 is also essential for the TLR-5-dependent immune response in 
human airway epithelial cells161.  
1.4.1 Reactive oxygen species 
 In disease, DUOX2 mutations have been found to cause hypothyroidism resulting in disrupted 
production of the hormones in the thyroid gland162. Little is known about DUOX2 and its links 
to cancers apart from its presence in thyroid cancers and in intestinal inflammation leading to 
colon cancer although these have not been extensively researched. In 2008, the silencing of 
DUOX2 through DNA methylation was found to play a role in lung cancer163. 
ROS are reduced derivatives of molecular oxygen that include hydroxyl (˙OH), superoxide (O˙2), 
nitroxyl radical (NO˙) and hydrogen peroxide (H2O2) among others, and are also known as free 
radicals. They are generated from various sources, including the electron transport chain in 
mitochondria, NADPH oxidases (including DUOX2) and ionizing radiation. In the 
mitochondrion, oxygen serves to act as the final electron acceptor at the end of the electron 
transport chain, but partially reduced oxygen can be produced in error. NOX and DUOX 
enzymes produce ROS by the trans-membrane catalysis of the NADPH-dependent reduction of 
oxygen to form superoxide, which can react with itself to form hydrogen peroxide. Ionizing 
radiation is a third source of ROS; the energy from radiation deposited in a cell results in the 
radiolysis of water into hydrogen peroxide and other radicals164. 
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Reduced oxygen, i.e. with unpaired electrons, is a highly reactive, unstable molecule that can 
react with other molecules to achieve a more stable state. This reaction, or oxidation, can damage 
DNA, lipids and proteins within the cell. At first it was thought that ROS were produced as a 
toxic and unwanted by-product of respiration, because there are enzymes whose sole duty is to 
eliminate ROS from the cell. However, since the discovery of proteins that only produce ROS165, 
it is now assumed that ROS is not produced accidentally and has an important biological 
function in the cell.  
ROS are present at a low level in normal cells and antioxidants are produced that can break them 
down to prevent any damage to the cell’s own components. Although ROS can have a damaging 
effect on the cell, one important normal function is in the immune response to bacteria. NOX in 
phagocytes is normally inactive but can be activated in response to the presence of 
microorganisms166 resulting in ROS production. ROS are toxic to microorganisms because they 
cause DNA, lipid and protein oxidation and superoxide can destroy their respiratory chains166.  
Normal cells can also harness the oxidation capacity of ROS to initiate signalling pathways but it 
is necessarily highly regulated by antioxidants to prevent damage. ROS can activate signalling 
pathways by oxidising their targets; some ROS have been found to be specific to their targets, 
e.g. superoxide targeting transcription factors and H2O2 targeting peroxidases and kinases, but 
others, e.g. hydroxyl radicals, are non-specific, and can oxidise most molecules167.   
Unregulated ROS production and inefficient removal by antioxidants can lead to oxidative stress 
triggering signalling pathways leading to dysregulation of the cell and potential transformation 
into a cancer. In general, ROS is increased in almost all cancers, which could have an effect on 
cancer growth, proliferation and progression due to the increase in genomic instability. Chronic 
exposure to high levels of ROS can cause cancer because of the DNA damage inflicted by ROS, 
followed by proliferation caused by modulation of cell cycle proteins. ROS can have an effect on 
the tumourigenic potential of the cell by the oxidation of proteins causing inhibition of tumour 
suppressor genes e.g. PTEN168 or epigenetic alteration causing activation of oncogenes. ROS 
inhibition of PTEN in cancer, by the oxidation of the catalytic site, amplifies receptor tyrosine 
kinase (including EGFR) signalling leading to cell proliferation and suppression of apoptosis169.  
Due to the frequency of ROS being involved in cancer, drugs to target ROS are being developed. 
One study reasoned that high ROS must mean there is high antioxidant production to 
counteract the damage by ROS because the cells do not die from ROS damage and therefore the 
cancer cells were vulnerable to further oxidative stress induced by drugs170. A drug that either 
increased ROS production or targeted the antioxidants could push a tumour cell further towards 
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DNA damage and ultimately cell death. Normal cells would suffer less because of their normal 
metabolic state so a specific drug should selectively target the cancer cells. 
ROS are also involved in the cellular response to radiation. Radiation kills cells by damaging their 
DNA and other cellular components such as mitochondria and membranes. The result of direct 
energy transfer of radiation in a cell is the radiolysis of water, producing H+ and OH-, which in 
turn produces hydrogen peroxide and superoxide (H2O2 and O2
-). ROS produced in response to 
radiation accumulates and has an additive damaging effect on DNA, mitochondria and 
membranes171. Radiation damage is dependent on ROS production; the more ROS already 
present in the cell when it is irradiated suggests that the radiation will have a greater effect171. In 
breast cancer stem cells, it has been shown that there are lower levels of ROS present causing a 
resistance to ionizing radiation172. This could lead to a requirement of tumour-specific therapy 
and drugs that address this situation of low levels of ROS possibly as a consequence of hypoxia. 
1.5 Hypoxia in rectal cancer 
Hypoxia is a state of low oxygen in tissues, which is common in cancers because the fast growing 
cancer cells often outstrip the local blood supply resulting in areas of low oxygen tension. This 
causes tumours to grow new blood vessels (angiogenesis) to overcome and adapt to the problem 
of low oxygen. Hypoxia is a negative prognostic feature of tumours because it correlates with 
therapy resistance, angiogenesis, invasiveness, metastasis and altered genomic instability173 174. 
This negative correlation means that tumour hypoxia could be exploited as a drug target strategy. 
The normal concentration of oxygen in human tissues is between 3.1% and 8.7%, whereas in 
tumours it is frequently between 1.3% and 3.9% with the concentration in solid tumours often 
less than 0.3%175. At early stages of development, tumours are able to grow by receiving oxygen 
from diffusion from the local environment and local blood vessels. As the tumour grows in size, 
it uses more oxygen for its increased metabolic processes so a reduced concentration of oxygen 
is present. With increasing cellular distance from a blood vessel and decreasing oxygen, cells 
proliferate abnormally and in areas of extreme hypoxia, apoptosis occurs. These factors serve to 
select cells that can adapt to hypoxia, with HIF-1 and invasion pathways activated176. Adaptation 
to hypoxia involves increasing the vasculature surrounding and pervading the tumour 
(angiogenesis) and upregulation of genes encoding glucose transporters thereby controlling the 
oxygen use through energy metabolism177.   
The main regulating and sensing molecule in hypoxic cells is Hypoxia Inducible Factor-1 (HIF-
1), a transcription factor that consists of two subunits, HIF-1α and HIF-1β. The alpha subunit is 
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induced by hypoxia whereas the beta subunit is constitutively expressed178. In non-hypoxic cells, 
HIF-1α is degraded by ubiquitin, but when hypoxic conditions pervade the cell, HIF-1α 
accumulates. Both VHL and TP53 proteins are known to bind to HIF-1α and as these are 
frequently lost or inactivated by mutations in tumour cells, HIF-1α accumulates178. Most of the 
target pathways of HIF-1α promote tumour growth but apoptosis and cell death are also end 
points of some activated pathways; the balance of these pathways are critical for tumours to 
survive. Along with regulating angiogenesis, proliferation and survival, HIF-1α also regulates 
VEGF (vascular endothelial cell growth factor). VEGF stimulates proliferation of new 
vasculature, increases vascular permeability and correlates with microvessel density in tumours179. 
VEGF is a protein that causes adaptation to hypoxia by increasing blood flow and therefore 
increasing oxygen concentration in the tumour. It also reduces apoptosis, which contributes to 
the continuing growth of the tumour, and has been shown to be linked to metastasis by 
invasion180. VEGF is induced in response to radiation to form new vasculature and is used as a 
target for chemotherapy drugs (e.g. Bevacizumab) to control response to radiation. VEGF 
inhibition leads to a delay in tumour growth after radiotherapy possibly by prevention of new 
vasculature to the tumour and therefore reducing its growth and spread181.  
Specifically in rectal cancer, it has been shown that over 50 % express HIF-1 and this was 
significantly linked to TNM stage, vascular invasion, survival and DFS 182. This could mean that 
HIF-1α could be used as a marker of poor prognosis or a target in order to improve patient 
outcome. Cells in hypoxic environments are often more resistant to radio- and chemotherapy: 
sensitivity to both increases with increasing oxygen. In the case of radiotherapy, this is because 
oxygen is needed during radiation to cause the maximum amount of DNA damage by the 
production of free radicals (ROS). At levels of very low oxygen, cells may be resistant to the 
killing effect of radiation, many survive post-therapy and may repopulate once the rest of the 
sensitive cells have died (recurrence of the tumour)179. More radiation (2-3 times more) is needed 
to have an effect on cancer cells that are severely hypoxic compared to cells that are well 
oxygenated181 and hypoxia can alter the function of DNA double strand break repair genes183. 
Cells in hypoxia are also resistant to chemotherapy because they are furthest from the blood 
vessels and therefore receive a reduced concentration of the drug. Cancer chemotherapeutic 
drugs often target the most highly proliferating cells as a means to destroy only cancer cells; 
hypoxic cells are usually slower at proliferating due to changes in the cell cycle and therefore are 
not killed as readily by such drugs183.  
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Regulation of angiogenesis by inhibition of either HIF-1 or VEGF is a therapy option proposed 
to control the tumour vasculature and increase the efficiency of therapy. Another method to 
control this is by inhibiting COX2. This protein is overexpressed in most colorectal cancers 
causing promotion of angiogenesis by increasing VEGF184. Binding of HIF-1α to the COX2 
promoter has revealed that COX2 is responsive to hypoxia and provides the cells with an 
essential adaptive response to reduced oxygen by increasing vasculature, therefore promoting 
tumour progression184. Targeting of COX2 with specific chemotherapy in hypoxic tumours 
could significantly increase the sensitivity of tumours to treatment. 
There are new drugs currently in trials that are inhibitors of HIF-1. These serve to oppose the 
effect of HIF-1 on the cancer (reduce tumour growth, vascularisation and metastasis) by 
decreasing the rate of HIF-1α synthesis185. The biggest obstacle with HIF-1 is that it controls so 
many genes, not only genes involved in angiogenesis and tumour cell survival, but also genes that 
control tumour growth arrest and cell death186. In reducing HIF-1 throughout the cell, the effects 
of HIF-1 on tumour cells leading to cell death may not occur.  
COX2 is an enzyme involved in prostanoid biosynthesis (biologically active lipids that respond 
to circulating hormones and are involved in the inflammatory response) and has been shown to 
be upregulated in most CRCs184 (50 % adenomas and 85 % adenocarcinomas) and is associated 
with poor prognosis187. Prostaglandin E2 (PGE2), a prostanoid, also occurs at higher levels in 
cancer tissue, which promotes survival and proliferation due to its links with the immune 
system188. COX2 upregulation can also have the effect of increasing angiogenesis as it enhances 
VEGF expression189. Recently it has been found to be linked to tumour hypoxia showing 
upregulation as a target of HIF-1α. The upregulation of COX2 represents an adaptive response 
to tumour hypoxia by increasing angiogenesis in order to survive184. NSAIDS target COX1 and 
COX2 and are commonly used to decrease the risk of CRC, however, prolonged use was found 
to be linked to elevated blood pressure producing an increased risk of cardiovascular events187. 
These side effects were predicted to come from the non-selective inhibition of both COX 
enzymes so selective COX2 inhibitors were developed (COXIBs e.g. celecoxib, rofecoxib). The 
COXIBs were found to prevent recurrence of sporadic CRC and reduce the polyp burden in 
FAP patients187.  
1.6 MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs that can regulate post-transcriptional gene 
expression and protein function in animals and plants. MiRNAs are normally 23 nucleotides (nt) 
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in length and are among the many other smalls RNAs (small interfering RNAs (siRNA) and 
piwi-interacting RNAs (piRNAs)) that are found in cells190. These miRNAs can direct 
transcriptional repression and mRNA degradation leading to a reduction of the target. 
1.6.1 Synthesis 
Instead of being produced from long dsRNA (double stranded RNA) like siRNAs, miRNAs are 
produced from specific precursors encoded within the genome (figure 8). A transcript may 
encode more than one miRNA or it may encode a miRNA within the intron of a gene. A 
primary miRNA (pri-miRNA) is transcribed in the nucleus, whereupon it folds into a hairpin 
loop structure. A typical pri-miRNA folds into an imperfectly paired ~33 bp stem with loops 
and segments not bound. Drosha is an RNase-III enzyme that is mostly found in the nucleus 
and it excises the stem loop from the pri-miRNA to form precursor miRNA (pre-miRNAs). 
After processing by Drosha, the pre-miRNAs are transported across the membrane by Exportin 
5 (Exp5) into the cytoplasm where they are processed further by Dicer into a short miRNAs. 
Dicer is another RNase-III enzyme that gets rid of the loop structure leaving a double-stranded 
mature miRNA. Once mature miRNA is available in the cytoplasm, it is incorporated into an 
RNA-induced silencing complex (RISC) along with an Argonaute (Ago) protein and together 
this complex negatively regulates post-transcriptional gene expression191 192.  
 
8. Figure 8. The synthesis and effects of miRNA in a cell. Pri-miRNA is transcribed from a 
gene in the nucleus, modified into pre-miRNA which is exported into the cytoplasm. Dicer processes the 
pre-miRNA into short fragments and then into mature miRNA. MiRNA within RISC binds to mRNA to 
either repress translation or to cleave the mRNA. Adapted from He and Hannon, 2004191. 
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A mature miRNA in the cytoplasm is unwound by Ago; this unwinding is preferential for one 
strand and the other, sometimes retained strand, is called the miRNA* strand. MiRNA, in 
complex with Ago and RISC specifically recognises and regulates particular mRNAs. MiRNA 
binding sites in mRNA are usually in the 3’ UTR region and are present in multiple copies. 
MiRNA binds to mRNA with nucleotides 2-8 with perfect complementarity causing cleavages of 
the mRNA strand (catalysed by Ago) and imperfect complementarity (with mismatches) causing 
repression of translation193.  
The synthesis of miRNAs is an important feature of cells to study and it has been found that 
they are often regulated by the same targets that they themselves regulate. This forms a double-
negative feedback loop whereby the target protein reduces the expression of the miRNA that, if 
expressed, would mimic loss-of-function of the target protein. Tight regulation of miRNAs is 
essential and this might be a method to limit the expression of miRNAs193.  
1.6.2 Function and prediction of targets 
The binding of miRNAs to mRNA mediates gene inhibition by either site-specific cleavage, 
enhanced mRNA degradation or translational inhibition. Most commonly, miRNAs direct 
translational repression, but occasionally at sites with near-perfect pairing complementarity, 
miRNAs can cause mRNA degradation by cleavage catalysed by Argonaute190. The mechanism 
of mRNA translational repression by miRNAs is not readily agreed and there are many proposed 
mechanisms. One method is that repression occurs because miRNAs block final protein 
translation at ribosomal post-initiation sites (3’ UTR), another method is that miRNAs recruit 
proteases to the ribosomes leading to degradation of the translated product and finally it has 
been suggested that miRNAs bind to the initiation sites (5’ UTR) to represses ribosome 
initiation194.  
In order to discover as many miRNAs as possible, miRNA profiling has become a more 
common approach. Although laboratory techniques such as genetic screening for miRNAs are 
helpful, computational searches of the genome are much faster and more reliable. Prediction of 
miRNA and their targets has been a difficult undertaking because of the ~23 nucleotides, not all 
are complementary to an mRNA target. One of the major advances in the attempt to predict 
miRNAs within the genome was the discovery that miRNA pairing to mRNA targets centred on 
nucleotides 2-7 of the 5’ end of the miRNA, called the ‘seed’190. This prediction capacity 
improved further with the ability to search computationally within the 3’ UTRs of mRNA to find 
the conserved 6-8 nucleotide match.  MiRNAs are grouped into families by the first 8 
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nucleotides, i.e. miRNAs with the same sequence at nucleotides 2-8, and so these all share the 
same targets. Once the searches were performed, it was discovered that there were a very many 
predicted targets for each conserved miRNA; an average of 300 targets per miRNA family190. 
 
9. Figure 9. The types of miRNA binding to mRNA190. Vertical lines between sequences indicate 
base pairing. A-C: Canonical 7-8 nt seed matches. D-E: Marginal 6 nt seed matches. F-G: Double binding 
sites with productive 3’ pairing. Figure from Bartel 2009190. 
The type of miRNA binding (figure 9) is varied with the most conserved being canonical 
binding: a seed match (nt 2-7) plus a match at position 1, position 8 or both. 6 nt binding sites 
are a second type, with only a seed match or an offset seed match (nt 3-8), but these have a 
reduced efficacy. A third type of binding is a seed match with additional binding at nt 13-16 of 
the miRNA. This third type is rare but has increased efficacy and can either be additional to a 6-7 
nt seed match or to compensate for a mismatch in the seed (figure 9, G). The efficacy of the 
seed match of miRNAs to mRNA depends on the type and number of nucleotides bound, the 
site number and spacing, and the position of the seed match on the mRNA (figure 10).  
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10. Figure 10. Efficacy of miRNA binding sites. Relative efficacy is a log scale of mean 
destabilisation of messages. A: efficacy depending on type of seed match, 6 nt matches (6 mer) are only 
marginally better than no site and 8 nt matches have the highest efficacy of seed matches. B: 
differentiated by their number and spacing, dual 7 nt matches have much higher efficacy if the spacing 
between them is cooperative. C; differentiated by their position on the mRNA UTR. Figure from Bartel, 
2009190. 
The efficacy of the seed match on the miRNA binding to the mRNA target will affect the degree 
of silencing or degradation as determined by the expression of the protein. Protein translation 
occurs firstly by initiation, followed by elongation and finally termination. Although the exact 
mechanisms of repression by miRNA binding to mRNA are not completely understood, there 
are a few proposed pathways that encompass all three areas of translation; post-initiation 
inhibition, miRNA interference with ribosomes at the initiation and elongation steps and roles 
for Ago and other proteins linked to miRNA in repressing initiation. All these models have 
evidence that backs them up but a single method that describes miRNA repression is not 
available, indicating that all these types of repression probably occur in cells with the method of 
repression being defined by the type, site and efficacy of miRNA binding to mRNA195. 
1.6.3 MiRNAs and cancer 
As miRNAs can regulate the expression of numerous proteins within the cell it seems likely that 
miRNAs will be involved in and contribute to the pathogenesis of human diseases. Already 
miRNAs have been found to be involved in cancer by participating in the control of tumour 
growth, differentiation, adhesion, apoptosis, invasion and metastasis196. Abnormal expression of 
miRNAs has been shown to be associated with different cancer types and a study found that 
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when the miRNA genome was mapped and tumour compared to normal tissue, that tumours 
have a characteristic miRNA expression profile197. The authors showed that this miRNA 
expression profile was more effective at clustering cancers into groups than mRNA profiling and 
this knowledge could be useful in clinical diagnostics in order to determine the tissue of origin of 
a metastasis as well as diagnosing undifferentiated tumours. 
4. Table 4. Altered miRNAs in CRC. Overexpressed or under-expressed miRNAs in CRC198 199. 
Overexpressed miRNAs Under-expressed miRNAs 
miR-10a miR-92 let-7 
miR-15b miR-106a miR-30c 
miR-17-5p miR-107 miR-133a 
miR-17-92 cluster miR-148a miR-143 
miR-19a miR-181b miR-145 
miR-20a miR-191  
miR-21 miR-200b  
miR-24-1 miR-200c  
miR-29b-2 miR-221  
miR-30c miR-223  
miR-31   
 
Several miRNAs have been shown to be involved in CRC, shown in the table above. In rectal 
cancer in particular, it has been shown that over 200 miRNAs are expressed differently 
compared to colon cancer200. MiR-21 has been studied in rectal cancer and it has been found to 
be upregulated. In colon cancer, this particular miRNA is known to be linked to poor survival 
and poor therapeutic outcome indicating that it could be used to predict survival and response to 
therapy201. More recently, miR-21 in rectal cancer has been shown to be affected by therapy; in 
post-therapy specimens, miR-21 expression was moderately lower than pre-therapy tissue202. This 
study also found that miR-143 and miR-145 were significantly upregulated in post-therapy tissue 
and there was a significant correlation between this upregulation and tumour regression 
indicating that these miRNAs could be used as biomarkers in the prediction of response to 
treatment.  
An important feature of miRNAs that could be exploited when searching for tumour biomarkers 
is their stability; most can persist for a long time due to their short length203. This feature has 
instigated an investigation to determine if these miRNAs are preserved in the circulatory system 
and other body fluids. Recently, there has been more evidence supporting the observation of 
circulating miRNAs, particularly in relation to cancer, where they could be used as a much less 
invasive indicator of the tumour’s stage, type and potential response to therapy204.  As the 
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knowledge of miRNAs and their links to cancer increases, correlations with clinico-pathological 
features and response to therapy will be identified and the use of miRNAs as either targets or 
predictive response biomarkers becomes more significant. 
1.6.4 MiRNAs and hypoxia 
As discussed earlier (section 1.5), hypoxia is a significant influence on cells and is especially 
widespread in tumours.  An early study on miRNAs and hypoxia indicated that there is likely to 
be a specific expression profile of miRNAs associated with a hypoxic environment205 and that 
there are miRNAs regulated by hypoxia. The authors found 27 miRNAs that were at least 1.5-
fold upregulated in 0.2 % O2 in more than two cancer cell lines (colon and breast) showing that 
there is a miRNA response to hypoxia which could have an impact on survival or prognosis. 
This ‘signature’ of hypoxia revealed miRNAs that were involved in the regulation of anti-
apoptotic proteins, oncogene signalling and proliferation, both important in cancer. 
1.6.4.1 MiR-210 
 Since miR-210 expression was found to be modulated by hypoxia and regulated by HIF-1α, 
more studies have found that miR-210 is one of the most sensitive miRNAs with regard to 
response to low oxygen. This miRNA is known to decrease mitochondrial function, upregulate 
glycolysis206, can increase the generation of ROS, and is involved in cell cycle regulation, DNA 
damage and repair. HIF-1α induces miR-210 by interacting with its promoter sequence and some 
of the validated targets of miR-210 include EFNA3 (a receptor tyrosine kinase), E2F3 (a 
transcription factor), RAD52 (a DNA repair enzyme)207, COX10 (cytochrome c oxidase 
assembly protein) and ISCU (iron-sulphur cluster scaffold homolog)206. Among these numerous 
functions, it is overexpressed in breast cancer and was found to be induced by HIF-1α and VHL. 
This study also showed that miR-210 is an independent prognostic factor; its expression levels 
showed a significant inverse correlation with DFS and OS in breast cancer208. In 2010, it was 
further shown that miR-210 correlates with disease recurrence and short OS in head and neck 
cancers207.  Although it is overexpressed in breast cancer, the gene is frequently deleted in 
ovarian cancer leading to low expression levels despite the hypoxic environment.  
In rectal cancer, there is no information in the literature about miR-210 known at present. As 
rectal cancers are frequently hypoxic, miR-210 could be upregulated, however, this needs to be 
proven as not all cancers, e.g. ovarian cancers, display the same miRNA profiles in response to 
hypoxia. If miR-210 was upregulated in hypoxic rectal tumours, it could play a part in response 
to therapy or act as a biomarker of response; an increased level indicating that the tumour was 
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hypoxic and more likely therefore to be resistant to radiotherapy. An investigation into the 
mRNA targets of miR-210 and subsequent protein expression may well be fruitful. MiR-210 
modulation of its targets by changes in expression could have an influence on cancer initiation, 
progression and metastasis. If the targets were identified then this will help determine if miR-210 
will be a useful target for therapy. 
1.7 Hypothesis and Aims 
Response to preoperative radiotherapy in rectal cancer is highly variable and has a significant 
influence on prognosis. The hypothesis of this research project, based on the background 
information, is that there is a subset of rectal cancers that are resistant to radiotherapy and that 
these can be determined by their genetic characteristics. We hypothesise that the varied response 
to radiotherapy will be due to the molecular characteristics of the tumour and that a panel of 
markers could be elucidated that will allow personalised treatment. A risk-adapted stratification 
of patients by their predicted response to therapy will be critical for administering the best 
healthcare for the individual, to improve survival and quality of life. 
We have a cohort of over 150 rectal cancers and also began collecting a panel of pre-therapy 
rectal cancers to be linked to post-therapy specimens; ethical approval the East London REC 
(09/H0703/106). We also have a panel of six rectal cancer cell lines for use in this study. 
DUOX2 was chosen to be studied in the six rectal cancer cell lines because it was shown by our 
laboratory’s previous work to be involved in radiation-induced tumour multiplicity150. Other 
studies have shown it to be expressed in the digestive tract157 and is hypermethylated and 
therefore silenced in lung cancer163. DUOX2 produces hydrogen peroxide, a reactive oxygen 
species, which aids damage to DNA and other cellular components when irradiated. In the 
presence of DUOX2, our hypothesis is that rectal cancer cells will be more sensitive to radiation 
due to the increase in ROS. In the reverse, an absence of DUOX2 will cause rectal cancer cells 
to be more resistant to radiation due to the reduced amount of ROS. A further hypothesis is that 
risk stratification of rectal cancer cells could also be achieved by profiling miRNA expression in 
order to determine those that may be associated with response to therapy. 
Overall, the aim of this project is to characterise the relationship between DUOX2 and response 
to radiotherapy in rectal cancer cells and assess the involvement of miRNAs. 
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Chapter 2 Materials and Methods 
2.1 Preparation of rectal cancer database 
A tissue bank that contained over 400 colorectal cancer tissue samples had been collated 
between 1998 and 2011 in compliance with the Human Tissue Act. Tissue was frozen 
immediately in liquid nitrogen upon resection from the specimen and stored at -80 °C. The 
information about each tissue pair (normal and tumour tissue) was contained in the Colorectal 
Cancer Tissue Bank Database. A separate database was prepared for our investigation containing 
data on patients with rectal cancer, using the information in the Colorectal Cancer Tissue Bank 
Database. This new database was named the Rectal Cancer Database and contained variables 
such as patient age, type of therapy, date of surgery, recurrence and survival data. It also covered 
information on the rectal tumour: stage, TNM status, amount of invasion and location within the 
rectum, tumour size before therapy and again at the time of surgery. A total of 150 cancers were 
rectal in origin. Part of this information is presented in appendix A.  
A database of rectal cancer patients who had received therapy, pathology data was prepared and 
used to identify patients that had received radiotherapy, chemoradiotherapy or no treatment. 
This database was used to find samples for extraction of miRNA for expression analysis, for in 
situ expression and immunohistochemistry. 
2.1.1 Neo-adjuvant Therapy Rectal Cancer Database  
A successful application was made to the East London Research Ethics Committee (REC) for 
approval to identify biomarkers of response to radiation in rectal cancer. Approval was also 
given to access the pathology archives at The Royal London Hospital to retrieve pathology 
blocks, to take extra biopsies at time of examination under anaesthetic (EUA) prior to 
commencement of neo-adjuvant therapy and to take samples from the resected specimen at time 
of surgery. The research project was approved by the East London REC and given the code 
09/H0703/106. Since approval in December 2009, biopsies were collected at EUA and at 
surgery. The number of patients diagnosed with rectal cancer and who had an EUA in our 
catchment area (The Royal London Hospital) was relatively low with around 10-15 per year. The 
intention was to extend our ethical approval to other collaborating sites, starting with Dr 
Glynne-Jones at Mount Vernon Hospital, for any follow-up studies.  
In order to protect the patient’s identity, a system of numbering the tissue samples, starting with 
001 was used. The biopsy material, labelled with an allocated laboratory number, was collected 
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and no personal details were received about the patient. The clinical care team involved in the 
case provided data on the tumour, therapy received and any other relevant clinical information. 
This data was set out in a database and linked to the allocated number, which was used as the 
only reference throughout the laboratory investigation.  
2.1.2 Tissue expression profiling 
In order to investigate expression of DUOX2 and DUOXA2 in colon and rectal cancer tissue, 
the commercial Gene Logic (Gaithersburg, MD, USA) database of Affymetrix (Santa Clara, CA, 
USA) HG-U133 GeneChip expression microarray data was made available to our lab through 
Genentech Inc., South San Francisco, CA, USA). Normalization was performed according to 
Affy's standard methods by using a reference pool of probe sets across each Chip. The signal 
intensities are linear within a given probe set. Probe sets were queried for the DUOX2 and 
DUOXA2 genes and mined data was supplied by Dr Adrian Judd (Genentech) along with 
pathology summaries for each tissue sample. The summaries were reviewed and any samples 
from patients with diverticulitis, ulcerative colitis and Crohn’s disease excluded from further 
analysis. Microarray signal intensities for the relevant probe sets were then compared between 
normal colorectal mucosal samples (n=129), villous adenomas (n=23) and CRCs (n=99). Signal 
intensities were also compared following division of colorectal samples by site, colonic or rectal. 
Comparisons were also made for both DUOX2 and DUOXA2 between a total of 2,971 tissues 
samples collected from twenty-nine different types of cancers (total number of all cancer 
samples, n=1,198), the relevant benign lesions (total number, n=183) and normal tissues (total 
number, n=1,590) from which the tumours arose. Finally, normal samples (n=1,441) from thirty-
four different types of tissue were compared for microarray signal intensities for both genes.  
2.2 Maintenance of rectal cancer cell lines  
Six rectal cancer cell lines were acquired: C80, C99, HRA19, HT55, SW837 and VACO4S (gift of 
Ian Tomlinson, Wellcome Institute of Human Genetics, Oxford). These cell lines had been 
derived originally from resected rectal carcinomas. Five were of male origin, one (HT55) was 
female and all patients were over 53 at the time of surgery and cell line creation (clinico-
pathological and genetic data in appendix B). The Dukes’ stage of the original tumours ranged 
from Dukes’ B to D (table 5). Mutation status for each cell line had been characterised209-212 
including APC, TP53, KRAS, BRAF and SMAD4, along with 18q21 status (lost in 60 % of 
CRCs) and this deletion includes SMAD2, SMAD4 and DCC213 214 (Appendix B). All cell lines 
are mismatch repair proficient so there is no discrimination in DNA repair between the cell lines. 
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5. Table 5:  Summary of patient age, gender and the Dukes’ Stage of the cancer used to 
produce rectal cancer cell lines 
 Age Sex Tumour Dukes’ stage 
C80  69  M  D  
C99  69  M  C  
HRA19  66  M  B  
HT55  54  F  Unknown  
SW837  53  M  C  
VACO4S  59  M  D  
 
2.2.1 Cell culture conditions  
All cell lines were cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM), with high 
glucose and L-Glutamine (PAA, E15-810). All DMEM was supplemented with 10 % 
volume/volume Foetal Bovine Serum (PAA, A15-151), 1 % penicillin and 1 % streptomycin 
(PAA, P11-010). The cells were incubated at 37 °C in a humidified atmosphere of 5 % CO2/95 
% air. The cells were removed from the bottom of the flask for harvesting, sub-culturing or to 
prepare frozen stocks using trypsin-EDTA (PAA, L11-003) when necessary. To remove the cells 
from the base of the flask, 2-3 ml trypsin-EDTA (10x) was added to each flask and left at 37 °C 
for 5-10 min. Once the cells were visibly coming away from the bottom, they were split into new 
flasks according to their confluence and rate of growth or used for further experiments. The 
medium in each flask was changed at regular intervals of four to five days. DNA, RNA and 
proteins were extracted using the methods below. 
2.3 RNA extraction 
RNA extraction and purification was undertaken as quickly as possible on ice to avoid 
degradation with final volumes stored at -80 °C.  
Tumour samples or biopsies were immediately placed in 500 μl RNAlater (Invitrogen, AM7021) 
to stabilise the RNA. The sample was stored in RNAlater at 4 °C until it was homogenised in 
buffer using a Tissue Ruptor (Qiagen, 9001273), followed by precipitation of RNA with ethanol. 
RNA purification was carried out using the RNeasy mini kit (Qiagen, 74106) in RNeasy spin 
columns, which purifies up to 100 μg total RNA in 35 μl RNase-free water. The resulting RNA 
was quantified using a nano drop and recorded as ng/μl. 
RNA extraction from cell lines was done using the TRIzol® method. 1 ml TRIzol® (Invitrogen, 
15596-026) was added to cells, followed by the chloroform-isopropanol extraction method. 0.2 
72 
 
ml of chloroform was added to the sample, followed by separation of the three phases. The 
uppermost phase was used in further reactions. 0.5 ml isopropanol was added to precipitate the 
RNA into a pellet followed by a wash in 75 % ethanol and then dissolved in 100 μl RNase-free 
H2O. The RNA was then passed through the RNeasy spin columns, according to the protocol 
and finally eluted in 35 μl RNase-free water. The resulting RNA was quantified using a nano 
drop and recorded as ng/μl. 
2.3.1 MiRNA extraction 
MiRNA was extracted from cells and from formalin fixed paraffin embedded (FFPE) tissue. To 
extract the miRNA from cells, the miRNeasy mini kit (Qiagen, 217004) was used to purify total 
RNA including small RNAs. Cells were lysed with 700 μl lysis reagent, incubated at room 
temperature for 5 min followed by the addition of 140 μl chloroform. The tubes were shaken, 
left at room temperature for 3 mins and then centrifuged at 12,000 x g at 4 °C for 15 mins. The 
upper aqueous phase was transferred to a new collection tube and 1.5 volumes of 100 % EtOH 
were added. This was transferred to an RNeasy mini column and the rest of the protocol 
followed, finally eluting total and small RNAs in a volume of 25 μl RNase-free H2O.  
FFPE tumour tissue sections on H&E (haematoxylin and eosin) stained slides were scored by a 
pathologist and the tumour tissue marked out with a thin pen on the back of the slide. Slides 
were cut and H&E stained by the ICMS Pathology Department (Royal London Hospital). Ten 
sections, each of 10 μm were used, producing a final depth of 100 μm (0.1 mm) to reduce cell 
damage and loss of miRNA, as recommended in the protocol. A kit called the RecoverAll Total 
Nucleic Acid Isolation Kit (Ambion, AM1975) was used to isolate the miRNA from these slides. 
The tumour tissue on non-stained slides was scraped off using a scalpel into a centrifuge tube 
and the protocol was followed to deparaffinise, protease digest and isolate the RNA. RNA was 
eluted in 60 μl RNase-free water, the concentration determined by nanodrop and then stored at -
80 °C until needed. 
2.4 DNA extraction 
DNA was extracted from the six rectal cancer cell lines. Medium was removed from the flask, 
cells were trypsinised, spun to collect in a pellet and lysed in 200 μl PBS (Sigma-Aldrich, P4417) 
with 2 % Proteinase K (Qiagen, 19131). The lysate was used for extraction of DNA, which was 
then stabilised using the QIAamp DNA mini kit (Qiagen 51306). EtOH was added to the 
sample and the lysate loaded onto the QIAamp spin column. The washes were followed 
according to the protocol and finally the DNA was eluted in 100 μl PCR (clean) water and the 
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concentration of DNA was determined by nanodrop. The DNA was frozen in 1.5 or 2 ml 
eppendorfs at -20 °C until needed. 
2.5 Protein extraction  
Protein was extracted from the six rectal cancer cell lines and all steps, including when the cells 
were still in the flask, took place on ice to reduce protein degradation. Medium was removed and 
flasks were placed on ice. Cells were washed twice with cold PBS, rocking for 10 min and then 
ice-cold lysis buffer was added. Lysis buffer consisted of Cell Lysis Reagent (Sigma-Aldrich, 
C2978) and Protease Inhibitor Cocktail (Sigma-Aldrich, P8340). Once lysis buffer was added to 
the flask, cells were scraped into one corner and aspirated into a pre-chilled eppendorf. At this 
point, the sample was sonicated on ice for 15 s to disrupt the cell membranes and potentially 
allow the necessary antibody to penetrate further into the cell. The mixture was then spun at 
15,000 rpm at 1 °C for 10 min to pellet the insoluble debris and the supernatant was carefully 
removed to another chilled eppendorf. Following this step, the protein was quantified using the 
protein assay or stored at -20 °C until needed. 
2.5.1 Protein assay 
Nine protein standards, consisting of dilutions of BSA and one water control, were made to give 
eight concentrations of protein (ranging from 800 to 6.25 μg/μl) and a blank control. 31 μl of 
the standards was added in triplicate to a 96 well plate. 1 μl of the samples plus 30 μl of water 
were also added in triplicate. The instructions for mixing the solutions of the Protein Assay (Bio 
Rad, 500-0113, -0114, -0115) were followed and detection solutions added equally to standards 
and samples carefully to avoid creating air bubbles. The plate was inserted into a plate reader and 
the absorbance of each well of the 96 well plate was read at 655 nm. A standard curve was 
generated using the absorbance of the standards and the concentration of each of the protein 
samples was determined from coefficient of the standard curve. Protein samples were stored at -
20 °C until needed for western blot (section 2.11). 
2.6 Methylation 
2.6.1 Bisulfite conversion of DNA 
The EZ DNA Methylation Kit (Zymo Research, D5002) was used to treat the DNA with 
bisulfite to convert unmethylated cytosines into uracil. Cytosines that were methylated (CpG 
sites) remained the same. Once converted, the methylation profile of the DNA was determined 
using specific primers (table 6) to amplify part of the promoter.  
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2.6.2 Methylation specific PCR 
Methylation specific PCR (MSP) was carried out using three primer sets; one non-specific set to 
amplify a large section of the promoter region of DUOX2 (universal primer), and the other two 
primers (MSP and USP) amplified smaller regions depending on methylation status. The 
universal primer was unbiased for CpG conversion sites and was used to amplify most of the 
promoter region, independently of methylation status. The amplified product was used for 
subsequent MSP and USP amplifications. For MSP, the primers only gave a product if the CpG 
regions within the primer were methylated and for USP, the primers only gave a product if the 
CpG regions were not methylated. The methylation status of DUOX2 in the six rectal cancer cell 
lines was tested with universally methylated DNA as a positive control. The PCR conditions 
were followed as described in Luxen et al163 with a slight variation for the USP primers; 61 °C 
annealing temperature for 24 cycles.  The PCR product was run on 3 % agarose gel with 5 % 
ethidium bromide (EtBr) and the bands were visualised using a UV light. A band for the MSP 
primers meant that the CpG sites were methylated where the primer bound. A band for the USP 
primers meant that the CpG sites were not methylated where the primer bound. A band for both 
meant that the DNA was partially methylated. 
6. Table 6: Promoter sequence and primer locations for DUOX2 MSP amplification.  
Promoter sequence of DUOX2: Chromosome 15; 43,173,145 – 43,192,901 
GATGAGCAGGAAGCTTGCTGCTAGAGCCA 
AAAACACTAGAATAACGATGAGCAGTGGAACGCTGAAGCCTGCGGCATGCCGGGGCTGGG 
GGTAAAAAGGCAGTACGCCGTTCCACAGGGTCATGCTGCACGCCGGCCGAGTGCTGCACG 
CAGGCGGGCAGGCAAGCCAGCAAGCTGGGGCTGCCTGGACGCGGGAGAGCGCGTCCTTGG 
CGTCTCTTTGCGTACAAGGCTGGGACCGAGTGGGCTGGTGAAGTCTGAGTCCTGCACCTC 
TCCGTTAAGGAAGCGTGGAGGTGGGCTGCTCTCAACGCTCTGGGGTTGGTACCGACAGAG 
TTTTTCTAGCCGGCGAGCGAAACTATTTCTCACTGTCTGTAGCCGTTACTTTCCTGGTTC 
TGCGGGTTGGCGCTGAGTTTGGAAGTCGCGCGGGACCCCTTTTATAGCAGCGTGGGCGAC 
GTGCCACACGGGTGTCCCAGCCCAGGGGCTGGTCTGAGCTGGAAGAGGTTGTGCAAATAA 
GGGCCCCACCTCCACGGCAGGAGGGTGAGCCCTAGGTCCAGATGCTCACACTGGCGCAGG 
TCTGTCCTGAGCCGACACCTGCACAGTGGCGAGACCAAGGACCCAGAGAGAAAGGTGAGA 
GTG 
DUOX2-Universal-a-F GATGAGTAGGAAGTTTGTTG Annealing: 54C, 35 
cycles DUOX2-Universal-a-R CACTCTCACCTTTCTCTC 
DUOX2-MSP-a-F GTAGTCGTTATTTTTTTGGTTTTGC Annealing: 64C, 18 
cycles DUOX2-MSP-a-R TACGGTAGGAGGGTGAGTTTTAG 
DUOX2-USP-a-F AGTAGTGGAATGTTGAAGTTTGTG Annealing: 61C, 24 
cycles DUOX2-USP-a-R TATGTAGGTGGGTAGGTAAGTTAGT 
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2.7 Pyrosequencing 
This method of sequencing allowed the detection of the activity of DNA polymerase in real time 
as the extension and synthesis of the complimentary strand occurred. DNA was bisulfite 
converted so that the CpG sites that were not methylated were converted to uracil and those that 
were methylated remained the same. The promoter region of DUOX2 was then amplified 
universally (irrespective of methylation) and the methylation status of the CpG sites determined 
by the pyrosequencing method (primers in table 7). This was carried out at the Genome Centre 
(SMD, Barts and The London, QMUL) and the results analysed.  
7. Table 7. Locations of pyrosequencing primers within the DUOX2 promoter region. 
Primers covered all CpG islands (n=39).  
DUOX2 promoter region for pyrosequencing 
GGAAAGGGGTGCTTGCTGCACCAGACTCCTGACTTCACTCCACCTGAGCCTCAATTCGACTATTCATG
GAGGCTCTTGTACAGTCTTACCTGTCCTGGGCCCTCAGGAGACAATCTGCCCATGAGCCTTCCCCCAC
TCTACCTGCACTATGAGGACACCCTTACCGAGTGGCCACGGATCCCCGGCAAGATGAGCAGGAAGCTT
GCTGCTAGAGCCAAAAACACTAGAATAACGATGAGCAGTGGAACGCTGAAGCCTGCGGCATGCCGGGG
CTGGGGGTAAAAAGGCAGTACGCCGTTCCACAGGGTCATGCTGCACGCCGGCCGAGTGCTGCACGCAG
GCGGGCAGGCAAGCCAGCAAGCTGGGGCTGCCTGGACGCGGGAGAGCGCGTCCTTGGCGTCTCTTTGC
GTACAAGGCTGGGACCGAGTGGGCTGGTGAAGTCTGAGTCCTGCACCTCTCCGTTAAGGAAGCGTGGA
GGTGGGCTGCTCTCAACGCTCTGGGGTTGGTACCGACAGAGTTTTTCTAGCCGGCGAGCGAAACTATT
TCTCACTGTCTGTAGCCGTTACTTTCCTGGTTCTGCGGGTTGGCGCTGAGTTTGGAAGTCGCGCGGGA
CCCCTTTTATAGCAGCGTGGGCGACGTGCCACACGGGTGTCCCAGCCCAGGGGCTGGTCTGAGCTG 
DUOX2 Pyrosequencing 1F GAAAGGGGTGCTTGCTGCACCAGACT 
DUOX2 Pyrosequencing 1R ACAGTCTTACCTGTCCTGGGCCCTCAGG 
DUOX2 Pyrosequencing 2F CCTGTCCTGGGCCCTCAGGAGACAAT 
DUOX2 Pyrosequencing 2R GGGTAAAAAGGCAGTACGCCGTTCCACA 
DUOX2 Pyrosequencing 3F GCCGGGGCTGGGGGTAAAAAG 
DUOX2 Pyrosequencing 3R ACAAGGCTGGGACCGAGTGGG 
DUOX2 Pyrosequencing 4F GGGCTGGGGGTAAAAAGGCAGT 
DUOX2 Pyrosequencing 4R GTACAAGGCTGGGACCGAGTGG 
DUOX2 Pyrosequencing 5F CCAGCAAGCTGGGGCTGCCTGGA 
DUOX2 Pyrosequencing 5R GGGTTGGTACCGACAGAGTTTT 
DUOX2 Pyrosequencing 6F CGTGGAGGTGGGCTGCTCTCAA 
DUOX2 Pyrosequencing 6R CCAGCCCAGGGGCTGGTCTGAGCTG 
 
The primers used spanned the whole of the promoter region for amplification for 
pyrosequencing. 
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2.8 Hypoxia 
Six rectal cancer cell lines were incubated for a given period of time under hypoxic conditions to 
investigate the influence of oxygen tension on DUOX2 mRNA expression and the expression of 
other genes and miRNAs. Three different oxygen tensions were used; 0.2 %, 2 % and 20.9 % 
(ambient oxygen or normoxia). The oxygen concentration was controlled by an Invivo2 1000 
Hypoxia Workstation (Ruskinn Life Sciences Ltd) with two chambers, one regulated at 2 % O2 
and the other at 0.2 % O2. The air inside the chambers was constantly sampled and the oxygen 
adjusted accordingly if it differed from the set concentration. 1 x 106 cells per T25 flask (VWR) 
were exposed to a selected oxygen concentration. Cells were seeded into T25 flasks and left for 
24 hours at ambient oxygen in an incubator to allow cells to adhere to the flask surface. After 24 
hours the medium was changed and the flasks moved to the O2 concentration as determined by 
the experiment. Each time cells were exposed to a low oxygen concentration, a matched flask of 
cells was left at normoxia as a control for the same time period. In various experiments the cells 
were either left for 24, 48, or 72 hours (figure 11) and RNA, DNA or protein extraction 
performed immediately upon removal.  
 
11. Figure 11. Timeline for hypoxic experiments. Cells were seeded in normoxia at 0 h, moved to 
hypoxia after 24 h and at 48 h, 72 h and 96 h cells were removed for extraction. 
The concentrations of oxygen used were due to the trade-off between producing a response to 
hypoxia whilst maintaining cells in culture. 2 % O2 was sufficient to induce a hypoxic response, 
but maintaining high cell yields required for the experiments. Despite the large number of studies 
using 1 % O2, 2 % O2 is a valuable experimental condition where HIF-1α has been shown to be 
at half maximal expression indicating a hypoxic response. 0.2 % O2 was used as a much reduced 
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level of oxygen, almost anoxic, in order to determine if the hypoxic response was further 
increased, or similar to 2 % O2.  
2.9 Irradiation 
Irradiation was given to T25 flasks of cells in a biological irradiator from a Cs-137 source. Flasks 
were sealed with parafilm before being transported to the irradiator as some experiments 
involved hypoxic conditions. Flasks were taken to the irradiator in a warm ice-box and the flasks 
placed in the irradiator on level 0, row 6 for 1 min 32 s to give 2 Gy irradiation or on level 2, row 
6 for 1 min to give 0.5 Gy irradiation. For each experimental variable (0.5 Gy or 2 Gy) there was 
a corresponding non-irradiated (sham) flask that acted as a control. The sham-irradiated flasks 
were placed next to the irradiator for the same amount of time but were not actually irradiated. 
The levels of irradiation used were similar to published experiments215 and were used as initial 
low levels of irradiation in order to prevent high levels of cell death.   
The timeline for experimental procedure shows the timing of each part of the irradiation (figure 
12). 
 
12. Figure 12. Timeline of events for the irradiation on hypoxic or normoxic cells. Cells were 
seeded at 0 h, moved to hypoxia at 24 h, irradiated at 48 h and removed at 96 h for extraction. 
 
2.10 Quantitative Reverse Transcription PCR (qRT-PCR) 
2.10.1 cDNA synthesis from RNA 
RNA was converted to cDNA using the RNA to cDNA kit (Applied Biosystems, 4387406). The 
amount of cDNA created using this kit was directly proportional to the amount of RNA in the 
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original sample and so was restricted to 2 μg total RNA per 20 μl reaction. The product of this 
reaction was used as the template for the qRT-PCR. 
2.10.2 qRT-PCR 
qRT-PCR was carried out using the TaqMan system (Applied Biosystems). The gene expression 
assay probe (with FAM, a fluorescent protein), TaqMan universal PCR master mix (ABI, 
4364338) and RNase-free water were mixed together in the correct concentrations to make the 
reaction mix. This was arranged on a plate with 30 ng/μl cDNA template and loaded onto the 
machine (7500 Real-Time PCR machine, Applied Biosystems). The program used was ‘relative 
quantification’ and the PCR cycle followed as given by the machine. Automatic fluorescent 
readings were taken at the extension stage of the cycle and the results recorded. Gene expression 
assays included DUOX2, DUOXA2, HIF-1α, NOX1, LGR5, PRKDC and GAPDH as the 
endogenous control. Experiments were completed a minimum of twice, each experiment 
containing four replicates for mRNA expression. In the legend of each figure n represents the 
number of replicates. 
The results of this program were analysed using SDS software and the Ct (cycle threshold) value 
given indicated the cycle number (out of 40) at which the level of fluorescence crossed the 
threshold value. The threshold value was ‘set to be above the baseline and sufficiently low to be 
within the exponential growth region of the amplification curve’216.  
 
13. Figure 13. An amplification plot from qRT-PCR. The baseline is the initial cycles of PCR in 
which there is little change in signal. Threshold is the level of ΔRn automatically determined by the 
software set to be above the baseline within the exponential growth of the amplification curve. The 
threshold is the line whose intersection with the amplification plot defines Ct.  
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To calculate the relative fold change value, the Ct values were normalised to the endogenous 
control GAPDH using the following equation: ΔCt = Ct target - Ct GAPDH. After 
normalisation, cell line ΔCt values were compared to the calibrator, ΔCt normoxia values using 
the equation to give ΔΔCt values: ΔΔCt = ΔCt Hypoxia - ΔCt Normoxia followed by calculating 
the fold change using the equation: Fold change = 2--ΔΔCt.  The calibrator for hypoxic 
experiments was the untreated control, normoxic cells, and for irradiated or hypoxic experiments 
was the untreated control, normoxic non-irradiated cells. The fold change calculation produced a 
result either between 0 and 0.99 (lower gene expression in hypoxia than normoxia) or above 1 
(higher gene expression in hypoxia than normoxia). Standard error values (SE) were calculated 
using the following equation: SE = SD/√n where SD was the standard deviation and n the 
sample size. 
An assumption of the 2-ΔΔCt method is that the amplification efficiency of the target and 
reference genes is the same i.e. primer-binding efficiency. In order to assess this efficiency, a 
cDNA dilution series could be performed with both target and reference genes, and the gradient 
of the line of best fit on a plot of ΔCt against cDNA dilution determined. If the value of the 
gradient is close to zero, the efficiencies of both genes are similar, and if the efficiencies are not 
similar, further analysis may need to be performed by absolute quantification method217. This was 
not undertaken because primers were produced by ABI and should have been as efficient as 
possible without the need for further testing. However, future experiments would take the 
amplification efficiency into account.  
2.10.3 Justification of endogenous controls 
Normalising the target gene to an endogenous control gene allows a correction for differing 
amounts of input RNA in the initial reaction. In order to determine if GAPDH was the best 
control for the conditions used, other recommended endogenous controls were tested for their 
expression levels in the cell lines used. Initially GAPDH was used along with 18S RNA and 
RPLPO. GAPDH and RPLPO were expressed at similar levels in both normoxia and hypoxia 
and the variance was 0.47 and 0.43 respectively.  This meant that GAPDH was used for all qRT-
PCR experiments as this gene was one of the two best endogenous controls to use for 
expression analysis under hypoxia and normoxia. 
2.11 Western Blot 
After the protein was quantified using the protein assay, the reaction mixture for each sample 
was prepared using water, 2 x Laemmli sample buffer (Sigma Aldrich, S3401), and protein so that 
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there was 100 μg protein per 30 μl sample. This was boiled at 95 °C for 5 min and loaded onto 
the western gel. Protein ladder (Invitrogen, LC5699) was added into the first well and 30 μl of 
the sample buffer loaded into any empty wells to prevent uneven movement down the gel. For 
the electrophoresis step, the gel was subjected to an electrical potential of 180 V for a maximum 
of 2 h. During this step, the proteins separated along the gel in order of size with the smallest 
moving the furthest.  
Once the electrophoresis step was complete, the gel was removed, soaked in transfer buffer 
along with the sponges, filter paper and membrane needed for the transfer step. The PVDF 
membrane was activated in methanol for 10 s before being soaked in transfer buffer. The stack, 
in the correct order (sponge, filter paper, gel, membrane, filter paper, sponge), was assembled 
and loaded into the tank for the transfer step. This consisted of a current of 200 A for a 
maximum of 3 h. The tank was surrounded by ice packs to prevent overheating. The transfer 
step caused the proteins to move from the gel to the membrane.  
Following this step the membrane was blocked with 4 % milk (99 % fat free) in PBS for 1 h at 
room temperature. The gel was left in coomassie blue stain overnight to stain any proteins left 
on it and to determine the quality of the transfer. After the blocking step, the membrane was 
incubated with the antibody at the correct dilution (table 8) in 10 ml milk blocking buffer 
overnight at 4 °C.  
After primary antibody incubation, the membrane was rinsed with ddH2O and then washed 
twice with milk blocking buffer for 10 min, twice with PBST (0.2 % Tween in PBS) for 10 min 
and a further wash in milk blocking buffer for 10 min. After these washing steps, the secondary 
antibody was incubated with the membrane at the appropriate concentration in 10 ml milk 
blocking buffer for maximum of 1 h. Once the secondary incubation was complete, the 
membrane was washed again in milk blocking buffer for 10 min, twice in PBST for 15 min and 
then rinsed with ddH2O. 
The visualising procedure allowed us to detect presence or absence of the protein on the 
membrane. This step consisted of ECL detection reagent (Fisher Scientific, GZRPN2132) mixed 
together in the correct concentrations and added to the membrane. Incubation with the ECL 
was for 5 min after which the membrane was taken to the dark room where photo-receptive 
paper was covered over the membrane and put through a processor to reveal the presence or 
absence of the signal indicating the protein of interest. 
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8. Table 8. The dilutions of antibodies for Western blots. Antibodies were from Becton 
Dickinson (HIF-1α), Santa Cruz (COX2 and EFNA3), Abcam (MCM2), Sigma Aldrich (β actin 
and α tubulin) and Proteintech (ISCU). 
Primary Antibody 
Primary 
Concentration 
Secondary Antibody 
Secondary 
Concentration 
HIF-1α (610959) 1:500-1,000 Goat anti-mouse 1:1,000 
COX2 (sc-1745) 1:400 Rabbit anti-goat 1:30,000 
MCM2 (ab4461) 1:10,000 Goat anti-rabbit 1:10,000 
EFNA3 (sc-73954) 1:200 Goat anti-mouse 1:10,000 
ISCU (14812-1-AP) 1:1,000 Goat anti-rabbit 1:10,000 
β Actin (A5316) 1:10,000 Goat anti-mouse 1:10,000 
α tubulin (T9026) 1:10,000 Goat anti-mouse 1:10,000 
 
For HIF-1α and COX2 analysis, protein lysate from two cell lines were kindly donated by A 
Greenhough and D Hicks (Department of Cellular and Molecular Medicine, University of 
Bristol). These included lysate from SW480 cells incubated under normoxia (HIF-1α negative 
control) and hypoxia (1 % O2, HIF-1α positive control) and lysate from HCA7 cells (COX2 
positive control). 
2.12 In situ hybridisation of DUOX2 
This technique was used to localise DUOX2 mRNA in tissue specimens. An antisense riboprobe 
of 600 bp was formed from a region that did not show significant homology to any other known 
gene sequences. The methods were followed as detailed in Senior et al., 1988218 with 
modifications as detailed in Poulsom et al., 1998219. The presence of hybridisable mRNA in the 
tissues studied was established in serial sections using an antisense β-actin probe. 
Autoradiography at 4 °C was performed before developing. Sections were examined under 
conventional or reflected light/dark-field conditions that allowed individual autoradiographic 
silver grains to be seen as bright objects on a dark background. The Rectal Cancer Database was 
used to select sections for this procedure. 
2.13 Survival assays 
In order to determine the effects of different culture conditions and levels of DUOX2 mRNA 
on cell survival, it is necessary to use colony-formation, sphere-formation and DNA damage 
assays. Colony formation and sphere-formation assays are robust methods to detect changes in 
cell survival after treatment with either hypoxia or radiation and have been used since the advent 
of cell culture220. One of the major problems in using these methods is human error from manual 
counting of colonies; overcoming this problem by using multiple observers increases the 
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accuracy, but is time-consuming and laborious. Improving this further was the introduction of 
computer-based algorithms to automate colony and sphere counting, reducing the error and 
time, increasing the reliability. A freely available densitometric software is ClonoCounter221, 
which has been reviewed well220: the published review found that there was a good correlation 
between the automated programme and the manual counters, and the programme produced 
reliable counts eliminating error after proper calibration. ClonoCounter was therefore considered 
a reliable alternative to multiple manual counting and was used to count the colonies in the 
survival assay. 
2.13.1 Colony-forming assay 
For the selected conditions, cells were trypsinised either after a specific amount of time in 
hypoxia or normoxia or after irradiation in hypoxia or normoxia. Following addition of trypsin, 
cells were counted and 500 seeded onto 6 well plates. The plates were then incubated at 37 °C at 
5 % CO2/95 % air until colonies that were large enough to see with the naked eye were present. 
This generally took 21-27 days and during this time the medium was changed at intervals of 3-5 
days. 3T3 fibroblast cells (kindly donated by Ken Parkinson) were used as feeder cells to restrict 
the movement of C99 cells and used at a seeding density of 1 x 104 per well of a six well plate 
with C99 cells. Once the colonies were visible, wells were washed twice with PBS, fixed with ice-
cold methanol for 5 min and finally stained with methylene blue for 5 min. After 5 min the stain 
was removed and the wells air-dried. Colonies were counted in each well of the 6 well plates and 
recorded. The plating efficiency (PE) was the number of colonies observed/the number of cells 
seeded onto the plate. From the PE, the surviving fraction (SF) (%) was calculated using the 
following equation: SF = colonies counted/cells seeded x (PE/100). This calculation corrected 
for the plating efficiency of the cells222. 
2.13.2 Sphere-forming assay 
Initially, non-adherent plates were prepared by plating a 12 mg/ml solution of polyHEMA 
(Sigma, P3932) in 95 % EtOH onto the bottom of the wells in a 48 well plate and allowing it to 
evaporate overnight. The medium used to suspend the cells was a 1 % Methyl cellulose medium 
(Sigma, M0387). The cells were detached as usual with trypsin and passed through a filter or a 
needle to ensure there were no clumps present. The cells were counted and resuspended at 1 x 
106 per ml in normal medium. 500 μl methyl cellulose medium was placed in the well and 50 μl 
of medium containing cells added on top. This gave 1000 cells per well. The plates were put in 
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the incubator for two weeks and the spheres observed and counted using a microscope once 
they were large enough (>25 cells). 
2.14  CD24 FACS analysis 
Another feature of cancer survival is the number of stem-like cells within the tumour as these are 
directly related to the amount of radio-resistance91 and correlate with tumour recurrence post-
surgery. Cancer stem cells (CSCs) are the cells that are more resistant to IR and if some CSCs 
remain after radiotherapy and surgical excision of the tumour, there is potential for the tumour 
to recur locally91. Chemotherapy is given in addition to radiotherapy in order to sensitise cells to 
the radiation effects and to reduce the recurrence of the cancer from resistant CSCs left after 
surgery223. In order to determine the number of CSCs in a tumour, an adequate stem cell or CSC 
marker must be used and currently these are debatable in CRC. As detailed in section 1.2, in 
2007, Barker et al. found that LGR5 marked colon stem cells in mice and colon cancers122. 
Following this in 2009, ALDH1 was found to be a marker of CSCs in CRC224 and other markers 
include: CD133, CD166, CD44, EpCAM126 and CD24225. In a preliminary investigation towards 
the end of this project, we used the marker CD24 to determine the quantity of stem-like cells in 
two rectal cancer cell lines. This marker was used because it correlates with reduced survival in 
CRC patients226 and Yeung et al.225 determined that CD44+CD24+ cells in CRC cell lines could 
self-renew, were the most clonogenic and were able to initiate tumours in vivo. CD24 is a cell 
surface marker and plays a role in cell interactions, adhesion and proliferation227. CD24 is known 
to be a prognostic marker in breast cancer228, non-small cell lung cancer229, prostate cancer230 and 
ovarian cancer231, but more recently, CD24 has been found not to correlate with prognosis in 
CRC232 despite previous reports linking CD24 expression to shortened patient survival226.  A 
combination of markers is known to improve selectivity of CSCs; co-expression of CD24 and 
CD133 ‘clearly identified the clonogenic cells with high fidelity’233 indicating that a panel of 
markers may better designate CSCs. Although enriching for more than one marker would have 
enabled more specific clonogenicity testing, this was a preliminary experiment and time was 
scarce, therefore only CD24 was used in this experiment.  Despite all the research into CSC 
markers, currently in CRC, there is not one suitable marker that has been proven to mark CSCs 
without fail and so CD24 was adequate for preliminary experiments quantifying stem-like cells. 
For FACS analysis, C80 and C99 cells were grown in normoxic and hypoxic conditions for 72 
hours before being labelled with a FITC-tagged CD24 antibody (Becton Dickinson, 555427). 
Accutase was added to the flasks after aspiration of the media to remove the cells from the 
surface. The cells were collected in DMEM and 10 μl CD24 antibody (1:100 concentration) was 
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added to 1 ml PBS containing 1 x 106 cells. This was incubated in the dark at room temperature 
for 20 min before washing and re-suspending in fresh PBS. DAPI (200 ng/μl final 
concentration) was added to stain the dead cells and the FACS was then performed. Results 
from the FACS were fluorescently analysed to determine the number of CD24 positive cells 
compared to the number of CD24 negative cells. 
FACS sorting was also performed in a similar way to FACS analysis but the resulting CD24 
positive or negative cells were sorted into separate tubes. After all cells were collected from the 
flasks, 500 μl CD24 was added to the suspension and vortexed. The suspension was kept in the 
dark for 20 min at room temperature followed by centrifugation to produce a pellet. The pellet 
was resuspended in 400 μl PBS and 2 μl DAPI (200 ng/μl final concentration), which was then 
ready to use on the FACS machine for flow sorting. Sorted cells were re-seeded into 6 well plates 
and incubated under normoxic conditions for 24 h when RNA extraction was performed. 
2.15 Immunofluorescence 
For immunofluorescence, cells were seeded onto cell culture treated slides (4 wells per slide) 
(VWR, 734-0088) that allowed them to be cultured on a microscope slide, fixed and stained in 
situ. 5 x 103 cells were seeded into each well and 500 μl medium added. Cells were grown to 
confluence, slides moved to hypoxia or normoxia for 24 h, irradiated and returned to hypoxia or 
normoxia for 48 h. At the correct time point, slides were washed twice with PBS, fixed with 4 % 
paraformaldehyde in PBS for 20 min and then stored in PBS in the fridge for up to 24 h.  
In order to access the slides more easily for antibody staining, the wells were removed so that 
only the slide and cells remained. To permeabilise the cells, they were washed three times in PBS, 
fixed with 100 % methanol at -20 °C for 10 min, washed a further three times in PBS and 
permeabilised in PBS-Triton (0.025 %) for 10 min. The slides were then washed three times in 
PBS for 5 to 10 min again before being blocked with 3 % BSA in PBS (blocking buffer) for 30 
min. Following this blocking step, the slides were incubated with the primary antibody diluted in 
blocking buffer overnight at 4 °C. After the primary antibody incubation, the slides were washed 
three times in PBS for 10 min followed by incubation with the secondary antibody protected 
from the light. This antibody was diluted in the same block for 30 min – 1 h at room 
temperature. The secondary antibody was anti-rabbit IgG with FITC conjugated to it. Finally, 
the slides were washed three times in PBS, also protected from the light, followed by the 
addition of mounting medium (Vectashield, Vectorlabs, H-1200) containing DAPI, which was 
used because it passed through the cell membranes to fluorescently stain the DNA. Vectashield 
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was the mounting medium used to stick the glass cover slip in place. One drop was added to the 
slide and a cover slip gently pressed on top. To seal the edges of the cover slip, clear nail varnish 
was painted in a thin line around the edge and allowed to dry. Slides were stored in the dark in 
the fridge for up to 24 h before they were visualised on the Zeiss Meta 510LSM confocal 
microscope. The FITC on the secondary antibody had an absorption wavelength of 495 nm and 
an emission of 528 nm and produced a green colour. DAPI produced a blue fluorescence colour 
with an excitation of 360 nm and an emission of 460 nm when bound to DNA. The confocal 
microscope and its software allowed analysis and accurate imaging. Metamorph software was 
used to analyse the images further and this allowed accurate detection and counting of nuclear 
foci. 
2.15.1 γH2AX antibody 
The primary antibody used was a rabbit polyclonal to gamma H2AX (phospho S139), a DNA 
double-strand break marker and this was used at 1:500 concentration followed by a FITC-tagged 
secondary antibody. 
2.16 MiRNA expression studies 
Initially, a profile of six rectal cancer cells lines, each at two different oxygen tensions, was 
undertaken by the Genome Centre (Queen Mary University of London) using the Illumina 
MicroRNA Universal Array Matrix chip. 2 μg of total RNA diluted in RNase-free water was sent 
in a 1.5 ml eppendorf on dry ice. There were 12 samples sent in total, six pairs of cell lines, one 
of the pair had been in hypoxia for 72 h and the other had been in normoxia for 72 h. Once the 
array was completed, the miRNA expression levels of each pair (hypoxia versus normoxia) were 
analysed against each other (e.g. C80 hypoxia compared to C80 normoxia) to determine the most 
significantly differentially expressed miRNAs using a t-test. After taking account for multiple 
testing using the Bonferroni correction, significance was applied (at p<0.01) and only those 
miRNAs passing this level of significance were considered for further investigation and 
validation.  
2.16.1 QRT-PCR for miRNA 
In order to validate the array findings further, three miRNAs (miR-1296, miR-339-5p and miR-
210) were chosen as they were either differentially expressed between cell lines (upregulated in 
some and downregulated in others, miR-339-5p and miR-1296) or because they were 
consistently different across most cell lines (miR-210).  MiRNA was extracted from two of the 
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cell lines in hypoxia and normoxia, C80 and C99, as per section 2.3.1, in order to test the miRNA 
expression levels. Following on from this validation, miRNA was also extracted from FFPE 
tissue sections and used for testing of miRNA expression levels in tissue (section 2.3.1). MiRNA 
was reverse transcribed using the microRNA Reverse Transcription Kit (ABI) and the miRNA 
expression assay (ABI) followed by qRT-PCR amplification of the miRNA. QRT-PCR 
amplification used ABI microRNA expression assays and the ABI 7500 real-time PCR machine 
and the relative quantification programme. Experiments were completed a minimum of twice, 
each experiment containing three replicates for miRNA expression. In the legend of each figure 
n represents the number of replicates Fold change values were calculated as detailed previously 
(section 2.10.2) using the 2-ΔΔCt method. The calibrator used was the untreated control for 
hypoxic experiments; normoxic cells. The calibrator for the tissue samples was an average of the 
normal tissue. TaqMan miRNA assays used included miR-210 (Cat. no. 000512, miRNA 
sequence CUGUGCGUGUGACAGCGGCUGA), miR-339-5p (Cat. no. 002257, miRNA 
sequence UCCCUGUCCUCCAGGAGCUCACG), miR-1296 (Cat. no. 002908, miRNA 
sequence UUAGGGCCCUGGCUCCAUCUCC), miR-16 (Cat. no. 000391, miRNA sequence 
UAGCAGCACGUAAAUAUUGGCG) and let-7a (Cat. no. 000377, miRNA sequence 
UGAGGUAGUAGGUUGUAUAGUU).  
2.16.2 Endogenous control verification 
Endogenous controls for miRNA expression included RNU43 and RNU6B. RNU43 was 
recommended by Applied Biosystems as a viable endogenous control for cell lines and so was 
used for all miRNA array validation experiments. RNU6B was also recommended but found by 
our experiments to be too variable in the cell lines to be useful as a control. 
For tissue sections, more controls were looked at because although there were recommendations 
for normal tissue controls, there were none for tumour tissue. In the literature miR-16, miR-1260 
and let-7a were recommended and tested in the tissue samples234. The endogenous control with 
the lowest variance in expression was miR-16. Ultimately, miR-16 and let-7a were both used in 
combination as endogenous controls, as recommended by Davoren et al234 for breast cancer 
tissue.  
2.16.3 Immunohistochemistry 
In order to validate the response of miR-210 to hypoxia in tumours, the HIF-1α responsive 
protein, Carbonic anhydrase 9 (CA-IX), was used to stain rectal cancer tumour tissue sections for 
hypoxic areas. ISCU was also validated in the same sections to determine if it was responsive to 
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miR-210. Rectal cancer tissue samples were selected from the Rectal Cancer Database for this 
procedure. Slides were cut (5 μm thick) from FFPE blocks of rectal cancer tissue followed by de-
waxing in xylene, hydration with ethanol (100 %), incubation with peroxidase blockers for 15 
min, followed by 90 % EtOH. The final stage before the antibody incubation was blocking with 
serum from the species the secondary antibody was raised in e.g. goat serum for secondary 
antibody goat anti-rabbit. Primary antibody incubation followed serum blocking; CAIX (Santa 
Cruz) was used at 1:50 dilution and ISCU (Proteintech) was used at 1:100 dilution. Slides were 
washed with PBS and incubated with a secondary antibody (bound to HRP). Slides were further 
washed, incubated with streptavidin-HRP, incubated with DAB to reveal the HRP followed by 
washing in haematoxylin to stain nuclei. Slides were then dehydrated in ethanol and xylene. 
Cover slips were placed on top of the slide and held in place with hard-drying slide mount and 
left to dry. The amount of protein present in each sample was detected under a microscope and 
correlated to the strength of brown-staining.  
Each time immunohistochemistry was undertaken, a control sample was also stained as a 
positive control to determine if the antibody worked correctly and a no-primary antibody control 
to determine that the washes were sufficient and there was not background staining. The CAIX 
control sample was stomach tissue and the ISCU control sample was normal colon tissue. 
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Chapter 3 RESULTS: DUOX2 has varied expression in rectal cancers and 
its expression is affected by changes in oxygen tension 
DUOX2 was selected as a potential marker of rectal cancer response to irradiation (IR) (as 
detailed in section 1.4) because of its production of hydrogen peroxide as a major source of 
ROS. The following sections present results from studies designed to determine if the expression 
of DUOX2 expression makes it a likely candidate biomarker to assess response to neoadjuvant 
radiotherapy. 
3.1 Rectal cancer database 
The Rectal Cancer Database was created to aid the selection of FFPE tumour samples for 
further analysis. The information in this database was obtained from the Colorectal Cancer 
Tissue Bank Database which had collected tissue from over 400 CRC patients at the Royal 
London Hospital between 1998 and 2011. The database (summarised in table 9) included patient 
information, such as age, sex, the date of surgery and the identification (ID) number assigned to 
each patient in order to anonymise the data. The mean age of patients was 68 with 96 male 
patients and 54 female patients (table 9). These numbers corresponded to the published data 
with the average age of rectal cancer at 67.6 years235 and was concordant with the earlier 
observation that the incidence of rectal cancer is higher in males than females (60.5 % male, 39.5 
% female)2 although not at such a  high ratio as in this database (64 % male, 36 % female). 
9. Table 9. A summary of clinico-pathological information in the Rectal Cancer Database. 
Number of patients, n. TNM status as: tumour size, T, regional lymph node involvement, N, and 
distant metastasis, M. (see also Chapter 1.1.4). Mx, distant metastases not evaluable. 
Number of Patients (n) 150 
Sex (n) 96 Male 54 Female 
Age at surgery Median: 68 Range: 19 to 96 
Dukes’ Stage A= 23 B= 58 C/C1=45 C2= 5 D= 7 N/A= 12 
T status (n) T0= 1 T1= 6 T2= 25 T3= 101 T4= 12 N/A= 5 
N status (n) N0= 90 N1= 38 N2= 16 N/A= 6 
M status (n) M0= 38 M1= 10 Mx= 97 N/A= 5 
Resection status (n) R0= 122 R1= 9 R2= 12 N/A= 7 
 
Tumour characteristics were also recorded and included Dukes’ Stage, TNM status, resection 
status, metastasis location (where possible), type and timing of therapy, recurrence and survival 
data. The Dukes’ Stage of the tumours (table 10) show a similar distribution to the published 
data2; however, there were fewer cases in our data where Dukes’ Stage was unknown compared 
to the published data, which may account for the higher number of cases Dukes’ Stage B and C 
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in our data set (table 10). Published data also took into account both colon and rectal cancers so 
the distribution of cases may have been different2. 
10. Table 10. Percentage of rectal cancer cases and 5-year survival by Dukes’ Stage at 
diagnosis compared to published CRC data. Published data from Cancer Research UK 
(1996-2002)2. 
Dukes’ Stage 
at diagnosis 
Percentage of cases (our 
data-rectal only) (%) 
Published percentage of 
cases (CRC)2 (%) 
Published five-year 
survival (CRC)2 (%) 
A 15.33 8.7 93.2 
B 38.67 24.2 77.0 
C 33.33 23.6 47.7 
D 4.67 9.2 6.6 
Unknown 8.00 34.3 35.4 
 
Table 10 shows a similar distribution of cases in our data by stage at diagnosis compared to the 
published data but with fewer unknown cases and more cases at earlier stages. Other data 
included in the database was TNM status, an analogous staging system, although more 
complicated, to Dukes’ Stage (section 1.1.4).  
This database was searched to identify samples for in situ hybridisation, immunohistochemistry 
(IHC) and miRNA analysis. Samples were numbered with ID codes according to the original 
Colorectal Cancer Tissue Bank Database and samples over the number 300 were used because 
they were more recent (post-2007). Fourteen cancer samples and one normal sample were finally 
selected by the availability of FFPE tissue blocks and information regarding these 15 rectal 
cancers is presented in appendix C. 
3.1.1 Pre-operative therapy database. 
This database was set up to contain information about the new biopsy samples that were taken 
before therapy (at EUA, as detailed in section 2.1.1) and at surgery, from rectal cancers. Ethical 
approval was obtained in December 2009 for this biopsy and tumour tissue collection with the 
aim of testing biopsy samples before therapy for expression of the chosen marker and linking 
this with post-surgery marker expression and clinicopathological data. Unfortunately, the lead 
Professor of Surgical Oncology moved to another hospital and a replacement was not found 
who was able to help with the biopsy collection so this part of the project could not continue.  
3.2 Commercially available DUOX2 antibody was non-specific 
In order to determine if DUOX2 was present at the protein level in rectal cancer cell lines, a 
western blot was performed. The image of the western blot is shown in figure 14. 
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14. Figure 14. DUOX2 antibody was not specific. Panel A is a western blot using DUOX2 
antibody (Abcam ab65813) against cell lysate from five rectal cancer cell lines, one colorectal 
cancer cell line (Colo26) and one lung cancer cell line (manufacturer’s recommended positive 
control, A549). DUOX2 molecular weight is 175 kDa. Panel B is a western blot using an 
antibody against β actin as a loading control. β actin molecular weight is 42 kDa.  
The DUOX2 western blot indicates multiple bands for each cell line and no band at the correct 
molecular weight for the positive control. Despite different loading concentrations (β actin), 
there was only a band at the correct molecular weight in SW837 and Colo26. According to the 
supplier of the DUOX2 antibody (Abcam), cell lysate from A549 (also from Abcam) was the 
manufacturer’s recommended positive control for DUOX2 and was tested on two different 
stocks of antibody and A549 cell lysate, but never produced a result.  
The DUOX2 antibody was also tested by immunohistochemistry on rectal cancer samples and a 
normal colon sample (figure 15). 
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15. Figure 15. DUOX2 immunohistochemistry on tissue sections. A, abnormal rectal tissue from 
a block containing rectal cancer; B, normal colon control tissue. IHC was performed following 
the methods in section 2.16.2 with the antibody at a concentration of 1:100. 
As can be seen in figure 15, the DUOX2 antibody did not specifically stain the areas of interest 
in the normal colon control (B). According to El Hassani157, “heavy DUOX staining should be 
found in both the cytoplasm and the brush border of epithelial cells”, but figure 15 B shows mild 
staining in all areas of the outer lining of the intestine and in the mucosa and submucosa. In 
rectal cancer, figure 15 A shows no staining in epithelial cells, but high staining in blood, blood 
vessels and other regions of the lamina propria. Other laboratories have reported similar 
problems with protein blotting and IHC using commercially available antibodies152.  
Note: During the writing up stage of this thesis, a DUOX2 antibody from Novus Biologicals 
became available and was tested for use with western blots and immunofluorescence (IF) by 
colleagues in the laboratory (R Jeffrey and R Poulsom) who have joined the laboratory recently. 
The IF results (supplementary figure) support the mRNA expression analysis in the following 
section and has been included in the thesis for completeness and are acknowledged as the work 
of these two colleagues.  
3.3 DUOX2 shows differential expression between normal colorectal mucosa and 
tumours 
Extensive GeneChip expression microarray data was made available through Genentech, 
following interrogation of the probe sets for the DUOX2 and DUOXA2 genes (expression data 
mined and provided by Dr Adrian Jubb, Genentech). On receipt of the expression data, the 
pathology summaries for each tissue sample were then reviewed and any samples (normal or 
tumour) from patients with diverticulitis, ulcerative colitis and Crohn’s disease were excluded 
from further analysis as DUOX2 mRNA expression is altered markedly in tissues from these 
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patients. Microarray signal intensities for the relevant probe sets were then compared between 
normal colorectal mucosal samples (n=129), villous adenomas (n=23) and CRCs (n=99) (Figure 
16).  
 
16. Figure 16. DUOX2 and DUOXA2 are upregulated in adenomas and colorectal cancers 
relative to normal intestinal mucosa. Data from expression arrays. Normal colon, n=114; 
colon adenoma, n=21; colon cancer, n=81; normal rectal, n=15; rectal adenoma, n=2; rectal 
cancer, n=18. Standard error of mean is indicated by the error bars. * indicates a significant 
difference in DUOX2 and DUOXA2 expression between normal, adenoma and cancerous 
tissues, all p<0.01. 
The expression of DUOX2 in normal colorectal tissue is relatively low and increases significantly 
in both adenomas and cancers with adenomas showing the highest levels of expression 
(adenomas, 10.7 fold over normal mucosa, p=0.0004; cancers, 5.1 fold, p=1x10-10; Figure 16). 
The same pattern of expression is seen for DUOXA2 where expression is again low in normal 
mucosa, but 10.0 fold higher in adenomas (p=0.0002) and 4.8 fold greater in cancers (p=0.009). 
Again, the highest levels of expression were seen in the adenomas. The same pattern of DUOX2 
and DUOXA2 expression indicates that the observed upregulation in tumours is likely to lead to 
an increase in functional protein, as DUOXA2 expression is necessary for maturation of the 
DUOX2 protein. 
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11. Table 11. Summary of statistical analysis for DUOX2 and DUOXA2 expression in 
colorectal tissue. Summaries include the average array expression signal (Mean), Standard error 
of mean (SEM), number of patients (n), fold change in expression compared to normal (Fold) 
and p values to indicate significance. N, normal; A, adenoma; C, cancer. 
DUOX2 Normal Adenoma Cancer 
Mean 512.4 5479.5 2597.3 
SEM 70.2 962.1 288.1 
n 129 23 99 
Fold  10.7 5.1 
P values A vs. C 
p=2.0E-04 
N vs. A 
p=4.0E-05 
N vs. C 
p=1.0E-10 
DUOXA2 Normal Adenoma Cancer 
Mean 136 1362.1 545.3 
SEM 11.3 279.1 58.1 
n 129 23 99 
Fold 
 
10 4 
P values 
A vs. C 
p=9.0E-03 
N vs. A 
p=2.0E-04 
N vs. C 
p=9.0E-03 
 
Other available published data from GEO profiles, NCBI, includes data on DUOX2 and 
DUOXA2 expression in normal colorectal mucosa compared to adenoma expression (figure 17). 
 
17. Figure 17. DUOX2 and DUOXA2 expression pattern in normal and adenoma colorectal 
tissue. Data taken from GEO profiles reported by Sabates-Bellver et al. 2007236. 32 samples for each 
DUOX2 and DUOXA2. 
The data in figure 17 agrees with our expression profile of DUOX2 and DUOXA2 from 
Genentech, indicating that DUOX2 and DUOXA2 expression is lower in normal colorectal 
mucosa than in colorectal adenomas. No data was available for colorectal cancers so a 
comparison was not possible. 
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The summarised data from expression of DUOX2 and DUOXA2 in colorectal tissues indicate 
that the two genes are more highly expressed in adenomas, followed by cancers and that all fold 
changes are significantly different to each other. The results from IF experiments support these 
observations (figure 18).  
 
18. Figure 18. Immunofluorescence detection of DUOX2 protein in two regions of an 
adenoma. The secondary antiserum was labeled with Cy3 (red), DNA in cell nuclei were stained with 
DAPI (blue), some tissue morphology is revealed by autofluorescence in the Cy5 channel (magenta).  
Thanks to Rosemary Jeffery and Richard Poulsom for this figure. 
In figure18, panel A, the region close to the muscularis propria (mu) reveals well differentiated 
epithelium has strong cytoplasmic staining for DUOX2 both above and below nuclei (white 
arrow indicates well orientated epithelium). In panel B, this deep invasive region shows a few 
well differentiated glands (white arrows) retaining strong staining for DUOX2 whereas the 
poorly differentiated tumour epithelium (black arrows) has weaker or borderline positive 
staining.  
Next DUOX2 expression, as measured by signal intensities from arrays, was investigated in the 
colon and rectal tissues separately to assess any differences in expression between the two sites.  
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19. Figure 19. DUOX2 and DUOXA2 are variably expressed between colon and rectal tissue. 
Data from expression array. Normal colon, n=114; colon adenoma, n=21; colon cancer, n=81; normal 
rectal, n=15; rectal adenoma, n=2; rectal cancer, n=18. Standard error of mean is indicated by the error 
bars.  
Notably, there was a 2.3 fold higher level of expression of DUOX2 in the rectum compared to 
the colon, but this was not significant (p=0.1) and there was no difference in fold change 
between the two sites for DUOXA2 (Figure 19). This indicates that there is unlikely to be a 
difference in the levels of functional protein between the two sites. There is also marginally 
higher expression of DUOX2, but not DUOXA2, in rectal compared to colonic cancers. Overall, 
the patterns of DUOX2 and DUOXA2 expression were the same in both colonic and rectal 
tissue with the highest expression in adenomas (All p values <0.006; Figure 19). It is possible 
that elevated DUOX2 expression in adenomas may play a part in induction of further genetic 
damage through production of elevated H2O2 levels. A summary of the statistics of colon and 
rectal tissue expression is presented in table 12. 
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12. Table 12. Summary statistics for DUOX2 expression in colon and rectal tissue types. 
Summaries include the average expression signal (Mean), Standard error of mean (SEM), number 
of patients (n), fold change in expression compared to normal (Fold) and p values to indicate 
significance. N, normal; A, adenoma; C, cancer. 
 Colon Colon Colon Rectum Rectum Rectum 
DUOX2 Normal Adenomas Cancer Normal Adenomas Cancer 
Mean 446.1 5494.8 2289.5 1016.8 5318.7 3982.4 
SEM 64.9 1024.4 309.6 329.3 3711.3 680.6 
n 114 21 81 15 2 18 
Fold  12.3 5.1  5.2 3.9 
p value A vs. C 
p=6.0E-03 
N vs. A 
p=8.0E-05 
N vs. C 
p=9.0E-08 
A vs. C 
N/A 
N vs. A  
N/A 
N vs. C 
p=6.0E-04 
DUOXA2 Normal Adenomas Cancer Normal Adenomas Cancer 
Mean 133.3 1404.1 499.7 157.3 921.1 750.9 
SEM 10.8 301.3 64.4 53.7 663.4 127.3 
n 114 21 81 15 2 18 
Fold 
 
10.5 3.7 
 
5.8 4.8 
p value A vs. C 
p=7.68E-03 
N vs. A 
p=4.0E-04 
N vs. C 
p=2.0E-07 
A vs. C 
N/A 
N vs. A  
N/A 
N vs. C 
p=3.0E-04 
It was not possible to compare the expression levels of rectal adenoma tissue with other rectal 
tissues because there were only two samples available from this study.  
To compare the results for colorectal tissues to other tissues, both normal and tumour, data was 
collated for both DUOX2 and DUOXA2 expression levels from a significant number of samples 
(n=2,971) collected from twenty-nine different types of cancers (total number of all cancer 
samples, n=1,198), the relevant benign lesions (total number, n=183) and normal tissues (total 
number, n=1590) from which the tumours arose. Interestingly, CRC is one of the few cancers 
that have a significant difference in DUOX2 and DUOXA2 expression between normal, benign 
(adenoma) and cancerous tissue (table 13). 
13. Table 13. Expression values of DUOX2 and DUOXA2 in 34 tissue types and their normal, 
adenoma and cancer cells. N = Normal tissue, B = benign tissue, C = cancer tissue and CIL = 
cancer in islets of Langerhans (pancreas), WBC = white blood cell. n = number of tissue 
samples, Mean is the average microarray signal, SEM is the standard error of mean, and p value is 
the significance of the difference in expression between tissue, for example, Brain DUOX2: N vs. 
C p=0.0117, indicates that there was a significant difference (p=0.0117) between DUOX2 
expression in brain cancer compared to normal brain tissue. 
  
DUOX2 expression DUOXA2 expression 
 
n Mean SEM p value Mean SEM p value 
ADRENAL (N) 14 79.5 10.9 
 
145.7 166.3 
 
ADRENAL (B) 12 403.1 245.5 
 
145.4 187.7 
 
ADRENAL (C) 4 5235.6 5102 
 
1365.9 1148.6 
 
BONE (N) 8 70.3 8.4 
 
74.2 31.1 
 
BONE (C) 22 93.7 54.1 
 
83.1 17.2 
 
BONE MARROW (N) 4 24.5 15.8 
 
37 10.3 
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DUOX2 expression DUOXA2 expression 
 
n Mean SEM p value Mean SEM p value 
BONE MARROW (C) 91 58.6 6.3 
 
66.7 15.8 
 
BRAIN (N) 72 39.4 4.6 
 
126.9 12.8 
 
BRAIN (C) 22 22.1 4.8 
N vs. C 
p=0.0117 
53.7 12.8 
N vs. C 
p=0.00014 
BREAST (N) 32 65.7 7.6 
 
55.2 9.5 
 
BREAST (B) 11 362.1 308.9 
 
145.9 73 
 
BREAST (C) 105 92.7 40.6 
 
60.4 8.9 
 
CERVIX (N) 67 312.3 36.1 
 
101.8 11.1 
 
CERVIX (C) 6 1027.3 317.7 
 
207.5 63.4 
 
COLORECTAL (N) 129 512.4 70.2 
N vs. B 
p=0.00004 
136 11.3 
N vs. B 
p=0.0002 
COLORECTAL (B) 23 5479.5 962.1 
B vs. C 
p=0.0002 
1362.1 279.1 
B vs. C 
p=0.009 
COLORECTAL (C) 99 2597.3 288.1 
N vs. C  
p=1E-10 
545.3 58.1 
N vs. C 
p=0.009 
ENDOMETRIUM (N) 16 58.8 12.3 
 
50.3 14.3 
 
ENDOMETRIUM (C) 47 69 10 
 
49.4 7.4 
 
OESOPHAGUS (N) 18 1192.5 215.1 
 
239.6 47.6 
 
OESOPHAGUS (C) 11 2102.6 960.4 
 
379.5 127.3 
 
HEAD & NECK (N) 6 507.6 126.2 
 
287.5 79.7 
 
HEAD & NECK (B) 20 60.6 20 
N vs. B 
p=0.016 
140.8 65.9 
 
HEAD & NECK (C) 20 342 137.2 
 
152.5 43.4 
 
KIDNEY (N) 77 74.9 8.9 
 
133 11.9 
 
KIDNEY (B) 11 95.8 37.6 
 
280.6 73.7 
B vs. C 
p=0.0186 
KIDNEY (C) 68 77 23.8 
 
73.6 8 
N vs. C 
p=0.00006 
LIVER (N) 37 122.5 37.8 
 
112.5 15.6 
 
LIVER (B) 3 72.2 39.1 
 
32.4 6.7 
N vs. B 
p=0.0004 
LIVER (C) 18 121.5 24 
 
108 19 
 
LUNG (N) 105 159.4 14.2 
 
45.7 4.2 
 
LUNG (C) 122 206.4 26.8 
 
94.3 11.2 
N vs. C 
p=0.00008 
LYMPHOID (N) 39 211.9 99.2 
 
52.9 10.1 
 
LYMPHOID (C) 174 72.7 7.7 
 
58 4.3 
 
MYOMETRIUM (N) 159 48.9 3.5 
 
49.6 4.7 
 
MYOMETRIUM (C) 5 64.3 23.4 
 
55.9 21.5 
 
NERVE (N) 15 54.8 12.7 
 
169.3 35.6 
 
NEUROENDOCRINE 
(C) 
20 438.5 210.7 
 
154.6 56.2 
 
OVARY (N) 127 112.7 38.9 
 
54.1 5.5 
 
OVARY (B) 15 198.2 57.8 
 
79.6 18.8 
 
OVARY (C) 94 189.5 64.4 
 
87.8 15.4 
N vs. C 
p=0.0421 
PANCREAS (N) 22 576.9 140.8 
 
167.8 33.9 
 
PANCREAS (B) 5 650.1 392.2 
 
130 64.5 
B vs. C 
p=0.00374 
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DUOX2 expression DUOXA2 expression 
 
n Mean SEM p value Mean SEM p value 
PANCREAS (C) 38 2122.6 293.4 
N vs. C 
p=0.00002 
438.9 67.7 
N vs. C 
p=0.00075 
PANCREAS (CIL) 8 120.5 29.5 
N vs. CIL 
p=0.0043 
68 24 
N vs. CIL 
p=0.02333 
PROSTATE (N) 40 303 145.5 
 
103.5 47.5 
 
PROSTATE (B) 37 211.4 24 
 
112.4 25.6 
 
PROSTATE (C) 70 108 16.3 
 
69.2 7 
 
SKIN (N) 52 147.6 9.7 
 
49.7 5.8 
 
SKIN (C) 11 419.4 254.3 
 
35.3 11.4 
 
S. INTESTINE (N) 171 296.9 85.1 
 
109.1 11.3 
 
S. INTESTINE (B) 3 1546.7 1170.4 
 
221.3 52.2 
 
S. INTESTINE (C) 16 500.3 272.1 
 
212.2 113.4 
 
SOFT TISSUE (N) 3 55.9 24.9 
 
76.9 13.2 
 
SOFT TISSUE (B) 27 63.2 9.4 
 
89 27.6 
 
SOFT TISSUE (C) 61 158 60.6 
 
71.4 13.4 
 
STOMACH (N) 47 1882.5 443.5 
 
396.2 76.4 
 
STOMACH (C) 33 1400 417.9 
 
314.2 77.4 
 
TESTIS (N) 20 544.6 130.9 
 
89.2 15.9 
 
TESTIS (C) 9 103.4 31.7 
N vs. C 
p=0.00358 
43.5 14.4 
 
THYMUS (N) 71 67.9 15.9 
 
67.8 16.5 
 
THYMUS (B) 6 29.6 9.3 
N vs. B 
p=0.04309 
48.6 17.4 
 
THYMUS (C) 4 40.9 16.3 
 
44.6 17.2 
 
THYROID (N) 14 4424.3 426.6 
 
749.4 168.7 
 
THYROID (B) 10 12352.6 3125.7 
N vs. B 
p=0.0327 
1423.4 423.6 
 
THYROID (C) 18 6508.1 1706.7 
 
606.4 174.6 
 
URINARY (N) 8 553.6 215.4 
 
136 47.4 
 
URINARY (C) 26 815.8 285.9 
 
179 67.8 
 
WBC (N) 217 50.9 3.6 
 
56.5 3.9 
 
WBC (C) 48 56.2 8.4 
 
60.1 7.2 
 
 
CRC has significant differences in both DUOX2 and DUOXA2 expression between normal, 
adenoma and cancer (table 13). Interestingly, pancreatic tissue also shows a significant 
upregulation for the DUOX2 and DUOXA2 genes in cancer compared to normal tissue 
(DUOX2, p=0.00002; DUOXA2, p=0.00075) and between cancer of the islets of langerhans 
(CIL) and normal tissue (DUOX2 p=0.0043, DUOXA2 p=0.0233). The role DUOX2 plays in 
pancreatic tumourigenesis warrants further investigation. 
Finally, normal samples (n=1,441) from thirty-four different types of tissue were compared for 
expression array signal intensities for both genes and the results shown in figure 20. 
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20. Figure 20. Variable expression of DUOX2 and DUOXA2 in 34 human body tissues. Data from expression array courtesy of Dr Adrian Judd, 
Genetech. Microarray signal intensities indicating absolute expression of DUOX2 and DUOXA2 in all tissue types. Standard error of mean (SEM) indicated by 
error bars and calculated from the range of signal intensities. WBC, white blood cell. 
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The highest expression of DUOX2 is in the gallbladder, followed by the thyroid and stomach 
(Figure 20). DUOX2 is known to be expressed in the thyroid tissue where, if mutated, can cause 
hypothyroidism162. DUOXA2 expression is lower than DUOX2, but as expected, is increased in 
those tissues with higher DUOX2 expression, e.g. gall bladder. The DUOXA2 expression 
follows the expression of DUOX2 in tissue types other than colorectal tissue. 
Following on from this data, we determined the expression of DUOX2 using an in situ probe to 
determine DUOX2 expression in our rectal tissue samples.  
3.4 In situ hybridisation of DUOX2 mRNA in rectal cancer tissue samples 
DUOX2 mRNA expression and location in rectal cancer tissue was sought using in situ 
hybridisation (ISH). An in situ probe was constructed that was complimentary to the DUOX2 
mRNA and so would be able to locate DUOX2 expression in tissue. The Rectal Cancer 
Database was used to search for appropriate blocks of rectal cancer tissue from which to collect 
slides. Eight rectal cancer samples followed by 13 non-inflamed (normal), 13 inflamed and five 
dysplastic CRC samples were sent for the in situ hybridisation (ISH) (conducted by Richard 
Poulsom and Rosemary Jeffery at CRUK in situ hybridisation service) and the results are shown 
below. 
A         B               C 
 
21. Figure 21. DUOX2 in situ hybridisation of normal, inflamed and dysplastic regions of 
human intestine. A, Normal section of human intestine; B, Inflamed section of human intestine; C, 
Dysplastic section of human intestine. DUOX2 expression is represented by the dark areas in the top 
panel and light areas in the bottom panel. With thanks to Richard Poulsom and Rosemary Jeffery, CRUK 
ISH service. 
ISH demonstrated the location of DUOX2 mRNA in the intestinal epithelial layer (Figure 21). In 
the normal gut section (figure 21, panel A), it is clear that DUOX2 mRNA is located at the 
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surface of the mucosa, near the lumen of the bowel (shown in black in the top panel and white 
in the bottom panel) and closest to where the bacteria would be present. The function of the 
DUOX2 protein to bacteria in the lining of the intestine is to produce hydrogen peroxide in such 
quantities that kills the invading bacterial cell. This response is tightly controlled237 because too 
much H2O2 would damage the cell’s own DNA and too little would allow an invasion of 
bacteria159. During inflammation, such as that associated with UC, DUOX2 expression occurs 
towards, but not into, the crypt (figure 21, B). Infection by bacteria in normal intestinal cells 
causes inflammation and there are proteins, involved in the inflammatory response, that could 
upregulate DUOX2, including p38-mediated activating transcription factor 2 (ATF2), which 
activates transcription of DUOX2. The p38 protein is a well known significantly increased 
protein in IBD and is dependent on the ‘presence and severity of inflammation’238 and, via 
ATF2, could be the mechanism by which upregulation of DUOX2 occurs in our specimens. By 
the time the tissue is dysplastic (figure 21, C) DUOX2 expression is located all along the mucosa 
and in the crypt. 
To correlate ISH data with the tissue expression array data indicating that DUOX2 expression is 
increased in adenomas and cancers, compared to normal tissue, but that adenomatous tissue 
tends to show higher expression than cancer, a CRC section with normal, adenomatous and 
cancer features was assessed for DUOX2 mRNA expression by ISH (figure 22).  
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22. Figure 22. Expression of DUOX2 mRNA in a CRC specimen assessed by 35S riboprobe in 
situ hybridisation and autoradiography. A, a section of FFPE tissue probed for DUOX2 mRNA, 
detected as black autoradiographic silver grains (Giemsa counter stain). B, tracing of all epithelium (red) 
and DUOX2-expressing epithelium (green). C, manual segmentation of regions into ‘normal’ (blue), 
‘adenocarcinoma’ (lilac), and ‘advancing edge adenocarcinoma’ (cyan). D, tracing of normal epithelium 
(red) and DUOX2-expressing epithelium in normal tissue (green). E, tracing of adenocarcinomatous 
epithelium (red) and DUOX2-expressing epithelium in adenocarcinomatous tissue (green). F, tracing of 
cancerous epithelium (red) and DUOX2-expressing epithelium in cancerous tissue (green) (With thanks to 
R. Poulsom and R. Jeffery).  
The ISH of DUOX2 mRNA probe in this tissue section revealed heterogeneous expression in 
the epithelium and the section was divided into areas of normal, adenocarcinoma and advancing 
edge cancer tissue (panel C, figure 22). A DUOX2 in situ probe was used to detect DUOX2 
mRNA and the pattern of staining in each tissue type reflected the results of the DUOX2 
microarray; DUOX2 expression in normal area was the lowest (7.0 %), was increased in 
adenocarcinomatous epithelium (42.7 %) and less prevalent in the advancing edge 
adenocarcinoma (28.0 %), but higher than normal tissue. Over the whole section, tracing of the 
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DUOX2-expression epithelium revealed that about one-third of epithelium was DUOX2 positive 
(36.6 %).  
 Additional rectal cancer sections were also processed for DUOX2 mRNA location and the 
results shown in figure 23.  
 
23. Figure 23. DUOX2 in situ hybridisation in normal and cancer sections. A, normal area of 
specimen removed for cancer; B and C, rectal cancer sections probed for DUOX2 expression. Eight 
rectal cancer samples were probed for DUOX2 mRNA and the control probe was β actin, which showed 
presence in all tumours. In situ hybridisation performed by R. Poulsom and R. Jeffery at CRUK ISH 
service and viewed in light field (left) and dark field (right). 
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Figure 23 shows images of DUOX2 mRNA location in a normal area adjacent to a specimen that 
was removed for cancer and two additional cancerous tissue sections. The pattern of DUOX2 
expression in panel A was similar to that of the inflamed section (figure 21, B) with expression 
on the apical surface of the mucosa and extending partly down towards the crypt. Figure 23, 
panel B shows a high proportion of the cancer section with DUOX2 expression; the gene is 
expressed in most of the surface of the mucosa as well as numerous other areas. In contrast, 
panel C shows expression of DUOX2 in relatively few regions of the cancer. This cancer was 
more disorganised but did show a couple of localised areas of DUOX2 expression (arrow heads). 
Of the eight rectal cancer samples, two showed high DUOX2 expression, five showed moderate 
expression and one showed little or no expression. The ISH experiments suggest that variation 
in levels of DUOX2 expression may exist between rectal cancers, with some cancers having a 
high DUOX2 expression whilst others have low levels of DUOX2 expression. This may relate to 
the degree of promoter hypermethylation within an individual cancer, although other local 
conditions may also influence DUOX2 expression. The variation of DUOX2 and DUOXA2 
from the gene expression profiling in adenomas was undetectable from our analysed data as 
there were only two rectal adenoma samples, however, in rectal cancers, (18 samples) the mean 
microarray signal for DUOX2 was 3982.4 with a SEM of 680.6 and for DUOXA2 the mean 
signal was 750.0, with a SEM of 127.3. The data from the GEO profiles only included 
adenomas, which again had high levels of variation in DUOX2 (Average 6333.8, SEM 712.5) 
with higher variation in DUOXA2 (Average 1929.8, SEM 275.9).  These values indicate that 
there was a reasonably wide range of DUOX2 expression that provided the mean microarray 
signal and these data correlated with the ISH results.  
3.5 The DUOX2 promoter was methylated in rectal cancer cell lines. 
Following the results showing that DUOX2 mRNA was present in rectal adenomas and cancers 
at a higher level than normal mucosa, the DUOX2 promoter was searched for differential 
methylation. The CpG-rich promoter region of DUOX2 is known to be methylated in lung 
cancer, which leads to downregulation of the gene163. Previous data from our research group150 
found that DUOX2 was within a susceptibility locus controlling radiation-induced tumour 
multiplicity in the Min mouse. Based on the two observations, it was predicted that DUOX2 may 
be altered in CRC and the mechanism by which this occurs could be via changes in methylation 
of the gene promoter. Methylation occurs in the promoter region of the gene to prevent 
transcriptional activation and so the methylation of the DUOX2 promoter region was 
investigated in the six rectal cancer cell lines (C80, C99, HRA19, HT55, SW837 and VACO4S) 
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using the methylation specific primers (MSP) on bisulfite-converted DNA (see section 2.6.2) and 
the products of PCR amplification viewed on an agarose gel after electrophoresis. The method 
that was followed for methylation analysis was the same as used in the published study 
describing methylation of the DUOX2 promoter in lung cancer163.  
The six cell lines (figure 24) showed either methylation in the promoter region of DUOX2 based 
on the presence of a PCR product from the MSP primers or no methylation in the promoter 
region of DUOX2 based on the presence of a PCR product from the USP primers.  
 
 
24. Figure 24. The DUOX2 promoter was methylated in six rectal cancer cell lines. A: Location 
of MSP and USP DUOX2 primers indicated with black arrows163. B: The methylation status of the 
DUOX2 promoter in six rectal cancer cell lines. Promoter regions were amplified with a universal primer 
followed by two more specific primer sets, MSP and USP. A band in the MSP PCR (177 bp) indicated a 
methylated promoter region and a band after USP PCR (121 bp) indicated an unmethylated promoter 
region. A band in both indicated partial methylation. Red arrows indicate the three rectal cancer cell lines 
that showed a band after USP PCR. 
The MSP primer analysis (figure 24, top panel of B) shows that all six cell lines had DUOX2 
promoter methylation as there was a PCR product at the predicted band size (181bp) in all six 
cell lines. The USP primer analysis (figure 24, bottom panel of B) shows that three cell lines, 
C99, HRA19 and VACO4S (red arrows) had a PCR product at the predicted band size (115 bp) 
from the USP primers. This means that C99, HRA19 and VACO4S had partial methylation in 
their promoter region because these cell lines had a PCR product from both MSP and USP 
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primers. The presence of a PCR product from MSP primers indicates that the MSP primers 
bound to the DNA because it was methylated and the presence of a PCR product from USP 
primers indicates that the primers bound to the DNA because there was no methylation. A PCR 
product from both MSP and USP primers indicates that the region that the MSP primers 
covered was methylated and the region that the USP primers covered was unmethylated giving 
an overall partial methylation, as in C99, HRA19 and VACO4S. Cell lines C80, HT55 and 
SW837 did not show a PCR product from the USP primers indicating that the USP primers did 
not bind to the DNA because it was methylated and the primers were specific for unmethylated 
DNA. The three cell lines, C80, HT55 and SW837, did have a PCR product from the MSP 
primers indicating that the MSP primers did bind to the DNA because it was methylated. 
Therefore C80, HT55 and SW837 had a methylated DUOX2 promoter region. 
Following MSP and USP analysis, pyrosequencing was used to determine the number of 
methylated and unmethylated sites in the promoter region in each cell line with more accuracy. 
3.6 The DUOX2 promoter was pyrosequenced to determine quantity of 
methylation at each CpG site. 
DUOX2 was pyrosequenced using primers to cover the whole region of the promoter in order 
to determine the amount of methylation at each individual CpG site.  The DNA from six rectal 
cancer cell lines (C80, C99, HRA19, HT55, SW827 and VACO4S) cultured in hypoxia (2 % O2) 
and normoxia conditions were bisulfite-converted and then pyrosequenced by the Genome 
Centre (Charterhouse Square, Barts and The London, Queen Mary University of London). Cells 
were grown under hypoxic conditions as this is a major feature of rectal cancers, which may 
influence gene expression (see also section 3.6.2). The locations of the primers within the 
DUOX2 promoter region are given in methods (section 2.7.1). 
C80 and C99 were the only cell lines that passed pyrosequencing quality control due to DNA 
degradation during the bisulfite conversion process in HRA19, HT55, SW837 and VACO4S. 
The results from C80 and C99 pyrosequencing are shown below. 
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25. Figure 25. DUOX2 promoter was methylated at a low level in C80 cells. C80 cells were incubated under either normoxia or hypoxia (2 % O2) for 72 
hours before DNA extraction. DNA was sent to the Genome Centre (Charterhouse Square, Queen Mary University of London) for bisulfite conversion and 
pyrosequencing. Results were given as a percentage of methylation over each primer pair. Each primer pair covered a maximum of 6 CpG islands. Fully methylated 
control DNA was run alongside C80 N and C80 H to ensure the bisulfite conversion completed properly. N, normoxia; H, hypoxia. 
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26. Figure 26. DUOX2 promoter was methylated in C99 cells. C99 cells were incubated under either normoxia or hypoxia (2 % O2) for 72 hours before 
DNA extraction. DNA was sent to the Genome Centre (Charterhouse Square, Queen Mary University of London) for bisulfite conversion and pyrosequencing. 
Results were given as a percentage of methylation over each primer pair. Each primer pair covered a maximum of 6 CpG islands. Fully methylated control DNA 
was run alongside C99 N and C99 H to ensure the bisulfite conversion completed properly. N, normoxia; H, hypoxia. 
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The DUOX2 promoter in C80 cells was shown in figure 25 to be methylated at a low level. The 
highest percentage of methylation in normoxic C80 cells was in primer pair 6 (36.75 %) and in 
hypoxic cells was in primer pair 7 (16.91 %). The average percentage of methylation in C80 N 
was 9.83 % and in C80 H was 5.78 %. There was a significant difference between DUOX2 
promoter methylation in C80 cells under normoxia and under hypoxia (p=0.012).  
Figure 26 indicates that DUOX2 promoter was methylated to a reasonable level with the average 
level of promoter methylation in normoxic C99 cells was 26.53 and in hypoxic cells 26.69. There 
was no significant difference between DUOX2 promoter methylation in normoxic or hypoxic 
cells.  
The difference between promoter methylation in C80 and C99 cells is presented in table 14.  
14. Table 14. Average DUOX2 promoter methylation in C80 and C99 cells under normoxia 
and hypoxia. Significant differences (p value) shown are between C80 and C99. 
Cell Line Methylation in normoxia (average) Methylation in hypoxia (2 % O2) (average) 
C80 9.83 5.78 
C99 26.53 26.69 
p value p<0.0001 p<0.0001 
 
The results presented in table 14 show that DUOX2 promoter in C80 cells was methylated at a 
low level in both normoxic and hypoxic cells and that C99 cells had just over a quarter of cells 
with DUOX2 promoter methylation in both normoxic and hypoxic cells. The difference between 
C80 and C99 cells under either normoxia or hypoxia was highly significant (p<0.0001) showing 
that C99 cells had significantly higher methylation than C80 cells in both normoxic and hypoxic 
cells.  
The pyrosequencing results in C80 and C99 cells showed opposite results than found from MSP 
analysis (section 3.5), which showed that C80 was methylated and C99 was partially methylated. 
Pyrosequencing is known to be accurate enough to measure percentage bisulfite-converted 
methylation over a promoter region239, however, MSP analysis does not detail the percentage 
methylation of a promoter, and it only gives a representative view of methylation (positive or 
negative PCR product). Therefore, the pyrosequencing results were taken as the more acceptable 
and accurate result showing that C80 cells had a low level of methylation and C99 cells had just 
over 25 % of CpG islands methylated in DUOX2 promoter. 
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Due to the differing level of DUOX2 promoter methylation in rectal cancer cell lines, DUOX2 
mRNA expression was investigated to determine if the level of methylation was biologically 
relevant in normoxia and hypoxia. 
3.7 DUOX2 mRNA expression was upregulated in rectal cancer cell lines 
maintained under hypoxic compared to normoxic conditions. 
Having determined that DUOX2 was fully or partially methylated in rectal cancer cell lines 
(section 3.2), expressed in normal rectal tissue and variably expressed in rectal cancer tissue (in 
situ, section 3.4), the next step was to determine the expression of DUOX2 mRNA in the rectal 
cancer cell lines. As the six cell lines were all partially or fully methylated, DUOX2 would be 
expected to be expressed at a low level in C99, HRA19 and VACO4S (partially methylated), and 
not expressed in C80, HT55 and SW837 (fully methylated).  
The expression of DUOXA2 was also determined in order to assess whether DUOX2, if 
present, would be able to produce an activated protein within the cell. The DUOXA2 protein, as 
described in section 1.4, is the DUOX2 activation factor and expression of this protein is needed 
for complete activation of DUOX2 at the cell surface membrane154.  
This section will also consider whether changes in oxygen tension, similar to those present in 
rectal cancers, can modulate the expression of DUOX2. Accordingly, DUOX2 and DUOXA2 
expression was determined after cell incubation in two different oxygen tensions (2 % and 0.2 % 
O2). HIF-1α expression was also determined to establish if expression was increased in the 
hypoxic conditions described below (section 3.5.2 and 3.5.3). The mechanism of HIF-1α 
upregulation in hypoxia is known to be by protein stabilisation (see section 1.5); however we 
wanted to see if expression was increased at the mRNA level in the rectal cancer cell lines and to 
compared it to DUOX2 and DUOXA2 expression. Under normoxic conditions, HIF-1α is 
targeted for degradation through hydroxylation using O2 followed by ubiquitination and 
degradation. During hypoxia, this process is inhibited due to the lack of available O2 and so HIF-
1α translocates to the nucleus where it binds to and transcribes hypoxia response genes. 
The RNA was extracted from six rectal cancer cell lines in normoxic (atmospheric O2) or 
hypoxic (2 % O2) conditions after 72 h and reverse transcribed into cDNA. The cDNA was then 
used as the template for qRT-PCR using TaqMan probes for DUOX2, DUOXA2, HIF-1α 
(Applied Biosystems), and using GAPDH (Applied Biosystems) as the recommended 
endogenous control. 
111 
 
3.7.1 DUOX2 and DUOXA2 mRNA expression was low in rectal cancer cell lines 
maintained under normoxic conditions. 
After RNA extraction from cell lines and cDNA synthesis, the expression levels of DUOX2, 
DUOXA2 and HIF-1α were determined using qRT-PCR. The results returned a Ct value (the 
point at which the fluorescence generated during the PCR reaction intersected the threshold line) 
between 1 and 40 (maximum number of cycles). A high value indicated a low expression level 
because the fluorescent amplification curve peaked at a later cycle indicating less starting 
material. When Ct values are more than 35, there is often only a single copy of the mRNA target 
and therefore a high level of variation and poorer precision, depending upon amplification 
efficiency. 
15. Table 15. Expression of DUOX2, DUOXA2, HIF-1α and GAPDH in six rectal cancer cell 
lines grown under normoxic conditions for 72 hours. Ct values indicate the cycle at which the 
fluorescent signal of the amplification curve intersects the threshold line. The threshold was set 
automatically for each expression assay by the qRT-PCR software (Applied Biosystems) to be 
within the exponential growth region of the amplification curve. The Ct values are averages of at 
least two experiments each with four replicates (n>8). 
Cell line DUOX2  DUOXA2  HIF-1α  GAPDH 
 Ct ±SE Ct ±SE Ct ±SE Ct ±SE 
C80 34.22  ±0.29 37.25  ±0.61 29.71  ±0.52 22.79 ±0.16 
C99 31.37  ±0.23 33.90  ±0.47 29.49  ±0.32 21.96 ±0.20 
HRA19 36.95  ±0.40 36.16  ±0.34 28.56  ±0.26 21.05 ±0.21 
HT55 35.73  ±0.59 34.74  ±0.37 31.00  ±0.32 22.67 ±0.14 
SW837 35.87  ±0.30 36.02  ±0.33 28.46  ±0.31 22.00 ±0.16 
VACO4S 37.78  ±0.19 37.85  ±0.43 29.70  ±0.40 22.46 ±0.21 
 
The data in table 15 gives Ct values to demonstrate that the expression of DUOX2 and 
DUOXA2 was extremely low. A Ct value above 35 indicated that the expression was very low 
(less than two copies of the mRNA) and hence was not as accurate as a Ct values less than 35, 
which indicated higher mRNA expression. In the experiment, DUOX2 Ct values were all 
between 31.37 (C99) and 37.78 (VACO4S) indicating low levels of DUOX2 expression. C99 had 
all DUOX2 Ct values below 35 and C80 had most Ct values below 35 (24 values out of 29 under 
35, average 34.22) (table 15). The other four cell lines (HRA19, HT55, SW837 and VACO4S) all 
had Ct values over 35 (low expression). The same was also true of DUOXA2 expression: C99 
was one of two cell lines to have Ct values below 35 (average of 33.90 (C99) and 34.74 (HT55)) 
and the other four cell lines (C80, HRA19, SW837 and VACO4S) all had Ct values over 35 (low 
expression) (table 15). However, HIF-1α was not expressed at a low level, as indicated by the 
lower Ct values with all cell lines returning Ct values below 35 (range = 28.46 to 31.00). 
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In summary, Ct values show that DUOX2 and DUOXA2 were expressed at a low level in all cell 
lines with the highest expression of DUOX2 and DUOXA2 in C99. It would appear therefore 
that rectal cancer cell lines have DUOX2 and DUOXA2 expression levels more consistent with 
normal mucosa than adenomas or cancers.   
3.7.2 DUOX2 mRNA expression in rectal cancer cell lines is increased in some lines 
maintained under 2 % oxygen compared to normoxia. 
After DUOX2, DUOXA2 and HIF-1α expression was determined in six rectal cancer cell lines in 
normoxia, the same three gene expression levels were determined for cells maintained in hypoxia 
(2 % O2). Expression was compared to the results for hypoxia to find out if the levels of 
DUOX2, DUOXA2 and HIF-1α were altered by lower oxygen levels. For these experiments, 
cells were incubated for 72 hours before RNA extraction. Hypoxia is a feature of over 50 % of 
rectal cancers and may have an effect on characteristics of the tumour and its response to 
therapy182 and 2 % O2 is a physiologically relevant level of oxygen
240. 
Expression of DUOX2, DUOXA2 and HIF-1α was calculated from the Ct values in normoxia 
and hypoxia, normalised to the endogenous control (GAPDH) to remove background ‘noise’. 
This was followed by calculation of relative fold change values for expression in hypoxia 
compared to normoxia using the equation 2-ΔΔCt as detailed in Livak et al..217 and in methods 
section 2.10.2. This relative fold change in expression indicated the difference in expression 
between hypoxia and normoxia (table 16 and figure 27). 
16. Table 16. Relative fold change in DUOX2, DUOXA2 and HIF-1α expression under 
hypoxia (2 % O2) in six rectal cancer cell lines compared to normoxia. Cells were incubated 
in hypoxia or normoxia for 72 hours prior to RNA extraction. DUOX2 and HIF-1α, n=12; 
DUOXA2, n=8.  
Cell Line DUOX2 DUOXA2 HIF-1α 
 
Relative fold 
change 
± SE 
Relative fold 
change 
± SE 
Relative fold 
change 
± SE 
C80 3.41 0.83 5.12 2.11 0.58 0.09 
C99 27.34 2.26 27.12 5.18 0.72 0.20 
HRA19 66.89 13.18 25.86 12.03 0.58 0.06 
HT55 8.50 2.25 11.44 4.66 0.96 0.14 
SW837 1.06 0.23 0.82 0.17 1.58 0.37 
VACO4S 1.06 0.22 1.39 0.43 1.32 0.30 
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27. Figure 27. Relative fold change in DUOX2 and DUOXA2 expression in hypoxia (2 % O2) 
compared to normoxia in six rectal cancer cell lines. Cells were incubated in hypoxia or normoxia for 
72 hours prior to RNA extraction. DUOX2, n<23 (C80 and C99 experiments completed 6 times; 
HRA19, HT55, SW837 and VACO4S, experiments completed twice (n<8)); DUOXA2, n=8; *, p<0.05.  
Table 16 and figure 27 detail the DUOX2, DUOXA2 and HIF-1α expression differences in 
hypoxia compared to normoxia in six rectal cancer cell lines. For DUOX2, the results indicated 
that HRA19 (66.89 fold) had the most marked fold increase in DUOX2 expression in hypoxia 
compared to normoxia. HRA19 increase in DUOX2 expression was followed by C99 (27.34 
fold) and HT55 (8.5 fold). The fold change values for C80 (3.41) suggested a very modest 
increase in expression in hypoxia whilst SW837and VACO4S showed no increase (1.06 fold in 
both cases). Overall, the range in expression change (1.06 to 66.89) was marked between the cell 
lines and this might indicate different levels or different mechanisms of expression control in 
hypoxia. The data does indicate that in some cell lines the response to changes in oxygen levels is 
rapid and able to overcome any repressive systems that limit DUOX2 expression in normoxia. 
Fold change values for DUOXA2 showed a similar trend to DUOX2 with a large fold increase in 
DUOXA2 expression in C99 (27.12) and HRA19 (25.86) in hypoxia compared to normoxia. 
These two cell lines also had the highest DUOX2 expression in hypoxia. C80 (5.12 fold) and 
HT55 (3.53 fold) both had modest increases in DUOXA2 expression in hypoxia. C80 had a 
higher increase in DUOXA2 than DUOX2 expression in hypoxia (5.12 fold and 1.46 fold) and 
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HT55 had a lower increase in DUOXA2 than DUOX2 expression in hypoxia (8.5 fold and 3.53 
fold). SW837 (0.82 fold) and VACO4S (1.39 fold) both had little change in DUOXA2 
expression, which was markedly similar to DUOX2. The expression of DUOX2 and DUOXA2 
together were comparable to what was expected; namely that DUOXA2 mRNA expression 
would need to be present in order for DUOX2 protein to be activated. The results show that the 
cell lines with the highest DUOX2 expression (C99 and HRA19) had the highest DUOXA2 
expression and the cell lines with the lowest DUOX2 (SW837 and VACO4S) also had the lowest 
DUOXA2 expression. 
 
28. Figure 28. Relative fold change in HIF-1α expression in hypoxia (2 % O2) compared to 
normoxia in six rectal cancer cell lines. Cells were incubated in hypoxia or normoxia for 72 hours 
prior to RNA extraction. HIF-1α, n=12; *, p<0.05. 
Figure 28 demonstrates that HIF-1α expression was significantly decreased in hypoxia (2 % O2) 
compared to normoxia in C80 (p=0.01), C99 (p=0.03) and HRA19 (p=0.0016). HT55, SW837 
and VACO4S had no significant change between hypoxia and normoxia. The significant 
decrease of HIF-1α in C80, C99 and HRA19 indicates that HIF-1α expression was not required 
by the cell and could be a result of accumulation of stabilised HIF-1α protein instead. As detailed 
in Blancher et al241, HIF-1α mRNA expression levels vary between cell lines and the amount of 
HIF-1α mRNA expression was not significantly related to HIF-1α protein levels. In another 
research study, HIF-1α mRNA levels were decreased in different cell lines in response to 
hypoxia, but accompanied by an increase in HIF-1α protein levels and upregulation of HIF-1α 
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target genes242. HIF-1α levels were determined to relate mRNA expression to HIF-1α protein 
expression in a later experiment (see section 4.1). 
The nature of the rapid increase in DUOX2 and DUOXA2 mRNA expression induced by 
changes in oxygen tension in some cell lines warrants comment, particularly that this may be 
linked to bacterial-induced changes in oxygen levels within infected tissue that switches on 
production of H2O2 in response to infection. It is now important to test whether incubation at 
much lower oxygen levels (0.2 % O2) further enhances expression of the DUOX2 genes. The 
results from the 0.2 % O2 incubation are shown below. 
3.7.3 DUOX2 mRNA expression in rectal cancer cell lines increases after incubation 
under 0.2 % oxygen compared to normoxia. 
Although 2 % O2 is a level of oxygen that could be found in tumours, HIF-1α mRNA expression 
was not influenced at 2 % O2 (see section 3.5.3). The maximal response of HIF-1α was seen by 
Jiang et al. (1996) at 0.5 % O2 with high (but not the highest) response at 0.25 % O2
240. This 
lower level of oxygen was used to establish if such a low level of oxygen tension can induce a 
significant change in DUOX2, DUOXA2 and HIF-1α expression compared to at 2 % O2. 
The six rectal cancer cell lines (C80, C99, HRA19, HT55, SW837 and VACO4S) were incubated 
in 0.2 % oxygen for 72 h prior to RNA extraction and the expression of DUOX2, DUOXA2 
and HIF-1α determined by qRT-PCR. The data is presented in the table below (table 17) where 
GAPDH was used as the endogenous control.  
17. Table 17. Relative fold change in DUOX2, DUOXA2 and HIF-1α expression in six rectal 
cancer cell lines in hypoxia (0.2 % O2) compared to normoxia. DUOX2, DUOXA2 and 
HIF-1α, n=8; *, p<0.05.  
Cell Lines DUOX2 DUOXA2 HIF-1α 
 Fold change ± SE Fold change ± SE Fold change ± SE 
C80 15.06 2.90 16.73 6.40 0.55 0.07 
C99 111.84 23.52 67.48 17.15 0.20 0.05 
HRA19 1053.71 83.32 4.56 1.58 0.68 0.15 
HT55 4.01 1.48 3.24 0.48 0.73 0.13 
SW837 0.67 0.20 0.79 0.30 0.35 0.07 
VACO4S 27.05 7.40 12.50 6.14 0.64 0.08 
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29. Figure 29. Relative fold change in DUOX2 and DUOXA2 expression in hypoxia (0.2 % 
O2) compared to normoxia in six rectal cancer cell lines. All cell lines, n=4. * indicates p=<0.05. 
Data labels added for DUOX2 expression in C99 and HRA19 as bars too large to fit on the figure.  
The relative fold change in DUOX2, DUOXA2 and HIF-1α expression in hypoxia (0.2 % O2) 
compared to normoxia are given in table 17 and figure 29. DUOX2 expression levels showed the 
largest increase in HRA19 (1053.71 fold) followed by C99 (111.84 fold) in hypoxia (0.2 % O2) 
compared to normoxia. VACO4S (27.05 fold), C80 (15.06 fold) and HT55 (4.01 fold) followed 
as the third, fourth and fifth largest increase in DUOX2 expression. SW837 (0.67 fold) was the 
only cell line to have a decrease in DUOX2 expression in hypoxia compared to normoxia.  
Compared to DUOX2 expression under 2 % O2, there were similar differences in expression at 
0.2 % O2. The cell line that had a remarkable change from 2 % to 0.2 % O2 was VACO4S (1.06 
fold at 2 % O2 and 27.05 fold at 0.2 % O2) with a large increase in expression under 0.2 % O2 
but no change under 2 % O2. C80, C99 and HRA19 showed similar but more exaggerated 
expression changes in 0.2 % O2 than 2 % O2: C80 (1.46 fold (2 %) to 15.05 fold (0.2 %)); C99 
(25.14 fold to 111.84 fold); HRA19 (66.89 fold to 1058.71 fold). HT55 had a reduced increase is 
DUOX2 expression under 0.2 % O2 (4.01 fold) compared to 2 % O2 (8.50 fold) and SW837 had 
no change in DUOX2 expression under 2 % O2 (1.06 fold) but a reduced expression of DUOX2 
under 0.2 % O2 (0.67 fold) compared to normoxia.  
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Overall, the range in DUOX2 expression (0.67 to 1053.71) was much greater than the range for 
DUOX2 at 2 % O2 (1.06 to 66.89). The larger range in DUOX2 expression at 0.2 % O2 could be 
because 0.2 % O2 elicits a much greater response in terms of elevated DUOX2 expression 
compared 2 % O2 in four (C80, C99, HRA19 and VACO4S) out of six cell lines. At 2 % O2, 
there would not be enough of a reduction in oxygen to initiate the HIF-1α transcription cascade 
but HIF-1α might not be stabilised fully at 2 %, whereas at 0.2 % HIF-1α would be much more 
stable and the response pathway activated to a higher degree. At 0.2 % O2, the HIF-1α 
transcribed genes may be present in greater abundance and the lower availability of O2 may have 
an effect on the expression of DUOX2, as seen in table 5, with a large increase in DUOX2 
expression at 0.2 % O2 compared to normoxia. 
DUOXA2 expression reacted in a similar way to DUOX2 expression in the six rectal cancer cell 
lines at 0.2 % O2 with concurrent increase or decrease in expression of DUOXA2 when DUOX2 
was increased or decreased in hypoxia (0.2 % O2). C80 (16.73 fold), C99 (67.48 fold), HT55 (3.24 
fold), SW837 (0.79 fold) and VACO4S (12.50 fold) all showed similar increases in DUOXA2 
expression to DUOX2 expression under 0.2 % O2. The cell line that did not follow this trend 
was HRA19 which had a much lower increase in DUOXA2 expression (4.56 fold) than DUOX2 
expression (1053.71 fold). This unequal increase in expression of the two genes may indicate that 
the DUOX2 protein, despite extremely high mRNA levels under 0.2 % O2, may not be 
functional within the cell because there was not a simultaneous increase in the expression of the 
maturation factor, DUOXA2, which is needed for activation of DUOX2154. HRA19 may have a 
mutation in the oxygen responsive element in the promoter preventing it from increasing 
expression in response to low oxygen, but also preventing the activation of a functional DUOX2 
protein, as DUOXA2 is required for this role. 
Comparing DUOXA2 expression levels under 0.2 % O2 with those under 2 % O2, it is clear that 
DUOXA2 expression follows DUOX2 expression in both 0.2 % O2 and 2 % O2. The only cell 
line that did not follow this trend was HRA19 where the DUOXA2 increase in expression was 
not as great as the DUOX2 increase in expression under 2 % O2 (DUOX2, 66.89; DUOXA2, 
25.85) and 0.2 % O2 (DUOX2, 1053.71; DUOXA2, 4.56) which could have indicated that the 
DUOX2 protein was not active in this cell line. 
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30. Figure 30. Relative fold change in HIF-1α expression in hypoxia (0.2 % O2) compared to 
normoxia in six rectal cancer cell lines. All cell lines, n=4. * indicates p=<0.05. 
Figure 30 demonstrates that HIF-1α was decreased in all cell lines under 0.2 % O2 but 
significantly in four cell lines (C80, p=0.021; C99, p=0.022; SW837, p=0.013; and VACO4S, 
p=0.039). There was a decrease in expression in HRA19 and HT55 but it was not significant 
(p=0.14 and 0.17, respectively). HIF-1α protein is stabilised during hypoxia with the maximum 
effect at 0.5 % O2 and over three fold induction at 0.25 % O2
240. Potentially, the accumulation of 
stabilised HIF-1α in the cell produces a negative feedback on HIF-1α expression, reducing gene 
expression when HIF-1α protein is accumulated, as seen in Bobarykina et al.242.  
In comparison to HIF-1α expression changes under 2 % O2, HIF-1α expression under 0.2 % O2 
varies the same amount (2 % range was 0.55, 0.2 % range was 0.53) but all cell lines have 
decreased expression under 0.2 % O2, whereas only 4 (C80, C99, HRA19 and HT55) cell lines 
showed decreased expression under 2 % O2.  
Following DUOX2, DUOXA2 and HIF-1α expression under 2 % O2 and 0.2 % O2, the cell lines 
were subjected to two different levels of IR under hypoxia (2 % O2) and normoxia to determine 
the effect of IR on DUOX2 expression. The oxygen tension chosen to perform the IR 
experiments in was 2 % O2 because, although 0.2 % O2 caused a greater effect in gene 
expression, 2 % O2 also caused a gene expression difference compared to normoxia and cells 
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grown under this condition (2 % O2) were more likely to grow and produce enough RNA for 
mRNA expression experiments. The results of the IR experiments are shown in section 3.5.4. 
3.7.4 The influence of irradiation on DUOX2 expression in rectal cancer cell lines. 
Radiotherapy is given to rectal cancer patients in order to shrink the tumour before surgery, as 
detailed in section 1.1.5.4. There is known to be a heterogeneous response to radiotherapy 
(including chemoradiotherapy) in rectal cancers with around 50 % of cancers (42 % tumour 
downsizing, Sprenger et al.83; 56 % partial and complete response, Farnault et al.3; approx. 30 % 
complete clinical response, Glynne-Jones et al.85) showing some form of response to therapy, but 
the remaining cancers did not show any response. This project aims to determine if DUOX2 
expression influences the response of rectal cancers (in this experiment, by using rectal cancer 
cell lines) to radiotherapy. The hypothesis to be tested in this experiment was that if DUOX2 is 
upregulated (e.g. C99 2 % O2), more H2O2 will be produced, which in turn increases ROS levels. 
The abundance of ROS in cells during IR is already known to modulate the effect of IR243 so an 
increased amount of ROS (e.g. C99 2 % O2 has high DUOX2 expression) will cause a decrease 
in cell survival and a better response to IR despite the lower oxygen tension.  
Two rectal cancer cell lines, C80 and C99 were chosen for the investigation of response to IR 
because of their difference in DUOX2 expression under 2 % oxygen (C99 had significantly 
upregulated DUOX2 and C80 had no significant DUOX2 change; see section 3.5.2). The 
DUOX2 expression differences in hypoxia between the two cell lines gave a control with no 
change in hypoxia (C80, low DUOX2 expression) and a subject with an inducible change in 
DUOX2 expression (C99, high DUOX2 under 2 % O2). This allowed comparison of the two cell 
lines after IR. Both cell lines were mismatch repair proficient and there are no mutation 
differences between C80 and C99 to cause differing response to IR. 
Firstly, differences in DUOX2 expression were determined under normoxic conditions after IR. 
C80 and C99 were cultured under normoxia (atmospheric O2) for 24 h prior to IR, followed by 
48 h of recovery in normoxia after IR as detailed in section 2.9. Two levels of IR were used: 0.5 
Gy and 2 Gy, which were known to be physiologically relevant levels of IR for cell lines215. In 
Hermann’s study215, a radiation dose of 0.3 Gy reduced colony-formation (a marker of cell 
survival) to 57 % compared to non-irradiated (No IR) cells. RNA was extracted from these cells 
48 h after IR (72 h after initial seeding) and the expression of DUOX2 determined (table 18).  
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18. Table 18. Relative fold change in DUOX2 expression in cells maintained under normoxic 
conditions and irradiated at 0.5 Gy and 2 Gy compared to normoxic non-irradiated (No 
IR) cells. A fold change value above 1 meant there was an increase in expression in irradiated 
cells compared to No IR cells and a fold change value below 1 meant there was a decrease in 
expression in irradiated cells compared to No IR cells. Cell death was corrected for by the 
normalisation of the target (DUOX2) to the endogenous control (GAPDH). 
Cell Line Irradiation (Gy) DUOX2 fold change ± SE 
C80 0.5 1.07 0.20 
C80 2 1.06 0.16 
C99 0.5 1.70 0.31 
C99 2 1.38 0.24 
 
 
31. Figure 31. Relative fold change in DUOX2 expression in normoxia irradiated cells 
compared to normoxic non-irradiated cells (No IR). A fold change value above 1 meant there was an 
increase in expression in irradiated cells compared to No IR cells and a fold change value below 1 meant 
there was a decrease in expression in irradiated cells compared to No IR cells. Normoxic No IR cells were 
used as the control so the values were 1. n=12; *, p<0.01. 
There was no significant change in DUOX2 expression in irradiated cells compared to No IR 
cells in C80 (1.70 fold and 1.60 fold, table 18 and figure 31). The DUOX2 expression result 
indicates that IR had no marked effect on DUOX2 expression in normoxic C80 cells. DUOX2 
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expression in C99 was increased (1.70 fold) in response to 0.5 Gy IR but this response was 
reduced marginally (1.38 fold) when more IR (2 Gy) was given.  
3.7.5 Effect of hypoxia (2 % O2) and irradiation on DUOX2 mRNA expression 
Following DUOX2 expression in normoxic conditions after IR, DUOX2 expression levels were 
determined in hypoxic cells and results compared to normoxic cells to determine whether 
DUOX2 expression changed after IR under hypoxic culture conditions. Previous experiments 
(section 3.7.2) have shown that DUOX2 expression was increased under hypoxia (2 % O2) in 
C99 cells (25.14 fold) but not in C80 cells (1.46 fold). Previous IR experiments (section 3.7.4) 
have shown that DUOX2 expression was not changed in C80 cells, but DUOX2 expression was 
changed in C99 cells after 0.5 Gy but not after 2 Gy. 
C80 and C99 cells were incubated following the conditions as described in the methods (section 
2.9) under normoxia or hypoxia. After 24 h incubation in hypoxia or normoxia, cells were 
irradiated with either No IR, 0.5 Gy or 2 Gy. Cells were then incubated for a further 48 h in 
either hypoxia (if hypoxic before IR) or normoxia (if normoxic before IR). 48 h after IR, RNA 
extraction was performed to determine DUOX2 expression (Table 19 and figure 32). 
19. Table 19. Relative fold change in DUOX2 expression in irradiated cells, hypoxic cells and 
irradiated hypoxic cells compared to non-irradiated, normoxic cells (No IR).  Sample size, 
n=12. A fold change value above 1 meant there was an increase in expression in irradiated cells 
compared to No IR cells and a fold change value below 1 meant there was a decrease in 
expression in irradiated cells compared to No IR cells. Cell death was corrected for by the 
normalisation of the target (DUOX2) to the endogenous control (GAPDH). N, normoxia; H, 
hypoxia. 
Cell line 
Non-irradiated 
fold change 
± SE 
0.5 Gy 
Irradiation fold 
change 
± SE 
2 Gy 
Irradiation fold 
change 
± SE 
C80 N 1.00 0.00 1.07 0.20 1.06 0.16 
C80 H 5.23 1.06 5.41 1.47 6.46 1.52 
C99 N 1.00 0.00 1.70 0.31 1.38 0.24 
C99 H 57.03 14.54 22.19 4.80 56.17 8.41 
 
122 
 
 
32. Figure 32. Relative fold change in DUOX2 expression compared to normoxic non-
irradiated cells. Sample size, n=12. A fold change value above 1 meant there was an increase in 
expression in irradiated or hypoxic cells compared to normoxic No IR cells and a fold change value 
below 1 meant there was a decrease in expression in irradiated or hypoxic cells compared to normoxic No 
IR cells. Cell death was taken into account by normalising to GAPDH, to reduce the background noise 
and give a constant level of expression to normalise all data to. *, p<0.05. N, normoxia; H, hypoxia; No 
IR, non-irradiated. 
DUOX2 expression was altered in irradiated cells, hypoxic cells and irradiated hypoxic cells 
compared to normoxic No IR cells. As detailed previously (table 18 and figure 31), C80 under 
normoxic conditions does not have a change in DUOX2 expression, however, under hypoxic  (2 
% O2, C80 H) conditions, DUOX2 expression increases (5.23 fold) compared to C80 normoxic 
No IR, but this expression does not alter with the addition of 0.5 Gy IR (5.41 fold, C80 H 0.5 
Gy). DUOX2 expression in C80 H cells increases further with 2 Gy IR (6.46 fold). The 
expression results for C80 indicate that IR does not affect DUOX2 expression in C80 cells under 
normoxic conditions, but that DUOX2 expression is increased in hypoxic C80 cells to a similar 
level with and without IR.  
DUOX2 expression in C99 cells under normoxia (table 18 and figure 31), increases a moderate 
amount (1.70 fold) after 0.5 Gy IR and after 2 Gy there was a lesser (1.38 fold). With the 
addition of hypoxia (2 % O2), DUOX2 expression increases (57.03 fold) compared to normoxia 
No IR, which was similar to the expression described before (section 3.7.2). In hypoxic cells 
after 0.5 Gy IR, DUOX2 expression was increased (22.19 fold) but not to the same level as 
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without IR. After 2 Gy IR in hypoxic cells, DUOX2 expression increases (56.17 fold) to a similar 
level as hypoxic cells without IR. The expression results indicate that DUOX2 expression was 
increased in normoxic cells after 0.5 Gy IR but had a reduced increase after 2 Gy IR. In hypoxic 
cells, DUOX2 expression was greatly increased without IR and after 2 Gy IR, but increased to 
lesser degree after 0.5 Gy IR.  
In summary, 0.5 Gy IR did increase DUOX2 expression in C99 normoxic cells compared to 
normoxic No IR cells and decreased DUOX2 expression in C99 hypoxic cells compared to 
hypoxic No IR cells. However, 2 Gy IR did not have a significant effect on C99 cells under 
either normoxia or hypoxia compared to their normoxia or hypoxia No IR counterparts. In C99 
cells also, it appears that hypoxia was the cause of the major increase in DUOX2 expression and 
2 Gy IR had no effect in either normoxia or hypoxic. Whereas 0.5 Gy IR caused a moderate, but 
significant increase in DUOX2 expression under normoxia compared to normoxic No IR cells, 
and a significant decrease in DUOX2 expression under hypoxia compared to hypoxic No IR 
cells. 
Overall, it appears that 2 Gy IR had no effect on DUOX2 expression in C80 and C99 cells, but 
0.5 Gy IR had a moderate effect on DUOX2 expression in C99 cells. Following these 
experiments, the next step was to determine the differences in survival between No IR cells and 
irradiated cells to discover if DUOX2 expression had an effect on survival and if DUOX2 was 
linked to HIF-1α protein and COX2 protein expression. 
3.8 Discussion 
The data in this chapter combines to give a picture of DUOX2, its regulation and expression 
levels under different conditions. The antibody was found to be non-specific, but the analysis of 
expression profiling data and in situ hybridisation were used to provide a detailed assessment of 
expression at mRNA level instead. The microarray provided expression data detailing that 
DUOX2 and DUOXA2 were expressed in colorectal tissue and that there was a significant 
increase in adenomas and cancers compared to normal tissue. There was no difference in 
DUOX2 or DUOXA2 expression between the two sites, colon versus rectum. In situ analysis 
determined that DUOX2 was present in the apical membranes of intestinal tissue and that 
expression was increased in inflamed regions. This followed published data showing that 
DUOX2 reacts to inflammation and microbial presence in the gut of Drosophila as a mediator of 
host defence; producing H2O2
244. In rectal cancer tissue specimens, in situ analysis showed 
DUOX2 as variably expressed. This was proposed as a possible contribution to a mechanism by 
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which rectal cancers were resistant to radiotherapy; low DUOX2 would cause radio-resistance 
and high DUOX2 would cause radio-sensitivity and expression levels would be dependent upon 
hypoxia.  
Rectal cancer cell lines showed that there were also varying degrees of DUOX2 promoter 
methylation, but that this was not linked to DUOX2 mRNA expression and therefore not likely 
to be biologically relevant with respect to oxygen modulated changes. Methylation has previously 
been proposed to be the control of expression of DUOX2 in lung cancer163, but the same was 
not found in rectal cancer cells. However, DUOX2 was found to be responsive to hypoxia, a 
common feature of rectal cancers182, with C99 and HRA19 exhibiting the highest increase in 
DUOX2 expression under 2 % O2 and 0.2 % O2, which is a novel finding. As DUOX2 is 
responsive to hypoxia, it could determine the fate of a cancer; high levels of DUOX2 could 
increase the amount of available H2O2, which rapidly degrades into water and oxygen, allowing 
increased DNA damage with irradiation, causing more cell death and radio-sensitivity. The 
reverse could be true for DUOX2 low cancers.  
In rectal cancers that have received radiotherapy, almost half respond and the rest do not3. 
DUOX2 was not affected by IR in C80 cell line, but was affected in C99 cell line. Interestingly, 
DUOX2 expression in C99 hypoxic cells was reduced by a very low level of IR, indicating that a 
low level of IR could reduce the killing effect in hypoxic cancers, compared to a high level or no 
IR at all. There was no low-dose IR sensitivity seen in normoxic cells, but a clear decrease in 
DUOX2 expression after a low dose of IR in hypoxic cells. Previous data indicates that low dose 
IR could increase the sensitivity of a cancer in specific circumstances e.g. prostate cancer with 
estradiol or genestein in ER-α and ER-β positive cells215, so it is plausible that low dose IR could 
increase the resistance of rectal cancer cells, by not inducing apoptosis effectively and by only 
causing minor damage.  
In summary, DUOX2 was present in colorectal tissue (increased in adenoma and cancer tissue), 
located in the apical membranes of the human intestine, was present to a higher level in inflamed 
tissue and was variably expressed in our panel of rectal cancer tissue. DNA methylation of 
DUOX2 as a method of expression control was difficult to conclusively determine from our 
data. Not all CpG sites were interrogated and the level of methylation linked to a gene 
expression change was difficult to determine from MSP analysis. Other types of methylation that 
were not researched in this project may also have altered DUOX2 expression e.g. CpG island 
shores as discussed in section 1.2.4. 
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Chapter 4 DUOX2 and DUOXA2 expression changes induced by 2 % O2 
are independent of HIF-1α and COX2 protein expression 
HIF-1α and COX2 protein expression were analysed in order to determine if the DUOX2 
expression results were dependent or independent of the expression of the two proteins. In 
response to low levels of oxygen in a cell, HIF-1α is stabilised by a reduction in its ubiquitination 
resulting in an accumulation of this protein178. An increase in HIF-1α allows its movement into 
the nucleus to bind to hypoxic-response elements (HRE) within gene promoters which induces 
their transcription245. Genes that are activated by HIF-1α (e.g. VEGF) are responsible for 
maintaining oxygen homeostasis and responding to stress induced by low levels of oxygen245. 
COX2 has been shown to be induced by HIF-1α and to be overexpressed in CRC cells184. This 
upregulation of COX2 is HIF-1α-dependent and is an adaptation to low levels of oxygen as it 
functions to upregulate prostaglandins (specifically PGE2) allowing cell survival and growth
184. 
COX2, acting via PGE2, can also stimulate the increase in VEGF, the pro-angiogenesis factor, 
allowing further adaptation to hypoxia184 (further details in section 1.5).  
Here, COX2 protein was investigated to establish if it increased in the rectal cancer cell lines in 
response to the levels of hypoxia known to upregulate DUOX2 mRNA expression. COX2 
protein levels were measured by western blot in hypoxic (2 % O2) and normoxic C80 and C99 
cells; HIF-1α protein levels were also assayed in the same manner as a marker of hypoxic 
response. The western blot technique (methods section 2.11) was used to determine the 
concentration of HIF-1α and COX2 in C80 and C99 cells after incubation under normoxic or 
hypoxic (2 % O2) conditions for 48 or 72 hours. The resulting bands on the blot represented the 
amount of protein present in the cells and the blots were analysed to quantify the protein using 
density measuring software (ImageJ). Antibodies used for the western blots and their working 
concentrations were described in chapter 2.11. Initially the protein was extracted from cells after 
incubation for 48 hours in either normoxia or hypoxia (2 % O2) in order to determine the 
presence of HIF-1α and COX2 and the results shown below.  
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33. Figure 33. HIF-1α and COX2 were not induced under 2 % O2 after 48 h. Western blots 
stained with antibodies against HIF-1α (top), COX2 (middle) and β Actin (bottom) in two rectal cancer 
cell lines, C80 and C99. Cell lines were incubated in either normoxia (N) or hypoxia (2 % O2, H) for 48 
hours prior to protein extraction. Protein from SW480 cells exposed to hypoxia (1 % O2) was used as the 
positive control (HIF-1α+) and protein from the same cell line exposed to normoxia was used as a 
negative control (HIF-1α-). Protein from HCA7 cells, known to have COX2 present, was used as the 
positive control for COX2 expression (COX2+). β Actin was used as a loading control. N, normoxia; H, 
hypoxia. Molecular weights: HIF-1α, 120 kDa; COX2, 72 kDa; β actin, 42 kDa. 
The western blot in figure 33 showed that the HIF-1α protein expression was absent under both 
normoxia and hypoxia (2 % O2) after 48 hours incubation time. The western procedure and 
antibody probe functioned correctly because there was a band, indicating the presence of a 
protein, in the HIF-1α positive control. The lack of HIF-1α protein indicates that these cells 
(C80 and C99) were not stabilising the protein after 48 hours of either normoxia or 2 % O2. It is 
known that HIF-1α responds to levels of oxygen lower than 2 % (peak HIF-1α induction at 0.5 
%) with levels of HIF-1α being very low in HeLa cells at 2 % O2 and the data in figure 31 
supports the published work240.  COX2 expression was also absent in C80 and C99 cells after 48 
hours under both normoxia and hypoxia (2 % O2) but the presence of a band in the positive 
control (COX2+) indicated that the western procedure and antibody probes also functioned 
correctly. The absence of COX2 when there was no HIF-1α present would be expected as 
COX2 is known to be upregulated by HIF-1α. However, COX2 is known to be upregulated in 
CRCs so had a band been present in the COX2 western, without HIF-1α upregulation, it may 
have indicated that COX2 was upregulated independently of HIF-1α in the two rectal cancer cell 
lines. This was not the case, and to summarise, HIF-1α and COX2 were not present in C80 or 
C99 cells after 48 hours of either normoxia or hypoxia (2 % O2).  
For further analysis, density measuring software was used to quantify the protein from the 
western blots (figure 34). β actin was present at an even level in all samples and this was used as 
127 
 
the control during the quantification analysis to reduce differences between loading samples. In 
order to provide a relative level of protein expression, the HIF-1α negative control was used as 
to normalise all data to and this provided a relative level of expression compared to the HIF-1α 
negative control e.g. HIF-1α expression in the HIF-1α positive control was 13.1 times higher 
than the HIF-1α negative control. The quantification of HIF-1α is shown in figure 34. 
 
 
34. Figure 34. HIF-1α protein was not expressed in C80 or C99 cells in normoxia or hypoxia (2 
% O2) after 48 h. HIF-1α relative protein expression in two rectal cancer cell lines under normoxia or 
hypoxia for 48 hours. Lysate from SW480 cells exposed to normoxia (HIF-1α-) and hypoxia (HIF-1α+) 
was used for the controls, with the former used to normalise the expression, therefore HIF-1α- control 
relative density was 1. Standard error (SE) was calculated using the following equation; SE=SD/√n where 
SD was the standard deviation and n the sample size. n=3; *, p<0.01. N, normoxia; H, hypoxia. A relative 
adjusted density value above 1 indicated an increase in HIF-1α expression in the sample compared to 
HIF-1α- and a relative adjusted density value below 1 indicated a decrease in HIF-1α expression 
compared to HIF-1α- control.  
As expected, figure 34 demonstrated that the HIF-1α expression was significantly higher 
(p=0.0047) in the HIF-1α+ control than the HIF-1α- control but this was the only significant 
change in the figure. There was no difference between normoxia and hypoxia (2 % O2) in either 
C80 (1.08, N; 1.25, H) or C99 (1.96, N, 1.61, H) cells indicating that HIF-1α did not respond to 2 
% O2 in these cell lines after 48 h.  
The protein expression of COX2 was also analysed and shown in figure 35. 
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35. Figure 35. COX2 protein expression was not altered by hypoxia (2 % O2) in two rectal 
cancer cell lines. C80 and C99 cells were incubated under normoxia or hypoxia for 48 hours. Lysate 
from HCA7 cells known to express COX2 (COX2+) was used as the positive control with HIF-1α- 
control used to normalise the data (relative adjusted density of 1). Standard error (SE) was calculated 
using the following equation; SE=SD/√n where SD was the standard deviation and n the sample size. 
n=3; *, p<0.05. N, normoxia; H, hypoxia. A relative adjusted density value above 1 indicated an increase 
in COX2 expression in the sample compared to HIF-1α- and a relative adjusted density value below 1 
indicated a decrease in COX2 expression compared to HIF-1α- control.  
Figure 35 demonstrates that COX2 protein expression was not altered by 48 h incubation under 
2 % O2 in C80 or C99 cells. As expected, COX2 expression in the COX2 positive control was 
significantly higher than COX2 expression in HIF-1α- control (p=0.02). Again, this was the only 
significant change with no change in COX2 protein expression in C80 (N or H) or C99 (N or 
H). From this data, it appeared that there could be a link between HIF-1α and COX2 expression 
but because both are not expressed in C80 and C99 under the time (48 h) and oxygen levels 
(normoxia or 2 % O2), a link could not be determined in these lines. 
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36. Figure 36. Relative fold change in DUOX2 and DUOXA2 expression in hypoxia (2 % O2) 
cells compared to normoxic cells after 48 h. Cells were incubated in hypoxia or normoxia for 48 h 
prior to RNA extraction. n<4.  
Figure 36 indicates that DUOX2 expression was highly upregulated in hypoxia in C99 cells after 
48 h hypoxic incubation, but was only upregulated a small amount in C80 cells. When comparing 
DUOX2 expression to the HIF-1α protein expression after 48 h, it was clear that DUOX2 was 
not regulated by HIF-1α as DUOX2 expression in C80 was not highly increased in hypoxia 
despite the increase in HIF-1α protein.  
In order to determine if HIF-1α protein was expressed after a longer period of time in hypoxia, 
cells were incubated under normoxia or hypoxia (2 % O2) for longer, 72 hours, and the results 
shown below in figure 37. 
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37. Figure 37. HIF-1α was induced by hypoxia (2 % O2) after 72 h incubation in C80 and C99 
rectal cancer cells. Western blots showing antibody staining against HIF-1α, COX2 and β actin in two 
rectal cancer cell lines under normoxia or hypoxia for 72 hours. Protein from SW480 cells exposed to 
hypoxia (1 % O2) was used as the positive control (HIF-1α+) and protein from the same cell line exposed 
to normoxia was used as a negative control (HIF-1α-). Protein from HCA7 cells, known to have COX2 
present, was used as the positive control for COX2 expression (COX2+). β Actin was used as a loading 
control. N, normoxia; H, hypoxia. Molecular weights: HIF-1α, 120 kDa; COX2, 72 kDa; β actin, 42 kDa. 
Figure 37 shows clearly the presence of HIF-1α in the positive control (HIF-1α+) and in the two 
cell lines (C80 H and C99 H) when incubated under hypoxia (2 % O2) for 72 hours. HIF-1α was 
not present in C80 or C99 cells under normoxia, in the HIF-1α- control or in the COX2+ sample. 
The western blot stained with the COX2 antibody showed the presence of COX2 in the positive 
control but there was an absence of COX2 in both cell lines during hypoxia and normoxia. 
There was also no COX2 present in either the HIF-1α+ or HIF-1α- controls. Published data has 
shown that COX2 is a direct target of HIF-1α in CRC cells184. However, the HIF-1α expression 
was relatively weak compared to the control and this may have limited COX2 expression. A 
longer time point may have seen a rise in COX2 expression as a consequence of further 
stabilisation of HIF-1α. DUOX2 and DUOXA2 are strongly expressed at the mRNA level after 
48 h (figure 36) and 72 h incubation under 2 % O2.  
Following the western blot, a density measuring software (ImageJ) was used to quantify the 
amount of protein in the western blots. β actin was present at an even level in C80 and C99 cell 
lines, with a small reduction in concentration in the control cell lines (HIF-1α-, HIF-1α+ and 
COX2+), and this expression was used to normalise the COX2 or HIF-1α expression during the 
quantification analysis. The results of this analysis are shown in figure 38. 
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38. Figure 38. HIF-1α protein was induced C80 and C99 cells under hypoxia (2 % O2) after 72 
h. HIF-1α relative protein expression in two rectal cancer cell lines under normoxia or hypoxia for 72 
hours. Lysate from SW480 cells exposed to normoxia (HIF-1α-) and hypoxia (HIF-1α+) was used for the 
controls, with the former used to normalise the expression, therefore HIF-1α- control relative density was 
1. n=3; *, p<0.05. N, normoxia; H, hypoxia. A relative adjusted density value above 1 indicated an 
increase in HIF-1α expression in the sample compared to HIF-1α- and a relative adjusted density value 
below 1 indicated a decrease in HIF-1α expression compared to HIF-1α- control. 
Figure 38 shows that the HIF-1α protein expression in C80 (p=0.012) and C99 (p=0.0068) cells 
after 72 hours of exposure to hypoxia (2 % O2) was significantly increased. There was also an 
expected significant difference between the two HIF-1α controls (p=0.0088) but no change in 
the COX2+ control compared to the HIF-1α- control. Figure 35 and 38 demonstrate that HIF-1α 
protein responded to hypoxia (2 % O2) after 72 hours incubation but did not respond after only 
48 hours incubation.  
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39. Figure 39. COX2 protein expression was not altered by hypoxia (2 % O2) in two rectal 
cancer cell lines. C80 and C99 cells were incubated under normoxia or hypoxia for 72 hours. Lysate 
from HCA7 cells known to express COX2 (COX2+) was used as the positive control with HIF-1α- 
control used to normalise the data (relative adjusted density of 1). n=3; *, p<0.05. N, normoxia; H, 
hypoxia. A relative adjusted density value above 1 indicated an increase in COX2 expression in the 
sample compared to HIF-1α- and a relative adjusted density value below 1 indicated a decrease in COX2 
expression compared to HIF-1α- control. 
Figure 39 demonstrates that COX2 expression was not altered by 72 h incubation in hypoxia (2 
% O2) despite HIF-1α upregulation (figure 38). This disparity in results indicates that COX2 
expression in C80 and C99 cells was independent of HIF-1α because when HIF-1α was 
upregulated (figure 38), there was not a concurrent upregulation of COX2 (figure 39). In fact, 
COX2 was not expressed in C80 or C99 cells under either normoxia or hypoxia. The COX2 
positive control was the only result to show a significant increase (p=0.01) compared to the HIF-
1α- control. The two HIF-1α controls showed equal, very low, amounts of COX2 (1.00 and 1.02 
relative density) with no difference between the two.  
Despite the increase in HIF-1α after 72 hours hypoxic incubation, there was no change in COX2 
expression as might be expected from published data184. The result seen in figure 38 and 39 may 
be due to the different types of cancer cell lines used and a weaker stabilisation of HIF-1α; Kaidi 
et al. used two CRC cell lines and two colorectal adenoma cell lines to prove that COX2 is a 
target of HIF-1α and also incubated their cells under 1 % O2 compared to our 2 % O2. 
The lack of COX2 expression at both time-points (48 h and 72 h normoxia or hypoxia) indicates 
that COX2 expression was independent of HIF-1α expression. This means that COX2 did not 
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show a response in expression when HIF-1α expression was increased in the two cell lines (C80 
and C99 hypoxia, 72h).  
4.1 Discussion 
HIF-1α was upregulated in response to 2 % O2 in C80 and C99 rectal cancer cells only after 72 
hours, not 48 hours incubation time. COX2 was not present either in normoxia or hypoxia at 
any time point during the experiments and the upregulation of HIF-1α is limited and has not 
influenced COX2 expression. Published data in CRC cell lines indicates that COX2 upregulation 
occurs in response to HIF-1α expression and that it is a vital hypoxia-adaptive response step184. 
HIF-1α expression increases exponentially as oxygen levels fall below 6 % O2
240 and in colorectal 
cancer cells responds to low oxygen levels within 3 hours184. The key differences between our 
data and the published work is the oxygen tension used (2 % O2 vs. 1 % O2) where 2 % O2 may 
produce a much weaker HIF-1α response than 1 % O2. Although in our cells, HIF-1α was 
upregulated at 72 h, it may have been upregulated prior to 48 h incubation; however, the increase 
in HIF-1α stability may have taken longer due to the higher oxygen level used.  
It was interesting to note that the HIF-1α mRNA expression levels (chapter 3), although variable 
between cell lines under normoxia, were not changed by hypoxia in three rectal cancer cell lines 
and significantly downregulated in the other three cell lines. In contrast, protein levels increased 
in response to hypoxia. Published work shows a similar effect in renal cell carcinoma (RCC) 
where there was a significant inverse correlation between mRNA and protein levels of HIF-1α246. 
In breast cancer cells, the same was also shown, with a decrease in HIF-1α mRNA during 
hypoxia accompanied by an increase in HIF-1α protein242. Therefore, our data supports 
observations reported in the literature. 
In relation to DUOX2 expression, section 3.7.2 (figure 28) details that DUOX2 expression was 
significantly increased in C99 cells under hypoxia (2 % O2, 72 h) but there was no change in 
DUOX2 expression in C80 cells in hypoxia compared to normoxia (72 h). The increase in HIF-
1α protein expression in C80 H indicates that DUOX2 expression was likely to be independent 
of HIF-1α because DUOX2 expression did not change in C80 H. C99 however, shows an 
increase in both DUOX2 expression and HIF-1α protein expression after 72 hours hypoxic 
incubation compared to normoxia. The concurrent increase of DUOX2 and HIF-1α (at 72 hours 
in C99) could indicate that DUOX2 was HIF-1α-dependent. However, since both C80 and C99 
cells showed HIF-1α upregulation after 72 hours in hypoxia, it is unlikely that DUOX2 
expression was HIF-1α-dependent in rectal cancer cell lines. The expression of both DUOX2 
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and DUOXA2 is not linked to the expression of COX2 due to the lack of COX2 expression in 
the cell lines where DUOX2 and DUOXA2 were both highly expressed. DUOX2 and DUOXA2 
expression at the 48 h time point (figure 36) was high in C99 cells (41 fold and 31.1 fold 
respectively) and low in C80 cells (3.4 fold and 0.8 fold respectively) confirming that HIF-1α 
presence does not cause DUOX2 upregulation as the presence of the HIF-1α protein was 
minimal at 48 hours.  
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Chapter 5 DUOX2 expression causes differences in cell survival, DNA 
damage and response to irradiation 
In order to determine the effect of DUOX2 upregulation and IR in C80 and C99 cells, cell 
survival and DNA damage analyses were completed. C80 and C99 cells were chosen because of 
their differences in DUOX2 expression after 72 hours under hypoxia (2 % O2); C80 had no 
change in DUOX2 expression and C99 had a significant increase in DUOX2 expression in 
hypoxic compared to normoxic cells (section 3.7.2). Survival analyses consisted of colony-
formation assays (section 5.1) and sphere-formation assays (section 5.2) and DNA damage was 
measured using γH2AX immunofluorescence (section 5.4). The survival assays and DNA 
damage quantification were completed on C80 and C99 rectal cancer cells under normoxia, 
hypoxia and after IR to assess the effect of hypoxia-induced DUOX2 expression and IR on cells. 
5.1 Colony-formation assay 
The colony-formation assay measured the rate of colony-formation, indicating the number of 
cells that survived treatment. Colony-formation is the ‘gold standard’ test of cell survival and 
radiosensitivity because it gives an indication of the rate of DNA repair and the impact this has 
on cell replication and survival220. A colony is a cluster of cells originating from one cell and the 
number of colonies is proportional to the number of cells that survived treatment (in this study, 
hypoxia or IR).  
The ClonoCounter programme221 was used to determine the number of colonies present in a 
well after hypoxic (2 % O2), normoxic or IR treatment. It is a freely available programme that 
used densitometric analysis to determine the number of colonies. A previous study220, 
independent to the creators of ClonoCounter, reviewed the counting ability of the software 
compared to manual counting by two skilled investigators. The results showed that there was a 
positive correlation between manual and automatic counting, that there were no significant 
differences in survival curves or other parameters tested and that ClonoCounter performed 
highly reproducible counts with minimum time and effort. For the reasons stated in the study220, 
and that other groups had also used it and published their results247, we decided to use 
ClonoCounter to count the colonies.  
C80 and C99 rectal cancer cells were grown in six-well plates (section 2.13) for 72 hours in 
hypoxia (2 % O2) or normoxia with IR after 24 hours (section 2.9). Following IR and incubation 
under hypoxia or normoxia, cells were fixed and stained with methylene blue and analysed using 
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colony-counting software221. An example of the analysis process using ClonoCounter of one well 
is shown below (figure 40). 
 
40. Figure 40. Screenshot of initial capture of one well of C80 colonies using ClonoCounter. 
The scanned image of the six-well plate was uploaded to the ClonoCounter221 software, a colony-counting 
programme. A red circle was drawn around the well of interest and the region to be captured (A). The 
image within the red circle was transferred to panel B in preparation for analysis. The culture area was 9.6 
cm2 per well. 
Figure 40 shows a screenshot of the ClonoCounter programme preparing an image for analysis. 
Once the cells on the six-well plate had been stained and dried, the plate was scanned and the 
image (.jpeg) was uploaded onto the programme. The scanned image of the six-well plate 
appeared in panel A and in order to count the colonies in one well, a circle was drawn around 
the well by hand. The red circle indicated the area of the image that contained the colonies to be 
counted. Once the red circle was in place, the image within the circle was transferred to panel B 
for analysis (figure 41).  
 
41. Figure 41. Screenshot of ClonoCounter analysis of one well of a six well plate of C80 
colonies. Using the image of the scanned six-well plate (A) and three settings; grey scale, number of 
pixels per colony and colony overlap, the ClonoCounter programme calculated the number of colonies(B, 
highlighted in green), whilst eliminating those that were too small (red) or not deemed colonies (grey).  
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Figure 41 details the colony-counting ability of ClonoCounter by assessing the area, colour scale 
and colour distribution within each colony. The area was calculated using the number of pixels 
per colony and this was set to between 2 and 4, depending on the size of the colonies in the 
plate. The colour scale (threshold) was from 0 (black) to 255 (white) and was set to eliminate the 
background colour leaving the colonies (much darker than background). For each scanned image 
the colour scale was marginally different and occasionally within the scanned image one well was 
darker than another, but for analysis, all threshold values were set to either 40 or 50 (depending 
on level of background colour) so that all gray levels above 50 were omitted and only the darkest 
pixels remained (colonies). The final parameter to set (gray width) was the most complicated part 
and it ‘tries to imitate the human eye, which is able to recognise single colonies from clustered 
colonies’221 by defining the number of gray levels considered to be one colony. The programme 
defined a colony by first realising the darkest points in the image (assuming that the centre of the 
colony would be the darkest) and then analysing the neighbouring shade. The gray width is the 
‘maximum allowed difference between the gray shades belonging to one colony’221. Decreasing 
the gray width resulted in a smaller colony size and allowed easier differentiation between 
clusters. The gray width was set to 2 (minimum, 0; maximum, threshold value) for all images 
indicating that points below 2 gray levels in difference were the same colony and points above 2 
gray levels in difference were separate colonies. 
After analysis by ClonoCounter, the results were collated and analysed to determine the average 
percentage of surviving cells for C80 under either hypoxia (2 % O2) or normoxia, with and 
without IR (No IR, 0.5 Gy and 2 Gy) and the results displayed in figure 42.   
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42. Figure 42. No difference in survival of C80 rectal cancer cells under normoxic or hypoxic 
(2 % O2) conditions and at three levels of irradiation (No IR, 0.5 Gy or 2 Gy). N, normoxia; H, 
hypoxia; No IR, non-irradiated (placed in the irradiation chamber but not irradiated). The number of 
colonies under N, No IR allowed calculation of the plating efficiency (PE) for each experiment (overall 
average = 0.49). The PE was used in the following equation to calculate the percentage of surviving cells; 
SF = colonies counted/cells seeded x (PE/100) where SF is the surviving fraction, PE is the plating 
efficiency and the number of cells seeded was 500. C80 cells under each condition were normalised to 
C80 normoxia, non-irradiated (N, No IR) cells. Sample size, n=10 (C80 N 2 Gy) to 24 (C80 N No IR).  
All survival values in figure 42 were compared to normoxic, No IR cells, which had survival of 
100 %, e.g. C80 H No IR cells had 24.27 % more cells surviving than C80 N No IR cells. Figure 
42 shows that there was no significant change in survival in C80 cells with and without IR under 
either hypoxia (2 % O2) or normoxia (range = 78.8 to 129.24 %). In normoxic cells, there was a 
small (5.4 % and 1.57 % respectively) but not significant decrease in survival with the addition of 
0.5 Gy and 2 Gy IR. The unaltered survival indicates that C80 cells were intrinsically radio-
resistant or that the dose of IR given was too low to have an effect. 
In hypoxia (2 % O2), there was no significant change in survival compared to normoxic cells. 
There was a small unexpected increase in survival (24 % more survival than N, No IR) compared 
to the normoxic cells that contradicted the prediction that hypoxia would decrease the survival 
of cells due to the reduction in oxygen availability. Cell survival would be expected to decrease 
under hypoxia because cell division is O2-depedent; hypoxia causes a decrease in cell 
proliferation because an increase in cell number would only increase O2 consumption
248. 
However, slightly reduced O2, as used in these experiments (2 % O2), may confer a survival 
advantage through changes in metabolism as the tumour cells may already be adapted to survival 
at low O2. 
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From previous experiments (section 3.7.5), DUOX2 was significantly increased (5.23 fold, 
p=0.02), in C80 hypoxic compared to normoxic cells, which could explain the increase in 
survival; an increase in DUOX2 would mean an increase in H2O2 production, potentially causing 
an increase in growth rate due to the H2O2 action on targets involved in cell cycle, signal 
transduction and transcription249. H2O2 has been seen to increase cell number by 50 % after 4 
days compared to the same cell line without H2O2
249. With the addition of 0.5 Gy IR to hypoxic 
(2 % O2) cells, survival was 78.86 %, 21% less than the survival of normoxic No IR cells. The 
decrease in survival could be caused by the killing effect of IR on the cells, although the decrease 
was not significant. After 2 Gy IR, the survival increased (129.24 %) again to a similar level of 
C80 hypoxic No IR cells (124.27 %). The DUOX2 expression (section 3.5.5) in C80 H 0.5 Gy 
(5.41 fold) and C80 H 2 Gy (6.46 fold) cells was significantly increased compared to normoxic 
No IR cells but the DUOX2 expression did not vary between hypoxic cells with or without IR 
(p>0.05). The variation in cell survival (higher in C80 H No IR and C80 H 2 Gy, lower in C80 H 
0.5 Gy) in irradiated C80 cells under hypoxia could not be due to DUOX2 expression because 
DUOX2 expression did not vary in these cells.  
Unfortunately C99 cells did not form colonies in this assay (figure 43, B) because either the 
motility of the cells was too high to allow clumps of cells to form, or the cells did not grow well 
at the low densities required for this assay. Feeder (3T3 fibroblast) cells were used in addition to 
C99 cells in an attempt to reduce the motility of C99 cells so that colonies would form, but again, 
C99 cells did not form colonies even with the addition of 3T3 cells. Also, an increased number 
of cells (1,000) were seeded into each well of the plate but the cells still did not form colonies. 
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43. Figure 43. C99 rectal cancer cells did not form colonies. C80 cells (A) formed colonies in all 
culture conditions (normoxia, hypoxia (2 % O2) and irradiation). C99 No IR cells (B) under normoxia did 
not form clumps of cells or colonies so the colony-counting programme, ClonoCounter, could not 
perform any analysis. The same was true for all C99 cells under normoxia, hypoxia (2 % O2), with and 
without irradiation.  
Figure 43 demonstrates the lack of colonies in C99 (B) cells compared to C80 (A) cells. 
Unfortunately survival analysis was not, therefore, available for C99 cells. 
Due to the lack of C99 colonies and in an attempt to determine the number of stem-like cells in 
C80 and C99, which may impact on the resistance of cells to IR, a sphere-formation assay was 
performed. 
5.2 Sphere-formation assay 
Sphere-formation assays are used to determine the cells with proliferative and tumour-initiative-
capacity250. These are the cells that are able to form spheres in suspension in vitro and a sphere-
forming assay is ‘the ultimate test for stem properties [of the cell] if they can form a tumour from 
a single cell’250. Therefore, the number of spheres correlates to the tumour-initiating capacity; the 
ability to form a tumour. CRC cells have been sorted into CD44 and CD133 positive and 
negative populations and sphere-forming assays conducted, along with xenografting into mice, to 
show that these two proteins were markers of tumour-initiating cells250. This marker is further 
discussed in the discussion. In this experiment, C80 and C99 rectal cancer cells were seeded into 
suspension culture (section 2.13.2 for methods) to determine the tumour-initiating capacity. 
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C80 and C99 rectal cancer cells were incubated in the appropriate cell culture conditions before 
being counted and seeded into suspension (1000 cells per well) in six well plates to determine the 
number of spheres they formed. Spheres were counted after two weeks incubation in normoxia 
(21 % O2) using a microscope and spheres larger than approximately 25 cells were included in 
the analysis. 
 
44. Figure 44. C80 rectal cancer cells showing sphere-forming capacity in normoxia, hypoxia 
(2 % O2, 72 hours) and irradiation. Sample size; n=3. Values were all compared to N No IR to 
determine the p value; *, p<0.05, t-test. N, normoxia; H, hypoxia; No IR, non-irradiated (placed in the 
irradiation chamber but not irradiated). Cells were incubated in normoxia or hypoxia for 24 h before 
being irradiated (or not irradiated) followed by a further 48 hours in normoxia or hypoxia. After 
normoxic or hypoxic incubation, cell culture plates were incubated in normoxic conditions until spheres 
could be seen (~14 days). 
Figure 44 presents the number of spheres formed in suspension from C80 rectal cancer cells 
under normoxia, hypoxia (2 % O2) and after IR. The percentage of C80 cells under normal 
culture conditions (N No IR) showed 7.9 % of the original number of cells (500 cells seeded) 
formed spheres (78.5 spheres). With the addition of 0.5 Gy IR to normoxic cells, there was a 
significant reduction (p=0.04) in the number of spheres formed (37.67 spheres) compared to N 
No IR, however, after 2 Gy IR the number of spheres increased (74.67 spheres) to a similar level 
to N No IR.  
C80 cells under hypoxia (2 % O2) had a decreased number of spheres (H No IR, 61.67 spheres; 
H 0.5 Gy, 51.33 spheres; H 2 Gy, 31.33 spheres) but the decrease was only significantly different 
to N No IR after 2 Gy IR (p=0.013). In relation to the survival of C80 cells, which showed 
potential radio-resistance, the sphere-forming assay did not show the same results. There was 
little change in survival of C80 cells with the addition of IR, leading to the conclusion that C80 
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cells were radio-resistant, but the number of spheres formed significantly decreased after 0.5 Gy 
IR indicating that IR did affect these cells. After 2 Gy IR, no change was seen compared to N 
No IR in normoxic cells indicating that 2 Gy IR had no effect, reinforcing the theory that C80 
cells are radio-resistant under normoxia potentially with low-dose radiation sensitivity (0.5 Gy). 
Under hypoxia, IR did reduce the number of spheres implying that hypoxia could sensitise C80 
cells in spheres to IR. 
C99 cells were also subjected to the sphere-forming assay to determine the number of tumour-
initiating cells in a C99 population under normoxia, hypoxia (2 % O2) and IR compared to C99 
normoxic, No IR cells (figure 45). 
 
45. Figure 45. C99 rectal cancer cells showing sphere-forming capacity in normoxia, hypoxia 
and irradiation. Cells were incubated in normoxia or hypoxia for 24 h before being irradiated (or not 
irradiated) followed by a further 48 hours in normoxia or hypoxia. Sample size; n=3. Values were all 
compared to N No IR to determine the p value; *, p<0.05, t-test. N, normoxia; H, hypoxia; No IR, non-
irradiated (placed in the irradiation chamber but not irradiated). 
Figure 45 demonstrates the sphere-forming capacity of C99 rectal cancer cells under normoxia, 
hypoxia (2 % O2) and after IR. From 1000 cells seeded, only 0.4 % of cells were able to form 
spheres and this was expressed by the low number of spheres for each culture condition (range 
= 0.33 to 4.33 spheres). The low number of spheres formed by C99 cells agrees with previous 
data (section 5.1), which showed that no colonies were formed from C99 cells. The highest 
number of spheres (4.33 spheres) was found in C99 cells under normoxia No IR with all other 
C99 cells under IR and hypoxia having lower number of cells. The addition of IR to normoxic 
cells decreased the sphere-forming ability equally (2.67 spheres after both 0.5 Gy and 2 Gy IR).  
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Hypoxia (2 % O2) alone further decreased the number of spheres formed (2 spheres) compared 
to but the addition of 0.5 Gy IR to hypoxic cells showed a minor increase (3 spheres) from C99 
H No IR. The addition of 2 Gy IR to hypoxic cells caused a further decrease in sphere-forming 
capacity with C99 H 2 Gy cells having the lowest number of spheres (0.33 spheres) and this was 
a significant decrease in number of spheres (p=0.02) compared to N No IR cells.  
Although numbers of spheres were low, in relation to DUOX2 expression in irradiated hypoxic 
cells (section 3.7.5), sphere-forming capacity seemed to be related to the expression of this gene. 
C99 H No IR cells showed a large increase (57.03 fold) in DUOX2 expression correlating with a 
sphere-forming capacity of 0.2 %. After 0.5 Gy IR (C99 H 0.5 Gy), DUOX2 expression 
decreased to 22.19 fold with a concurrent increase in sphere-forming capacity of 0.3 %. With the 
further addition of 2 Gy IR (C99 H 2 Gy), DUOX2 expression increased again to 56.17 and 
sphere-forming capacity greatly reduced to 0.03 %. This high increase in DUOX2 expression and 
reduction in sphere-forming capacity could be related because DUOX2 protein may inhibit the 
sphere-formation by release of H2O2 causing DNA damage and cell apoptosis (reducing the 
number of cells available for sphere-formation). However, H2O2 is known to stimulate 
proliferation in fibroblasts249, so much more experimental evidence would be needed to 
determine the effect of H2O2 on rectal cancer cells.  
In addition, C99 cells did not easily form spheres (maximum number of spheres = 5/1000). The 
low number of spheres (0.5 % of total) could not accurately determine the difference in tumour-
initiating capacity and so the results were not reliable enough to make a valid conclusion linking 
DUOX2 expression and sphere-forming ability.  
Following the sphere-forming assay for tumour-initiating capacity, the next experiments were 
used to confirm the results seen in section 5.2 and to determine DUOX2 expression in cells that 
could form spheres (CD24+) and those that could not (CD24-). 
5.3 Presence of CD24 in C80 and C99 rectal cancer cells 
Following the sphere-forming assay that determined the tumour-initiating capacity (the number 
of spheres indicated the number of cells that could form a tumour) of C80 (7.85 % to 3.1 %) and 
C99 (0.4 % to 0.03 %) cells, fluorescence-activated cell sorting (FACS) was performed on C80 
and C99 cells to support the results seen previously (section 5.2). Stem cells are considered to be 
the cells that have the tumour-initiating capacity and the cells that will form spheres in culture. 
Tumour-initiating cells are also (often, but not always) known as cancer stem cells and these are 
the cells responsible for tumour growth and therapy resistance227. 
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FACS was used to sort cells labelled with a CD24 fluorescent antibody (section 2.14 for 
methods). CD24 is a proposed CRC stem cell marker and has been used alone and  in 
conjunction with CD44 to sort for cells that can self-renew and the CD24+/CD44+ cells are able 
to form all CD24 and CD44 populations (CD24 and CD44 positive and negative cells)225. CD24 
has also been seen to identify the most clonogenic CRC cells in a population in combination 
with CD133 marker suggesting a combination of markers can recognise tumour-initiating cells233. 
CD24 was also significantly associated with tumour-forming ability in pancreatic cells251 and was 
used in this study as a marker of clonogenic cells. C80 and C99 rectal cancer cells were cultured 
in normoxia, hypoxia (2 % O2) and given IR (0.5 Gy or 2 Gy) followed by labelling with CD24 
to determine the clonogenicity (tumour-forming ability) of the cells and FACS analysis and the 
results shown in figure 46 and 47. 
 
46. Figure 46. CD24 was highly expressed in C80 rectal cancer cells. Cells were incubated in 
normoxia or hypoxia for 24 h before being irradiated (or not irradiated) followed by a further 48 hours in 
normoxia or hypoxia. C80 rectal cancer cells cultured under normoxia, hypoxia (2 % O2) and after 
irradiation were stained for 20 min with FITC-tagged CD24 antibody and sorted into CD24+ and CD24- 
cells using a FACS machine. FACS analysed live cells using DAPI staining (DAPI stained dead cells) and 
the live cells were used to sort for CD24. The total % of live cells did not add up to 100 because some 
cells had intermediate CD24 staining and so were not included. N, normoxia; H, hypoxia; No IR, non-
irradiated (placed in the irradiation chamber but not irradiated). 
CD24 expression in C80 rectal cancer cells was high (figure 46), with the lowest expression (66.7 
% of live cells) in C80 hypoxic (2 % O2) cells after 0.5 Gy IR and the highest expression (80.4 % 
of live cells) in C80 normoxic cells after 0.5 Gy IR. CD24- C80 cells correlated to CD24+ cells 
with the highest percentage (21.5 %) of CD24- cells in C80 H 0.5 Gy and the lowest percentage 
(10. %) of CD24- cells in C80 N 0.5 Gy. The results in figure 43 indicated that CD24+, or the 
cancer stem cells were plentiful in C80 rectal cancer cells, which correlated with the high sphere-
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forming and high colony-forming ability of C80 cells. In addition, the low response of C80 cells 
to IR agreed with the CD24 results because stem cells are inherently more resistant to 
radiation227. 
Upon closer analysis of CD24 expression and C80 sphere-formation, results were slightly 
different. Only 7.8% of cells formed spheres (N, No IR) but a much higher percentage of cells 
were CD24+ (74.2%). The difference in sphere-formation and expression of CD24 may be due 
to the range of cells that have CD24 positivity. It may be true CD24 labels a subset of rectal 
cancer cells that have the propensity to form a tumour, but potentially not all CD24-labelled cells 
were able to form spheres in culture, hence the additional markers (e.g. CD133 and CD44) used 
in published work to highlight only the tumour-initiating cells. The percentage of live cells 
containing CD24 remained at a constantly high level in all C80 cells (66.7 % to 80.4 %) but the 
sphere-forming ability of C80 cells varied with the addition of IR and hypoxia; significantly 
reduced number of spheres in C80 N 0.5 Gy cells (37.7 %, p=0.04) and C80 H 2 Gy cells (31.3 
%, p=0.01). The change in sphere-forming ability was not reflected in the expression of CD24 
and this may have been due to the fact that not all CD24-labelled cells were tumour-initiating 
cells. C99 cells were also stained for CD24 using the same process described above and the 
results shown in figure 47.  
 
47. Figure 47. CD24 was expressed at a lower level in C99 rectal cancer cells than C80 cells. 
Cells were incubated in normoxia or hypoxia for 24 h before being irradiated (or not irradiated) followed 
by a further 48 hours in normoxia or hypoxia. C99 rectal cancer cells cultured under normoxia, hypoxia (2 
% O2) and after irradiation were stained for 20 min with FITC-tagged CD24 antibody and sorted into 
CD24+ and CD24- cells using a FACS machine. FACS analysed live cells using DAPI staining (DAPI 
stained dead cells) and the live cells were used to sort for CD24. The total % of live cells did not add up 
to 100 because some cells had intermediate CD24 staining and so were not included. N, normoxia; H, 
hypoxia; No IR, non-irradiated (placed in the irradiation chamber but not irradiated). 
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Figure 47 demonstrates the expression of CD24 in C99 rectal cancer cells. The percentage of 
CD24+ cells under normoxia No IR was much less (46.3 %) than C80 N, No IR cells (74.2 %). 
The low number of CD24+ cells in the normal population (cultured under normoxia, without 
IR) indicated that there were few tumour-initiating cells in the C99 cell population and this 
confirmed the previous data that C99 cells did not form colonies (section 5.1) and formed very 
few (0.04 %) spheres (section 5.2). However, the percentage of CD24- cells was also low (10.2 
%) and did not compensate for the low level of CD24 positivity; it would be expected that the 
cells would either be CD24+ or CD24- and so the level of one would compensate for the other, 
but this was not the case because of the high levels of intermediate CD24 staining that was not 
included. There were similar levels of CD24- cells in both C80 and C99 cells (average = 15.4 % 
and 17.4 % respectively), but very different levels of CD24+ cells (average = 74.1 % and 37.9 % 
respectively). 
Although levels of CD24+ cells varied moderately in normoxia with and without IR (range = 
45.1 % to 52.1 %), CD24 expression in C99 cells under hypoxia with and without IR did vary 
(18.4 % in C99 H No IR to 37.7 % in C99 H 2 Gy) (figure 44). CD24 expression showed a 
decrease in C99 hypoxic cells (18.4 %) compared to normoxic cells (46.3 %), with a concurrent 
increase in CD24- population (34.4 %). Under hypoxia, the population of CD24+ cells increased 
with the addition of 0.5 Gy (27.9 %) and 2 Gy (37.7 %) and the CD24- population had a steady 
decline (H 0.5 Gy, 24.9 %; H 2 Gy, 16.2 %). The lowest amount of CD24 expression (in hypoxic 
No IR cells) was not reflected in the sphere-forming assay where the lowest amount of sphere-
formation was in hypoxic cells with the maximum amount of IR (2 Gy). In C99 H 2 Gy cells, 
CD24 expression had risen (37.7 %) to levels marginally lower than C99 N No IR cells (46.3 %) 
indicating that IR in a hypoxic environment had the effect of enriching for the CD24-labelled 
tumour-initiating population. This suggests that CD24+ cells are more radio-resistant, indicating 
that tumour-initiating of stem cells are more resistant to therapy91.  However, this did not 
correspond to increased sphere-formation ability, as would be expected with the increase in 
tumour-initiating (CD24+) cells. 
In summary, the results indicate that C80 cells had a high level of CD24+ cells under all culture 
conditions (average = 74 %), which corresponds to the colony-formation assay (49 % of cell 
formed colonies in N No IR) and sphere-formation (7.8 % of cells formed spheres in N No IR), 
all of which were higher than in C99 cells. C99 cells showed a lower level of CD24+ cells 
(average = 37.9 %), which corresponded to no colony formation and a low level of sphere-
formation (0.04 % of cells in N No IR).  
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Other FACS markers of apoptosis that could have been used were Annexin V or Caspase to 
quantify the apoptotic cells or a Sub G1 assay to measure the number of cells in each stage of the 
cell cycle. These experiments were performed, but the yield of cells after IR and reduced 
numbers of cells in the G1 phase provided problems in analysis. 
Following the colony-formation, sphere-formation and CD24 FACS, DNA damage was 
determined (section 5.4) in order to validate the findings in section 5.1, 5.2 and 5.3. It would be 
expected that cells with lower survival (low colony-formation, C99) and low sphere-forming 
ability (C99) would have had higher amounts of DNA damage and so cells would be undergoing 
apoptosis. In addition, with increased DUOX2 expression (C99 H) more H2O2 would be 
produced and in combination with IR, more DNA damage would be expected due to the 
additive effect of ROS causing DNA damage with IR. CD24+ cells (e.g. C80 cell line) would also 
be expected to have reduced DNA damage due to their intrinsic radio-resistance. DNA damage 
was determined using γH2AX, a DNA double-strand break (DSB) marker252. 
5.4 DNA damage analysis using γH2AX as a marker 
γH2AX is a highly sensitive DNA DSB marker, which is phosphorylated in response to 
‘genotoxic agents, ultra violet, hydroxyurea-mediated replication arrest and at physiological sites 
of recombination during class switching’253. Once it is phosphorylated, a ‘focus’ is created at the 
DSB site that allows accumulation of other DNA break repair proteins254. The γH2AX foci are 
easily visualised inside the nuclei and this makes it an easy marker of DNA damage to use for 
this study. Immunofluorescence was used by staining cells (section 2.13) with a FITC-tagged 
antibody against γH2AX, which was visualised using a confocal microscope (γH2AX, green; 
figure 32). The number of foci per nucleus increases with increasing DNA DSBs and therefore 
DNA damage. Cells that were stained with γH2AX antibody and DAPI (4',6-diamidino-2-
phenylindole, blue) were cultured under normoxia, hypoxia (2 % O2) and given IR and the 
number of foci per nucleus counted using image analysis software.  
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48. Figure 48. Example of confocal images of C80 and C99 cells show different levels of 
γH2AX foci (green) per nucleus. A, C80 DAPI (nuclei, blue) stained cells; B, C80 γH2AX stained cells 
(green); C, C80 composite image; D, C99 DAPI stained cells; E, C99 γH2AX stained cells; F, C99 
composite image. A set of four images of at least four cells per image were taken for each cell line under 
each culture condition (normoxia, hypoxia (2 % O2) and irradiation).  
Figure 48 shows an example of γH2AX and DAPI staining in C80 (figure 48, A-C) and C99 
(figure 48, D-F) cells; C80 cells grow in clusters, whereas C99 cells in show a more dispersed 
phenotype. The images support the previous data (section 5.1) that described C80 cells as a 
colony-forming phenotype and C99 as less likely to form colonies.  
The images, once captured, were uploaded onto MetaMorph software (Molecular Devices, USA) 
and the number of foci per nucleus was counted (figure 46) for each cell line under all six culture 
conditions (N No IR, N 0.5 Gy, N 2 Gy, H No IR, H 0.5 Gy and H 2 Gy).  
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49. Figure 49. Images of C80 (A) and C99 (B) stained with γH2AX and foci highlighted in 
white by MetaMorph. Images were processed to determine the number of foci per nucleus with 
background parts of the image (non-nuclei) removed. MetaMorph recognised the nuclei using the DAPI 
image and the foci by the brightest spots on the γH2AX image. A, C80 γH2AX stained cells with foci in 
white; B, C99 γH2AX stained cells with foci in white. 
Figure 49 demonstrates how the MetaMorph software determines the number of foci per 
nucleus. Initially, the nucleus (DAPI, blue) was selected by the programme and parts of the 
image that were non-nucleus were removed in order to count foci only in the nucleus. Once the 
background image was removed, only the nuclei remained and the programme counted the 
number of foci per nucleus (figure 49) and the results were calculated and presented in figure 50. 
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50. Figure 50. DNA damage varies in C80 cells under normoxia, hypoxia (2 % O2) and 
irradiation. DNA damage indicated by the average number of γH2AX granules per nucleus. Cells were 
incubated in normoxia or hypoxia for 24 h before being irradiated (or not irradiated) followed by a 
further 48 hours in normoxia or hypoxia. Standard error (SE; error bars) was calculated using the 
following equation; SE=SD/√n where SD was the standard deviation and n the sample size. n=4; *, 
p<0.05 compared to N, No IR. N, normoxia; H, hypoxia; No IR, non-irradiated (placed in the irradiation 
chamber but not irradiated). 
Figure 50 details the number of foci per nucleus in C80 cells cultured under normoxia (N), 
hypoxia (2 % O2, H) and after IR (0.5 Gy or 2 Gy). The number of γH2AX foci per nucleus was 
directly proportional to the amount of DNA damage in each cell. As figure 50 demonstrates, 
there was a low level of DNA damage in C80 cells under normoxia showing few (7.07 foci per 
nucleus) DSBs in normoxic, No IR cells and an increasing number of foci with increasing IR (0.5 
Gy, 9.21 foci; 2 Gy, 11.66 foci). The increasing number of foci with the addition of IR was 
expected as IR is given to tumours to destroy them by causing DNA damage leading to 
apoptosis. However, IR did not seem to have an effect on survival (figure 42) indicating that 
these cells are able to repair the damage and continue to grow. 
Under hypoxia (2 % O2) without IR, DNA damage was significantly reduced (2.83 foci per 
nucleus, p=0.01), but this would be expected due to the decreased availability of oxygen and 
reactive oxygen species that aids DNA damage. However, under hypoxia, ROS are known to be 
stimulated further causing stabilisation of HIF-1α255, but the increased level of ROS could cause 
increased DNA damage, which was not seen here. The low levels of HIF-1α mRNA expression 
under hypoxia in C80 cells, although higher than in normoxia, may indicate that there were also 
low levels of ROS contributing little to the stability of HIF-1α and reducing the DNA damage 
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effect. With the addition of 0.5 Gy IR the number of foci per nucleus was still low (2.42 foci, 
p=0.01), a similar level as hypoxic No IR cells. After 2 Gy IR DNA damage increased (4.66 foci) 
compared to H No IR cells, but this was still lower than normoxic No IR cells. This DNA 
damage decrease in hypoxic cells correlates to the small increase in colony-forming, (section 5.1) 
in H No IR and H 2 Gy cells, which shows an increase in survival. A decrease in DNA damage 
would be the cause of an increase in survival as fewer cells would die if there was a low level of 
DNA damage within the cells. However, an increase in DNA damage after 2 Gy IR could be the 
result of the stronger IR reacting with the potentially more abundant ROS available causing more 
DNA damage than H No IR.  
Following the C80 DNA damage analysis, C99 cells were also analysed and the data presented in 
figure 51.  
 
51. Figure 51. DNA damage varies in C99 cells under normoxia, hypoxia (2 % O2) and 
irradiation. DNA damage indicated by the average number of γH2AX granules per nucleus. Cells were 
incubated in normoxia or hypoxia for 24 h before being irradiated (or not irradiated) followed by a 
further 48 hours in normoxia or hypoxia. Standard error (SE; error bars) was calculated using the 
following equation; SE=SD/√n where SD was the standard deviation and n the sample size. n>4. N, 
normoxia; H, hypoxia; No IR, non-irradiated (placed in the irradiation chamber but not irradiated). 
Figure 51 demonstrates the amount of DNA damage in C99 cells by the number of γH2AX foci 
per nucleus. Under normoxia without IR, C99 cells showed a low level of DNA damage with 
2.84 γH2AX foci per nucleus and this DNA damage increased with increasing IR (0.5 Gy, 3.6 
foci; 2 Gy, 4.6 foci). Increased DNA damage with increased IR would be expected as IR is used 
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to destroy cells by directly damaging the DNA causing apoptosis, however, this increase was not 
significant. 
Under hypoxia (2 % O2) without IR, C99 cells showed a higher level (3.74 foci) of DNA damage 
compared to N No IR cells. However, under hypoxia with IR, there was increased DNA damage 
(H 0.5 Gy, 5.06 foci; H 2 Gy, 4.99 foci) compared to H No IR cells, but it was not a significant 
change. This result does agree with the hypothesis that DUOX2 radio-sensitises cells because 
DUOX2 expression was high in C99 cells under hypoxia and IR (section 3.6.5) producing more 
H2O2 and more DNA damage. None of the changes in DNA damage in C99 cells (under 
normoxia, hypoxia or IR) were significantly different, but they did show a trend towards 
significance.  
In summary, under normoxia, DNA damage in C80 and C99 cells showed a trend of increased 
with increasing IR. None of the changes were significant under normoxia but there was a trend, 
which was expected due to the effect of IR on DNA. 
5.5 Discussion 
The hypothesis was that if DUOX2 expression was high (in C99 under hypoxic conditions) the 
DUOX2 protein would produce hydrogen peroxide, which would degrade into ROS and this 
abundance of ROS would lead to high DNA damage after irradiation. To link DUOX2 mRNA 
expression in C80 and C99 cells under hypoxia to DNA damage, table 20 was assembled. 
20. Table 20. Summary of predicted versus actual results in relation to DUOX2 expression 
and DNA damage. The hypothesis predicted that DUOX2 would produce hydrogen peroxide, 
which would decay into ROS, at high enough levels to cause DNA damage. Under normoxia, 
DUOX2 was found to be low in both cell lines, but under hypoxia there was a difference in 
DUOX2 expression; low in C80 and high in C99. The difference in DUOX2 expression was 
predicted to cause differences in the DNA damage. As seen in the results, there was a difference 
in DNA damage results. DNA damage was compared to normoxic No IR cells. 
 Prediction 
C80 
Prediction 
C99 
Results: 
C80 H 
Results: 
C80 H IR 
Results: 
C99 H 
Results: 
C99 H IR 
DUOX2 
expression 
Low High Low Low High High 
DNA 
damage  
Low High  Low 
(p=0.01) 
Low (0.5 Gy 
p=0.01) 
High (non 
sig) 
High (non 
sig) 
 
In C80 cells under hypoxia (low DUOX2 expression, table 20), DNA damage was significantly 
lower than C80 N No IR cells and stayed low even with the addition of IR. Low DUOX2 would 
suggest low H2O2 production and so low ROS in an environment of low oxygen leading to 
reduced DNA damage, as seen in figure 50. 
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In C99 cells under hypoxia, which had high DUOX2 expression (table 20), DNA damage was 
higher than N No IR cells indicating that in cells with high DUOX2 expression, there was a 
higher level of damage, although this was not significant. With the addition of IR, there was a 
marginally higher level of DNA damage that agrees with the prediction (table 20). The results in 
C99 support the hypothesis that high DUOX2 would produce high H2O2 leading to high ROS 
and higher DNA damage after IR. 
Relating colony-formation, sphere-formation, number of CD24+ cells and DNA damage, table 
21 details the predicted and establish results.  
21. Table 21. Summary of predicted versus actual results in relation to colony formation, 
sphere-formation, CD24 expression and DNA damage. The prediction is that high colony-
formation (survival), high sphere-formation (tumour-generating capacity) and high CD24+ cells 
would have low DNA damage. Low DNA damage would result in higher survival and a large 
population of CD24+ cells, which are more resistant to therapy, would result in a high sphere-
forming capacity.  
Experiment 
Prediction 
C80 
Prediction 
C99 
Results: 
C80 H 
Results: 
C80 H IR 
Results: 
C99 H 
Results: 
C99 H IR 
Colony formation 
(survival) 
High Low High High - - 
Sphere-formation 
(tumour-generating 
capacity) 
High  Low 
High 
(61.67) 
High 
(51.33 - 
31.33) 
Low (2.00) 
Low (3 - 
0.33) 
CD24+ 
(tumourigenicity) 
High Low High High Low  Mid 
DNA damage Low  High Low (2.83) 
Low (2.42 
-4.66) 
Higher 
(3.74) 
Higher 
(5.06 - 
4.99) 
 
Colony-formation, sphere-formation, CD24 positivity and DNA damage appear to follow the 
hypothesis that the more cells that are able to form colonies and spheres will inherently be more 
CD24+ (tumourigenicity marker) and because these cells form colonies and are more stem-like, 
they will suffer less DNA damage. It is known that stem-like cells are the cells that, after 
irradiation, have the capacity to cause a tumour recurrence91 and the first two assays in table 21 
describe this ability to form colonies or spheres. It would be expected that a cell line that has 
more CD24+ cells would have reduced DNA damage, potentially because stem-like cells are 
known to be more resistant to radiation91.  
The results in table 21 show that C80 and C99 correspond to the prediction. The results, taken 
together, indicate that C80 cells were radio-resistant; a reduction in DUOX2 in C80 cells seems 
to protect cancer cells from DNA damage after irradiation allowing an increase in survival. 
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In C99 cells, the opposite occurs; no colonies formed, few spheres formed and the cell line had 
fewer CD24+ cells. C99 cells also had high levels of DNA damage, which correlated to the 
hypothesis that a cell line without many stem-like cells would have higher DNA damage after 
irradiation because the cells are less radio-resistant. The combined results from C99 cells suggest 
that this cell line was more radio-sensitive than the C80 cell line, potentially due to the increase in 
DUOX2 mRNA expression. 
The data in chapter 5 concluded the study on the effect of DUOX2 expression, hypoxia and IR 
in rectal cancer cells and the results are further discussed in section 7. 
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Chapter 6 The miRNA expression profile is altered by hypoxia in rectal 
cancer 
MicroRNAs (miRNAs) can alter the expression of proteins and are altered in cancer197. In this 
section, the potential use of miRNAs as a marker of rectal tumour response to irradiation is 
considered. Hypoxia is likely to be a significant factor in cellular radiation response. 
Consequently, an unbiased microarray screen was used to identify any miRNAs that were either 
significantly increased or decreased in hypoxic (2 % O2) rectal cancer cell lines. Validation of 
these findings was completed using qRT-PCR of miRNAs and their mRNA targets; western blot 
was used to determine miRNA target protein expression. 
6.1 MicroRNA microarray expression in hypoxia and normoxia 
Six rectal cancer cell lines (C80, C99, HRA19, HT55, SW837 and VACO4S) were incubated in 
hypoxia (2 % O2) or normoxia (atmospheric O2) for 72 h. Following this incubation, miRNA 
was extracted using the methods in section 2.3.1 and sent to the Genome Centre (Charterhouse 
Square, Barts and The London, Queen Mary University of London) for the microarray 
hybridisation to be performed using an Illumina MicroRNA Universal Array Matrix chip. The 
microarray results are given as an average miRNA expression signal following normalisation for 
each cell line in both normoxia and hypoxia. The signals of each pair (e.g. C80 Normoxia versus 
C80 Hypoxia) were compared to determine the most significantly different miRNAs in hypoxia 
compared to normoxia. After analysis, the Bonferroni correction was applied to the data and the 
significantly upregulated (p<0.01) miRNAs in hypoxia compared to normoxia shown in table 22.  
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22. Table 22. Upregulated miRNAs in hypoxia (2 % O2) compared to normoxia (only those with p<0.01). Bonferroni correction ([p value x n] where n 
was the sample size) was applied and shown in the table as p value for difference in expression between normoxia and hypoxia. P values shown are in 
scientific annotation, 4.83E-33 is the same as 4.83 x 10-33 and all miRNAs shown have a Bonferroni corrected p value<0.01. The order of miRNAs 
presents the most significantly differentially expressed miRNAs at the top of the table. * indicates miRNA star form, e.g. miR-221*. 
C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
614 4.83E-33 1238 2.54E-33 10b 2.54E-33 1228 2.41E-33 100 1.42E-33 1234 4.02E-33 
339-5p 4.83E-33 1248 2.54E-33 135b 2.54E-33 126* 2.41E-33 106a 1.42E-33 15a 4.02E-33 
29c 4.83E-33 1290 2.54E-33 31:09.1 2.54E-33 1296 2.41E-33 106b 1.42E-33 185 4.02E-33 
29b 4.83E-33 31:09.1 2.54E-33 210 2.54E-33 139-5p 2.41E-33 107 1.42E-33 200a 4.02E-33 
210 4.83E-33 29b 2.54E-33 22 2.54E-33 210 2.41E-33 1296 1.42E-33 20a 4.02E-33 
135b 4.83E-33 374a 2.54E-33 221* 2.54E-33 22 2.41E-33 135b 1.42E-33 210 4.02E-33 
1290 4.83E-33 375 2.54E-33 29b 2.54E-33 30c-1* 2.41E-33 141 1.42E-33 215 4.02E-33 
1281 4.83E-33 429 2.54E-33 29c 2.54E-33 339-5p 2.41E-33 148a 1.42E-33 29b 4.02E-33 
1234 4.83E-33 493* 2.54E-33 374a 2.54E-33 365 2.41E-33 148b 1.42E-33 452*:9.1 4.02E-33 
589 9.81E-10 624* 2.54E-33 429 2.54E-33 424 2.41E-33 15a 1.42E-33 614 4.02E-33 
30a 2.99E-09 642 2.54E-33 577 2.54E-33 424* 2.41E-33 17 1.42E-33 7 4.02E-33 
192 3.08E-09 647 2.54E-33 598 2.54E-33 503 2.41E-33 181a 1.42E-33 98 4.02E-33 
1225-3p 2.10E-08 7-1* 2.54E-33 610 2.54E-33 642 2.41E-33 181c 1.42E-33 7-1* 9.71E-12 
10b 2.99E-07 938 2.54E-33 624* 2.54E-33 647 2.41E-33 186 1.42E-33 let-7e 2.82E-11 
203 7.00E-07 132 1.46E-11 660 2.54E-33 941 2.41E-33 18a 1.42E-33 429 1.18E-10 
141 7.17E-07 29c 5.42E-11 9 2.54E-33 335 5.97E-10 200a 1.42E-33 19b 1.59E-10 
19b 3.24E-05 660 7.28E-11 203 6.94E-12 193b* 9.03E-10 20a 1.42E-33 1248 1.41E-09 
31:09.1 8.15E-05 663 3.80E-10 1234 5.83E-11 29c 1.40E-09 21* 1.42E-33 500 3.58E-09 
429 2.11E-04 1285 1.92E-09 425 5.83E-11 493* 1.76E-09 210 1.42E-33 146a 9.39E-09 
374b 5.63E-04 146a 3.02E-07 141 8.06E-11 874 2.03E-09 221* 1.42E-33 17 1.09E-08 
7-1* 8.47E-04 10a 5.96E-07 30a 8.06E-11 768-3p:11.0 5.63E-06 27a 1.42E-33 380 1.03E-06 
106b 3.02E-03 203 1.53E-06 30a* 1.07E-10 614 1.43E-05 29b 1.42E-33 193a-5p 1.28E-06 
1259 4.16E-03 335 4.41E-05 18a 4.74E-10 625* 1.51E-05 30e 1.42E-33 106b 1.48E-06 
1238 4.66E-03 155 6.51E-05 517a/b 7.68E-10 215 2.55E-05 339-5p 1.42E-33 148a 1.83E-06 
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C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
374a 5.00E-03 20:09.1 1.24E-04 549 8.36E-10 135b 4.73E-05 34a 1.42E-33 24 2.86E-06 
215 5.00E-03 1826 5.53E-04 215 4.38E-09 589 6.72E-05 378* 1.42E-33 26b 6.58E-06 
  
598 6.55E-03 629* 8.51E-09 1274a 8.34E-05 424 1.42E-33 34a 1.25E-05 
    
768-3p:11.0 8.49E-08 923 8.94E-05 425* 1.42E-33 1273 1.81E-05 
    
493* 1.74E-07 886-3p 9.06E-05 429 1.42E-33 126* 2.22E-05 
    
126* 6.88E-07 768-5p:11.0 1.15E-04 486-3p 1.42E-33 584 4.95E-05 
    
30e 7.56E-07 374a 3.39E-04 589 1.42E-33 192 2.59E-04 
    
15b* 4.00E-06 576-5p 2.45E-03 9 1.42E-33 1290 2.72E-04 
    
15a 4.54E-06 574-3p 7.27E-03 378 1.13E-10 449a 3.78E-04 
    
365 6.07E-06 
  
185* 3.47E-09 574-5p 3.78E-04 
    
7-1* 2.46E-05 
  
31 2.82E-08 1281 3.84E-04 
    
181a-2* 5.74E-05 
  
503 3.98E-08 625 9.94E-04 
    
148a 5.76E-05 
  
542-5p 5.70E-08 421 1.18E-03 
    
454 1.14E-04 
  
194 3.61E-07 938 1.66E-03 
    
146b-5p 1.27E-04 
  
140-3p 3.08E-06 664 1.90E-03 
    
490-5p 2.60E-04 
  
203 3.36E-06 10a* 1.90E-03 
    
30c 4.00E-04 
  
30a* 6.74E-06 141 2.57E-03 
    
574-3p 6.34E-04 
  
31:09.1 9.80E-06 28-5p 3.39E-03 
    
335 7.09E-04 
  
29c 1.05E-05 152 4.00E-03 
    
768-5p:11.0 1.69E-03 
  
27b 1.11E-05 194 5.31E-03 
    
148b 1.99E-03 
  
30c 1.29E-05 
  
    
200a 2.07E-03 
  
9* 1.82E-05 
  
    
7 6.71E-03 
  
19b 2.64E-05 
  
    
339-5p 9.96E-03 
  
625* 2.96E-05 
  
        
152 3.25E-05 
  
        
146a 3.46E-05 
  
        
624* 3.49E-05 
  
        
185 5.80E-05 
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C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
        
29a 3.14E-04 
  
        
22 1.09E-03 
  
        
17* 1.17E-03 
  
        
532-5p 2.57E-03 
  
        
768-
3p:11.0 
2.67E-03 
  
        
362-5p 5.11E-03 
  
     
  
  
31* 9.47E-03 
  
 
 
23. Table 23. Downregulated miRNAs in hypoxia compared to normoxia (only those with p<0.01). Bonferroni correction was applied ([p value*n] 
where n was the sample size) and shown as p value for difference in expression between normoxia and hypoxia. P values shown are in scientific 
annotation, 8.04E-33 is the same as 8.04 x 10-33 and all miRNAs shown have a Bonferroni corrected p value<0.01. The order of miRNAs presents the 
most significantly differentially expressed miRNAs at the top of the table. * indicates miRNA star form e.g. miR-23a*. 
C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
1268 1.64E-31 1296 4.39E-33 1268 4.39E-33 23a* 4.02E-33 23a* 2.47E-33 326 4.77E-29 
296-3p 1.96E-19 193a-3p 4.39E-33 23a* 4.39E-33 23b* 4.02E-33 7-1* 2.47E-33 193b 5.39E-25 
23a* 1.01E-18 339-5p 4.39E-33 92a-1* 4.39E-33 362-5p 4.02E-33 1238 2.47E-33 663b 1.60E-23 
25:09.1 1.63E-11 1268 7.26E-32 92b* 2.97E-26 92a-1* 4.02E-33 938 2.47E-33 886-3p 1.88E-21 
92a-1* 1.31E-10 326 1.11E-31 483-5p 1.40E-25 29b-1* 4.70E-31 504 2.47E-33 339-5p 9.43E-21 
493* 8.26E-09 491-5p 1.22E-31 1224-5p 1.88E-23 615-5p 8.54E-25 92b* 8.83E-33 493* 8.16E-20 
663b 2.53E-08 886-3p 5.40E-31 615-5p 3.51E-22 25* 5.38E-22 505* 7.64E-28 1296 1.24E-19 
615-5p 8.55E-08 378* 1.10E-27 29b-1* 1.08E-21 27b* 8.18E-22 509-3p 4.09E-27 671-3p 6.44E-18 
326 1.74E-07 17* 5.75E-25 23b* 7.30E-20 513a-5p 6.63E-19 23b* 5.84E-24 874 1.65E-16 
675 5.31E-07 1274a 3.03E-22 25* 4.84E-18 1268 4.36E-18 513b 2.38E-21 1268 2.83E-16 
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C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
425* 4.95E-06 550* 5.55E-20 1249 5.63E-17 513b 6.26E-18 483-3p 1.39E-20 296-5p 3.66E-16 
23b* 1.68E-05 125b 2.70E-18 877 1.02E-16 27a* 2.23E-15 92a-1* 2.32E-20 106b* 1.61E-10 
664* 1.87E-05 106b 2.53E-17 1229 2.56E-16 509-3p 5.38E-15 1229 1.27E-19 1274a 2.44E-10 
296-5p 8.16E-05 589 3.60E-16 1826 3.64E-14 25:09.1 1.43E-14 193b* 1.99E-19 99b 8.52E-10 
let-7b* 0.0001521 93* 7.68E-15 1237 1.03E-10 335* 9.58E-12 574-5p 3.35E-19 1285 4.62E-08 
629 0.000952 29b-1* 5.91E-13 324-5p 3.24E-10 1229 3.67E-11 1290 9.88E-18 15b* 8.71E-07 
  
21* 1.75E-12 193a-5p 1.15E-08 146a 4.13E-11 324-5p 9.04E-17 574-3p 9.33E-07 
  
18a* 2.57E-12 452*:9.1 1.83E-07 508-3p 9.72E-11 760 6.54E-16 1226 1.23E-06 
  
615-5p 9.50E-12 663b 5.28E-07 506 2.23E-10 let-7b* 3.08E-15 675 2.33E-06 
  
17 2.33E-11 1247 1.62E-06 296-3p 9.73E-10 1268 8.77E-15 93* 2.33E-06 
  
25:09.1 2.39E-10 744 1.91E-06 449a 1.40E-09 346 2.02E-13 1229 2.86E-06 
  
92a-1* 7.59E-10 let-7b* 4.96E-06 532-5p 1.35E-08 18b* 1.32E-12 615-5p 3.06E-06 
  
500 1.93E-09 760 1.00E-05 500 3.82E-06 1227 2.25E-12 23a* 4.17E-06 
  
1307 2.13E-09 423-5p 3.45E-05 509-3-5p 4.11E-06 877* 2.38E-12 331-3p 6.21E-06 
  
331-3p 3.66E-09 625 7.50E-05 33:09.1 2.45E-05 25* 4.37E-12 92b* 1.61E-05 
  
148b 8.50E-09 1227 0.0001554 200a* 0.0001529 1247 5.35E-12 191* 0.0003327 
  
629 1.32E-08 513b 0.0002676 190b 0.0001804 1237 2.55E-09 636 0.000378 
  
193b 1.46E-08 505* 0.0005024 98 0.000397 886-3p 4.14E-08 886-5p 0.0005856 
  
502-
3p,500* 
3.93E-08 let-7d* 0.0010559 196b 0.0005084 202*:9.1 4.52E-08 1307 0.0006044 
  
150* 3.75E-06 1180 0.0017826 483-3p 0.0018156 1273 7.16E-08 378* 0.002305 
  
23b* 5.86E-06 603 0.0059289 769-3p 0.0018363 603 1.13E-07 25* 0.0025656 
  
501-5p 2.40E-05 
  
194* 0.001891 296-3p 1.58E-07 1249 0.0033624 
  
886-5p 2.40E-05 
  
107 0.0018972 1226 4.34E-07 361-3p 0.0040182 
  
25* 2.48E-05 
  
1180 0.0077287 1249 5.55E-07 576-5p 0.005173 
  
874 3.01E-05 
  
29a* 0.0078539 566 9.49E-07 589 0.0065379 
  
140-3p 3.31E-05 
    
1468 1.79E-06 324-3p 0.0070238 
  
182* 4.64E-05 
    
1301 5.44E-06 
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C80 
miRNAs 
P value 
C99 
miRNAs 
P value 
HRA19 
miRNAs 
P value 
HT55 
miRNAs 
P value 
SW837 
miRNAs 
P value 
VACO4S 
miRNAs 
P value 
  
501-3p 4.93E-05 
    
1826 5.60E-06 
  
  
107 6.59E-05 
    
517c 1.69E-05 
  
  
769-3p 6.97E-05 
    
664* 1.78E-05 
  
  
106b* 0.0003895 
    
941 2.01E-05 
  
  
181a 0.0004093 
    
423-5p 3.46E-05 
  
  
361-3p 0.0004937 
    
1234 4.65E-05 
  
  
425* 0.0006192 
    
29b-1* 0.0002168 
  
  
532-5p 0.0009853 
    
302d 0.0005587 
  
  
128 0.0012222 
    
375 0.0013404 
  
  
54:09.1 0.0024243 
    
654-3p 0.0021893 
  
  
449a 0.0085214 
    
615-5p 0.0070436 
  
  
29c* 0.0085469 
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Table 22 presents the most significantly (only miRNAs with p values<0.01 were shown in table 
22) upregulated miRNAs in hypoxia (2 % O2) compared to normoxia. There were 26 
significantly upregulated miRNAs in C80, 27 in C99, 48 in HRA19, 33 in HT55, 59 in SW837 
and 44 in VACO4S. The most significantly upregulated miRNAs are at the top of the table with 
the lowest p value (most significant) of 4.8 x 10-33 in C80 (miR-614).  
The most significantly downregulated miRNAs in hypoxia (2 % O2) compared to normoxia in 
rectal cancer cell lines are shown in table 23. The most highly downregulated miRNAs in 
hypoxia (p=4.39 x 10-33) were miR-1296 (C99) and miR-1268 (HRA19). The least significant 
(p=0.0085469) miRNA in table 23 was miR-29c* in C99. After allowing for Bonferroni 
correction to give a significant corrected p value of <0.01, C80 had 16 significantly 
downregulated miRNAs, C99 had 49, HRA19 had 31, HT55 had 35, SW837 had 48 and 
VACO4S had 36. 
Results were reviewed and analysed to determine the miRNAs that were significantly upregulated 
or downregulated in two or more cell lines and the most common differentially regulated 
miRNAs across the six rectal cancer cell lines in each category (upregulated or downregulated) 
are shown in the tables table 24 and 25.  
24. Table 24. Common upregulated miRNAs in rectal cancer cell lines in hypoxia (2 % O2) 
compared to normoxia. The miRNAs that were significantly (p<0.01) upregulated in more than 
one cell line are shown with the number of hits out of six in the left column and the details of the 
upregulation in each cell line on the right. 1 indicates significant (p<0.01) upregulation in cell line, 
0 indicates no significant (p>0.01) difference in expression. * indicates miRNA star form. 
No. of 
hits (/6) 
MiRNA C80  C99 HRA19 HT55 SW837 VACO4S 
5 miR-29c 1 1 1 1 1 0 
5 miR-210 1 0 1 1 1 1 
5 miR-29b 1 1 1 0 1 1 
5 miR-429 1 1 1 0 1 1 
4 miR-135b 1 0 1 1 1 0 
4 miR-141 1 0 1 0 1 1 
4 miR-151:9.1 1 1 1 0 1 0 
4 miR-203 1 1 1 0 1 0 
4 miR-7-1* 1 1 1 0 0 1 
4 miR-339-5p 1 0 1 1 1 0 
3 miR-106b 1 0 0 0 1 1 
3 miR-126* 0 0 1 1 0 1 
3 miR-215 0 0 1 1 0 1 
3 miR-22 0 0 1 1 1 0 
3 miR-335 0 1 1 1 0 0 
3 miR-374a 0 1 1 1 0 0 
3 miR-493* 0 1 1 1 0 0 
3 miR-589 1 1 0 1 1 0 
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No. of 
hits (/6) 
MiRNA C80  C99 HRA19 HT55 SW837 VACO4S 
3 miR-614 1 0 0 1 0 1 
3 miR-1234 1 0 1 0 0 1 
3 miR-1290 1 1 0 0 0 1 
3 miR-146a 0 1 0 0 1 1 
3 miR-148a 0 0 1 0 1 1 
3 miR-15a 0 0 1 0 1 1 
3 miR-19b 1 0 0 0 1 1 
3 miR-200a 0 0 1 0 1 1 
3 miR-624* 0 1 1 0 1 0 
2 miR-1296 0 0 0 1 1 0 
2 miR-365 0 0 1 1 0 0 
2 miR-424 0 0 0 1 1 0 
2 miR-503 0 0 0 1 1 0 
2 miR-625* 0 0 0 1 1 0 
2 miR-642 0 1 0 1 0 0 
2 miR-647 0 1 0 1 0 0 
2 
miR-768-
5p:11.0 
0 0 1 1 0 0 
2 miR-10b 1 1 1 0 0 0 
2 miR-1238 1 1 0 0 0 0 
2 miR-1248 1 1 0 0 0 0 
2 miR-1296 0 0 0 1 1 0 
2 miR-148b 0 0 1 0 0 1 
2 miR-152 0 0 0 0 1 1 
2 miR-17 0 0 0 0 1 1 
2 miR-185 0 0 0 0 1 1 
2 miR-18a 0 0 1 0 1 0 
2 miR-192 1 0 0 0 0 1 
2 miR-20a 0 0 0 0 1 1 
2 miR-221* 0 0 1 0 1 0 
2 miR-30a 1 0 1 0 0 0 
2 miR-30a* 0 0 1 0 1 0 
2 miR-30c 0 0 1 0 1 0 
2 miR-30e 0 0 1 0 1 0 
2 miR-34a 0 0 0 0 1 1 
2 miR-660 0 1 1 0 0 0 
2 miR-9 0 0 1 0 1 0 
2 miR-938 0 1 0 0 0 1 
 
There were 28 miRNAs that were significantly upregulated in two cell lines, 17 miRNAs in three 
cell lines, 6 miRNAs in four cell lines and 4 miRNAs in five cell lines (table 24). The most 
commonly upregulated miRNAs included miR-29c (upregulated in all cell lines except 
VACO4S), miR210 (except C99), miR-29b (except HT55) and miR-429 (except HT55). In total 
there were 45 miRNAs upregulated in two or more cell lines. 
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25. Table 25. Common downregulated miRNAs in cell lines in hypoxia compared to 
normoxia. The miRNAs that were upregulated in more than one cell line are shown with the 
number of hits of the left and the details of the upregulation in each cell line on the right. 1 
indicates significant downregulation in cell line, 0 indicates no difference in expression. * 
indicates miRNA star form. 
No. of 
hits (/6) 
MiRNA C80  C99 HRA19 HT55 SW837 VACO4S 
6 miR-1268 1 1 1 1 1 1 
5 miR-23b* 1 1 1 1 1 0 
5 miR-25* 0 1 1 1 1 1 
5 miR-615-5p 1 1 1 1 0 1 
5 miR-92a-1* 1 1 1 1 1 0 
5 miR-23a* 1 0 1 1 1 1 
4 miR-1229 0 0 1 1 1 1 
4 miR-29b-1* 0 1 1 1 1 0 
3 miR-296-3p 1 0 0 1 1 0 
3 miR-513b 0 0 1 1 1 0 
3 miR-565:9.1 1 1 0 1 0 0 
3 miR-1249 0 0 1 0 1 1 
3 miR-326 1 1 0 0 0 1 
3 miR-663b 1 0 1 0 0 1 
3 miR-886-3p 0 1 0 1 1 0 
3 miR-92b* 0 0 1 0 1 1 
2 miR-107 0 1 0 1 0 0 
2 miR-483-3p 0 0 0 1 1 0 
2 miR-500 0 1 0 1 0 0 
2 miR-509-3p 0 0 0 1 1 0 
2 miR-532-5p 0 1 0 1 0 0 
2 miR-769-3p 0 1 0 1 0 0 
2 miR-1226 0 0 0 0 1 1 
2 miR-1227 0 0 1 0 1 0 
2 miR-1247 0 0 1 0 1 0 
2 miR-1274a 0 1 0 0 0 1 
2 miR-1296 0 1 0 0 0 1 
2 miR-1307 0 1 0 0 0 1 
2 miR-1826 0 0 1 0 1 0 
2 miR-193b 0 1 0 0 0 1 
2 miR-27b* 0 0 0 1 0 0 
2 miR-296-5p 1 0 0 0 0 1 
2 miR-324-5p 0 0 1 0 1 0 
2 miR-331-3p 0 1 0 0 0 1 
2 miR-339-5p 0 1 0 0 0 1 
2 miR-361-3p 0 1 0 0 0 1 
2 miR-378* 0 1 0 0 0 1 
2 miR-425* 1 1 0 0 0 0 
2 miR-493* 1 0 0 0 0 1 
2 miR-505* 0 0 1 0 1 0 
2 miR-629 1 1 0 0 0 0 
2 miR-664* 1 0 0 0 1 0 
2 miR-675 1 0 0 0 0 1 
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No. of 
hits (/6) 
MiRNA C80  C99 HRA19 HT55 SW837 VACO4S 
2 miR-760 0 0 1 0 1 0 
2 miR-874 0 1 0 0 0 1 
2 miR-886-5p 0 1 0 0 0 1 
2 miR-93* 0 1 0 0 0 1 
 
The most common significantly downregulated miRNAs across the six cell lines are detailed in 
table 25. There was one miRNA that was downregulated in all six cell lines (miR-1268), 5 
miRNAs downregulated in five cell lines (miR-23b*, miR-25*, miR-615-5p, miR-92a-1* and 
miR-23a*), 2 miRNAs downregulated in four cell lines, 8 in three cell lines and 31 in two cell 
lines. In total, 47 miRNAs were downregulated in two or more cell lines. 
Within these common upregulated and downregulated miRNAs, there were some interesting 
miRNAs that were significantly upregulated in some cell lines, but also significantly 
downregulated in others (table 26). These miRNAs could be interesting as the differentially 
expressed miRNAs could provide an explanation of the difference in cell line characteristics 
defined previously (section 3, 4 and 5); cell lines with opposing features would provide very 
useful experimental tools. Table 26 shows three miRNAs that have significant upregulation in 
two or more cell lines and significant downregulation in two or more cell lines.  
26. Table 26. Different expression of miRNAs between cell lines. 1, significantly upregulated 
miRNA in hypoxia compared to normoxia; 0, no difference in miRNA expression.  Up, 
upregulation; down, downregulation. * indicates miRNA star form. 
No of 
hits 
(/6) 
MiRNA Regul
ation 
C80  C99 HRA19 HT55 SW837 VACO4S 
4 miR-339-5p Up 1 0 1 1 1 0 
2 miR-339-5p Down 0 1 0 0 0 1 
3 miR-493* Up 0 1 1 1 0 0 
2 miR-493* Down 1 0 0 0 0 1 
2 miR-1296 Up 0 0 0 1 1 0 
2 miR-1296 Down 0 1 0 0 0 1 
 
The three miRNAs: miR-339-5p, miR-493*, and miR-1296 were interesting because of their 
different expression between the cell lines. These miRNAs were studies because they allow 
comparison of the miRNA between cell lines and more easily allows determination of functional 
activity and target prediction, without the need for antisense miRNA experiments to knock 
down the miRNA (table 26). MiR-339-5p was significantly upregulated in hypoxia in C80 
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(p=4.83 x 10-33), HRA19 (p=0.0099), HT55 (p=2.41 x 10-33) and SW837 (p=1.42 x 10-33), but 
significantly downregulated in hypoxia in the remaining two cell lines; C99 (p=4.39 x 10-33) and 
VACO4S (p=9.43 x 10-21). In this case, miR-339-5p was studied further because of its association 
with tumour migration and invasion as detailed below (section 6.2.1).  
MiR-493* was upregulated in hypoxia in C99 (p=2.54 x 10-33), HRA19 (p=1.74 x 10-7) and HT55 
(p=1.76 x 10-9) and downregulated in hypoxia in C80 (p=8.26 x10-9) and VACO4S (p=8.16 x 10-
20). However, this miRNA was not studied further because it is a star-form, the complimentary 
strand of miR-493, and is predicted to rapidly degrade after exit from the RISC complex and 
therefore has little or no expression191. In the literature, one of the only published articles using 
miR-493* is in Chinese and indicates (from the abstract - article in Chinese) that miR-493* 
expression is upregulated in prolactinoma and correlates with the serum level of prolactin 
(produced by the tumour)256. Another article found that miR-493* was enriched in pancreatic 
islets compared to muscle and liver257, however, these are the only two articles about this miRNA 
and as its function is not wholly known, it was not investigated further.  
The third miRNA in table 26 that was differentially expressed in cell lines was miR-1296 with 
significant upregulation in hypoxia in HT55 (p=2.41 x 10-33) and SW837 (p=1.42 x 10-33) and 
significant downregulation in hypoxia in C99 (p=4.39 x 10-33) and VACO4S (p=1.24 x 10-19). 
This miRNA was studied further alongside miR-339-5p as detailed below.  
The next step was to validate the results of the microarray by selecting the miRNAs in table 26 
for further study. 
6.2 MiRNA validation 
6.2.1 MiR-339-5p 
MiR-339-5p is known to play a role in preventing tumour migration and invasion and was 
associated with BCL-6 in breast cancer cells in vitro258. Ex vivo, miR-339-5p has been shown to be 
expressed at a lower level in breast tumour tissue compared to benign tissue and this was 
associated with increased metastasis. Higher expression of miR-339-5p was associated with 
better prognosis and survival rates in breast cancer patients258. This information was important in 
our decision to study this miRNA further because it might have a role in rectal cancer prognosis 
and survival rate. The six rectal cancer cell lines were subjected to hypoxic (2 % O2) or normoxic 
treatment followed by miRNA extraction and the product used for qRT-PCR analysis of miR-
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339-5p and the results shown below. The hypoxic/normoxic incubation and miRNA extraction 
was independent of the incubation and extraction performed for the microarray. 
 
52. Figure 52. MiR-339-5p expression was affected by hypoxia. Fold change in miR-339-5p 
expression in hypoxia (2 % O2) compared to normoxia: six rectal cancer cell lines were subjected to 72 h 
normoxia or hypoxia and the miRNA extracted, reverse transcribed and used for qRT-PCR analysis. C80 
and C99, n=9; *, p<0.05. HRA19, HT55, SW837 and VACO4S, n=3; *, p<0.05.  
C80 and HRA19 had significantly increased miR-339-5p expression in hypoxia compared to 
normoxia (p=0.012 and 0.0052 respectively; figure 52) and SW837 and VACO4S had 
significantly decreased miR-339-5p expression in hypoxia compared to normoxia (p=0.027 and 
0.019 respectively). C99 and HT55 did not show a significant difference. These expression 
results did not entirely replicate the results from the microarray; however there was a significant 
upregulation in C80 and HRA19 and significant downregulation in VACO4S, similar to the 
microarray. Unlike the microarray where C99 showed significant miR-339-5p downregulation in 
hypoxia, there was no change in C99 miR-339-5p expression in the qRT-PCR analysis. HT55 
showed miR-339-5p expression upregulation in the microarray, but no miR-339-5p expression 
change in the qRT-PCR. MiR339-5p expression in SW837 showed the opposite in the qRT-PCR 
than the microarray with significant downregulation in the former. Despite the interesting 
results, miR-339-5p was not pursued further at this stage because targets of this miRNA have 
only been predicted, not yet proven. 
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6.2.2 MiR-1296 
One of the other miRNAs that was selected for further validation was miR-1296. The microarray 
returned results that indicated that miR-1296 was upregulated in hypoxia in HT55 and SW837 
and downregulated in C99 and VACO4S. In a literature search, miR-1296 was found to be 
downregulated in prostate cancer, to be a regulator of minichromosome maintenance protein 2 
(MCM2) and may have a role in cell cycle check points259. Loss of miR-1296 produces an 
increase in MCM2 proteins, as seen in prostate cancer. The qRT-PCR validation of miR-1296 
results are shown below (figure 53). 
 
53. Figure 53. MiR-1296 expression was reduced by hypoxia. Fold change in miR-1296 
expression in hypoxia (2 % O2) compared to normoxia; six rectal cancer cell lines were subjected to 72 h 
normoxia or hypoxia and the miRNA extracted, reverse transcribed and used for qRT-PCR analysis. C80 
and C99, n=9; *, p<0.05. HRA19, HT55, SW837 and VACO4S, n=3; *, p<0.05. 
Figure 53 indicates the expression change of miR-1296 in hypoxia compared to normoxia. C80, 
C99 and HRA19 all showed no significant change in hypoxia compared to normoxia, but HT55, 
SW837 and VACO4S all showed significant downregulation in hypoxia compared to normoxia 
(p=0.0005, 0.0004 and 0.001 respectively). Some of these results were different from the 
microarray results; the microarray showed no change in C80 and HRA19, the same as the qRT-
PCR results, but the microarray showed upregulation of miR-1296 in HT55 under hypoxia 
whereas the qRT-PCR results showed a significant decrease in miR-1296 expression (p=0.0005). 
C99 showed significant miR-1296 downregulation in the microarray but no change in qRT-PCR 
results. SW837 had upregulation of miR-1296 in the microarray, but the qRT-PCR showed 
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downregulation (p=0.0004). Finally, VACO4S showed consistent downregulation of miR-1296 
in both the microarray and the qRT-PCR (p=0.001). Further analysis of miR-1296 in the six 
rectal cancer cell lines continued with analysis of MCM2 protein expression by western blot 
(section 6.3.1). It was expected that a decrease in the expression of miR-1296 in hypoxia (2 % 
O2) in HT55, SW837 and VACO4S would lead to an increase in MCM2 presence in hypoxia. 
6.2.3 MiR-210 
MiR-210 was in the top significantly different miRNAs in hypoxia compared to normoxia in five 
out of six cell lines (table 24) and the only cell line that did not show a change in miR-210 
expression in hypoxia compared to normoxia was C99. Importantly, miR-210 is known to be 
increased by hypoxia in multiple cell lines in response to HIF-1α stabilisation (for HIF-1α 
protein expression for C80 and C99, (section 4.1) increased in breast cancer samples compared 
to normal breast tissue and linked to breast cancer prognosis (miR-210 expression inversely 
correlated with DFS and OS)208. In addition, miR-210 was found to be a marker of tumour 
hypoxia, disease recurrence and short OS in head and neck cancer207. These were major reasons 
to continue to validate this miRNA in rectal cancer cell lines. The six rectal cancer cell lines were 
validated by qRT-PCR after incubation in hypoxia (2 % O2) or normoxia for 72 h and miRNA 
extraction, and the results shown in figure 54. 
 
54. Figure 54. MiR-210 expression is increased by hypoxia (2 % O2). Figure show fold change in 
miR-210 expression in hypoxia (2 % O2) compared to normoxia in six rectal cancer cell lines. The cell 
lines were subjected to 72 h normoxia or hypoxia followed by miRNA extraction, reverse transcription 
and qRT-PCR analysis. C80 and C99, n=9; *, p<0.05. HRA19, HT55, SW837 and VACO4S, n=6; *, 
p<0.05. 
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As shown in figure 54, miR-210 was validated as it was shown to be significantly upregulated by 
hypoxia (2 % O2) in all six cell lines (C80, C99, HRA19, HT55 and VACO4S, all with p<0.0001 
and SW837, p=0.0243). This is in accordance with the microarray apart from miR-210 
expression in C99, which was significantly increased in the validation qRT-PCR but had no 
significant change in the microarray.  
6.3 Assessment of potential targets for miR-1296 and miR-210 
MicroRNAs are known to specifically target the mRNA to either silence expression by 
translational repression or mRNA degradation. Two miRNAs were picked from the microarray, 
as detailed above, and were studied to determine if the miRNA in question had a functional 
effect on a potential target. The target chosen for miR-1296 was MCM2259 (section 6.3.1) and the 
target for miR-210 was ISCU206 (section 6.3.2) as both had been investigated in the literature and 
were not based solely on computer prediction. 
6.3.1 MiR-1296 
MiR-1296 expression was significantly downregulated in HT55, SW837 and VACO4S cells under 
hypoxia (2 % O2) compared to normoxia from qRT-PCR analysis (figure 53). A known target for 
miR-1296 is MCM2. In this case, as miR-1296 is downregulated in hypoxia, the prediction is that 
MCM2 would be significantly upregulated in hypoxia. MCM2 is a protein that forms a complex 
with other MCM proteins, and this complex ‘has helicase activity and facilitates DNA 
replication’259. An increase in the MCM2 proteins during hypoxia would be useful for the cell to 
aid increased proliferation and MCM2 and associated proteins are upregulated in cancers260. A 
western blot (figure 55) reveals the protein expression level in five rectal cancer cell lines in 
hypoxia (2 % O2) and normoxia. The HRA19 cell line was not easy to culture in large quantities 
and so there were not enough cells for protein extraction, hence HRA19 was not included in this 
analysis. HeLa was used as the manufacturer’s (Abcam) recommended positive control. The 
western blots for MCM2 are shown in figure 55 and 56. 
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55. Figure 55. Western blot depicting MCM2 protein expression in C80 and C99 cells under 
normoxia (N) and hypoxia (H). HeLa was used as the positive control and β actin was used to 
normalise MCM2 expression.  
 
 
56. Figure 56. Western blot depicting MCM2 protein expression in C80 and C99 cells under 
normoxia (N) and hypoxia (H). HeLa was used as the positive control and MCM2 expression was 
normalised to β actin.  
Figure 55 and 56 detailed the MCM2 protein expression in five rectal cancer cell lines in hypoxia 
and normoxia with HeLa cell lysate used as the positive control. MCM2 expression was 
calculated using density measuring software to quantify the protein and the results shown in 
figure 57. 
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57. Figure 57. MCM2 protein expression in cell lines under normoxia and hypoxia (2 % O2). 
HeLa cell lysate was used as a positive control and all samples were normalised to HeLa. β actin was used 
as the loading control and all samples normalised to their respective β actin level. N, normoxia; H, 
hypoxia. *, p<0.05. 
Figure 57 shows the relative protein expression in five rectal cancer cell lines in hypoxia and 
normoxia with HeLa cell lysate as the positive control. All five rectal cell lines showed lower 
MCM2 expression than the positive control and there was a difference between normoxia and 
hypoxia in C80 and C99; increased MCM2 expression in hypoxia (2 % O2). C80 (N 0.57, H 0.71) 
and C99 (N 0.64, H 0.75) had the highest relative MCM2 protein expression and HT55 (N 0.14, 
H 0.15), SW837 (N 0.25, H 0.27) and VACO4S (N 0.12, H 0.12) had much lower expression.  
In relation to miR-1296 expression, C80 and C99 showed no change in expression in hypoxia (2 
% O2) compared to normoxia but these two cell lines did show increases in MCM2 protein 
expression. This was unexpected as a decrease in miR-1296 expression could have caused an 
increase in MCM2 expression, which was not seen. However, there are many other factors that 
could have caused the increase in MCM2 expression in hypoxia. In the three cell lines that 
showed a significant decrease in miR-1296 expression in hypoxia, HT55, SW837 and VACO4S 
(figure 53); there was not a corresponding increase in MCM2 expression in hypoxia, as expected. 
A clear association between miR-1296 and MCM2 protein expression could not be identified by 
these experiments and the results suggested that MCM2 protein expression was not under 
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control of miR-1296 and that factors other than this miRNA are influencing MCM2 expression 
under hypoxic conditions. 
6.3.2 MiR-210 
Following miR-210 expression validation in rectal cancer cell lines, a literature search was 
performed to find targets of miR-210 identified by experimentation. The targets that have been 
found are shown in table 27.  
27. Table 27. Targets of miR-210 as discussed in the literature. Full name and functions are 
given. Search results using review: Devlin et al261. PubMed search criteria: Gene, miR-210 
function; miR-210 AND target. 
Target gene 
abbreviation 
Target full name Function 
ACVR1B 
Activin A receptor, 
type 1B 
Involved in cell cycle regulation262 263 
AIMF3 
Apoptosis-inducing 
factor, mitochondrion-
associated, 3 
Associated with apoptosis264 
CASP8AP2 
Caspase-8-associated 
protein-2 
Regulates apoptosis265 
COX 10 
Cytochrome c oxidase 
assembly protein 
Encodes a protoheme that participates in the biosynthesis of 
heme-α, essential in COX complex206 
E2F3 
E2F transcription 
factor 3 
Involved in cell cycle regulation266 
EFNA3 Ephrin A3 
Receptor protein tyrosine kinase. Involved in cardiovascular 
development and vascular re-modelling267,268 
FGFRL1 
Fibroblast growth 
factor receptor-like 1 
Transmembrane receptor involved in signalling269 
GPD1L 
Glycerol-3-phosphate 
dehydrogenase 1-like 
Catalyses conversion on sn-glycerol-3-phosphate to glycerine 
phosphate266 
HOXA1 Homeobox A1 Regulate gene expression, morphogenesis and differentiation269 
HSD17B1 
Hydroxysteroid (17β) 
dehydrogenase 1 
An enzyme expressed in the placenta and involved in 
preeclampsia270 
ISCU1/2 
Iron sulphur cluster 
scaffold protein 
Essential for assembly of Fe-S clusters, a component of the 
mitochondrial electron transport chain206 
MNT MAX binding protein Transcriptional repressor and antagonist of Myc271 
NDUFA4 
NADH dehydrogenase 
1 alpha subcomplex 4 
NADH dehydrogenase activity and transfers electrons from 
NADH to the respiratory chain262 
NPTX1 Neuronal pentraxin 1 Involved in hypoxic-ischemic injury266 272 
RAD52 RAD52 homolog DNA repair factor273 
SDHD 
Succinate 
dehydrogenase subunit 
D 
Involved in the TCA cycle and electron transfer chain in 
mitochondria274 
VMP1 
Vacuole membrane 
protein 1 
Cell autophagy and down-regulated in metastatic breast 
cancer275 
 
173 
 
Of all the targets of miR-210 shown in table 27, ISCU was chosen as an interesting target to 
pursue further as it has been proven to be a target by four separate research groups206 266 276 277 and 
the ISCU protein is an essential part of the mitochondrial transport chain, can control the levels 
of ROS production277 and loss of miR-210 can cause altered mitochondrial function and 
disruption of homeostasis206. The ISCU protein has not been studied before in rectal cancer with 
respect to hypoxia and expression of miR-210.  
The prediction was that as miR-210 was significantly upregulated in hypoxia (figure 54), the miR-
210 target (ISCU) would be significantly downregulated in hypoxia. Downregulation of ISCU in 
colon and breast cancer cells was shown to reduce the oxygen consumption activity by 30%206 
and could cause decline of mitochondrial function by reducing Fe-S delivery to target protein 
and this could further impact the transport of electrons in the electron transport chain277. 
Initially, this reduction in respiration could help adapt the cells to low oxygen levels and transfer 
from aerobic to anaerobic respiration. Here the technique of qRT-PCR was used to detect ISCU 
mRNA expression (figure 58) as in other published work206 277. If ISCU mRNA decreases with 
increasing miR-210 expression then ISCU protein analysis will follow to determine if ISCU 
protein was affected by a change in miR-210 expression under hypoxic conditions.  
 
58. Figure 58. ISCU mRNA expression is significantly decreased under hypoxic conditions in 
six rectal cancer cell lines. Six rectal cancer cell lines were subjected to 72 h normoxia or hypoxia (2 % 
O2) followed by RNA extraction, cDNA synthesis and qRT-PCR analysis. All cell lines, n=4; *, p<0.05. A 
fold change below 1 indicates that the expression level is higher in normoxia than hypoxia; all fold change 
values were below 1 for ISCU expression. 
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ISCU mRNA expression was significantly decreased in all rectal cancer cell lines in hypoxia 
compared to normoxia (figure 58), as predicted by miR-210 expression changes. HRA19, C80 
and C99 had the highest miR-210 induction in hypoxia (21.01, 10.63 and 9.22 fold increase 
respectively) and the highest reduction of ISCU expression in hypoxia (0.48, 0.57 and 0.43 fold 
respectively), which correlates with the prediction that as miR-210 increases, ISCU expression 
decreases. HT55, SW837 and VACO4S all had significant induction of miR-210 in hypoxia, 
although all were below a fold change of 5.2 (4.76, 3.80 and 5.15 fold respectively). These three 
cell lines had a smaller ISCU expression reduction in hypoxia (0.72, 0.67 and 0.70 fold 
respectively), which also correlates with a prediction that a small increase in miR-210 expression 
in hypoxia was concurrent with a small decrease of ISCU expression in hypoxia.  
Following the ISCU mRNA analysis, the next step was to verify the ISCU protein expression to 
determine if the ISCU mRNA expression correlated to the protein expression and therefore a 
functional effect (reduced oxygen consumption and more glycolytic activity277). Figures 59 and 60 
detail the western blots of ISCU in C80, C99, HT55, SW837 and VACO4S. 
 
59. Figure 59. Western blot depicting ISCU protein expression in C80 and C99 cells under 
normoxia (N) and hypoxia (H). HeLa cell lysate was used as the positive control and β actin was used 
to normalise ISCU expression. 
 
60. Figure 60. Western blot depicting ISCU protein expression in C80 and C99 cells under 
normoxia (N) and hypoxia (H). HeLa cell lysate was used as the positive control and β actin was used 
to normalise ISCU expression. 
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Figures 59 and 60 show the western blots of ISCU protein expression in five rectal cancer cell 
lines. The next figure (figure 61) shows the results of the quantification of the western blots 
using densitometric software.  
 
61. Figure 61. A reduction of ISCU protein expression in cell lines under hypoxia compared to 
normoxia. Five rectal cancer cell lines were incubated in hypoxia (2 % O2) for 72 hours followed by 
protein extraction. HeLa cell lysate was used as a positive control, as recommended by the manufacturer 
of the ISCU antibody (Proteintech), and all samples were normalised to β actin protein expression and 
compared to HeLa (recommended positive control). N, normoxia; H, hypoxia. 
The ISCU protein expression in five rectal cancer cell lines compared to the positive control 
(HeLa) are shown in figure 61. Four of five cell lines showed marked downregulation of ISCU 
protein in hypoxia compared to normoxia (C80, HT55, SW837 and VACO4S). No significance 
values were obtained because the protein was only extracted once for one experiment. There was 
no reduction in protein expression in C99, only a slight increase in hypoxia. The HRA19 cell line 
was not used in this analysis because of culturing issues preventing large enough quantities of cell 
lysate for protein extraction. 
ISCU mRNA expression was significantly reduced in hypoxia in all six rectal cancer cell lines and 
ISCU protein was downregulated in four out of five cell lines. It should be noted that there are 
24 miRNAs predicted to target ISCU mRNA including miR-210 (miRDB)278, but to date only 
miR-210 has been proven experimentally to modulate expression of this protein277.  
It is important to investigate findings from cell lines in tissue and so next rectal cancer tissue 
sections were investigated for miR-210 expression, hypoxia levels and ISCU protein expression 
in the next section (section 6.4). 
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6.4 Rectal cancer tissue validation of miR-210 
Although the rectal cancer cell lines provided clear evidence of an increase in miR-210 
expression in hypoxia compared to normoxia, this need to be confirmed in vivo using rectal 
cancer tissue. Hypoxia in rectal cancer is a highly frequent occurrence182. Rectal cancers surgically 
removed from patients have been preserved in FFPE blocks and in the next section a total of 
fourteen rectal cancer blocks have been selected for further analysis.  
6.4.1 MiR-210 expression in rectal cancer tissue 
Following the consistent upregulation of miR-210 in all six rectal cancer cell lines, 14 rectal 
cancer tissue specimens were selected from the Rectal Cancer Database and sections taken from 
FFPE blocks. The sections were scraped and miRNA extracted using the procedure in section 
2.3.1 and expression levels determined (figure 62). 
 
62. Figure 62. Increased miR-210 expression is a consistent feature of rectal cancers. Tumour 
samples (T) and one dysplastic sample (D) were compared to the average of four normal controls. Fold 
change calculated using the following equation: ΔCt = Ct target - Ct endogenous control, ΔΔCt = ΔCt 
tumour - ΔCt normal average, RQ = 2--ΔΔCt. MiR-16 and let-7a were combined as the endogenous 
controls, as recommended in Davoren et al. 2008234 as they were the most stable pair of endogenous 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
5.5 
6.0 
6.5 
3
6
9
 T
 
3
8
0
 T
 
4
0
1
 D
 
3
5
8
 T
 
3
4
8
 T
 
3
8
7
 T
 
3
8
2
 T
 
3
7
4
 T
 
3
3
5
 T
 
3
8
1
 T
 
3
7
6
 T
 
3
8
3
 T
 
4
0
1
 T
 
3
8
4
 T
 
3
7
2
 T
 
Fo
ld
 c
h
an
ge
 in
 e
xp
re
ss
io
n
 c
o
m
p
ar
ed
 t
o
 a
ve
ra
ge
 n
o
rm
al
 
ti
ss
u
e 
ex
p
re
ss
io
n
 
Tissue samples 
Fold change in miR-210 expression 
* 
* 
* 
* * 
* * 
* 
* * * 
* 
24.52 
177 
 
controls in breast cancer tissue. Standard error (SE, error bars) was calculated using the equation: 
SE=SD/√n where SD was the standard deviation of the samples and n was the sample size. 401 T, 387 T, 
382 T, 376 T, 374 T, 372 T, 369 T, 335 T and 401 D, n=6. 384 T, 383 T, 381 T, 380 T, 358 T and 348 T, 
n=12. *, p<0.05 (t-test). Red line indicates no change in expression; above shows increased miR-210 
expression and below indicates reduced miR-210 expression. Increase in miR-210 expression in 372 T 
was 24.52 fold, as indicated by the data label. 
MiR-210 expression was assessed in 14 rectal cancer tumour tissue samples and the results in 
figure 62 showed that there was a varied level of expression between the samples. The miR-210 
expression of sample 372 T was the highest at 24.52 fold increase compared to the average 
normal miR-210 expression (p<0.0001). Six further tumour samples (384 T, 401 T, 383 T, 376 T, 
335 T and 374 T) had significantly increased miR-210 expression (4.47 to 2.01 fold increase, 
p<0.05) compared to the average normal samples. The rest of the samples apart from 381 T, 382 
T and 387 T (no significant difference) all had significantly decreased miR-210 expression in 
tumour samples (348T, 358 T, 380 T and 369 T; 0.63 to 0.17 fold, p<0.01) compared to the 
average normal samples. 401 D was the only dysplastic sample analysed and had significantly 
lower miR-210 expression (0.44 fold, p=0.0016) compared to the average normal.  
The miR-210 expression results in rectal cancers shown in figure 62 indicated that there was a 
wide range in miR-210 expression between samples with some having increased expression and 
some decreased expression compared to the average normal samples. It remains to be seen if this 
was a feature of different degrees of hypoxia in the tissues. 
6.4.2 MiR-210 expression correlation with tissue hypoxia 
A measure of hypoxia in the tumour regions that were assayed for miR-210 expression was 
needed to test the link between hypoxia and increased miR-210 expression.  The prediction was 
that those samples expressing the highest miR-210 (372 T, 384 T, 401 T, 383 T and 376 T) 
would be hypoxic and those tumour samples expressing the lowest miR-210 (369 T, 380 T, 401 
D, 358 T and 348 T) would not be hypoxic. The indicator of hypoxia used in rectal cancer 
samples was carbonic anhydrase 9 (CAIX) as it has been previously shown to be expressed in 73 
% of rectal cancers279, it contains a hypoxia-responsive element in its promoter region and is 
known to be an endogenous marker of cellular hypoxia and HIF-1α activity280. The 
immunohistochemistry (IHC) process, as detailed in section 2.16.2, was completed on serial 
sections used for miR-210 analysis. Areas for analysis of staining were matched to regions used 
for extraction for miRN-210 analysis. The staining results categorised CAIX protein presence by 
percentage staining and this took into account extent and intensity of staining according to 
Korkeila et al.281. 
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The scoring was performed by two independent observers (one trained pathologist) and results 
combined. The extent of staining was used to group rectal cancer tissue sections into percentage 
staining which indicated the extent of tumour hypoxia. Tumours with high CAIX staining 
reflected more extensive hypoxic regions280. The results were calculated in percentage to include 
extent and intensity and examples are shown in figure 63.  
 
63. Figure 63. Representative examples of CAIX staining in rectal cancer tissue. Panels A and 
D show positive and negative controls (stomach) respectively. Panels B, C and E show very weak, strong 
and moderate staining respectively. Panel F illustrates the regional nature of CAIX staining. Membranous 
immunoreactivity increases along with general staining intensity (B>E>C). 
Different levels of CAIX staining are shown in figure 63. CAIX staining varied from low (figure 
63, B) to high (figure 63, C) in different samples. Focal staining in panel F indicates localised 
hypoxic tissue. The results of staining analysis are shown in figure 64. 
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64. Figure 64. CAIX was expressed at increasing levels in relation to miR-210 expression 
rectal cancer tumour tissue. Tissue from 14 rectal cancer samples was stained using IHC for CAIX. A 
positive and negative control were used to confirm correct staining of the antibody, both controls were 
completed in stomach tissue, known to be positive for CAIX282. Percentage staining of CAIX took into 
account the extent and intensity of staining. Rectal cancer tissue samples were ordered on the x-axis by 
miR-210 expression: black, higher miR-210 expression in tumour compared to average of normal tissue; 
dark grey, no change in miR-210 expression (382 T); light grey, reduced miR-210 expression in tumour 
compared to average of normal tissue. 387 T showed no result because there was no tumour tissue left on 
the slide for IHC analysis. A significant positive correlation was observed between CAIX expression and 
miR-210 expression, r=0.83, p=0.003 (Spearman’s rank). 
Figure 64 details the expression level of CAIX in rectal cancer tissue samples. A published 
study281 investigating CAIX staining in rectal tissues used a graded system for evaluation of 
staining by grouping into positive and negative followed by calculating the proportion of positive 
staining and combining it with intensity. The proportion of positive staining was grouped into 
three categories: 10-25 %, 26-50 % and over 50 %. The system used to analyse the data in this 
experiment was the same as in Korkeila et al.281, but the percentages were not grouped into the 
categories to allow for the Spearman’s rank calculations. 
In general, figure 64 indicates that there was a varied level of CAIX protein expression in rectal 
cancer tissue with some samples having little or no staining (369 and 380) and some samples 
having high levels of CAIX (383 and 372). The average expression of all samples was 45.5 %. 
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In relation to miR-210 expression, CAIX protein expression was higher in the samples with miR-
210 expression over 1 (figure 62 and 64) and lower in the samples with miR-210 expression 
under 1 (figure 62 and 64). The average CAIX expression in tissue samples with miR-210 fold 
change in expression over 1 was 56.25 % and 29.5 % in tissue samples with miR-210 fold change 
in expression under 1. A Spearman’s rank (r) correlation was performed to determine the 
relationship between the two sets of data and the result was 0.83 (p=0.003). The Spearman’s 
rank indicated that there was a significant positive association between miR-210 expression and 
CAIX expression. This indicates that hypoxia does influence miR-210 expression in rectal cancer 
tissue. 
Following the CAIX analysis, a target of miR-210, ISCU, was determined in the same rectal 
cancer samples. 
6.4.3 Validation of ISCU as a target of miR-210 in rectal cancer tissue 
Following the confirmation that ISCU protein expression largely correlated to ISCU mRNA 
expression in rectal cancer cell lines and was inversely related to miR-210 expression in cell lines, 
the next step was to determine if ISCU protein expression was inversely correlated to miR-210 
expression in the tumour tissue samples. The ISCU protein expression in tumour samples was 
achieved by immunohistochemistry on the same 14 rectal cancer samples as were used for CAIX 
expression. However, the optimisation of ISCU by IHC proved problematic because of muscle 
staining.  
If ISCU was a valid target of miR-210, then as miR-210 expression increased, ISCU protein 
would decrease, thereby showing an inverse correlation. It is possible that other factors also 
influence ISCU expression in rectal cancer samples, including other miRNAs that target ISCU 
for degradation. Further optimisation of ISCU IHC was taking place as this thesis was being 
written. 
6.5 Discussion 
In summary, the results of the microarray and qRT-PCR validation in cell lines indicated that 
miR-1296 was downregulated in hypoxia in three of six rectal cancer cell lines and these three 
had a corresponding upregulation of the miR-1296 target, MCM2, in vitro. The results also 
showed that miR-210 was induced by hypoxia in all six rectal cancer cell lines with a concurrent 
decrease in ISCU mRNA and protein expression (although not in all cell lines). In rectal cancer 
tissue samples, miR-210 was influenced by tumour hypoxia, as denoted by expression of the 
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HIF-1α-responsive protein CAIX. Therefore, in vitro miR-210 was induced by hypoxia and 
targeted ISCU for degradation and in vivo miR-210 was induced by hypoxia and the effect on the 
target ISCU protein expression is yet to be determined.  
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Chapter 7 Discussion  
The following chapter will discuss the DUOX2 expression results in rectal cancer cells, how 
expression might be linked to the methylation status of the gene’s promoter region and 
determined by changes in oxygen status. Also, how the presence of DUOX2 in tissue might 
influence HIF-1α and COX2, cause DNA damage and influence cell survival. Finally, how 
hypoxia modulates miRNA expression in rectal cancer cell lines and tissues will be discussed.  
7.1 DUOX2 is expressed in the apical membrane of the intestine 
DUOX2 is known to be expressed in the salivary glands, stomach, duodenum, colon, rectum, 
pancreas, testes and airway epithelial cells283 and an essential protein for DUOX2 function is 
DUOXA2, the DUOX maturation factor 2, which allows translocation of DUOX2 to the 
membrane for full functionality284. DUOX2 was variably expressed in thyroid cancers156 and 
mutations in DUOX2 cause hypothyroidism due to insufficient hydrogen peroxide generation283. 
DUOX2 is also expressed along the human digestive tract157, with heavy expression along the 
brush border of epithelial cells; data which supports our results. El Hassani et al.157 used 
immunostaining to determine the location of DUOX2, whilst our results were from in situ 
analysis of the DUOX2 mRNA. The DUOX2 antibody is commercially available from two 
companies (Santa Cruz and Abcam) and although we used both of these antibodies, neither 
produced a valid result (in addition, the recommended positive control did not produce a band at 
the right molecular weight - 175 kDa - on westerns. El Hassani et al. used an antibody that they 
raised themselves and although other groups have used the commercial antibodies165 285 286, they 
either did not use the antibody for western blots or the western blots seem inconclusive with 
more than one band close to the correct molecular weight165. Other information conveyed by 
word of mouth152 agrees with our conclusions regarding the antibody, therefore we thought it 
more valuable to detect DUOX2 using an in situ probe. 
Our mRNA data complements El Hassani’s in concluding that DUOX2 is expressed in the 
apical membrane of the intestinal epithelium. 
7.2 DUOX2 expression is increased in inflammation 
DUOX2 is part of the response to bacterial infection in the gut as it produces ROS (H2O2), 
which is lethal to microbes, and this process has been demonstrated in the rectum285. The role of 
H2O2 in microbial control was first revealed in Drosophila, where knockout of Duox caused an 
increase in fly death from microbial infection, but mortality was rescued by reintroducing Duox, 
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restoring the ability to destroy bacteria244. Although this has not yet been demonstrated in 
humans, the product of DUOX2, H2O2, is predicted to interact with lactoperoxidase to produce 
hypothiocyanite, which may be the cause of the bactericidal action in the intestine287. Data of 
DUOX2 expression in patients with Crohn’s disease (inflammatory condition) indicates that 
DUOX2 is upregulated in disease-unaffected tissue compared to the control group, which may 
show that it is responsive to pro-inflammatory signals even in unaffected areas288. Our in situ data 
clearly shows an increase in DUOX2 expression in inflamed and dysplastic areas of the intestine 
in a UC patient.  
In inflamed tissue, DUOX2 expression is higher, indicating that the immune response 
upregulates DUOX2288 in order to respond to microbial infection. In UC DUOX2 is upregulated 
most likely in response to inappropriate inflammatory signals and this has the potential to 
adversely affect the tissue through oxidative stress from increased H2O2 production. Dysplastic 
tissue also showed increased expression of DUOX2.  DNA damage (possibly caused by oxidative 
stress from increased DUOX2 and therefore H2O2) may cause abnormal genetic changes 
producing mutations that lead to cellular transformation. Long-lasting regions of inflammation in 
the intestine are inherently more likely to transform into cancers (via dysplasia) and this is 
demonstrated by the increased risk for CRC in UC patients: 18.4 % after 30 years of the 
disease289. Chronic inflammation can promote risk of cancer by activating signal cascades 
involved in inhibiting apoptosis and inducing cell proliferation289 and by oxidative stress (ROS 
production) induced by inflammation36 indicating DUOX2, as a major source of ROS in the 
intestine, could be involved in this process. 
7.3 DUOX2 was expressed in sporadic colon and rectal cancers and adenomas 
It was proposed that normal functioning of DUOX proteins was necessary for microbial 
homeostasis, but persistently activated DUOX2, as in hypoxic or chronically inflamed cells, may 
produce an elevated level of H2O2 causing adverse effects on the tissue
290. In the intestine, 
DUOX2 is responsive to microbial infection and helps achieve microbe homeostasis through its 
positive and negative regulation159 and therefore dysregulation of this pathway could cause a 
change in microbial host defence. We predicted that there could be a significant variation in the 
expression of DUOX2 in rectal cancers and that expression might be related to the response of 
the cancers to radiotherapy: no DUOX2 would predict low ROS and radio-resistance, whereas 
high DUOX2 would predict high ROS and radio-sensitivity.  
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The microarray data confirmed the prediction that DUOX2 and DUOXA2 expression in rectal 
adenomas would be higher than in normal tissue. This corresponds to our preliminary theory 
that DUOX2 is expressed at an early stage in tumourigenesis (at adenoma stage), potentially in 
response to marginally lower oxygen levels, and that this expression increase over normal tissue 
may then be reduced in late-stage tumours where hypoxic adaptation may have occurred. An 
earlier microarray analysis found a 10.63 fold increase in DUOX2 expression (p=0.00011) 
between flat adenoma and normal mucosa and also an increase in polypoid adenomas found, 
albeit at a lower level (26.5 % less than flat adenomas)291. However, this paper did not include 
DUOXA2 expression so the potential functionality of the protein was unknown. The data 
regarding DUOX2 expression could help increase understanding about the adenoma-carcinoma 
sequence from normal tissue to adenoma and cancer and about the pathogenesis of this disease. 
Determining the genetic expression profile of a cancer has the potential to aid therapeutic 
choice. There were different expression levels of DUOX2 in our panel of rectal cancers, which 
could indicate the stage of cancer; high DUOX2 may indicate an early cancer and low DUOX2 a 
later stage cancer. However, this would require many more samples to prove any association 
between DUOX2 expression levels and stage. Interestingly, there has recently been a study 
published that analysed the effect of a drug (a COX2 inhibitor) on gene expression in a colon 
cancer cell line (HT29) and the authors showed that DUOX2 was one of a number of genes that 
allowed discrimination between CRC and normal colonic tissue (30.06 fold change), followed by 
an expression reversal of DUOX2, again amongst other genes, when a COX2 inhibitor was 
added292. The same study also identified that the drug was more effective at reversing the 
expression changes at the adenoma stage, rather than cancer292, meaning that genetic testing to 
determine the progression of CRC may aid treatment choices. Our research into DUOX2 
expression in adenomas and cancers furthers the understanding of the adenoma-carcinoma 
tumourigenesis and may help to explain the difference in tumour response to treatment at 
different stages. 
The results of the in situ analysis showed that there was a variety of expression levels of DUOX2 
in rectal cancer tissue, from no DUOX2 to high DUOX2, and future work would relate this 
expression to response of the tumour to radiotherapy. The response to radiotherapy was not 
possible to determine in these cancers because data, i.e. regression grade, was not available for 
pre- and post-surgery, as this information was not included in our database or the hospital’s 
database. MRI scans were searched pre-surgery to relate size of tumour pre- and post-surgery, 
but only a few MRI scans were available and not all provided adequate information. However, 
the data presented does suggest that further studies are warranted. 
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In situ analysis and microarray expression results could indicate that DUOX2 is overexpressed in 
some cancers, producing high levels of H2O2 and potentially leading to increased response to 
irradiation. The median (4120.4) and range (112.5-10622.2) of DUOX2 expression from the 
microarray agrees with this theory, however, outcome data was not available for the microarray 
results and the samples used did not have neoadjuvant therapy. The cancers with high DUOX2 
may have developed through the inflammatory pathway (not necessarily chronic inflammation) 
where DUOX2 was overexpressed in presence of inflammation, as seen in airway epithelia where 
H2O2 generation against pathogens is dependent on DUOX2
161. The cancers with low DUOX2 
expression, and therefore low H2O2 production, could be more resistant to therapy because 
reduced H2O2 would mean lower ROS and lower DNA damage with irradiation. This could also 
indicate a molecular ‘switch’ in late-stage cancers with DUOX2 ‘switched off’ as a late event in 
cancer progression. Reduced expression may also be due to loss of a ‘wet’ epithelial surface 
within a cancer, although some expression was not in deeper regions of the cancer possibly 
through entrapment. However, as only eight rectal cancers were used for in situ analysis and of 
those only two showed high expression of DUOX2, it was not possible to link DUOX2 
expression to stage of cancer or to other database information. There are now plans to increase 
sample numbers to test these ideas. 
Following confirmation of expression of DUOX2 and DUOXA2 in CRC at different stages 
(high in adenoma) and variable DUOX2 expression levels in our rectal cancer tissue panel, 
methylation of the DUOX2 promoter was investigated to determine if this could be the cause of 
variation in DUOX2 expression.  
In order to answer some of the fundamental questions regarding the mechanisms of radiation 
resistance in rectal cancer, it was necessary to use rectal cancer cell lines as a model system. The 
cell lines provided a base on which to begin initial investigations and the results produced 
provides impetus for further studies in clinical samples. Although the cell lines provided a model, 
replication of a human rectal cancer is not exact as the tissue microenvironment is not recreated. 
As DUOX2 is methylated in lung cancers163 causing silencing of the gene, it was proposed that 
methylation of DUOX2 could be the cause of variation in expression of DUOX2 mRNA in 
rectal cancer tissue. In order to test this theory, six rectal cancer cell lines were used as a 
complement to the data on rectal tissue. Cell lines are an adequate pre-clinical representation of 
human cancers with unlimited potential to replicate and provide a useful platform on which to 
found studies on clinical samples291. Cell lines allow researchers to ask questions and find 
preliminary answers that would be otherwise impossible in human cancer specimens. 
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Alternatives to cell culture are animal models, however, these are time-consuming to initiate, 
expensive to maintain and there is no good animal model of rectal cancer. Cell lines do not 
replicate the physiological complexity of tumours. Despite these shortcomings, cell lines can be 
used in panels to account for mutational heterogeneity between cell lines and to provide a pre-
clinical cancer model. However, most studies only use one or two cell lines and do not account 
for genetic heterogeneity. Data on biomarkers and drug response from cell lines, for example, 
can be extrapolated to clinical specimens to be further validated, with mixed success293. A recent 
advance on monolayer cell culture and to provide a more realistic model of cancer in the future 
is to grow cells in spheroids in three-dimensional assays; cells are seeded in suspension and by 
mixing with other cells, form a more cancer-like culture method293. 
The results from the rectal cancer cell lines indicated that the DUOX2 promoter was partially or 
fully methylated in all six cell lines. The difference in methylation levels could have provided the 
reason for the difference in DUOX2 expression in rectal cancers: DUOX2 may be methylated in 
the cancers with low or no DUOX2 expression and may be partially or not methylated in the 
cancers with high DUOX2 expression. Specifically the results show that from C80 MSP analysis, 
DUOX2 promoter was methylated, but pyrosequencing of the promoter in C80 cell lines showed 
low levels of overall methylation (9.83 % methylation). In contrast, the C99 cell line MSP analysis 
revealed the DUOX2 promoter to be partially methylated, but pyrosequencing showed a higher 
level of methylation (26.53 % methylation). MSP analysis was a more crude method to detect 
methylation as it only revealed the methylation status at locations where the primers were 
situated, whereas pyrosequencing was a much more robust and quantitative measure of 
methylation with high sensitivity and specificity across all of the CpG sites within the DUOX2 
promoter. Although the MSP and pyrosequencing results did not match, I would be inclined to 
accept the pyrosequencing as the more accurate result as stated by Christians and colleagues294 
following their extensive review of MSP, pyrosequencing and another semi-quantitative method. 
Another way of detecting methylation levels of the DUOX2 promoter without pyrosequencing 
would have been to use cell line clones. Cells seeded at very low density in order to pick 
individual clones would then have been grown separately and sequenced to determine the 
methylation along the desired promoter. Many clones would have been needed to determine the 
percentage of methylation in the cell line at each CpG site and in this situation, it was decided 
that pyrosequencing was a quicker and more precise method as detailed in Irahara et al. 2010239 
and most recently, Christians et al. 2012294. Both studies found that pyrosequencing was an 
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improved and reliable method of measuring methylation in FFPE tissues from colon cancer, 
normal colon, blood and glioblastoma in order to accurately predict clinical outcome239 294. 
Silencing of a gene by methylation is an epigenetic event whereby methylated CpG sites cause 
transcriptional repression, it is a common feature of CRCs where tumour suppressor genes are 
inactivated and is an early event in some cancers140. Methylation is the addition of a methyl group 
to a cytosine nucleotide and in mammals, most CpG sites (a cytosine-guanine nucleotide next to 
each other with the potential to be methylated) are methylated (90 - 98 %), but there are specific 
regions in promoters of certain genes, CpG islands, where most sites are not methylated allowing 
gene transcription29. When CpG islands are methylated, the gene expression is silenced through 
transcriptional blocking and this regularly occurs on tumour suppressor genes in CRC29.  
The extent of methylation of a promoter has previously been related to the extent of mRNA 
expression; extensive methylation of p14ARF promoter region (a tumour suppressor commonly 
silenced in CRC) produced very low levels of p14ARF mRNA and unmethylated cell lines 
produced, in one case, 1760-fold more p14ARF mRNA295. In order to confirm that methylation 
was the only event causing the difference in mRNA expression, Zheng et al. cultured CRC cells 
with 5-aza-2’-deoxycytidine (AZA)295, an inhibitor of methyltransferase that causes de-
methylation of the DNA. The cells cultured in this way with initially high levels of methylation 
and low p14ARF mRNA levels with the addition of AZA showed a 100-fold induction of mRNA, 
indicating that a reduction in methylation by AZA treatment can rescue expression of a gene295. 
To further investigate the effect of methylation on the DUOX2 promoter in rectal cancer cell 
lines, treatment with AZA would be a suitable future experiment. With the addition of AZA, the 
cell lines with the highest DUOX2 promoter methylation would be expected to have increased 
mRNA levels if methylation was the only factor regulating expression. 
DUOX2 is silenced by promoter methylation in lung cancer163, and our results show that rectal 
cancer cell lines also have moderate to high levels of methylation of DUOX2. Despite the 
differing methylation status, all rectal cancer cell lines showed low levels of DUOX2 mRNA 
expression under normoxic conditions, with the highest mRNA level in C99 (26.5 % 
methylation) and the lowest in VACO4S, HRA19 (both partially methylated) and C80 (10 % 
methylation). The DUOX2 mRNA expression did not correlate to the level of methylation and 
the results indicated that there were other factors influencing DUOX2 mRNA expression other 
than methylation of the promoter region of DUOX2.  
Alternative mechanisms of gene expression regulation in this case could be via the ATF2 
protein, a transcription factor that can binds to the DUOX2 promoter regions and is activated 
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via the p38 MAPK pathway159. In normal conditions (normoxia), this protein is unstable and is 
degraded by ubiquitination, however, during hypoxia ATF2 protein expression is increased due 
to increased protein stability and inhibition of ubiquitination296. If ATF2 protein is stabilised 
during hypoxia, more ATF2 would be available to bind to ATF2-binding site in DUOX2 
promoter increasing DUOX2 expression in response to hypoxia. To test if DUOX2 was 
influenced by ATF2 in hypoxia, investigating the stability of ATF2 in hypoxia would be 
important (qRT-PCR and western blot), followed by knocking out ATF2 in hypoxic cells using 
ATF2-specific siRNA and observing the level of DUOX2 expression. If ATF2 was solely 
responsible for the hypoxic response of DUOX2 expression, in ATF2-negative hypoxic cells no 
DUOX2 expression would be observed. Currently, apart from regulation by IFN-γ and ATF2, 
no other proteins are known to regulate DUOX2 expression. 
Other factors affecting the expression of DUOX2 could be the lack of stimulation from 
interferon-gamma (IFN-γ) or from a rhinovirus in cell culture158. In the respiratory tract, 
DUOX2 expression was induced by IFN-γ158, a protein essential for immunity against viral and 
bacterial infections and is produced in the immune response297. In cell culture, there is no 
bacterial or viral infection, therefore the immune response was likely not activated and DUOX2 
expression would not have been induced. To test this response, IFN-γ could be transfected into 
the cells and the response of DUOX2 mRNA expression monitored.  
In addition to DUOX2 expression, mRNA levels of DUOXA2, the DUOX2 maturation factor, 
were also investigated and this showed concurrent low levels of expression, with the highest 
expression in C99. On chromosome 15, the location of DUOX2 and DUOXA2 are anti-parallel 
and almost overlap (within 300 bp) so the promoter could be responsible for expression of both 
genes, as suggested previously284, hence the common expression. It has been suggested that there 
is a common bidirectional promoter for these two genes based on the location of the genes and 
that DUOX2 is only functional when DUOXA2 is also expressed284. This was tested by 
expressing either protein individually in cells and detecting the amount of H2O2 released; only 
when DUOX2 and DUOXA2 were both present was there an increase in H2O2 production 
indicating both were necessary for activation of DUOX2284. In evolutionary terms, the location 
of these two genes next to each other could have provided an advantage if they were under a 
common bi-directional promoter, giving another level of DUOX2 regulation or activation. An 
example of this providing a benefit to the cell is two heat shock proteins (HSP60 and HSP10, a 
chaperone and its co-chaperone) where the transcription level of HSP60 is higher than that of 
HSP10 under normal conditions, but during heat-shock, the promoter activity increased 12 fold 
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in response allowing concurrent transcription of both response genes to the stimulus298. 
Currently, the bi-directional promoter control of DUOX2 and DUOXA2 is only predicted 
because of the tightly linked expression levels and the close and opposite direction of the genes 
on the DNA, but as yet no research has been published confirming this. The microarray data in 
this project indicated that the two genes did have linked expression due to the similar expression 
levels in colon and rectal cancer, adenoma and normal tissue. To test this hypothesis, the 
DUOX2/DUOXA2 promoter could be inserted into a plasmid containing two reporter genes on 
either side of the promoter, and if both were transcribed this would prove that the promoter was 
bi-directional.  
HIF-1α expression was also determined in the rectal cancer cells lines to be at a moderate to high 
level, however, despite moderate mRNA expression, the HIF-1α protein is known to be 
degraded under normoxic conditions by VHL in an oxygen-dependent manner299. Due to this 
degradation, moderate HIF-1α mRNA expression would not have a functional effect on the cell. 
In order to test the effect of hypoxia on the expression of DUOX2 and DUOXA2, cells were 
incubated under 2 % O2 followed by qRT-PCR. 
7.4 DUOX2 expression was influenced by moderate and low levels of oxygen (2 % 
and 0.2 % O2) 
Hypoxia is a major feature of many cancers, including rectal cancers, which show upregulation of 
HIF-1α (indicating hypoxia) in over 50 % of cases182. HIF-1α expression was related to TNM 
stage and vascular invasion (hypoxia increased vascular invasion) in a rectal cancer cohort182. 
Hypoxia is also a known feature of inflammation and given the direct link between inflammation 
and DUOX2 expression shown in this study the expression of this gene was examined under 
normoxia and hypoxia. A panel of six rectal cancer cell lines were incubated in 2 % and 0.2 % 
oxygen and significantly increased levels of DUOX2 mRNA were observed in C99 and HRA19 
cells under 2 % O2, and in all cell lines except SW837 under 0.2 % O2 compared to normoxia. 
Under 2 % O2, there was a non-significant increase in DUOX2 expression in C80, HT55, SW837 
and VACO4S. Pyrosequencing indicated that C99 had methylation of the DUOX2 promoter in 
25 % of cells, which did not change after hypoxic incubation. Despite the constant level of 
methylation in C99 cells, DUOX2 expression was still significantly changed by hypoxia, 
indicating that methylation was not sufficient to cause silencing under hypoxia. Hypoxia is a 
condition of inflammation often associated with an increased O2 consumption by microbes, 
immune cell activity or by local vasoconstriction. By experimentally inducing hypoxia in the 
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rectal cancer cell lines, an inflammatory-like response may have been created, causing the 
increase in DUOX2 expression, which does not appear to be modulated by methylation.  
Alternative proteins that may be regulating DUOX2 expression are ATF2, which has a binding 
element near to the transcription initiation site of DUOX2159 as detailed earlier, and IFN-γ, but 
no other proteins are known to regulate DUOX2 expression. 
In addition to DUOX2 expression analysis, DUOXA2 expression was also characterised in the 
rectal cancer cell lines and this showed similar increases in expression to DUOX2 under hypoxia 
(both 2 % and 0.2 % O2). The exception was in HRA19 under 0.2 % O2 that had a significant 
increase in DUOX2 without any increase in DUOXA2, which may indicate that DUOX2, 
although present at extremely high mRNA levels, was not active at the protein level in this cell 
line. All other cell lines showed similar expression of DUOX2 and DUOXA2 under hypoxia. 
DUOXA2 and DUOX2 proteins are co-expressed and dimerisation of these two is necessary for 
translocation of DUOX2 to the Golgi and to the plasma membrane or other intracellular 
compartments and DUOXA2 is required for full DUOX2 functionality284. The concurrent 
expression of DUOX2 and DUOXA2 in our cell lines reflects the proposal that there is a 
common bidirectional promoter that regulates expression of both genes at the same time.  
More recently, IFN-γ has been found to upregulate the levels of DUOXA2 as well as DUOX2300; 
further supporting the bi-directional promoter theory, but also that IFN-γ induction of DUOX2 
produces an active and functional DUOX2 protein because of the co-induction of DUOXA2. In 
this case the activity of DUOX2 was proven by measuring intracellular ROS and extracellular 
H2O2 levels
300. Previous research during my project (data not included) on three different 
colorimetric methods of H2O2 detection in cells was not successful as no H2O2 (at least not 
above the minimum level measured in the assay) was detected in any cells, under any conditions 
with either of the three methods. One of the main problems in detecting H2O2 was its short half 
life and the presence of antioxidants that scavenge ROS in the media. In future experiments, 
detecting H2O2 concentration using an adequate assay would provide additional validation of 
DUOX2 activation and function within the cell. Ongoing work in the laboratory has succeeded 
in detection of H2O2 from cells using a more sensitive fluorometric assay based on Amplex Red. 
This technique has shown that there is indeed a significant increase in H2O2 levels in C99 cells 
under hypoxia after 72 h compared to normoxia (31 μM H2O2 released over 1 h in normoxia 
compared to 75 μM in hypoxia, representing a 2.4 fold increase when cells are incubated in 
hypoxia301). The mitochondrial membrane potential remained unchanged in cells over this time 
191 
 
period, implicating DUOX2 as the source of H2O2, a finding in accordance with the mRNA 
expression data presented in this thesis. 
HIF-1α mRNA expression under 2 % O2 was decreased in C80, C99 and HRA19, and under 0.2 
% O2 was decreased in C80, C99, SW837 and VACO4S. This may potentially have been because 
of a negative feedback mechanism reducing gene expression if the protein is stabilised as a 
consequence of hypoxia. Under normoxic conditions, HIF-1α is expressed, but the protein is 
rapidly degraded by interacting with VHL299, but under hypoxia (generally below 2 % O2) HIF-1α 
protein is stabilised by inhibition of prolyl hydroxylase enzymes, which use O2 to target HIF-1α 
for degradation under normoxia248. To determine if there is a HIF-1α negative feedback system 
in place, over expression of HIF-1α could be experimentally induced potentially by reducing 
HIF-1α ubiquitination under normoxic conditions and confirming the expression level of HIF-1α 
mRNA in response to the increased HIF-1α protein. 
In summary, it can be hypothesised that ATF2 is the most likely regulator of DUOX2 in 
response to low oxygen levels.  
7.5 DUOX2 was influenced by irradiation in C99 rectal cancer cell line 
Radiotherapy, as detailed in section 1.1.5.4, is the standard therapy given before surgery to rectal 
cancers in order to shrink them to allow more efficient surgical excision and reduced local 
recurrence. Radiotherapy is the application of ionising radiation directed at the cancer cells 
causing direct DNA damage and indirect damage via generation of ROS. DNA damage from 
irradiation is used to destroy the cancer cells. The aim of the experiment was to determine if 
irradiation affected DUOX2 mRNA expression levels in cancer cells. If DUOX2 expression is 
increased then more DNA damage may be present (as a consequence of more ROS through 
increased H2O2 production) sensitising the cells to irradiation and if the DUOX2 levels were 
reduced (lower ROS) the cells may be more able to survive irradiation due to reduction in DNA 
damage. DUOX2 expression might be a predictor of radiation response. 
The levels of irradiation used were 0.5 Gy and 2 Gy of total irradiation, chosen because they 
were used in published experiments on radiosensitivity of prostate cancer cells215 and in CRC 
cells302. The results showed that DUOX2 expression was not changed by either level of 
irradiation (0.5 Gy or 2 Gy) in C80 cells. This cell line therefore provided an excellent model on 
which to test the effect of irradiation on cells with low DUOX2 mRNA expression. A 
contrasting model was to use C99 cells, where DUOX2 expression was significantly increased 
under hypoxia. In normoxic cells, irradiation had an effect on the expression of DUOX2, causing 
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it to increase after both IR doses and significantly after 0.5 Gy. This increase in DUOX2 
expression after a low level (0.5 Gy) of IR under normoxia may provide further evidence that 
methylation of the DUOX2 promoter did not influence DUOX2 expression and this accords 
with findings detailed earlier on DUOX2 response to hypoxia. An upregulation of DUOX2 in 
response to ionising radiation suggests that this gene is part of a wider stress response that would 
involve other genes involved in cellular survival. A higher level (2 Gy) of IR did not significantly 
increase DUOX2 expression and this could be due to the IR causing more substantial damage 
that fatally disrupts the DNA damage repair process and increases the apoptotic response.  
A potential way in which DUOX2 gene regulation could have been altered following IR in this 
instance was through GADD45 (Growth arrest and DNA damage-inducible protein family) and 
p38 MAPK proteins. GADD45 induces expression of p38 MAPK and one of the downstream 
proteins is ATF2, a known regulator of DUOX2. GADD45-like genes are induced by DNA 
damage and other environmental stresses and activate the kinase pathway involving p38 
MAPK303. Increased expression of p38 MAPK can regulate cell cycle, slowing it down to allow 
for DNA damage repair and potentially improving cell survival303. GADD45 was found to 
upregulate ATF2 in cells transfected with GADD45 and this upregulation of GADD45 protein 
was cytotoxic303, potentially indicating that a low level of GADD45 activation by IR would slow 
cell cycle and a high level would cause apoptosis. DUOX2 could therefore be upregulated in 
normoxic cells via GADD45-p38 MAPK-ATF2 pathway activation in response to DNA 
damage. 
Initially, research into DUOX2 and its expression after IR was instigated because of previous 
data from our lab150 that detailed that DUOX2 was within a QTL region responsible for 
increased IR-induced polyposis indicating that DUOX2 may have influenced tumourigenic 
capacity after irradiation. Hence it is possible that DUOX2 may be involved in the radiation-
induced response in the tumour and that DUOX2 could affect the response of the tumour to 
radiotherapy. Radiation is known to induce in prostate cancer cells cytoplasmic accumulation of 
ATF2, preventing the movement of ATF2 into the nucleus304. The effect that this might have on 
DUOX2 levels could be to reduce its expression, as seen in hypoxic 0.5 Gy IR C99 cells. The 
low level of IR (0.5 Gy) could induce the changes in ATF2, preventing it binding to and 
upregulating DUOX2 in response to hypoxia, thereby producing the lower level of DUOX2 
expression. At the higher level of IR (2 Gy) the cell may be recovering from more substantial 
damage and the DUOX2 expression level may have stayed the same. 
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In conclusion, the DUOX2 expression was only altered by 0.5 Gy IR in C99 cells. Under 
normoxia, an increase in DUOX2 after 0.5 Gy could have been due to induction of GADD45 
increasing ATF2 in response to IR. Under hypoxia, with already high levels of DUOX2 and 
ATF2, 0.5 Gy could have caused a reduction in the ability of ATF2 to translocate to the nucleus 
preventing DUOX2 upregulation. In order to test the two theories, after confirmation that ATF2 
upregulates DUOX2, GADD45 would be knocked out in normoxic IR cells and DUOX2 
expression examined, and to transfect ATF2 into hypoxic IR cells to test if DUOX2 expression 
increased. To confirm the functionality of DUOX2, a H2O2 detection assay would be performed. 
The mechanisms involved in the conflicting reactivity of DUOX2 to different levels of IR were 
difficult to understand, but the aim of the IR experiments was to test the effect of IR in terms of 
DNA damage on DUOX2-high and DUOX2-low cells, and the next sections discusses these. 
7.6 DUOX2 expression was independent of COX2 protein expression and HIF-1α 
protein induction 
The western blot experiments determined that HIF-1α protein was present in hypoxic samples 
after 72 hours of 2 % O2 incubation, but not 48 hours, and that COX2 was not expressed in 
rectal cancer cells. Hypoxic incubation times of 48 h and 72 h were used in our experiments 
because this was sufficient time for the induction of DUOX2 mRNA (as detailed previously) and 
the purpose of testing the levels of HIF-1α protein was to determine if DUOX2 expression 
could be linked to HIF-1α expression. Currently, there is no data in the literature linking DUOX2 
and hypoxia, so this was a novel finding. Determining if DUOX2 was under control of HIF-1α 
and/or COX2 was important. DUOX2 is highly expressed in C99 cells after 72 h incubation 
under 2 % O2, and the western indicates that HIF-1α protein is also upregulated after 72 h 
incubation compared to normoxia.  However, DUOX2 is not upregulated in C80 cells after 72 h 
hypoxic incubation, but HIF-1α was, indicating that DUOX2 expression is not a HIF-1α-
dependent gene implying that there is another mechanism of DUOX2 upregulation. As detailed 
previously, the mechanism by which DUOX2 could be upregulated in response to hypoxia is 
more likely to be through ATF2. ATF2 and HIF-1α are directly linked as ATF2 contributes to 
HIF-1α stability by preventing p53 binding causing a reduction in HIF-1α degradation296. The 
time of response of ATF2 to hypoxia occurs within 1 hour and is continuous during hypoxia296 
allowing appropriate time for transcription and accumulation of DUOX2 within the cell. 
However, because not all cell lines had upregulation of DUOX2 under hypoxia it must indicate 
that either there were alternative disruptions to this p38 MAPK-ATF2 pathway, or that there 
may be inactivating mutations in any of the DUOX2-linked proteins preventing upregulation of 
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DUOX2. Mutations could easily be tested for by sequencing of the ATF2, p38 MAPK or 
DUOX2 gene, however, only DUOX2 mutations are known in the literature, which cause 
hypothyroidism or thyroid cancer283 and have not been investigated in intestinal cancer or related 
to hypoxia. 
The HIF-1α protein expression was determined after 48 h and 72 h, but testing the protein 
expression after 12 h and 24 h of incubation may have improved the understanding of the 
process of response to hypoxia. HIF-1α is known to respond to 1 % O2 after only 3 h in CRC 
cells and is continuously expressed at 24 h184. The fact that our results show no HIF-1α induction 
at 48 h under 2 % O2 indicate that the rectal cancer cell lines may have adapted to hypoxia by 
switching metabolism and therefore do not respond as other cancer cells or may have already 
responded and expression diminished by 48 h. Another mechanism could be a feedback loop 
modulating HIF-1α degradation under moderate levels of hypoxia (2 % O2): a potential increase 
in ROS through DUOX2 may cause the degradation of HIF-1α, causing the reduction seen at 48 
h. This feedback affecting HIF-1α degradation by ROS has been predicted by Qutub et al.305. 
Here different levels of oxygen and ROS levels would influence the levels of HIF-1α protein by 
either changing gene transcription or degrading the protein. In order to understand this better, 
testing the levels of HIF-1α protein at more intervals after initiating hypoxia and linking it to 
DUOX2 expression would be informative. In addition, if the levels of HIF-1α protein in more 
rectal cancer cell lines did correlate with DUOX2 expression, knocking out HIF-1α in hypoxic 
cells and testing expression of DUOX2 would provide additional confirmation that DUOX2 
expression was independent of HIF-1α protein accumulation. Although DUOX2 is upregulated 
in hypoxia in some rectal cancer cell lines, from the evidence presented here, it is unlikely that 
HIF-1α protein and DUOX2 expression are directly linked and must, therefore, be induced by 
some other mechanism. 
COX2 protein was investigated because data in the literature suggests it is a protein induced by 
HIF-1α by binding to a HIF-1α responsive element in the COX2 promoter and represents an 
adaptation mechanism that promotes cell survival and angiogenesis184. We predicted that this 
mechanism may be upregulated in rectal cancer cells allowing adaptation, but evidence presented 
here suggested that it was not. Investigating other targets of HIF-1α may allow a more thorough 
examination of the mechanism of rectal cancer cell adaptation to hypoxia, and targets would 
include those known in the literature to affect cell survival and angiogenesis186. There was one 
minor difference between our investigations and those of Kaidi et al. that might have affect the 
expression of COX2: we used 2 % O2 whereas they used 1 % O2 and the higher level of HIF-1α 
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at this amount of oxygen may have caused HIF-1α accumulation to reach a threshold level to 
cause transcription of COX2 that might not have been reached at 2 % O2.  
Overall, COX2 did not appear to be co-ordinated with HIF-1α expression in rectal cancer cell 
lines. There are a few studies that link COX2 over-expression to rectal cancer specifically, but 
one study linking COX2 to overall survival excluded rectal cancers from their analyses due to 
poorer prognosis306. Other studies have determined that COX2 is a predictor of poor prognosis 
in rectal cancer with COX2 over expression producing reduced response to CRT ‘highlighting 
COX2 in mediating radio-responsiveness’307. COX2 inhibitors, which have shown efficacy as 
radio-sensitizers due to the activity against prostaglandins, have been shown to be effective in 
locally advanced rectal cancer in causing tumour regression prior to surgery. Therefore, in rectal 
cancers, COX2 must play a role for the COX inhibitor to have such an effect. It is most likely 
that in our experiment, the level of oxygen was not low enough to elicit a change in COX2. 
Testing at smaller time intervals would provide better understanding of expression levels of 
COX2. However, there may be other factors regulating COX2 expression. This raises important 
questions regarding the suitability of a cell line-based model of carcinogenesis and could mean 
that in rectal cancer cell lines COX2 could be downregulated or under alternative expression 
control than in tumours. However, the initial finding that COX2 is under transcriptional control 
of HIF-1α was found in CRC cell lines, so it would be expected to be observable in rectal cancer 
cell lines, if present, at 1 % oxygen. 
7.7 Cell survival and DNA damage 
The aim of investigating cellular survival and DNA damage was to assess the response of rectal 
cancer cells with differing levels of DUOX2 to radiation. The hypothesis was that cells with high 
DUOX2 (C99 H) would be sensitive to IR because of the increased H2O2 presence and therefore 
increased DNA damage. Cells with low DUOX2 (C80 H) would be more resistant to IR because 
of reduced H2O2 preventing additional DNA damage. Overall, the results appeared to fit the 
hypothesis very well, with C99 cells having more DNA damage and reduced survival in hypoxia 
after IR than in normoxia and C80 cells showed reduced DNA damage and survived well despite 
being irradiated. 
C99 cells presented a problem with regard to the survival experiments, as they did not form 
colonies despite the addition of feeder cells. An effect of prolonged exposure to hypoxia was 
seen to reduce the plating efficiency of HeLa cells by 70 % compared to normoxic cells up to 60 
h incubation308. An experiment testing IR on cells incubated for a shorter time in hypoxia to 
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reduce the effect on plating efficiency may have provided additional information on cell survival. 
However, this may have reduced the DUOX2 expression and therefore prevent the use of high 
DUOX2 versus low DUOX2 cells to test the effect of IR. Alternative survival assays include 
flow cytometry analysis for the population of apoptotic cells by staining with Annexin V: a 
phospholipid-binding protein that binds to apoptotic cells and can be used to determine the 
amount of apoptosis within a cell population309. It would be expected to show high apoptosis in 
C99H and low apoptosis in C80H. A different assay to quantify the apoptotic rate is the TUNEL 
assay, which labels DNA fragmentation followed by quantification by flow cytometry176. Both of 
these assays would have been a useful, potentially more accurate method of detecting the 
survival of cells after IR, but were not completed due to the high cost of multiple flow cytometry 
experiments and the number of cell samples required for analysis. In this case, survival analysis 
by colony-formation was an adequate indicator and is used often in published work when 
establishing the effects of IR on cell lines220. 
In contrast to C99 cells, C80 cells showed no change in survival under normoxia after the 
addition of IR, and showed minor, but non-significant changes under hypoxia, indicating that IR 
and hypoxia did not have an effect on C80 cells. This may have been because the cells were 
already adapted to hypoxia; a potential outcome of growing in colonies is upregulation of 
glycolysis (Warburg effect) in a positive feedback loop with HIF-1α, and other survival 
adaptations (HIF-1 activates anti-apoptotic enzymes and angiogenic proteins)310. To detect if 
there were hypoxic adaptation differences between C80 and C99 cells, measuring the uptake of 
glucose would allow calculation of glycolytic rate and investigating the expression of glycolysis-
associated genes would also indicate differences in glycolysis between C80 and C99 cells.  
The sphere-forming assay, however, did show a reduction in the number of spheres after a low 
dose of IR under normoxic conditions and a decline in the number of spheres formed under 
hypoxia with an increased IR dose. The reduction after 0.5 Gy IR could have been due to low-
dose sensitivity, as seen in prostate cancer cells215. A prostate cancer cell line (LNCaP) grown in 
vitro with Genistein and estradiol showed reduced survival after low-dose (0.5 to 1.5 Gy) IR and 
higher survival at 2 Gy IR, and the same cell line grown without drugs also showed increased 
sensitivity at low-dose IR215. This low-dose sensitivity was similar to our results under normoxia, 
indicating C80 cells were resistant to the effects of high dose IR. Under hypoxia, opposite to 
what was expected, C80 cells were sensitive to the killing effects of IR as there was a decline in 
the number of spheres formed with increasing IR. As it is known (section 3.6.5) that DUOX2 
expression was increased to a moderate amount in hypoxic IR C80 cells, this could be the way in 
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which radiation-sensitivity occurs (increased H2O2 and therefore ROS leading to increased DNA 
damage). To investigate the possibility that DUOX2 is the mechanism by which C80 cells 
become sensitive to IR under hypoxia, transfecting a DUOX2 siRNA into hypoxic cells and 
counting the spheres after IR would produce an answer. However, as the increase in DUOX2 
mRNA was small, it is likely that there were other mechanisms causing the decrease in sphere-
formation and a reduction in the tumourigenic capacity or plating efficiency of the cell line. The 
tumourigenic capacity could potentially be investigated using a different method of transplanting 
the cells into mice to form a xenograft and testing the ability of the cells to form tumours. The 
number of cells required for the xenograft to form a tumour would be directly linked to the 
tumourigenic capacity250. 
C99 sphere numbers were low, confirming the previous data that these cells do not form 
colonies and suggesting they have low tumourigenic capacity. The results showed that C99 cells 
were more sensitive to IR than C80 cells as there was a reduction in sphere number after IR. 
With the addition of hypoxia, C99 cells still had reduced sphere-forming ability compared to 
normoxic non-IR cells and the biggest reduction in spheres was in C99 hypoxic 2 Gy cells. This 
indicated that C99 cells are sensitive to IR in normoxia, and hypoxia sensitises these cells further, 
which showed a good correlation with the hypothesis. Under hypoxia and with the addition of 
IR, there was a correlation between DUOX2 expression and sphere-formation: Hypoxic cells 
showed a high increase in DUOX2 expression and a decrease in sphere-formation (although not 
significant). The correlation between sphere-formation and DUOX2 expression under hypoxia, 
normoxia and IR indicates that DUOX2 presence could sensitise C99 cells further to IR. An 
exciting next step would be to determine if the artificial addition of DUOX2 to rectal cancer cells 
did reduce survival after IR. As indicated by our results, inserting DUOX2 into normoxic cells 
would sensitise cells to IR by increasing the killing effect. Transfecting DUOX2 followed by IR 
and a survival assay, either sphere-formation or Annexin V flow cytometry, would indicate if this 
was the case. Further experiments investigating DUOX2 activation and survival analyses after 
increasing levels of IR would aid the understanding of DUOX2 and whether it had a radio-
sensitising effect. Although two doses of IR compared to a control is sufficient to provide data 
for a working hypothesis, further investigations would provide more evidence towards a valid 
conclusion. 
The results in this chapter support the hypothesis that high DUOX2 expression can sensitise 
cells to IR even during hypoxia. 
198 
 
7.8 Differences in the frequency of CD24 positive cells may explain the disparity 
in the tumourigenic capacity of the two rectal cancer cell lines 
CD24 is a putative stem cell marker that is overexpressed in several tumour types, including 
ovarian cancer231, breast cancer228, non-small cell lung cancer229, prostate cancer230, pancreatic 
cancer311, gastric cancer312 and is related to poor prognosis and more aggressive disease313. CD24 
inhibitors reduce the rate of cell proliferation indicating that CD24 is necessary for this 
process232.  
CD24 expression in C80 and C99 cells was very different and correlated well with previous 
results. Together the data presented suggests that CD24 is a marker of tumourigenic potential. 
Although we did not perform xenografts to prove that CD24+ cells are the only tumourigenic 
cells, the difference in colony-formation ability does support the conclusion. In the literature, 
CD24+ pancreatic cells were found to be significantly associated with tumour formation ability in 
xenografted mice (with more than 500 cells per xenograft) indicating high tumourigenicity251 and 
in CRC, patients with cytoplasmic CD24 positivity showed significantly reduced overall patient 
survival indicating the CD24 positive cells are more likely to survive after therapy and surgery226. 
However, there are multiple published studies linking CD24 negative cells with radiation-
resistance in breast cancers314, so there is still research to be done to confirm that in rectal 
cancers, CD24 positive cells mark the radio-resistant population and is linked with high cell 
survival and low patient survival. Therefore our conclusion that CD24 provides evidence for the 
different survival profiles of the two cell lines regards further validation; increasing the range of 
cell lines and experiments would increase the understanding of tumourigenicity of rectal cancer 
cells. Further investigations into alternative markers of stem cells in rectal cancers include 
researching LGR5 and ALDH1227 and examining the expression of these two markers in relation 
to the two cell lines with different DUOX2 expression and survival statistics would be useful. 
The best marker of CSCs could be decided by xenografting variable numbers of FACS-sorted 
cells and detecting the combination that produces a heterogeneous tumour from the fewest 
number of sorted cells. This process would require the use of mouse models for xenografting 
and although useful, as it more closely reflects an in vivo cellular environment, but these are 
expensive and require specialist support. Furthermore DUOX2 expression in CD24+ cells could 
be investigated to determine the expression levels in tumourigenic cells and non-tumourigenic 
cells. This would provide direct data on whether DUOX2 expression is linked to CD24+ cells.  
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7.9 DNA damage correlated with colony-formation, sphere-formation and CD24 
positivity 
DNA damage was quantified using an antibody against the marker γH2AX, a histone involved in 
the DNA double strand break repair. Foci of γH2AX at DSBs allow visualisation of the amount 
of DNA damage that has occurred in the cells; more foci per cell equates to more DNA damage. 
Although γH2AX is well known as a useful marker of DSBs, mice lacking H2AX can still carry 
out essential DNA repair functions indicating that H2AX is not essential for DNA repair, but it 
was necessary for other functions including growth and immunity315. γH2AX has been used in 
many studies to show a wide range of events, including IR sensitivity tests254. In our study, 
γH2AX was used as a marker of DNA damage and the number of foci per cell was used to 
quantify the damage. C80 cells demonstrate increasing DNA damage with increasing IR in 
normoxic cells, but with the addition of hypoxia, the DNA damage was significantly reduced. 
The reduction of DNA damage under hypoxia with and without the addition of IR followed the 
previous trend that despite the addition of IR in hypoxia, there was no significant decrease in the 
number of colonies formed. There was a reduction in the number of spheres formed and this 
may have been because the IR killed some of the CD24+ cells, as detailed by the reduction in 
CD24, causing a reduction in spheres under hypoxia. Low levels of DUOX2 in C80 cells 
correlated to a considerably lower than normal level of DNA damage in hypoxic (and hypoxic 
IR) cells. This would have been expected due to the reduced abundance of oxygen and ROS to 
have an additive effect on DNA damage during IR. The low level of DUOX2 and low level of 
DNA damage could have together contributed to the increased ability of this cell line to form 
colonies and spheres (proven by the increased level of CD24+ cells). Potentially due to the low 
level of DUOX2 expression, the C80 rectal cancer cell line was seen to be resistant to the killing 
effects of IR.  
C99 cells had a very different DNA damage pattern; there was an increase in the amount of 
DNA damage with increasing IR under normoxia, as expected, and with the addition of hypoxia 
and IR, the DNA damage stayed high. The high levels of DNA damage in IR and hypoxic cells 
correlates well with the reduced number of spheres formed and the reduced amount of CD24+ 
cells, especially in hypoxic IR cells. Higher DNA damage could have contributed to the 
reduction in sphere-formation and reduced number of CD24+ cells and this may have occurred 
due to the increased DUOX2 mRNA expression. These results together indicate that DUOX2, in 
producing H2O2, may have been responsible for sensitising C99 cells to the killing effects of IR. 
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In the literature, the use of γH2AX as a marker of DSBs has been found to be more sensitive 
than other methods of DSB detection; however, a potential flaw in our experiment could have 
been the time of culturing after IR. Significantly, Rothkamm and Lobrich showed that the 
number of γH2AX foci in cells was reduced when cells were allowed to grow after IR and that 
the slow reduction in foci was most likely due to an elimination of damaged cells, rather than 
DNA repair252. This could have caused a lower number of foci to be recorded than were actually 
produced, but the level of elimination or repair of DSBs seems to be over a longer time period 
than the 48 hours we used between the time of IR and the time of cell fixation. Hence, there 
should not have been a large difference in the numbers of DSBs. To test this, fixing the cells at 
variable times after IR would detail how the level of DSB repair changed over time and 
conducting a DNA fragmentation characterisation experiment would allow detection of the 
numbers of cells at each stage of the cell cycle, indicating the numbers of cells undergoing 
apoptosis (multiple DSBs) and the numbers dividing (no DSBs). Strikingly, the numbers of 
γH2AX foci still present in cells that were released from their checkpoint arrest after IR was still 
high (20 DSBs)316 instead of complete DNA damage repair, as expected. This could contribute 
further to the chromosomal aberrations seen in cancer cells, but could also contribute to the 
killing effect of IR. 
Alternative data in the literature supports our hypothesis that DUOX2 is linked to DNA damage 
through ROS; lower levels of ROS in a subset of cancer stem cells produces a reduced amount 
of DNA damage and allows these cells to survive better after IR compared to normal cells172. To 
test this further in rectal cancer cells, investigating the levels of ROS and γH2AX in the whole 
population after hypoxia and IR, and investigating the levels of ROS and γH2AX with DUOX2 
knocked out, would aid understanding of the link between DUOX2, ROS and DNA damage. It 
would be hoped that knocking out DUOX2 in hypoxic cells would cause a decrease in ROS 
generation and an increase in radio-resistance because of a reduced amount of DNA damage. 
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7.10 MiRNA analysis  
A microarray profiling experiment was carried out on a panel of six rectal cancer cell lines to 
identify miRNAs differentially expressed between hypoxic and normoxic culturing conditions. 
MiRNAs showing hypoxic-responsive expression may be useful as indicators of hypoxia in tissue 
and potentially, of radiation-resistance. The microarray identified a number of significantly 
differently expressed miRNAs and two sets of data were produced: upregulated miRNAs in 
hypoxia, and downregulated miRNAs in hypoxic. To highlight the potentially most important 
miRNAs, the most consistently up- and down-regulated miRNAs across the six rectal cancer cell 
lines were determined. There were four upregulated miRNAs (including miR-210) in five cell 
lines and two downregulated in all six cell lines in hypoxia compared to normoxia. The main 
miRNA chosen to investigate further was miR-210 as it was significantly upregulated in five out 
of six cell lines (microarray data) and it was validated in all six cell lines by qRT-PCR. This 
miRNA has also been the subject of a number of investigations, mostly involving cell lines other 
than rectal cancer, which have demonstrated the link with increased expression and hypoxia. For 
example, Kulshreshtha et al.317 found only 27 significantly (p<0.01) upregulated miRNAs in 
hypoxia (0.2 % O2) after 24 hours in colon and breast cancer cell lines. The results included an 
upregulation of miR-210, but miR-339-5p and miR-1296 were not present as they were in the 
data presented here. The researchers used a bead-based microRNA profiling array that only 
contained a maximum of 381 miRNA probes, compared to the 1145 probes that were in our 
microarray, and these 381 probes did not contain miR-339-5p or miR-1296, but did include miR-
210197. The comparatively low number of probes tested may have been due to the time of 
analysing before larger arrays were available to produce the large data sets that cover all known 
miRNAs.  
There are limitations in using the luminescence-based screening technology that may have left 
some miRNAs undetected either because they failed to hybridise to the probe, were below the 
detection limits or because they exceeded detection threshold limits. This needs to be 
acknowledged and results from microRNAs compared against other detection technologies 
based on sequencing or copy number counting would be useful. However, the former is much 
more expensive, whilst the latter is currently limited to 700 miRNAs.  
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7.11 MiR-210 expression was consistently induced by hypoxia and targets ISCU in 
rectal cancer cell lines 
A microarray-based analysis of differential miRNA expression between hypoxia and normoxia in 
six rectal cancer cell lines found that miR-210 was consistently upregulated by hypoxia in five out 
of six cell lines. This finding was validated by qRT-PCR, which found significant miR-210 
upregulation in all six rectal cancer cell lines in hypoxia compared to normoxia. This miRNA is 
known  to be induced by hypoxia in other cancers (breast cancer208, head and neck cancer207, 
renal clear cell carcinoma (RCC)318) and is negatively related to outcome207. Our expression 
results indicated that, as well as in hypoxic cell lines, miR-210 is commonly induced by hypoxia 
in rectal tumours. In order to investigate this further, a target of miR-210, ISCU was examined as 
it is an essential part of the mitochondrial transport chain and can control ROS production206.  
Our cell line ISCU expression results indicated that when miR-210 expression was upregulated, 
ISCU mRNA expression was significantly downregulated. There was also a degree of 
downregulation that corresponded to the degree of miR-210 induction i.e. the three rectal cancer 
cell lines with the highest miR-210 induction had the lowest ISCU mRNA expression (rectal 
lines C80, C99 and HRA19). These results support data in previously published studies 
investigating ISCU expression in response to miR-210 expression in colon, breast, and 
oesophageal cancer cell lines206. However, mRNA level is not always an accurate measure of the 
expression at the protein level. Accordingly, a western blot was performed on protein samples 
from five cell lines (HRA19 was not used because of very low protein yields) to determine ISCU 
protein expression in both hypoxia and normoxia. The blot showed decreased ISCU protein 
expression in hypoxia in most of the cell lines (4/5). Of the five cell lines, the two that had the 
highest miR-210 expression (C80 and C99) only had a relatively small decrease in ISCU protein 
expression compared to the other cell lines. The difference in mRNA expression and protein 
expression could be due to the accumulation or stabilisation of the protein within the cell. 
Another possible factor modulating ISCU protein levels are other miRNAs: there are 24 
miRNAs predicted to target ISCU mRNA278 (including miR-210) and these could have resulted 
in increased or decreased expression and thereby influenced ISCU protein. However, at present 
there are no experimentally proven miRNAs linked to ISCU protein expression other than miR-
210. 
Downregulation of ISCU by miR-210 in rectal cancer cell lines could be part of the adaptive 
response allowing cells to switch from respiration to the glycolytic pathway. ISCU is an essential 
protein involved in the electron transport chain and loss of ISCU can cause reduction in oxygen 
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consumption206 potentially allowing the cell to survive on less oxygen. This adaptive response 
from induction of miR-210 is essential for cancer cells in hypoxic tumours to survive and 
correlates with poor patient prognosis261. Inhibiting this glycolytic pathway may be a mechanism 
by which the adaptation of cancer cells to hypoxia could be reversed to reduce the chance of 
radiation resistance, as seen in Chen et al. 2010206, where addition of 3-brommo-2-
oxopropionate-1-propyl ester (3-BrOP), an antiglycolytic agent, caused preferential killing of 
cancer cells with elevated glycolytic activity206. The remaining cells would therefore not be 
adapted as well to hypoxia and would be more sensitive to other mechanisms of cell killing, e.g. 
radiation. A molecular profile of tumours with this type of activity would aid selection of patients 
that could benefit more significantly from the additional treatment of antiglycolytic agents. In 
our rectal cancer cells, this could be tested in a similar way, by adding increasing concentrations 
of 3-BrOP to cells in hypoxia to detect differences in cellular survival compared to a no 
treatment control. Potentially, 3-BrOP would cause an increase in cell death due to its inhibitory 
action on glycolysis.  
Additional investigations in rectal cancer cell lines would include further analysis of the predicted 
targets of miR-210, including those involved in cellular proliferation (HOXA1 and FGFRL1277), 
and linking cell response to irradiation with miR-210 expression to determine if miR-210 is 
involved in radiation sensitivity. These experiments are planned as part of the follow up studies 
to this thesis.  
7.12 MiR-210 was expressed in rectal cancer tissue 
Following validation that miR-210 was induced by hypoxia in rectal cancer cell lines and targeted 
ISCU mRNA, investigations into rectal cancer tissue were carried out to determine if the same 
induction occurred in tissue. 
We have established a link between miR-210 expression and hypoxia in vivo by examining a panel 
of rectal tumour samples. Although miR-210 was expressed from a low to a high level in tumour 
regions from across the panel, levels of expression were associated with hypoxia, as indicated by 
CAIX expression. Our data supports published research in other tumour types, for example,  
Camps et al. 2008208 determined that miR-210 expression is correlated with hypoxia in breast 
cancer208. They normalised miR-210 expression in breast cancer to ten pools of ten normal breast 
tissue RNAs and linked miR-210 expression with a hypoxic signature; a panel of 99 genes with 
altered expression in hypoxia. In the panel of breast cancers, miR-210 also correlated with 
patient outcome: patients with low miR-210 had a longer ten-year survival rate (77.1 %) 
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compared to those with high miR-210 (53.6 %). Our data was determined using similar methods 
of qRT-PCR for expression of miR-210, but we did not have a panel of separate normal rectal 
tissue controls. Instead, we used matched normal areas of tissue on the same slide, near to the 
tumour, determined microscopically by a pathologist, to normalise miR-210 expression. This 
may have introduced error into our results because, as discussed in King et al. 2001319, the normal 
area of a specimen is not easy to define as ‘the definition of normal actually represents a dynamic 
state’ and the minor differences in cell development or progression to tumour may not be 
detectable under the microscope319. The expression of genes and miRNAs in the apparently 
normal areas of tissue adjacent to the tumour may have been altered due to the proximity to the 
tumour, as seen in breast tissue320 and CRC321. However, our results did provide a significant 
result and warranted further investigation in a larger panel of rectal samples, including matched 
control and cancer, and normal rectal tissue samples taken from disease-free patients. 
Although there is likely to be genetic heterogeneity within and between rectal tumours200 322, our 
approach of targeting small regions for investigation of both miRNA expression and protein 
expression should help to reduce this confounding factor. There is also potential to establish 
how heterogenic rectal cancers are by taking multiple regions from multiple tumours for 
comparison. Using laser capture micro dissection, smaller areas and single cells of the tumour 
could be investigated for differences in miRNA expression, linked to protein expression subject 
to overcoming technical issues of miRNA extraction. ISH protocols are currently being 
developed within the laboratory to precisely locate the expression of this miRNA; routine 
localisation of miRNAs in tissues needs to be established to allow further understanding of how 
these molecules work. Alternative approaches to identifying the genetic profile and characterising 
cancers include 3-D analysis of the whole tumour, as completed in the prostate gland, to display 
the ‘complete spectrum of tumour progression in an appropriate context’323. However, this 
approach is extremely time consuming - over 2000 cells were dissected from one patient’s 
sample, followed by RNA extraction and microarray experiments - and analysis of the numerous 
data is complicated. Other methods of expression validation across tumours, ISH for miRNAs 
and mRNAs would be a possible further experiment and would help provide detailed location of 
expression. 
We used CAIX as the marker of hypoxia in our tissue as CAIX has a hypoxia-responsive 
element in the promoter and is regulated by HIF-1α280. This is the mechanism by which CAIX is 
tightly controlled by hypoxia. CAIX is a robust marker of tumour hypoxia and has previously 
been used in CRC tissues to indicate hypoxic regions of tumours, correlated to poor therapy 
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response and reduced disease-free survival279. The correlation with survival may be due to the 
hypoxic nature of CAIX positive tumours being inherently more resistant to radiotherapy, 
decreasing the likelihood of survival. In other cancers, including non-small-cell lung cancer, 
bladder, breast, brain, and head and neck cancer, CAIX is an indicator of poor prognosis281, 
further supporting its use in our research. 
CAIX has been linked to miR-210 expression324, and the response of miR-210 may be due to the 
hypoxia-response element upstream of the miRNA coding sequence269. The proven link with 
miR-210 and hypoxia implies that miR-210 could be used as an alternative marker for hypoxia in 
tumours; potentially a less invasive one if it can consistently be detected in the blood and linked 
to tumour hypoxia. This has already been proven in pancreatic cancer325 where, according to 
authors, miR-210 was consistently and reliably detected in blood plasma (elevated in pancreatic 
cancer patients) although this was not directly linked to hypoxia or miR-210 expression in each 
patient’s tumour.  
An examination of the survival data in relation to miR-210 expression indicated that there was 
no apparent difference in survival between high miR-210 and low miR-210 expression. A larger 
sample size with adequate survival data and follow up statistics would be necessary to test this 
association. As part of future studies to continue these investigations, collaborations with others 
are currently being sought.  
7.13 ISCU as a proposed target of miR-210 in rectal cancer tissue 
The IHC for ISCU in tissue was inconclusive due to the inconsistent staining and inadequate 
optimisation. ISCU is an iron cluster assembly protein and is essential for the assembly of Fe-S 
clusters in the respiratory electron transport chain and the tricarboxylic cycle, and a knockdown 
of ISCU in colon cancer cells caused a 30 % reduction in oxygen consumption activity206. If 
ISCU was regulated by miR-210, ISCU may play a role in tumour adaptation to hypoxia by 
reducing oxygen consumption in the cell. This is supported by the fact that miR-210 is 
overexpressed in some cancers and correlated to tumour prognosis; adaptation to hypoxia 
signifies that tumour is capable of avoiding cell death due to lack of oxygen and is therefore 
more likely to be resistant to radiotherapy. In order to further investigate the relationship 
between miR-210 and ISCU in vivo, apart from correct optimisation of ISCU IHC, more tissue 
samples would be required for expression analysis and correlating the data with survival statistics 
could help aid the progress of miR-210 as a marker of poor prognosis in rectal cancer. Further 
work investigating other validated targets of miR-210 (from data in cell lines) could allow 
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identification of tumours that will respond or not respond to therapy and provide enhanced and 
tailored treatment options. 
7.14 DUOX2 and miR-210 
Data from this research has provided a link between DUOX2 and hypoxia in rectal cancer, 
shown that DUOX2 is linked to increased cell death in response to irradiation in rectal cancer 
cell lines and provided a satisfactory argument for further investigation of DUOX2 as a 
candidate predictive marker of response to radiotherapy. We have also found that miR-210 is 
correlated to hypoxia in vivo and is likely to be linked to patient outcome in rectal cancer. 
Together these data suggest that DUOX2 and miR-210 could possibly be used together to 
predict rectal tumour response to radiotherapy. The ability to predict response to treatment is a 
major step forward in patient care and allows tailored treatment options to improve patient 
outcome. Currently in rectal cancer, CAIX has been proposed as a marker to distinguish 
responders (significantly lower CAIX) and non-responders326 highlighting the role of hypoxia in 
tumour response. Breast cancer patients currently receive tailored treatment through the use of 
the marker HER2; Trastuzumab directly targets HER2 and patients without HER2 positive 
tumours (75-85 % of patients) will not respond to treatment327. In CRC, current genetic testing 
prior to chemotherapy to predict response includes KRAS (patients with wild-type KRAS will 
respond to cetuximab67) and VEGF (Bevacizumab directly inhibits VEGF71). However, as yet 
there are no conclusive predictive markers of rectal cancer response to radiotherapy, despite the 
obvious difference between responders and non-responders3 and genome-wide microarray 
searches for predictive markers112. The most recent data on predictive markers in rectal cancer 
includes a 13-gene signature of response to chemoradiotherapy, which predicts response with 86 
% accuracy (in 57 patients), but this is yet to be confirmed in a larger data set328.  
The overall outcome of our data provides exciting novel markers of hypoxia in rectal cancer, 
which, once validated in a larger data set, could offer a new predictor of response of rectal 
cancers to radiotherapy. 
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Appendix A 
1. Table 1. Rectal cancer database: full information on each cancer patient in order of anonymous log number. Sex: 0=F, 1=M. R (resection status): 
0=curative resection, 1=microscopic residual, 2=macroscopic residual. Mets (metastases): 0=no mets, 1=mets. Start: date of treatment. Protocol: type of 
treatment. Therapy: 0=no therapy, 1=chemotherapy, 2=radiotherapy, 3=chemoradiotherapy. Timing: 0=pre-op therapy, 1=post-op therapy. Rec (recurrence): 
1=recurrence present. Loc (location of metastasis). Current: 0=alive, 1=dead. Cause (cause of death): 0=dead of other causes, 1=dead of cancer). Survival in 
years. Database compiled by N Sengupta, A Ghosh, N Suraweera, S McDonald, M Thaha, S Dorudi and A Silver. 
Log DOB 
Se
x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
2 05/05/1929 1 05/06/1998 69 A T1N0M0 0 0 05/06/1998 Surgery   0   1   01/05/2006 1 1 7.90 
3 13/06/1936 0 19/05/1998 62 B T3N0M0 0 0 19/05/1998 Surgery   0       14/08/2006 0   8.24 
4 23/12/1942 0 04/06/1998 55 A T1N0M0 0 0 04/06/1998 Surgery   0       01/04/2007 0   8.82 
8 03/02/1936 1 02/05/1998 62 B T3N0M0 0 0 02/05/1998 Surgery   0       04/08/2001     3.26 
9 29/12/1929 0 27/05/1998 68 B T3N0M0 1 1 27/05/1998 Surgery AP resection 3 2 1 Lung 13/08/2000 1   2.21 
                  12/08/1998 RT Pelvis                 
                  13/04/1999 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
                  05/05/1998 RT Lateral ribs                 
20 15/05/1920 0 12/03/1998 78 B T3N0M0 0 0 12/03/1998 Surgery   2 2     13/10/1998 1 1 0.59 
                    RT                   
24 11/08/1950 1 22/01/1998 47 C2 T3N2M0 0 1 22/01/1998 Surgery 
AP resection 
+ Ileostomy 
3 2 1 Liver 09/09/1998 1   0.63 
                  30/03/1998 
Chemotherap
y 
5FU/FA (Machover  
regime)  
              
                  29/06/1998 RT Pelvis                 
                  01/09/1998 
Chemotherap
y 
Irinotecan                 
28 08/12/1930 0 08/01/1998 67 B T3N0M0 1 0 08/01/1998 Surgery   0       05/01/2001 1 1 2.99 
30 02/12/1933 0 12/11/1998 65 B T3N0M0 0 0 12/11/1998 Surgery   0       01/07/2007 0   8.63 
38 12/06/1925 1 29/09/1998 73 B T3N0M0 0 0 29/09/1998 Surgery 
Anterior 
resection 
2 2     11/06/1999 0   0.70 
                    RT F/U                 
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Log DOB 
Se
x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
41 03/05/1918 1 08/09/1998 80 B T3N0M0 0 0 08/09/1998 Surgery   0       01/01/2008 0   9.31 
52 08/02/1939 0 03/02/1999 60 D T3N1M1 2 1 03/02/1999 Surgery   0       07/02/1999 1 0 0.01 
53 19/08/1914 0 08/04/1999 85 C1 T3N1M0 0 0 08/04/1999 Surgery   0       19/10/2004 1 0 5.53 
55 31/05/1913 0 14/05/1999 86 B T2N0M0 0 0 14/05/1999 Surgery   0       13/01/2003 1 0 3.67 
57 04/05/1930 1 27/05/1999 69 D T3N0M1 2 1 27/05/1999 Surgery 
Abdominoperineal 
Excision 
    Liver 15/04/2001 1   1.89 
58 31/07/1935 0 16/03/1999 64 C1 T3N1M0 0 0 08/03/1999 RT Rectum 2 1     18/02/2000 0   0.93 
                  16/03/1999 Surgery AP resection                 
                  19/04/1999 
Chemotherap
y 
5FU/FA 
(Machover  
regime) 
1 2             
60 21/08/1955 1 28/04/1999 44 B T3N0M0 0 0 28/04/1999 Surgery   0       20/03/2008 0   8.90 
61 14/12/1933 1 17/03/1999 65 C1 T3N1M0 0 0 17/03/1999 Surgery   1   1   26/06/2008 0   9.28 
62 25/02/1924 1 13/03/1999 75 B T3N0M0 0 0 13/03/1999 Surgery   0       03/06/2001 1 0 2.23 
68 01/07/1936 1 21/07/1999 63 B T3N0M0 0 1 06/07/1999 RT Pelvis 2 1 1 Lung 13/06/2002 1   2.90 
                  21/07/1999 Surgery Low anterior resection               
                  20/09/1999 
Chemotherap
y 
Quasar 
(colorectal 
trial) 
1 2             
69 13/12/1947 1 29/06/1999 52 C T3N1M0 0 1 29/06/1999 Surgery 
Anterior 
resection 
1 2     28/04/2006 0   6.83 
                  13/09/1999 
Chemotherap
y 
5FU/FA (Machover  
regime) 
              
70 10/03/1949 1 15/07/1999 50 A T2N0M0 0 0 15/07/1999 Surgery   2       01/10/2001 1 0 2.21 
71 22/09/1952 1 03/08/1999 47 C T4N1M0 0 1 03/08/1999 Surgery 
Anterior 
resection 
1 2     15/12/2003 0   4.37 
                  06/09/1999 
Chemotherap
y 
5FU/FA (Machover  
regime) 
              
74 17/10/1946 1 24/08/1999 53 N/A N/A 
N
/
A 
N/A 24/08/1999 Surgery           15/11/2001 0   2.23 
75 07/06/1938 1 24/08/1999 61 B T3N0M0 0 N/A 16/08/1999 RT Pelvis 2 1 1   01/07/2005 0   5.85 
                  24/08/1999 Surgery 
Anterior 
resection 
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Log DOB 
Se
x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
                  08/11/1999 
Chemotherap
y 
Quasar 
(colorectal 
trial) 
1 2             
76 22/04/1929 0 18/08/1999 70 B T3N0M0 0 0 05/08/1999 RT Rectum 2 1     06/08/2007 0   7.97 
                  18/08/1999 Surgery 
Anterior 
resection 
                
81 09/03/1941 1 15/09/1999 59 B T3N0M0 0 0 15/09/1999 Surgery   0   1   01/06/2004 0   4.71 
83 09/05/1920 1 06/10/1999 79 A T2N0M0 0 0 06/10/1999 Surgery   0       08/11/2007 0   8.09 
84 26/10/1932 0 13/10/1999 67 N/A N/A 
N
/
A 
N/A 13/10/1999 Surgery   0       22/11/2001 0   2.11 
85 28/06/1933 1 26/10/1999 66 B T3N0M0 0 0 26/10/1999 Surgery 
Anterior 
resection 
0       30/12/2002 1 0 3.18 
86 31/12/1919 0 27/10/1999 80 C T3N1M0 2 0 27/10/1999 Surgery   0   1   15/01/2003 1 1 3.22 
87 29/05/1932 1 27/10/1999 67 C T3N1M0 0 0 27/10/1999 Surgery   0       01/11/1999 1 0 0.01 
89 01/11/1915 0 02/11/1999 84 B T3N0M0 0 0 02/11/1999 Surgery   0       03/08/2004 0   4.75 
90 18/04/1947 0 03/10/1999 52 B T3N0M0 0 0 03/10/1999 Surgery 
Resection 
colorectal 
CA 
0       08/11/2007 0   8.10 
95 22/06/1924 1 30/11/1999 75 A T2N0M0 0 0 30/11/1999 Surgery   0       31/10/2003 0   3.92 
104 13/12/1929 0 04/04/2000 70 C2 T3N2M0 0 N/A 04/04/2000 Surgery 
Anterior 
resection 
1 2     17/01/2008 0   7.79 
                  22/05/2000 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
105 14/08/1928 1 05/04/2000 72 B T3N0M0 1 0 05/04/2000 Surgery   2   1   01/03/2008 1   7.90 
106 14/02/1923 0 20/04/2000 77 A T2N0M0 0 0 20/04/2000 Surgery   0       16/09/2005 0   5.41 
108 27/05/1923 1 10/05/2000 77 A T2N0Mx 0 0 10/05/2000 Surgery           21/05/2000 1 0 0.03 
110 01/12/1938 1 06/06/2000 62 C 
T3N1/2
Mx 
2 1 16/03/2000 RT Pelvis 2 1     26/11/2000 1 0 0.47 
                  06/06/2000 Surgery Extended Hartmann's           
Septic
aemia 
  
                  06/09/2000 
Chemotherap
y 
5FU/5FU/LV 
(De 
Gramont) 
1 2             
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Log DOB 
Se
x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
111 23/08/1935 1 07/06/2000 65 B T3N0Mx 0 1 07/06/2000 Surgery 
Anterior 
resection 
3 2 1 
Prost
ate 
07/12/2007 1   7.50 
                  21/08/2000 RT Pelvis                 
                  03/03/2004 
Chemotherap
y 
5FU/5FU/Oxaliplatin               
114 28/11/1925 1 08/06/2000 75 C T3N1Mx 0 0 08/06/2000 Surgery   0       03/10/2001 1 0 1.32 
118 06/12/1922 0 01/08/2000 78 B T3N0Mx 0 0 01/08/2000 Surgery           07/10/2003 1   3.18 
125 09/02/1916 1 13/09/2000 85 C1 T3N2Mx 1 0 13/09/2000 Surgery   2 1 1   08/08/2002 1 1 1.90 
126 10/03/1932 0 04/10/2000 69 C1 T3N2Mx 0 1 19/09/2000 RT Pelvis 2 1 1 
Liver/
Lung 
10/03/2004 1   3.43 
                  04/10/2000 Surgery Low anterior resection               
                  24/11/2003 
Chemotherap
y 
5FU/5FU/LV 
(De 
Gramont) 
1 2             
131 03/12/1973 1 14/11/2000 27 B T3N0Mx 0 0 14/11/2000 Surgery   1   1   01/02/2005 1 1 4.22 
132 13/05/1931 1 15/11/2000 70 B T3N0Mx 0 0 15/11/2000 Surgery       1   01/11/2007 1   6.96 
136 05/10/1933 1 09/01/2001 67 B T3N0Mx 0 0 09/01/2001 Surgery   2 1 1   01/10/2006 1 1 5.72 
137 01/03/1921 1 24/01/2001 80 B T3N0Mx 1 0 24/01/2001 Surgery           16/12/2005 1 0 4.89 
138 19/01/1947 1 07/02/2001 54 C T3N0Mx 0 0 07/02/2001 Surgery 
Anterior 
resection 
1 2     28/11/2005 0   4.80 
                  27/03/2001 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
140 23/01/1931 0 21/02/2001 70 C T3N1Mx 2 1 21/02/2001 Surgery 
Anterior 
resection 
3 2   Lung 15/05/2003 1   2.23 
                  04/04/2001 
Chemotherap
y 
Irinotecan + De Gramont               
                  12/07/2002 RT L-spine                 
                  12/09/2002 RT T/L spine                 
141 13/02/1923 1 27/02/2001 78 C T3N1Mx 0 1 12/02/2001 RT Pelvis 2 1     09/01/2003 1   1.86 
                  27/02/2001 Surgery AP resection                 
                  03/04/2001 
Chemotherap
y 
5FU/5FU/LV 
(De 
Gramont) 
1 2             
142 22/04/1941 1 28/02/2001 60 C1 T4N1Mx 1 0 28/02/2001 Surgery   2   1   20/02/2002 1 1 0.98 
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x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
143 28/11/1924 0 11/03/2001 76 C2 T3N1M1 2 1 11/03/2001 Surgery 
Pan-
proctocolect
omy + 
excision of 
liver mets 
1 2     15/02/2003 1   1.93 
                  13/06/2001 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
147 22/04/1934 0 01/05/2001 67 B T3N0M0 0 1 01/05/2001 RT Pelvis 2 1 1 
Kidne
y 
16/05/2005 1   4.04 
                  01/05/2000 Surgery AP resection                 
                  05/12/2003 
Chemotherap
y 
5FU/5FU/Ox
aliplatin 
3 2             
                  21/01/2004 
Chemotherap
y 
Oxaliplatin/Capecitabine               
                  27/10/2004 RT 
Pelvis + 
Vulva 
                
148 23/01/1942 0 02/05/2001 59 C1 T3N2Mx 2 0 02/05/2001 Surgery           19/05/2003 1 1 2.05 
150 08/02/1929 0 09/05/2001 72 C T3N1Mx 0 0 09/05/2001 Surgery   0       25/12/2001 1 0 0.63 
151 26/04/1922 0 06/06/2001 79 A T2N0Mx 0 0 06/06/2001 Surgery           07/04/2005 0   3.84 
161 16/02/1929 0 14/08/2001 72 C T3N1Mx 0 N/A 14/08/2001 Surgery 
Anterior 
resection of 
rectum + 
sigmoid 
colon 
1 2     13/12/2007 0   6.33 
                  25/09/2001 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
162 08/12/1926 1 15/08/2001 75 B T3N0Mx 0 0 15/08/2001 Surgery           12/12/2001 1 0 0.33 
163 23/04/1923 0 28/08/2001 78 N/A N/A 
N
/
A 
N/A 28/08/2001 Surgery           11/10/2001 0   0.12 
165 29/06/1933 0 10/09/2001 68 C1 T3N1Mx 0 1 10/09/2001 Surgery 
Anterior 
resection 
1 2   Liver 08/09/2002 1 1 0.99 
                  27/11/2001 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
169 12/12/1919 1 28/11/2001 82 N/A N/A N N/A 28/11/2001 Surgery           03/01/2002     0.10 
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Log DOB 
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x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
/
A 
170 31/10/1936 1 04/12/2001 65 A T2N0Mx 0 0 04/12/2001 Surgery           10/09/2007 0   5.77 
172 05/12/1940 1 05/12/2001 61 B T3N0Mx 0 0 05/12/2001 Surgery           20/10/2004 1 1 2.87 
174 25/10/1921 1 13/12/2001 80 C1 T3N1Mx 0 0 13/12/2001 Surgery           25/02/2002 1 0 0.20 
175 06/01/1925 0 19/12/2001 77 C1 T3N1Mx 0 0 19/12/2001 Surgery   2 1     15/09/2004 1 0 2.74 
176 01/09/1931 0 09/01/2002 70 C T3N1Mx 0 1 09/01/2002 Surgery 
Anterior 
resection + 
Extended 
hemicolecto
my 
3 2 1 
Uteru
s 
17/01/2008 1   6.02 
                  12/03/2002 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
                  22/08/2005 RT + 5FU Pelvis                 
177 23/02/1938 1 09/01/2002 64 A T1N0Mx 0 0 09/01/2002 Surgery       1   15/02/2004 1 1 2.10 
178 24/02/1938 1 16/01/2002 64 C T3N1Mx 0 1 03/01/2002 RT Pelvis 2 1   
Breas
t 
17/01/2008 0   6.00 
                  16/01/2002 Surgery Low anterior resection               
                  18/03/2002 
Chemotherap
y 
5FU/5FU/LV 
(De 
Gramont) 
1 2             
179 25/02/1938 0 23/01/2002 64 B T3N0Mx 0 0 23/01/2002 Surgery   0       11/09/2003 1 1 1.63 
182 25/02/1934 1 05/02/2002 68 B T3N0Mx 0 0 05/02/2002 Surgery   0       21/05/2004 0   2.29 
186 19/05/1926 1 27/02/2002 76 C T4N1Mx 0 1 27/02/2002 Surgery 
Anterior 
resection 
1 2   
Liver/
Lung 
09/03/2008 1   6.03 
                  18/03/2003 
Radio 
frequency 
ablation 
Liver                 
                  09/02/2004 
Chemotherap
y 
Capecitabine                 
                  19/02/2009 
Chemotherap
y 
Capecitabine                 
189 16/07/1937 1 13/03/2002 65 B T2N0M0 1 0 13/03/2002 Surgery AP resection 1 2     09/08/2007 0   5.41 
                  13/05/2002 Chemotherap 5FU/5FU/LV (De               
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Log DOB 
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x 
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Last time 
alive 
Current Cause 
Survi
val 
y Gramont) 
190 23/08/1927 1 19/03/2002 75 B 
T3N0M
X 
0 0 19/03/2002 Surgery   2 1     05/07/2007 0   5.30 
191 30/12/1940 1 20/03/2002 61 A 
T2N0M
X 
0 0 20/03/2002 Surgery       1   23/04/2003 1 1 1.09 
192 07/04/1950 1 09/04/2002 52 B 
T3N0M
X 
0 0 09/04/2002 Surgery           21/06/2007 0   5.20 
193 10/11/1938 0 10/04/2002 63 B T3N0Mx 0 0 10/04/2002 Surgery 
Extended 
Hartmann's 
+ Caecal 
Polypectomy 
0       24/02/2004 0   1.88 
195 11/05/1965 1 23/04/2002 37 B T2N0Mx 0 1 04/02/2002 RT Rectum 2 1 1 Lung 05/09/2006 1   4.37 
                  23/04/2002 Surgery Low anterior resection               
                  07/07/2003 
Chemotherap
y 
5FU/5FU/Ox
aliplatin 
3 2             
                  01/03/2004 Surgery Pelvic exenteration               
                  24/09/2004 
Chemotherap
y 
Oxaliplatin/Capecitabine                
                  09/06/2005 RT Sacrum                 
                  15/11/2005 
Chemotherap
y 
Irinotecan/Capecitabine               
196 24/09/1933 1 30/04/2002 69 B 
T3N0M
X 
0 0 30/04/2002 Surgery           10/12/2002 1 0 0.61 
200 17/04/1934 1 27/05/2002 68 C T3N1Mx 0 0 27/05/2002 Surgery   0       03/11/2004 1 0 2.44 
204 27/09/1921 1 12/06/2002 81 A T2N0Mx 0 0 12/06/2002 Surgery   2 1     26/04/2005 1 0 2.87 
215 31/01/1949 1 09/10/2002 54 A 
T2N0M
X 
0 0 09/10/2002 Surgery           01/04/2008 0   5.48 
224 02/09/1938 0 22/01/2003 64 A 
T2N0M
X 
N
/
A 
0 22/01/2003 Surgery           08/05/2008 0   5.29 
225 07/07/1932 1 23/01/2003 71 B 
T2N0M
X 
0 0 23/01/2003 Surgery           01/02/2008 0   5.02 
226 06/09/1928 1 18/12/2002 74 D T3N0M1 
N
/
1 18/12/2002 Surgery       1   01/12/2005 1 1 2.95 
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x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
A 
230 28/08/1969 0 09/04/2003 34 C1 
T3N1M
X 
0 0 09/04/2003 Surgery   1       09/07/2004 1 1 1.25 
234 19/03/1926 0 20/08/2003 77 C1 
T3N2M
X 
0 0 20/08/2003 Surgery   2 1     27/08/2003 1 0 0.02 
239 11/01/1927 1 29/10/2003 77 C1 
T3N1M
X 
0 0 29/10/2003 Surgery   0       08/05/2008 0   4.53 
240 30/04/1942 1 30/10/2003 62 C1 
T3N2M
X 
0 0 20/10/2003 RT Pelvis 2 1     17/10/2008 0   4.97 
                  30/10/2003 Surgery AP resection                 
                  24/11/2003 
Chemotherap
y 
5FU/5FU/Ox
aliplatin 
1 2             
242 06/06/1949 0 28/11/2003 54 C1 
T2N1M
X 
0 N/A 28/11/2003 Surgery 
Anterior 
resection + 
Loop 
Ileostomy 
1 2     18/09/2008 0   4.81 
                  06/01/2004 
Chemotherap
y 
5FU/5FU/LV (De 
Gramont) 
              
243 26/01/1940 1 14/11/2003 64 A 
T2N0M
X 
0 0 14/11/2003 Surgery                   
245 10/08/1933 1 03/12/2003 70 B 
T3N0M
X 
0 0 03/12/2003 Surgery   0       01/09/2007 0   3.75 
249 15/03/1923 1 07/01/2004 81 B 
T3N0M
X 
0 0 07/01/2004 Surgery 
Anterior 
resection 
0       01/10/2004 1 0 0.73 
250 10/04/1920 0 09/01/2004 84 A 
T2N0M
X 
0 0 09/01/2004 Surgery 
Anterior 
resection 
        29/02/2004 1 0 0.14 
252 25/06/1942 1 14/01/2004 62 C1 
T3N1M
X 
0 0 29/12/2003 RT Pelvis 2 1     07/12/2007 0   3.90 
                  14/01/2004 Surgery AP resection                 
                  24/02/2004 
Chemotherap
y 
5FU/5FU/LV 
(De 
Gramont) 
1 2             
257 12/01/1933 0 08/03/2004 71 B 
T3N0M
X 
0 0 08/03/2004 Surgery                   
258 28/06/1919 0 15/03/2004 85 B T3NXM 0 0 15/03/2004 Surgery           11/08/2004 1 0 0.41 
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Log DOB 
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x 
Surgery Age Dukes' TNM R Mets Start Intervention Protocol Therapy Timing Rec Loc 
Last time 
alive 
Current Cause 
Survi
val 
X 
259 19/06/1927 1 05/04/2004 77 C1 
T3N2M
X 
0 0 05/04/2004 Surgery           23/11/2006 1 0 2.63 
260   1 01/04/2004   D T4N0M1 0 1 01/04/2004 Surgery   1       01/03/2006 1   1.91 
264 10/12/1929 1 13/05/2004 74 N/A 
T3N0M
X 
N
/
A 
0 13/05/2004 Surgery 
Low anterior 
resection 
3       02/05/2008 1 0 3.97 
271 01/04/1937 1 21/04/2004 67 B T3N0M0 0 1 19/01/2004 RT + 5FU/FA Pelvis 3 1   
Liver/l
ung 
31/08/2008 1   4.36 
                  21/04/2004 Surgery 
Anterior 
resection 
                
                  28/03/2006 
Surgery + 
RFA 
Laparoscopic wedge resection               
                  16/04/2007 
Chemotherap
y 
Capecitabine 1 2             
278 06/04/1930 1 01/08/2004 74 N/A T3N0Mx 0 0 01/08/2004 Surgery Colectomy 0       21/12/2004 0   0.39 
280 29/03/1927 1 11/08/2004 77 B T3N0M1 2 1 11/08/2004 Surgery 
Anterior 
resection + 
End 
colostomy 
formation 
3 2   Lung 06/08/2007 1   2.98 
                  08/11/2004 
Chemotherap
y 
Capecitabine                 
                  18/05/2002 
Chemotherap
y 
Oxaliplatin/Capecitabine               
                  20/07/2007 RT Whole brain                 
289   1 24/08/2005   N/A T4N2Mx 0 0 24/08/2005 Surgery                   
294 26/11/1953 1 10/02/2006 52 C T2N1M0 0 1 10/02/2006 Surgery 
Anterior 
resection + 
Loop 
Ileostomy 
3 2 1 Lung 04/12/2008 0   2.81 
                  30/05/2006 
Chemotherap
y 
5FU/5FA/Oxaliplatin               
                  16/08/2007 Surgery Mini thoracotomy                
                  08/11/2007 Surgery Resection of distal colon +             
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x 
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Last time 
alive 
Current Cause 
Survi
val 
necrotic tissue pelvis  
                  27/12/2007 RT Pelvis                 
                  30/07/2008 
Radio 
frequency 
ablation 
Lung                 
                  16/10/2008 Surgery 
Laparotomy + SB 
resection 
              
304 17/11/1944 1 10/03/2005 60 N/A T2N0Mx 0 0 10/03/2005 Surgery 
Low Anterior 
Resection 
3 2 1   09/01/2008 0   2.83 
                  Post-op RT + Chemotherapy                 
306 17/03/1930 1 23/11/2005 76 N/A T4N0Mx 2 0 23/11/2005 Surgery 
Extended 
Hartmann's 
0   0 
Previ
ous 
renal 
carcin
oma 
24/04/2008 0   2.42 
307 19/08/1923 1 10/11/2005 82 N/A T3N2Mx 0 0 10/11/2005 Surgery Hartmann's 0       24/02/2006 1 0 0.29 
311 21/04/1923 0 21/01/2006 83 C1 T3N1Mx 1 1 25/01/2006 Surgery 
Extended 
Hartmann's 
1 2 0 
Liver 
+ 
Lung 
29/12/2008 0   2.94 
                  20/09/2006 
Chemotherap
y 
Coin (oxaliplatin/Capecitabine)              
                  13/02/2008 
Chemotherap
y 
Irinotecan + De Gramont               
                  29/08/2008 
Chemotherap
y 
Irinotecan/5FU/Cetuxima
b 
              
314 23/12/1928 1 02/03/2006 77 A T2N0Mx 0 0 02/03/2006 Surgery 
Rectosigmoi
d - 
Hartmann's 
0 0 0   18/05/2007 0   1.21 
316 16/10/1942 0 29/03/2006 63 B T3N0Mx 0 0 19/12/2005 
RT + 
Chemotherap
y 
Pelvis 5FU 3 1 0   16/04/2007 0   1.05 
                  29/03/2006 Surgery Low Anterior Resection               
                  27/09/2006 
Chemotherap
y 
5FU/FA/Oxal
iplatin 
1 2             
318 27/07/1940 1 28/04/2006 66 A T1N0Mx 0 0 28/04/2006 Surgery Anterior 0   0   08/01/07 0   0.70 
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Survi
val 
resection 
320 05/07/1935 1 18/05/2006 71 C2 T3N2Mx 0 0 18/05/2006 Surgery   3 2 0           
                  postop RT + Chemotherapy                 
321 26/01/1934 0 24/05/2006 72 C1 T4N2Mx 0 0 preop RT short course 2 2 1     1 0   
                  24/05/2006 Surgery Extended Hartmann's               
322 01/04/1939 1 25/05/2006 67 B T3N0Mx 0 0 25/05/2006 Surgery   0   0   18/05/2007 0   0.98 
330 20/07/1946 1 19/07/2006 60 B T3N0Mx 0 0 18/07/2002 Surgery 
Anterior 
resection 
0   0   21/08/2008 0   2.09 
331 10/08/1950 1 20/07/2006 56 B T3N0Mx 0 0 preop 
RT + 
Chemotherap
y 
Long course 3 1 0   05/10/2007 0   1.21 
                  20/07/2006 Surgery                   
335 08/08/1910 1 16/08/2006 96 B T3N0Mx 0 0 16/08/2006 Surgery Hartmann's 1   0   13/09/2006 1 1 0.08 
                    
Chemotherap
y 
Palliative                 
341 11/05/1940 0 18/10/2006 66 C1 T3N1Mx 0 0 18/10/2006 Surgery 
Hartmann's, 
TAH + BSO 
1 2 0   22/01/2009 0   2.26 
                  06/12/2006 
Chemotherap
y 
5FU/FA/Oxaliplatin               
346 24/04/1931 1 24/01/2007 76 B T2N0Mx 0 0 24/01/2007 Surgery Low Anterior Resection   0   15/11/2007 0   0.81 
348 17/03/1926 0 07/02/2007 81 D T3N1M1 2 1 07/02/2007 Surgery 
Hartmann's 
+ Liver 
resection 
2   0 Liver 25/07/2008 1 1 1.46 
                    RT                   
350 27/07/1938 0 21/02/2007 69 A T2N0Mx 0 0 21/02/2007 Surgery 
Anterior 
resection 
0   0   24/01/2008 0   0.92 
352 01/01/1938 1 15/03/2007 69 B T3N0Mx 0 0   RT Short course 2 1 0   15/02/2008 0   0.92 
                  15/03/2007 Surgery Low Anterior Resection               
353 01/11/1971 0 21/03/2007 35 A T2N0Mx 0 0 21/03/2007 Surgery 
Low Anterior 
Resection 
0   0   21/01/2008 0   0.84 
354 03/02/1926 0 28/03/2007 81 A T1N0Mx 0 0 28/03/2007 Surgery 
Anterior 
resection 
0   0   29/11/2007 0   0.67 
358 01/05/1952 1 25/04/2007 55 D T4N1M1 0 1 25/04/2007 Surgery   0   0   29/09/2007 1 1 0.43 
365 18/08/1942 1 13/06/2007 65 C1 T3N1Mx 0 0 13/06/2007 Surgery Subtotal 0             ? 
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x 
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alive 
Current Cause 
Survi
val 
Sig colectomy 
369 26/06/1929 1 18/07/2007 78 B T3N0Mx 0 0 18/07/2007 Surgery   0       28/10/2011 0   4.28 
371 21/05/1924 1 05/09/2007 83 B T3N0Mx 0 0   RT 
Previously 
for prostate 
cancer 
2 1 0   15/05/2008 0   0.69 
                  05/09/2007 Surgery Anterior resection               
372 17/02/1942 1 13/09/2007 66 D T3N1M1 0 1   
RT + 
Chemotherap
y 
  3 1 1 Liver 22/11/2007 0   0.19 
                  13/09/2007 Surgery 
Low Anterior Resection + Liver 
resection 
          
374 24/04/1968 0 19/09/2007 39 C1 T3N2Mx 2 0 23/04/2007 
RT + 
Chemotherap
y 
RT + 
Capecitabine 
- Rectum 
3 1 1   08/10/2009 1 0 2.05 
                  19/09/2007 Surgery Extended Hartmann's               
                  17/03/2008 
Chemotherap
y 
5FU/FA/Oxal
iplatin 
1 2             
                  02/01/2009 
Chemotherap
y 
Irinotecan/Panitumumab               
376 22/10/1923 1 28/09/2007 84 B T3N0Mx 0 0 28/09/2007 Surgery 
Anterior 
resection 
0               
380 08/04/1938 0 21/11/2007 70 B T3N0Mx 0 0 21/11/2007 Surgery 
Low Anterior 
Resection 
0       16/12/2007 1   0.07 
381 30/05/1936 1 21/11/2007 71 C1 T4N1Mx 0 0 21/11/2007 Surgery 
High Anterior 
Resection 
1 2 0   10/11/2011 0   3.97 
                  08/01/2008 
Chemotherap
y 
5FU/FA/Oxaliplatin               
382 15/03/1952 1 28/11/2007 56 C1 T3N1Mx 0 0 28/11/2007 Surgery 
Low Anterior 
Resection 
        08/02/2008 0   0.20 
383 
Ile 
11/08/1988 1 16/01/2008 19 C1 T3N0Mx 0 0 16/01/2008 Surgery   0       26/07/2011 0   3.52 
383 
Rec 
11/08/1988                                     
384 28/06/1924 1 01/02/2008 84 C1 T4N2Mx 1 0 01/02/2008 Surgery 
Anterior 
resection 
0       12/07/2011 0   3.44 
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alive 
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Survi
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385 10/06/1978 0 14/02/2008 30 N/A T0N0Mx 0 0   
RT + 
Chemotherap
y 
  3 1 0           
                  14/02/2008 Surgery                   
386 24/08/1954 1 21/02/2008 53 B T3N0Mx 0 0 13/02/2008 RT Pelvis 2 1     22/12/2008 0   0.84 
                  21/02/2008 Surgery 
Panproctolco
lectomy 
UC 
backgroun
d 
              
                  21/05/2008 
Chemotherap
y 
Oxaliplatin/C
apecitabine 
1 2             
387 01/05/1927 1 21/02/2008 81 C1 T4N1Mx 0 1 09/02/2008 RT Pelvis 2 1   Liver 22/10/2008 0   0.67 
                  21/02/2008 Surgery 
Anterior 
resection 
      
reduction in liver 
mets 
      
                  16/06/2008 
Chemotherap
y 
Capecitabine 1 2             
388 25/03/1955 0 05/03/2008 53 A T1N0Mx 0 0 05/03/2008 Surgery 
Panproctolco
lectomy 
UC 
backgroun
d 
              
389 19/12/1930 1 07/03/2008 77 B T3N0Mx 0 0   RT 
Previously 
for prostate 
cancer 1998 
2 1             
                  05/03/2008 Surgery 
Laparoscopic-assisted 
extended Hartmann’s 
              
395 20/03/1955 1 05/06/2008 53 N/A N/A 0 N/A 05/06/2008 Surgery 
Subtotal 
colectomy 
UC 
backgroun
d 
              
396 31/01/1922 0 25/06/2008 86 C2 T3N1Mx 0 0 25/06/2008 Surgery 
Extended 
Hartmann's 
0               
398 12/04/1938 0 09/07/2008 70 C1 T3N2Mx 0 0 09/07/2008 Surgery 
Low anterior 
resection + 
col-anal 
anastomosis 
1 2     21/01/2009 0   0.54 
                  05/09/2008 
Chemotherap
y 
5FU/FA/Oxaliplatin               
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401 19/02/1936 1 01/08/2008 72 B T4N0Mx 2 1   
RT + 
Chemotherap
y 
year before 
surgery 
2 1   Liver 08/04/2009 1 1 0.68 
                  01/08/2008 Surgery APER                 
426 28/06/1949 1 16/01/2009 60 C1 T3N2M1 0 1   
Chemotherap
y 
3 cycles 1 1   1         
                  16/01/2009 Surgery 
Anterior 
resection 
                
431 04/10/1940 0 25/02/2009 68 A 
T2N0M
X 
0 N/A 25/02/2009 Surgery 
Low anterior 
resection 
0               
434 05/12/1928 1 16/04/2009 80 B 
T3N0M
X 
0 N/A 16/04/2009 Surgery AP resection 0               
                  29/06/2009 Surgery 
Resection of small bowel due to ischaemia. Previous 
colostomy site excised and refashioned. No cancer. 
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2. Table 2. Genetic characteristics of cancer organised by anonymous log number. MSI 
(Microsatellite instability): 0=MSI-, 1=MSI+. CIN (Chromosomal instability): 0=CIN-, 1=CIN+. 
MACS (Microsatellite and chromosome stable): 0=MACS-, 1=MACS+. KRAS (Kirsten rat sarcoma 
viral oncogene homolog): 0=no mutation. BRAF (v-raf murine sarcoma viral oncogene homolog B1): 
0=no mutation. NA = not available. Empty box = not tested yet. Database compiled by N Sengupta, 
A Ghosh, N Suraweera, S McDonald, M Thaha, S Dorudi and A Silver. 
Log no. MSI+ CIN+ MACS KRAS BRAF 
2 0         
3 0         
4 0         
8 0     0 0 
9 0         
20 0         
24 0         
28 0         
30 0 1       
38 0 1       
41 0 1   G12V 0 
52 0     G12D 0 
53 0         
55 0     0 0 
57 0     G13D 0 
58 0     G13D 0 
60 0         
61 0         
62 0     0 0 
68 0   1     
69 0         
70 0 1   G12D 0 
71 0         
74 0     NA 0 
75 0 1   0 0 
76 0         
81 0   1 0 0 
83 0     0 0 
84 0     G12D 0 
85 0   1 0 0 
86 0     0 0 
87 0 1   G13D 0 
89 0   1 G12D 0 
90 0   1 G13D 0 
95 0 1       
104 0         
105 0     0 0 
106 0 1   0 0 
108 0   1 0 0 
110 0     G12R 0 
111 0 1   0 0 
114 0 1   0 0 
118 0 1   0 0 
125 0     0 NA 
126 0   1 0 0 
131 0 1       
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Log no. MSI+ CIN+ MACS KRAS BRAF 
132 0   1 0 0 
136 0   1 0 0 
137 0     0 0 
138 0 1   0 0 
140 0     0 0 
141 0 1   G12D 0 
142 0     0 V599E 
143 0         
147 0   1 0 0 
148 0     0 0 
150 0   1 0 0 
151 0   1 0 V599E 
161 0 1   0 0 
162 0 1   0 0 
163 0     0 0 
165 0 1   0 0 
169           
170 0 1       
172 0     0 0 
174 0   1     
175 0         
176 0   1     
177 0   1     
178 0 1   G12V 0 
179 0 1       
182 0 1   G13D 0 
186 0   1 0 0 
189 0     0 0 
190 0   1 NA 0 
191 1         
192 1     G12D V599E 
193 0 1   0 0 
195 0   1     
196 0 1   0 0 
200 0 1   G13V 0 
204 0     0 0 
215 1     0 0 
224 0         
225 0     G12S 0 
226 0     0 0 
230 0         
234       0 0 
239 0         
240 0     0 0 
242 0     0 0 
243 1     0 0 
245 0     0 0 
249           
250 0     G13D 0 
252 0     0 0 
257 0         
258 0     NA NA 
259 0     NA 0 
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Log no. MSI+ CIN+ MACS KRAS BRAF 
260 0     0 0 
264 0         
271           
278           
280 0     0 0 
289           
294           
304 0 1 0 0 0 
306 0 0 1 0 0 
307 0 0 1 0 0 
311 0 1 0 0 0 
314 0 1 0 G12D 0 
316 0 0 1 0 0 
318 0 1 0 0 0 
320 0 1 0 G12D 0 
321 0 0 1 0 0 
322 0 0 1 0 0 
330 0 1 0 0 0 
331 0 1 0 0 0 
335 1 1 0 0 0 
341 0 0 1 G12A 0 
346 0 0 1 0 0 
348 0 0 1 G12D 0 
350 0 1 0 0 0 
352 0 1 0 0 0 
353 0 1 0 0 0 
354 1 1 0 0 0 
358 0 1 0 0 V599E 
365 Sig 0 1 0     
369 0 1 0 G12D 0 
371 1 1 0 G12D 0 
372 0 1 0 G12D 0 
374 0 0 1 0 0 
376 0 1 0 0 0 
380 0 1 0 0 0 
381 0 1 0 0 0 
382 0 0 0 G13D 0 
383 Ile 1* 0 0     
383 Rec 1* 0 0 G12D 0 
384 0 0 1 0 0 
385           
386 0 0 1 0 0 
387 0 0 1 0 0 
388 0 1 0 0 0 
389 0     0 0 
395           
396   0   G12D 0 
398   1   0 0 
401   0   0 0 
426           
431           
434           
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Appendix B 
1. Table 1. Clinicopathological data, allelic loss at APC, and mutation status. Sex (M=male, F=female), Age, Dukes’ Stage and LOH are all features of the 
original patient or their tumour. Cell line data: includes MSI and 18q21 status and mutation status of APC, TP53, KRAS, BRAF and SMAD4. Mutations and 
18q21 status from: Rowan et al. (C80, C99, HRA19, HT55 and SW837), Kirkland and Bailey (HRA19), Watkins and Sanger (HT55) and McBain et al. (VACO4S).  
Name Sex Age Dukes' Differentiation LOH Cell morphology MSI APC mutation 
Trp53 
mutation 
KRAS 
mutation 
BRAF 
mutation 
SMAD4 
mutation 
18q21 
status 
Other mutations 
C80 M 69 D 
 
No 
 
MSI- 
 
E4 codon 
52, 
Gln>stop 
A146V Wt 
1,051 
G>C, 
Missense 
2 copies 
 
C99 M 69 C Moderate LOH 
 
MSI- 1,367 (CAG>TAG) 
  
None 1 copy 
 
 
HRA19 M 66 B Well LOH Polarised monolayers MSI- 1,450 (CGA>TGA) 
E8 codon 
273, 
Arg>His 
 
None 
  
 
HT55 F 54 
 
Highly No 
 
MSI- 
1,131 (CAA>TAA), 
1,303 (CAA>TAA) 
E6 codon 
213, 
Arg>Leu 
Wt N581Y None 2 copies 
MET oncogene 
expressed 
SW837 M 53 C Poor LOH Epithelial-like MSI- 1,450 (CGA>TGA) 
E7 codon 
248, 
Arg>Trp E 
Codon 
12  
None 1 copy 
p16=Methylated; 
MINT1,2,12&31= 
partially methylated 
VACO4S M 59 D Moderate 
 
Disorganised grape-
like multicellular 
clusters 
MSI- 
    
None 
  
References: 
1. Rowan A, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, et al. APC mutation in sporadic colorectal tumours: a mutational 
"hotspot" and interdependence of the "two hits". Proceedings of the National Academy of Sciences 2000;97(7):3352-7. 
2. Kirkland SC, Bailey IG. Establishment and characterisation of six human colorectal adenocarcinoma cell lines. British Journal of Cancer 
1986;53:779-85. 
3. Watkins J, Sanger C. Properties of a cell line from human adenocarcinoma of the rectum. British Journal of Cancer 1986;53:779-85. 
4. McBain JA, Weese JL, Meisner LF, Wolberg WH, Wilson JKV. Establishment and characterisation of human colorectal cancer cell lines. Cancer 
Research 1984;44:5813-21. 
246 
 
Appendix C 
1. Table 1. Fourteen rectal cancer samples and one normal FFPE sample selected for further analysis in miRNA study. Log no is the anonymous log number 
designated at time of surgery with the letter T (tumour) or N (normal) after the log number. Status of tumour: T=Tumour, N=node, M=metastasis, R=resection 
status (0=curative, 1=microscopic residual, 2=macroscopic residual), Mt=metastasis. Location is the location of metastasis or recurrence. Therapy given pre-
operatively (pre-op) or post-operatively (post-op) where RT=radiotherapy, CT=chemotherapy and CRT=chemoradiotherapy. MSI=microsatellite instability, 
CIN=chromosomal instability and MACS=microsatellite and chromosomal stable cancers. Mutation status of KRAS and BRAF are detailed. Current patient 
status as dead or alive and the cause of death are detailed. Survival in years. Database compiled by N Sengupta, A Ghosh, N Suraweera, S McDonald, M Thaha, S 
Dorudi and A Silver. 
Log No Date of birth Date of surgery Age 
Dukes’ 
Stage 
T N M R Mt Location Surgical Protocol Pre-op 
Post-
op 
MSI CIN MACS KRAS BRAF Current 
Cause of 
death 
Date last 
seen 
Survival 
307 N 19 Aug 1923 10 Nov 2005 82 C2 3 2 x 0 0 
 
Hartmann's 0 0 0 0 1 0 0 Dead Pneumonia 24/02/2006 0.290 
335 T 08 Aug 1919 16 Aug 2006 96 B 3 0 x 0 0 
 
Hartmann's 0 CT 1 1 0 0 0 Dead Cancer 13/09/2006 0.077 
348 T 17 Mar 1926 07 Feb 2007 81 D 3 1 1 2 1 Liver 
Hartmann's + Liver 
resection 
RT 0 0 0 1 G12D 0 Dead Cancer 25/07/2008 1.462 
358 T 01 May 1952 25 Apr 2007 55 D 4 1 1 0 1 
  
0 0 0 1 0 0 V599E Dead Cancer 29/09/2007 0.430 
369 T 26 Jun 1929 18 Jul 2007 78 B 3 0 x 0 0 
  
0 0 0 1 0 G12D 0 Alive 
 
28/10/2011 4.279 
372 T 17 Feb 1942 13 Sep 2007 66 D 3 1 1 0 1 Liver 
Low Anterior Resection 
+ Liver resection 
CRT 0 0 1 0 G12D 0 Alive 
 
28/11/2007 0.208 
374 T 24 Apr 1968 19 Sep 2007 39 C1 3 2 x 2 0 
Local 
recurrence 
Extended Hartmann's CRT CT 0 0 1 0 0 Dead 
Small bowel 
obstruction 
08/10/2009 2.053 
376 T 22 Oct 1923 28 Sep 2007 84 B 3 0 x 0 0 
 
Anterior resection 0 0 0 1 0 0 0 
  
N/A 
 
380 T 08 Apr 1938 21 Nov 2007 70 B 3 0 x 0 0 
 
Low Anterior Resection 0 0 0 1 0 0 0 Dead N/A 16/12/2007 0.068 
381 T 30 May 1936 21 Nov 2007 71 C1 4 1 x 0 0 
 
High Anterior Resection CT 0 0 1 0 0 0 Alive 
 
10/11/2011 3.970 
382 T 15 Mar 1952 28 Nov 2007 56 C1 3 1 x 0 0 
 
Low Anterior Resection 0 0 0 0 0 G13D 0 Alive 
 
08/02/2008 0.197 
383 T 11 Aug 1988 16 Jan 2008 19 C1 3 0 x 0 0 
  
0 0 1* 0 0 G12D 0 Alive 
 
26/07/2011 3.524 
384 T 28 Jun 1924 01 Feb 2008 84 C1 4 2 x 1 0 
 
Anterior resection 0 0 0 0 1 0 0 Alive 
 
12/07/2011 3.441 
387 T 01 May 1927 21 Feb 2008 81 C1 4 1 x 0 1 Liver Anterior resection RT CT 0 0 1 0 0 Alive 
 
22/10/2008 0.668 
401 T 19 Feb 1936 01 Aug 2008 71 B 4 0 x 2 1 Liver APER CRT 0 
 
0 
 
0 0 Dead Cancer 08/04/2009 0.684 
 
